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ABSTRACT 
 
JEANETTE ANNE STINGONE: Maternal exposure to criteria air pollutants during pregnancy and 
congenital heart defects in offspring 
(Under the direction of Andrew F. Olshan, PhD) 
 
Toxicological and epidemiological literature suggests that maternal exposure to air 
pollutants during pregnancy has the potential to disrupt fetal development, resulting in adverse 
pregnancy outcomes in offspring.  The goal of this dissertation was to explore the relationship 
between maternal exposure to carbon dioxide, nitrogen dioxide, ozone, coarse and fine particulate 
matter and sulfur dioxide during the window of fetal cardiac development, weeks 2 through 8 of 
pregnancy, and congenital heart defects (CHDs) in offspring within the context of the National Birth 
Defects Prevention Study (NBDPS), a large population-based case-control study.  Specific Aim 1 
sought to explore the relationships between pollutants and individual CHDs in a novel way, by 
assessing individual weeks of exposure in addition to a seven-week summary measure and utilizing 
hierarchical regression models to address the issue of multiple inference.  These relationships were 
also explored in a multipollutant context by using principal components analysis to construct source-
factor models.  Positive associations were observed for several pollutants and CHDs in both single-
pollutant and source-factor analyses. Assessing individual weeks of fine particulate matter exposure 
revealed potential windows of greater susceptibility, including week 2 for tetralogy of Fallot (odds 
ratio, OR 1.98 95% confidence interval, CI 1.11,3.46) and week 5 for pulmonary valve stenosis (OR 
1.83 95% CI 1.08,3.12) when contrasting women in the highest and lowest deciles of exposure.  
Women who used supplements containing folic-acid, a methyl donor involved in the regulation of 
DNA methylation processes, had lower odds of offspring with CHDs associated with fine particulate 
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matter exposure than women who did not report taking supplements, suggesting a potential 
mechanism underlying these associations.  Specific Aim 2 sought to compare the monitor-derived 
estimates of fine particulate matter and ozone exposure to model-derived estimates with greater 
temporal and spatial resolution.  This comparison revealed little effect of the greater temporal 
resolution and found observed differences in results using monitor-based versus model-based 
exposure estimates potentially attributable to the spatial differences in the composition of 
particulate matter.  The findings of this dissertation support further avenues of research including 
how risk of CHDs varies by the composition of fine particulates and the quality of maternal nutrition.  
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CHAPTER 1 
 
1. INTRODUCTION AND SPECIFIC AIMS 
 
 
Over the past few decades, the availability of ambient air pollutant monitoring data has led 
to extensive research investigating the health effects of exposure to air pollution on adults and 
children.1,2 In the last decade, a growing number of studies have examined prenatal exposure to air 
pollutants and a variety of adverse birth outcomes.3-27 The pollutants most often examined are the 
criteria air pollutants identified by the Clean Air Act: carbon monoxide (CO), nitrogen dioxide (NO2), 
particulate matter less than 10 µm in aerodynamic diameter (PM10) and less than 2.5 µm in 
diameter (PM2.5), ozone (O3), and sulfur dioxide (SO2).  
 
Epidemiologic studies provide some evidence of an association between congenital heart 
defects (CHDs), the most common class of birth defects, and exposure to criteria air pollutants.  
However, results have been inconsistent, with observed associations between pollutants and 
specific defects not replicated in subsequent studies.5,8,16,18,22-25 Because the observed effect 
estimates are small, exposure misclassification and confounding can have a large impact on results, 
potentially contributing to these discrepancies.  One potential source of misclassification is the use 
of ambient measurements taken at a single stationary monitor to assign exposure, regardless of the 
distance from the maternal residence.  Spatiotemporal prediction models, which predict a gridded 
air pollutant surface from multiple sources of data, including emissions and meteorological data, 
may provide a better estimation of exposure in areas with low monitoring density.28 
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Misclassification can also arise from assigning exposure using residence at delivery, instead of 
complete residential histories.29,30  Important associations may be masked when individual CHDs are 
aggregated into etiologically heterogeneous groupings, when pollutants are examined individually, 
without adjusting for other copollutants, or by residual confounding from the incomplete or 
inaccurate information on confounders contained in administrative data sources used for many 
studies.31,32 Additionally, analytic methods often do not easily allow for exploring multiple windows 
of exposure through the course of pregnancy, nor do they account for the underlying spatial and 
temporal correlation in the data which can impact precision of estimates.33  
Although mechanisms behind the associations between air pollutants and birth defects are 
not well elucidated, Baccarelli et al has shown exposure to particulate air pollution was associated 
with decreased DNA methylation.34  Considered in conjunction with previous research which found 
associations between measures of maternal DNA methylation during pregnancy and birth defects, 
there may be potential for altered DNA methylation mechanisms to play a role in the association 
between particulate matter and CHDs.35  Because folate acts as a methyl donor that is necessary to 
initiate and regulate DNA methylation processes, it is possible that a woman’s folate status during 
pregnancy may modify impacts from particulate matter, and that women with low folate levels may 
be especially vulnerable to the impacts of air pollutants.36  To date, no studies have examined the 
role of folate as a potential modifier in the relationship between particulate matter and birth 
defects, as most studies utilizing administrative databases lack detailed nutrition information. 
The goal of this dissertation is to utilize the National Birth Defects Prevention Study 
(NBDPS), a large population-based national case-control study of birth defects with detailed 
residential history, nutrition and other covariate information in order to investigate the relationships 
between maternal exposure to criteria air pollutants during pregnancy and CHDs.  The specific aims 
are: 
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Specific Aim 1:  To determine whether exposure during pregnancy to individual criteria air 
pollutants, assessed using measurements from stationary air monitors, is associated with CHDs  
Subaim 1a:  To determine if the relationship between exposure to PM2.5 and CHDs is 
modified by use of folic-acid supplements early in pregnancy 
Subaim 1b:  To explore the effect of multiple pollutants on CHDs using principal components 
analysis (PCA) 
Specific Aim 2:  To utilize the greater spatial and temporal resolution of exposure estimates derived 
from deterministic pollutant simulation models to investigate the association between select criteria 
air pollutants and CHDs 
Subaim 2a: To compare effect estimates and model fit when using monitoring data and 
output from a statistical model which combines the two in order to assign women’s 
exposure during pregnancy 
Subaim 2b: To determine if the addition of rural populations, who are often excluded from 
studies due to large distance from monitoring sites, affects the observed relationship 
between exposure to criteria air pollutants and CHDs 
 
Specific Aim 1 will be accomplished by linking data from the NBDPS to measured ambient 
levels of criteria air pollutants obtained from EPA’s repository of air quality monitoring data, known 
as the air quality system (AQS).  Specific Aim 2 will focus on PM2.5 and ozone and will utilize modeled 
exposure estimates derived from the EPA’s community multiscale air quality (CMAQ) model, a 
deterministic pollutant simulation model, as well as a downscaler spatiotemporal statistical model 
which combines the gridded cell predictions of CMAQ with monitoring data to point locations.28   
  
CHAPTER 2 
 
2. BACKGROUND 
 
2.1   Ambient Air Pollution 
Ambient air pollutants are any solid, liquid, or gaseous substance found in the outdoor air, 
resulting from either natural or man-made processes.  For centuries, there has been concern over 
the impact of contaminants in the air on the health of exposed populations.  As far back as the 18th 
century, Bernardo Ramazzini discussed in his treatise De Morbis Artificum the case of a 
manufacturing plant in a small town outside of Modena where “fumes given off by the vitriol which 
so tainted the air nearby that it was rendered unhealthy and dangerous for the lungs”.37  In 1931, 
the New York Academy of Medicine published its first report on the effect of air pollution on health, 
concluding that the air pollution problem in New York City and other cities was a “serious menace to 
health”.38 Two decades later, following the Great Smog of London in 1952, the U.S. federal 
government began to address the issue by passing the Air Pollution Control Act of 1955, which 
provided federal monies for air pollution research.39  In 1963, the first Clean Air Act was passed, 
which provided funds and authorization for federal research into air pollution monitoring and 
control.  A few years later, the Air Quality Act of 1967 expanded monitoring studies and began to 
regulate interstate air pollution transport.  However, it was the Clean Air Act of 1970 that created 
specific federal and state regulations designed to limit pollutant emissions and to expand 
enforcement of these regulations.39  The Clean Air Act focused on the monitoring and regulation of 
six ubiquitous pollutants which were linked to harmful effects on human health.  These pollutants  
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known as the criteria air pollutants are: carbon monoxide (CO), lead, nitrogen oxides (NOx) with a 
particular focus on nitrogen dioxide (NO2), ozone (O3), particulate matter (PM) of different sizes, and 
sulfur dioxide (SO2).   The National Ambient Air Quality Standards (NAAQS) for these pollutants are 
provided in Table 1.40 
 
Table 2.1: Current National Ambient Air Quality Standards for the Criteria Air Pollutants 
 Primary Standard Secondary Standard 
Pollutant Level Averaging Time Level Averaging Time 
Carbon Monoxide 9 ppm (10 mg/m
3
) 8-hour
┼
 None 
35 ppm (40 mg/m
3
) 1-hour
┼
  
Lead  0.15 µg/m
3
  Rolling 3-Month 
Average 
Same as Primary 
Nitrogen Dioxide 53 ppb  Annual  Same as Primary 
100 ppb 1-hour± None 
PM10 150 µg/m
3
 24-hour
€
 Same as Primary 
PM2.5 12.0 µg/m
3
 Annual  (averaged over 
3 years) 
Same as Primary 
35 µg/m
3
 24-hour± Same as Primary 
Ozone 0.075 ppm  
(2008 std)  
8-hour 
¥
 Same as Primary 
0.08 ppm  
(1997 std)  
8-hour
¥
  Same as Primary 
0.12 ppm 1-hour  Same as Primary 
Sulfur Dioxide 0.03 ppm  Annual  0.5 ppm 3-hour
┼
 
0.14 ppm 24-hour
┼
   
75 ppb  1-hour None 
*reproduced from  http://www.epa.gov/air/criteria.html; primary standards are defined as limits to protect public health, 
while secondary standards set limits to protect public welfare, which includes protecting damage to animals, crops, 
vegetation, and buildings   
┼
 cannot be exceeded more than once per year 
±the 3-year average of the 98th percentile at each monitor within an area cannot exceed the limit 
€ 
cannot be exceeded on average more than once per year over a 3 –year period 
¥3-year average of the fourth-highest daily maximum 8-hour average 
 
As a result of increased monitoring and regulation mandated by the Clean Air Act of 1970 
and its subsequent amendments, the concentration of pollutants in air has greatly diminished.41  
Despite these improvements, there are many areas of the US which remain in non-attainment of the 
NAAQS standards.  Additionally, research indicates that these pollutants may have health effects 
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below current regulatory levels, particularly among vulnerable populations such as the elderly, children, 
asthmatics, people with preexisting heart conditions, pregnant women and developing fetuses.42,43  The 
extensive monitoring system begun to oversee compliance with the Clean Air Act provides a valuable 
resource for air pollution epidemiology and public health research, as the availability of exposure 
estimates for the entire United States greatly facilitates human health studies into the effects of the 
criteria air pollutants. 
2.1.1 Criteria Air Pollutants 
As a result of the Clean Air Act and changes in motor vehicle and industrial technologies, the 
ambient air concentration of all of the criteria air pollutants has decreased.  However, since the 
reduction and eventual removal of lead from gasoline, the concentration of lead in the air has dropped 
more than any other pollutant.  From 1980-2009, the amount of lead found in ambient air has dropped, 
on average, 93%.44  Subsequently, the primary route of exposure to lead is through dust and soils, and 
not inhalation of ambient air.  Therefore, lead will not be included in this study of criteria air pollutants 
and birth outcomes.  Below is a brief description of each of the criteria air pollutants, including 
information about sources, variability, and general toxicity.  More detailed information on potential 
mechanisms for their action on reproductive and birth outcomes are included in Section 2.1.1.6. 
 2.1.1.1 Carbon Monoxide (CO) 
Description and Sources 
Carbon monoxide is a colorless, odorless gas emitted from incomplete combustion of 
organic materials.  The EPA estimates that 95% of CO emissions in the US are from man-made 
sources, with more than two-thirds resulting from motor vehicle emissions.45  Since the late 
1970s when motor vehicles became equipped with catalytic convertors, which convert CO into 
carbon dioxide, the levels of CO in ambient air have been greatly reduced, approximately 80% 
since 1980. Subsequently, the ability for ambient CO to be used as a marker for exposure to 
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motor vehicle traffic has been diminished.  People are also exposed to CO through use of 
tobacco products and exposure to environmental tobacco smoke.   
Temporal and geographic variability 
CO is highest in late winter, when weather inversions trap ambient air pollutants closer 
to the earth’s surface.  Daily patterns in CO levels follow the use of motor vehicles, with highest 
levels corresponding to morning and early evening rush hours.  Ambient levels tend to be 
greater at higher altitude, and are also greater in urban areas, corresponding to greater 
amounts of motor vehicle use.45   
Toxicity 
CO primarily acts by displacing oxygen and binding with hemoglobin in the blood to 
form carboxyhemoglobin.  This reduces the oxygen-carrying ability of the blood and the amount 
of oxygen transported to tissues and organs, with the degree dependent upon the amount of CO 
exposure.  High exposures of CO can lead to severe tissue hypoxia.   Exposures to CO from the 
ambient air and/or exposure to tobacco smoke are generally lower than the level associated 
with severe toxicity, but have been shown to cause more subtle hypoxic effects.  Additionally, 
CO can bind with heme in proteins in other areas of the body, including myoglobin in muscle 
tissue, certain transcription factors, and in proteins involved in physiological regulatory 
processes that may utilize endogenous CO.  It is hypothesized that exposure to exogenous CO 
may disrupt these regulatory processes, which include nitric oxide cell-signaling pathways, 
energy metabolism, and mitochondrial respiration.45  
2.1.1.2 Nitrogen Dioxides (NO2) 
Description and Sources 
Nitrogen dioxide is also a gaseous pollutant produced through combustion processes, 
often with nitrogen oxide (NO) and other oxidized nitrogen compounds.  In conjunction with 
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volatile organic compounds and hydrocarbons, NO2 is a precursor for ozone formation, as well as 
other air toxics including nitro-PAHs, which are formed either directly through combustion of 
fuels or in the atmosphere.  NO2 also contributes to the acidification of particulate matter in the 
ambient air.  While the relative contribution of sources can vary by local area, the primary 
sources of NO2 are motor vehicles and electricity generation.
46   
 Temporal and Geographic Variability 
Similar to other air pollutants, NO2 is higher in winter due to weather inversions and 
tends to fluctuate according to periods of high motor vehicle use.  Ambient levels of NO2 often 
peak during morning rush hour and tends to be higher in urban areas, particularly in the 
Northeastern United States.46 
 Toxicity 
NO2 is highly water soluble, and when inhaled, reacts with moisture in the airways to 
produce nitric acids, which irritate the airways.  Further, NO2 can react with unsaturated fatty 
acids in the body, initiating the production of free radicals, which can cause protein oxidation, 
lipid peroxidation, and cell membrane damage.  At high exposures, NO2 will displace oxygen and 
bind with hemoglobin in the blood stream to form methemoglobin, which can lead to hypoxia.46  
2.1.1.3 Ozone (O3) 
Description and Sources 
Ozone is a secondary pollutant.  It is formed from atmospheric reactions involving 
sunlight and other air pollutants and is not directly emitted from a mobile or fixed source.   The 
two primary classes of ozone precursors are NOx and VOCs.   As discussed above, the primary 
source of atmospheric NOx is motor vehicle exhaust, while the primary source of VOCs is solvent 
use, followed closely by on-road vehicles.47 
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Temporal and Geographic Variability 
Because ozone forms as a result of photochemical reactions in the atmosphere, ambient 
levels tend to be higher in summer when sunlight is greater and in the mid-afternoon, when 
enough time as passed for the reactions to take place.  In many areas of the United States, 
ozone isn’t monitored in the winter months.  Similar to other pollutants, ambient ozone levels 
are higher in urban areas, but geographically tend to be greater in the warm areas of the West 
and Southwest, as opposed to the Northeast.47 
 Toxicity 
Ozone is a highly reactive gas and, similar to NO2, its main method of action is through 
oxidation, particularly of unsaturated fatty acids in the extracellular lining fluid of the respiratory 
tract.  Ozone-mediated oxidation reactions generate free radicals, which can then react to form 
cytotoxic nonradicals.  The byproducts of these reactions may provide the mechanism for non-
pulmonary health effects by initiating/propagating inflammatory effects or increasing oxidative 
stress.47 
2.1.1.4 Particulate Matter (PM) 
Description and Sources 
Particulate matter (PM) refers to a heterogeneous mixture of solid and liquid particles 
that can vary in size, shape and composition based on their source.  Classified by particle 
diameter, the most commonly monitored and investigated classes are PM10 and PM2.5.  The 
subscript refers to the diameter size of the particles included in the grouping.  Often PM10 is 
used to refer to PM10-2.5 which includes particles with diameters between 2.5 and 10 microns in 
diameter.  This is often referred to as coarse PM.  PM2.5 is referred to as fine PM, while 
particulates with diameter less than 0.1 microns are designated as ultrafine.  Primary 
particulates result from a specific source, while secondary particles are created through the 
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oxidation of pollutant gases.   Coarse PM is more likely to consist of primary particulates.  The 
predominant source of primary PM10 is road dust, while the predominant source of primary 
PM2.5 is wild fires, followed by road dust and electricity generation.  The majority of PM2.5 is 
secondary particles, formed through processes such as coagulation, where two small particles 
combine to form one, condensation, when gases combine to form a single particle or through 
nucleation where gases react to form products with very low vapor pressure and then undergo a 
phase change to create an ultrafine particle.  In addition to size, PM can be further classified by 
its primary chemical constituents.  The primary chemical species of PM2.5 investigated are 
sulfate, nitrate, organic carbon, elemental carbon, total carbon, and water-soluble metals.48   
 Temporal and geographic variability 
In general, PM peaks during cooler temperatures, although this varies based on 
geography and composition of the particles.  Certain chemical species of PM2.5 exhibit more 
seasonality than others.  For example, organic carbon particulates peak during the fall and 
winter in the western United States and between spring and fall in the southeastern United 
States, while elemental carbon is relatively stable.  Concentrations of sulfate in particulates peak 
during warmer temperatures when more oxidation of SO2 occurs.  In contrast, nitrate species 
peak during cooler temperatures when there is more temperature-driven partitioning and 
volatilization.  Both PM10 and PM2.5 peak twice during the day, once in the morning, 
corresponding to rush hour and the breakup of the overnight inversion layer and again starting 
during the evening rush hour and extending into the later evening hours corresponding to 
changes in atmospheric layers.   
Geographically, coarse PM is found in warmer, drier climates such as the West and 
Southwest while PM2.5 has higher ambient levels in the northeastern areas of the United States, 
particularly in urban areas.  There is also geographic variability among the different chemical 
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species of PM2.5.  In the eastern United States, sulfate is the most common component followed 
by organic carbon, while in the western part of the country, organic carbon is most prevalent.48   
 Toxicity 
Both its chemical composition and the surface characteristics of the particulate are 
thought to give PM oxidative potential, causing injury and inflammation within the respiratory 
cells.  It is also suggested that exposure to PM can indirectly cause inflammation by triggering a 
release of reactive oxidative species from respiratory cells.  These oxidative species can impact 
intracellular signaling pathway at low levels, while higher levels can lead to DNA damage and 
cellular toxicity.    It is hypothesized that pulmonary inflammation can lead to systemic 
inflammation through the release of cytokines, potentially explaining associations between PM 
and non-respiratory health effects.48  Additionally, previous research suggests that exposure to 
PM can change plasma viscosity and endothelial function.49  Recently, it has been hypothesized 
that PM may also play a role in promoting epigenetic changes, by reducing DNA methylation, 
which is involved in regulating cellular processes such as gene transcription, genomic imprinting, 
and chromosome stability.34 
2.1.1.5 Sulfur Dioxide (SO2)  
Description and sources 
SO2 is a gaseous pollutant whose primary source is electricity generation, followed by 
fossil fuel combustion and industrial processes.  Because of these sources, SO2 is generally 
thought of as a marker of regional pollution, as opposed to a pollutant like NO2 which is more a 
marker for local, motor vehicle pollution.  Volcanoes and wildfires can also contribute to SO2 in 
the ambient air, but to a much lower amount than processes related to human activity.50     
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Temporal and Geographic Variability 
There is no strong, seasonal trend for SO2 that is consistent across the United Dates.  
Levels are highly dependent upon prevailing winds.  Oxidation of SO2 is greater at higher 
temperatures, sometimes causing lower measured levels in the warmer months.  SO2 levels in 
the ambient air tend to peak mid-day, and reach their lowest levels overnight.  SO2 levels are 
higher in the Eastern United States, particularly the Mid-Atlantic and Northeastern sections.50  
Approximately 80% of SO2 emissions in the US come from the 31 states bordering or east of the 
Mississippi River.51 
Toxicity 
 Highly water-soluble, SO2 is absorbed by moisture in the nasal and respiratory tracts and 
can be broken down into bisulfites and sulfites, which get distributed throughout the body via 
the bloodstream.  Bisulfites can react with a number of biomolecules, including nucleic acids 
which can lead to mutational events.  Additionally, through autoxidation, bisulfites can generate 
free radicals which can be distributed systemically and are hypothesized to contribute to 
observed associations between SO2 exposure and cardiac events.
52 
2.1.1.6 Toxicity Specific to the Pre-and Perinatal Time Period 
General toxicity of the individual criteria air pollutants was summarized above.  The 
potential for developmental toxicity of these pollutants is not well characterized, but it is 
hypothesized that the developing organs and body systems of a fetus are particularly vulnerable 
to environmental insult.53   It is also possible that the relative dose received by the fetus may be 
different than what is received by maternal tissues following exposure.  For example, 
differences in maternal and fetal kinetics and hemoglobin binding affinity are thought to cause 
the measured concentration of carboxyhemoglobin to be 10-15% higher in the fetus than in the 
mother, following CO exposure.54    
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As described by Slama et al, air pollutants could directly impact the fetus, as they readily 
pass through the placenta, or the effects could be indirect, mediated by effects on the mother 
and/or the placenta.13  Some of these mechanisms include triggering epigenetic changes in the 
mother or the fetus, affecting maternal-fetal nutrient exchange through changes in plasma 
viscosity, endocrine disruption through alteration of the mother’s progesterone production (e.g. 
activation of the hypothalamic-pituitary-adrenal axis), direct disruption of organogenesis, and 
release of cytokines and induction of oxidative stress in the mother contributing to systemic 
inflammation in the fetus. There is also the possibility that air pollutants could impact the germ 
cells of either the mother or the father.  Proposed biological mechanisms are further discussed 
in Section 2.2.6 and 2.3.5.   
2.1.2 Methods of Exposure Assessment 
 Exposure to ambient air pollution can be assessed in multiple ways.  Personal air monitoring, 
where an individual wears a sampling device for a specified period of time, is the only method which 
directly measures an individual’s exposure to ambient air pollutants.  However, due to the cost and 
infeasibility of having large numbers of pregnant women reliably wear bulky air monitors, most large-
scale studies do not utilize this technology.  All other exposure assessment methods use some other 
measurement as a proxy for direct personal exposure.  Some methods directly measure ambient levels 
of pollutants at centralized locations and use that as a proxy of individual exposure, while others use 
sophisticated mathematical prediction models to estimate pollutant concentrations using knowledge of 
emissions and atmospheric chemistry.   Below, the different methods are briefly discussed, listed from 
the most crude method of assessment to the most complex.   
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2.1.2.1 Proximity-based 
Proximity-based measures use the distance from an individual’s location to a source of 
exposure as a proxy for an individual’s exposure to air pollution.  There is no direct 
measurement or estimation of air pollutant concentrations in the ambient air.  This method is 
often utilized in studies examining motor vehicle traffic, with exposure assessed as distance to a 
primary roadway.  It has also been used in studies which examine fixed sources of pollutants 
such as industrial operations or power plants.  This method is easy to implement, but is subject 
to high levels of misclassification.55  It is grounded in the assumption of isotropic dispersion, that 
pollutants will disperse from the emission source equally in all directions.  This assumption often 
does not hold for air pollutants due to wind direction and atmospheric reactions between 
pollutants from different sources.  While there are techniques to deal with incorporating 
distance to multiple sources, they are often not complete, leaving the potential for unaccounted 
sources of exposure.  Additionally, interpreting findings based on these proximity measures can 
be difficult since it is often unclear how much of each pollutant were emitted by the source.55     
2.1.2.2 Emissions Inventories 
Emissions inventories are source-specific, comprehensive listings of air pollutant 
emissions for a defined geographic area, during a specified period of time.  In the United States, 
they are often compiled at the state and/or local level and then submitted to the Environmental 
Protection Agency for inclusion in the National Emissions Inventory database.56  Again, pollutant 
concentrations are not directly measured, but emissions of specific pollutants are reported for 
different pollution sources.  Currently, the EPA mandates reporting the emissions of criteria air 
pollutants, while emissions of hazardous air pollutants and greenhouse gases can be submitted 
on a voluntary basis by the states and local agencies. The pollutant sources which are 
inventoried fit into the following categories: 
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Facility/point sources: large, fixed sources of pollutants that are mandated to report 
their emissions of individual pollutants directly to the state/local agencies.  These often 
include large industrial facilities, power plants, etc.   
Area/Non-point sources:  smaller, fixed sources of pollutants that are either too 
numerous, too small, or to impractical to mandate individual reporting of emissions.  
Instead, emissions from these sources are reported in the aggregate.  Non-point sources 
could include dry cleaners, commercial solvent use within a specified county, etc. 
Onroad/Non-road : motor vehicles and off-road vehicles, engines and equipment used 
for construction and other activities.  The emissions from these sources are estimated, 
often at the county level by a local or state agency, and reported in aggregate. 
Events: sudden or unexpected events that emit pollutants into the atmosphere.  
Examples would be wildfires, natural disasters, etc.  These are reported as necessary by 
the state and local agencies. 
Biogenic:  naturally occurring emissions.  These are not reported, but are directly 
estimated by the EPA and then included in the NEI. 
Data from the NEI are publicly available, and relatively consistent for all regions of the United 
States.  Additionally, these emissions have been reported and recorded for many years allowing 
for historical examination of emission trends.  The smallest level of aggregation though is often 
the county level.  This can make obtaining a proxy for individual exposure difficult, as all people 
within the same county would have the same assigned exposure.  It can also be difficult to 
assess temporal differences in exposure as the emissions are usually reported as an annual 
average.56     
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2.1.2.3 Measurements at Centralized Ambient Air Monitors  
This method directly measures concentrations of air pollutants in samples of the 
ambient air.  Air monitors are often stationary as part of a fixed monitoring network, but they 
can be mobile or set up by an individual investigator or agency for a specific purpose.  Because 
the Clean Air Act mandated that every state establish a network of air monitoring stations for 
criteria air pollutants, measurements from these centralized, stationary air monitors are often 
utilized in air pollution epidemiology.  The monitors in this network are called the State and 
Local Air Monitoring Stations (SLAMS) and the data from these stations is reported to and 
compiled by EPA.  There are other national air-monitoring networks including the National Air 
Monitoring Stations , the Special Purpose Monitors ,  and the Photochemical Assessment 
Monitoring Stations which supplement the SLAMS network.57  To ensure that measurements 
taken in different states and local areas are consistent across the United States, the EPA has 
published detailed reference and equivalent methods to measure the concentrations of specific 
air pollutants in the ambient air that must be used by the SLAMS.58    General descriptions of the 
most commonly used methods for each criteria pollutant are briefly described below: 
Carbon Monoxide:  A sample of ambient air is drawn into a chamber where it is exposed to a 
beam of infrared light while a chamber with no ambient air contains another beam of 
infrared light.  Because CO absorbs infrared radiation, measuring the decrease in intensity of 
the beam exposed to the ambient air corresponds to the CO concentration of the sampled 
air.59   
Nitrogen Dioxide: Nitric oxide (NO) reacts with ozone to produce light at wavelengths 
greater than 600nm.  NO2 is measured by comparing the intensity of light produced when 
NO2 in ambient air is first converted into NO and then reacted with ozone to the intensity of 
light produced when ambient air is reacted with ozone, without converting the NO2 to NO.
60     
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Ozone: Ozone absorbs UV light at wavelengths of 254nm.  Using this knowledge, a 
photometric method to measure ozone concentration is utilized by comparing the 
absorption of an ambient air sample to an ambient air sample where the ozone has been 
reduced to molecular oxygen.61   
Particulate Matter: Air samplers draw ambient air into a specially-shaped inlet and through 
a particle size separator, after which particles of the specified size are deposited onto a 
filter.  The filter is then weighed and the mass of the particles is the difference between that 
weight and the weight of the filter alone.  The concentration is expressed as the measured 
mass of the particles divided by the total amount of air that was sampled.  Special monitors 
with three separate filters are used to measure the different chemical species of PM2.5.  The 
filters are sent to a centralized laboratory and particles on the Teflon filter are used to 
assess total mass and the presence of elements/metals.  The nylon filter is analyzed using 
filter extraction and ion chromatography for anions (e.g. sulfate, nitrate) and cations (e.g. 
potassium, sodium), while the quartz filter is analyzed for organic and elemental carbon 
using a thermal optical transmittance method.62   
Sulfur Dioxide:  When SO2 reacts with ultraviolet (UV) energy, it emits light of a specific 
wavelength.  SO2 in air is measured by passing a sample of ambient air into a chamber 
where it reacts with UV energy and the light emitted is measured and used to calculate the 
SO2 concentration.
63 
Often, the measurements taken at the air monitor closest to an individual’s location, 
usually the location of residence at a specified point in time, will be used to assign exposure.  
This may provide a good exposure proxy where individuals live close to a monitor, but may be 
less appropriate in rural areas where monitors may be very far from an individual’s location.  
Additionally, using the single closest monitor does not account for wind, topography, and other 
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factors that may influence air concentrations at the individual’s location, nor does it account for 
measurements taken at other monitors that may also be in close proximity or in a more relevant 
geographical position (i.e. upwind as opposed to downwind of an individual’s location).   
2.1.2.4 Geostatistical Models using Monitoring Data 
Using measurements taken at centralized air monitors, geostatistical models estimate 
ambient levels of pollutants at locations between monitors using interpolation techniques.  The 
most common technique is called kriging and it examines spatial patterns in the measurements 
taken at multiple monitoring stations in order to model the variation and estimate pollutant 
levels, with corresponding standard errors, at other locations of interest.  These models are 
most effective when there is a dense, evenly-distributed network of monitors, which is often not 
in the case in suburban and rural areas.  Additionally, these methods may not reflect local 
sources of pollutants since they are dependent upon the available monitoring data at distant 
points.  Similar to measurements taken at the closest monitor, exposure estimates obtained by 
kriging do not incorporate wind, topography, secondary atmospheric reactions, and other 
factors that could influence ambient levels of pollutants at an individual’s location.55,64 
2.1.2.5 Land Use Regression Models 
Land use regression models (LURs) utilize topography and land use characteristics in 
their estimation of ambient pollutant levels at non-measured locations.  An LUR uses 
measurements obtained from a network of air monitoring stations as a dependent variable and 
land use variables such as traffic counts, road networks, topography, meteorology, and 
proximity to industrial sources as the independent variables in order to estimate parameters 
that can be applied to locations without monitoring stations, in order to predict pollutant 
concentrations.  While generally successful in studying intraurban pollutant levels, these models 
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are often limited to studies of smaller geographic areas, due to the density of the air monitoring 
network and level of detailed information on other factors needed for its implementation.  
Additionally, the model often has limited generalizability and cannot be applied to areas with 
different land characteristics or pollutant sources, restricting its use to small areas very similar 
to where the model was originally developed.65   
 2.1.2.6 Deterministic Prediction Models 
Rather than using measurements taken at centralized fixed monitors as the basis for 
interpolating or predicting ambient pollutant levels at non-monitored locations, deterministic 
prediction models utilize information on emissions, fate-transport of pollutants, atmospheric 
chemistry and production of secondary pollutants, and meteorology in order to predict a 
pollutant concentration surface for a specified geographic area.  The simplest form of this 
model, a dispersion model, is based on Gaussian plume equations which are used to represent 
how pollutants are generated and transported in the ambient air.64  Integrated meteorological-
emissions models, another deterministic numerical-based model, utilizes those same multiple 
sources of data but then mathematically simulates the dynamic processes that occur in the 
atmosphere in order to predict pollutant concentration surfaces.55  The EPA’s Community Multi-
scale Air Quality (CMAQ) model is an example of an integration meteorological-emissions model 
and will be discussed in more detail in Section 3.2.2.2.66  In order to improve pollutant 
prediction, models which combine the numerical output from the simulation models with 
monitoring data through hierarchical Bayesian techniques have also been developed.67  One 
example of this hierarchical, spatiotemporal model which utilizes output from the EPA’s CMAQ 
model is discussed in more detail in Section 3.2.2.2.  Although deterministic prediction models 
are computationally more intensive, they utilize much more available information to model how 
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pollutants are distributed in the ambient air, providing a more accurate proxy estimation of 
exposure at an individual’s location. 
2.1.2.7 Probabilistic Exposure Models 
While the deterministic models described above utilize large amounts of data to predict 
ambient levels of pollutants in the ambient air, they do not account for human activity, time-
spent indoors, and other factors that can lead to misclassification when ambient estimates are 
used as proxy exposures for an individual.  Probabilistic exposure models attempt to incorporate 
human activity into pollutant exposure models by simulating the population’s exposure as they 
move through multiple microenvironments during their daily life.68    Data on individual activities 
that are incorporated into the models comes from detailed diaries kept my people living within 
the area the model is being developed.  Because they are estimating population exposures on 
an aggregate level such as census block or block group, the outputs from these models yield a 
range of exposures or an estimated percentage of residents in a given area who are above a 
certain exposure.69  Because they do not output a single exposure estimate that can be applied 
to an individual, their utility in epidemiologic studies of etiologic disease-exposure relationships 
are somewhat limited. 
 
 It should be noted that in addition to the measured and/or predicted ambient levels of 
pollutants described above, there are biological measures which reflect exposure to air pollutants.  
Previous studies have utilized urinary measurements of gasoline additives, concentrations of polycyclic 
aromatic hydrocarbons (PAH) DNA-adducts in plasma, and other biological markers of exposure 
measured in sputum, urine, and/or blood in order to investigate the impact of air pollution on health 
outcomes.12,70-72  However, for many of these markers, multiple collections would be necessary, as it is 
unclear how reflective of exposure during pregnancy a single measurement might be.  Additionally, due 
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to the large expense of collecting and analyzing biospecimens, they have not been utilized in large-scale 
studies.   
2.2 Congenital heart defects 
2.2.1 Definition and Diagnosis 
Congenital heart defects (CHDs), also referred to as cardiac birth defects or congenital heart 
disease, are generally defined as any abnormality in the structure and/or function of the heart or great 
vessels, which is present at birth.  This definition results in a heterogeneous group of defects that vary 
anatomically, embryologically, in severity, and, potentially in etiologic risk factors.73  Depending upon 
the classification system used, there can be over 30 distinct groups of CHDs, with each group potentially 
containing defects of slightly varying phenotype and/or combinations of multiple defects.  CHDs can be 
diagnosed prenatally using a fetal echocardiogram or after the infant is born using other imaging and 
diagnostic technologies, such as echocardiograms, electrocardiograms, chest X-rays, MRIs and CT scans.  
If a defect is not detected during prenatal screening, usually only defects that cause symptoms in the 
infant will be detected and diagnosed.  These symptoms include irregular heartbeats, irregular 
breathing, poor weight gain, swelling of the extremities, and cyanosis.73 
2.2.2 Prevalence, Morbidity and Mortality  
Birth defects occur in 1 in 33 live-births in the United States annually.  Of these, CHDs are the most 
common group, with birth prevalence estimates ranging from 4 to 14 per 1,000 live-births.73  Reviewing 
44 studies of the prevalence of CHDs, Hoffman et al estimated the median birth prevalence of CHDs to 
be approximately 7.7 per 1000 live-births.74  The authors concluded that variability in estimates tended 
to be dependent upon how the birth defect cases were ascertained (i.e. intensive active-monitoring 
programs vs. use of defect reporting in administrative databases) and the inclusion of more prevalent, 
but minor defects, such as small ventricular septal defects (VSDs), in later studies which have been more 
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easily diagnosed with newer technologies.  They noted that the birth-prevalence of more severe forms 
of CHDs was relatively stable at 1.3 per 1000 live-births.74  Studies published since the Hoffman review 
have been consistent with these findings.  Two studies in the US, one in Atlanta75 and one in California76, 
had differing overall prevalence of CHDs, 6.2 vs. 3.2 per 1000 live-births respectively, but found the 
same prevalence of severe defects at 1.3 per 1000 live births.  The study in Atlanta had similar findings 
to a consortium study in Europe, which observed an overall prevalence of 6.6 per 1000 live-births and a 
prevalence of 1.3 per 1000 live births for severe defects.77  Other studies in France, Sweden, and Taiwan 
had similar prevalence estimates for severe CHDs.73   
It should be noted that birth-prevalence is defined as the number of infants with diagnosed CHDs 
divided by the total number of live-births during a given time period.  Because CHDs can cause 
spontaneous abortions, stillbirths or lead to elective terminations, some studies include fetal deaths 
after 20 weeks due to a cardiac birth defect and elective terminations due to a cardiac birth defect in the 
calculation.  But elective termination data are sometimes not available.  Some studies have tried to 
quantify the impact of missing data on elective terminations, but have found considerable variability in 
the effect on estimates.78,79  Differences in these impacts are dependent upon the utilization of prenatal 
diagnosis and elective terminations of fetuses with defects.80  It can be difficult to estimate the impact of 
elective terminations for single, isolated CHDs.  A study in Atlanta found that 8% of pregnancies with 
fetuses with prenatally diagnosed defects were electively terminated.81  However, that figure included 
all CHDs.  CHDs are more prevalent in fetuses with chromosomal abnormalities like trisomy, and the 
termination rate among those fetuses has been increasing and tends to vary by population.82,83  The 
termination rate among single, isolated CHDs is likely lower.  
 The contribution of CHDs to early, spontaneous fetal loss, before 20 weeks, is not well understood 
and thus calculations of incidence are not feasible due to difficulty in determining total number of 
pregnancies at risk and ascertainment of defects at early stages of pregnancy.  It is hypothesized that  
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severe CHDs may be more prevalent among early fetal losses, causing an underestimation of the true 
incidence of defects when examining only late fetal loss and live-births.73  Although all defects are 
present at birth, the majority of CHDs are not diagnosed prenatally and some diagnoses are delayed 
until many months after birth, when they begin to affect the infant’s breathing and growth.  This 
delayed diagnosis is more common among defects such as ASDs and VSDs, which may result in minor or 
no symptoms.  Rarely, minor defects can be undiagnosed well into adulthood.  
Table 2.2: Typical fetal cardiac development by week of pregnancy, measured from conception 
 
In addition to being the most common group of birth defects, CHDs are also the leading cause of 
birth-defect related death.  The age-standardized mortality rate for cardiac birth defect related deaths in 
the US from 1999-2006 was 1.78 per 100,000.84 There have not been very many long-term follow-up 
studies among infants born with birth defects to examine long-term prognosis and mortality.  Within the 
Texas Birth Defects Registry from 1996-2003, it was observed that 8% of infants born with a cardiac 
birth defect died within the first year of life.85  Nationally, it is estimated that about half of cardiac-
defect related deaths occur during the first-year of life, with approximately 70% of those occurring 
Week Cardiac Developmental Events 
3 Endocardial tubes form from cells in the cardiogenic plate and move toward each other, eventually 
fusing to form a single heart tube with separate “sections” that will form the chambers of the heart.  
The heart tube than moves into the thoracic region.  
4 Fusion of the endocardial tubes is complete, and the heart begins to beat.  Pericardial cavity is formed.  
Heart tube begins to grow and fold upon itself, creating the positions and early structures of the fetal 
heart.  Ventricles begin to dilate.  The pulmonary artery begins to form on the left wall of the atrium. 
The endocardial cushions appear/form the atrioventricular canal. 
5 The truncal swellings, which will eventually form the septum in the outflow tract that contributes to 
the formation of the aorta and pulmonary trunk, begin to form.  The partitioning of the atrium begins.  
The ostium (foramen) secundum, forms.   
6 The foramen ovale forms and establishes the primary path of the fetal circulatory system.  Endocardial 
cushions begin fuse to partition the atrioventricular canal and eventually form the mitral and tricuspid 
valves. 
7 The growth of the ventricles is completed, and the ventricular septum, which divides the two 
ventricles, stops growing.  The coronary sinus is formed.   
8 The aorta and pulmonary trunk are completely separated. 
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during the neonatal period (<28 days post-birth).  In the US, 4.2% of all neonatal deaths have a cardiac 
birth defect listed as the underlying cause.86  Among infants who survive the first year of life, 76% of 
birth-defect related mortality occurs in adulthood.84  Improvements in surgical interventions and 
treatments have greatly improved prognosis, and the mortality rates of CHDs have been decreasing 
among all age-groups.84,87  Currently there are 1.4 million children and adults living in the US who were 
diagnosed with a cardiac birth defect.  Even after corrective surgery and/or medication regimens, many 
people born with a CHD will have physical limitations and ongoing complications throughout their 
lifetime.  Some of these complications include infectious endocarditis, arrhythmias, reoperations on 
their defects, heart failure, and in rare cases pulmonary hypertension.73  Additionally, women with CHDs 
are more likely to have pregnancy complications, including having a child with a CHD.88 
2.2.3 Cardiac Development and Relevant Time 
Periods of Exposure 
CHDs result from alterations from normal 
heart development, which occurs during weeks 3 
through 8 of pregnancy.  Cardiac development in a 
typically developing embryo is summarized, by 
week of pregnancy, in Table 2.2.89   
Following week 8, the heart’s development is 
mainly complete, and it continues to grow in size 
along with the fetus.    However, fetal circulation is different than circulation following birth (Figure 2.1).  
In typical human circulation, blood enters the heart from the body through the right atrium, travels into 
the right ventricle and then into the pulmonary artery where it receives oxygen from the lungs.  The 
pulmonary vein carries oxygen-rich blood to the left atrium, where it enters the left ventricle and is then 
pumped out to the tissues of the body.  During fetal life, oxygen is delivered from the mother to the 
Figure 2.1: Fetal Heart Circulation  
http://www.merckmanuals.com/home/sec23/ch265
/ch265b.html 
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fetus through the placenta and umbilical cord.  Because the fetal lungs are not in use, temporary fetal 
structures, the foramen ovale and the ductus arteriousus, shunt blood away from the pulmonary 
circulatory system.  The foramen ovale allows blood to pass directly from the right atrium to the left 
atrium, bypassing the right ventricle where it would normally be sent to the pulmonary artery.  The 
ductus arteriousus connects the pulmonary artery directly to the aorta, shunting any blood that didn’t 
pass through the foramen ovale away from the lungs.  Once the fetus is born and takes his/her first 
breath, pressure changes cause these two structures to close and blood to flow through the pulmonary 
circulatory system, ensuring oxygen-carbon dioxide exchange.  Many CHDs impact the infant by shunting 
blood within the heart in a way that reduces oxygenation of the body organs and tissues.90                                                                    
Most studies of CHDs focus on exposures only during the first 2 months of pregnancy, when the 
structure of the fetal heart is developing.  However, because of the potential for epigenetic changes in 
either the mother and/or the germ cells to contribute to the development of CHDs, exposures prior to 
pregnancy may also be relevant.13 Additionally, insults in late pregnancy can impact the normal closure 
of remnants of the fetal circulation system.  For example, ibuprofen taken in the 3rd trimester has been 
shown to cause premature closure of the ductus arteriousus.73  Whether certain late-pregnancy insults 
can prevent closure has not been examined.   
As stated above, defects occur when these developmental events fail to proceed and/or complete 
properly.  In the following section, details on individual defects, including formation and resulting 
morbidity are described. 
2.2.4 Classification and Description of CHDs 
 As written above, CHDs are a heterogeneous group of defects.  Recently, an international 
collaborative committee, led by the Society for Thoracic Surgeons (STS), created a standard 
nomenclature of congenital heart surgery, which included 150 individual diagnoses, the majority of 
which were individual structural defects.91   In the clinical setting, CHDs are described using these 
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individual diagnoses.   On the population level, because there are so many different individual 
phenotypes, aggregation is required to ensure consistency for surveillance and research purposes, as 
well as to avoid extremely small sample sizes.  While there are classification schemes based on the 
clinical severity of the defects73 or on the pathogenetic mechanisms underlying the defects92, most are 
based on anatomical location of the defect.31,93,94  The International Classification for Diseases (ICD) 
codes have been used to classify CHDs94, although most surveillance programs in the US utilize the 
classification system developed by the British Pediatric Association93, which was subsequently modified 
by the Centers of Disease Control.  These BPA/CDC codes are more detailed than the ICD codes.  
Recently, the STS has developed a classification scheme based on the standardized nomenclature 
mentioned above.95  Although there are some differences between these classification schemes, they all 
utilize multiple levels of aggregation starting with categories broadly based on anatomy and/or 
developmental considerations, which are then further broken down into specific individual defects.   
Below, the broadest groupings of CHDs used by the STS classification system are listed and 
described.91,96  More detailed descriptions of some of the more common defects within those groups are 
also included.96  The National Birth Defects Prevention Study (NBDPS), the source of the data for this 
proposal, utilizes a different classification scheme that was created explicitly for the purposes of that 
study.97  Because the NBDPS excludes certain classes of defects, the STS groupings are more 
comprehensive for a general overview.  The NBDPS 
classification scheme will be described in detail in 
Section 3.2.1.3.   
2.2.4.1 Ventricular Septal Defects 
The most prevalent of the CHDs, 
ventricular septal defects (VSDs) are defects Figure 2.2: Ventricular Septal Defect  
http://www.merckmanuals.com/home/sec
23/ch265/ch265b.html#v815583 
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located in the wall, or septum, which separates the left and right ventricle.  VSDs are 
hypothesized to arise from abnormal folding of the heart during development.  As shown in 
Figure 2.2, this enables left-to-right shunting of blood within the heart, disrupting normal 
ventricular volume and pressure.  These defects range in size and severity, with smaller VSDs 
causing no symptoms and often closing on their own as the heart grows.  Larger VSDs can cause 
pulmonary hypertension and may require surgery.  VSDs can be further classified by where in 
the septum they are located: in the membranous section (the most common of the defects), in 
the muscle, in the subpulmonary outlet or in the 
inlet/atrioventricular section.  Only membranous and 
muscular VSDs are included in the VSD group heading.  
VSDs in the outlet are classified under the heading of 
conotruncal defects, and VSDs in the atrioventricular 
section are classified under the heading of atrioventricular 
septal defects.    
2.2.4.2 Atrial Septal Defects 
Atrial septal defects (ASDs) are another common defect, which are located in the 
septum which separates the left and right atrium (Figure 2.3).  Similar to VSDs, ASDs, can cause 
left-to-right shunting of blood.  They vary by size and severity, and small ASDs are often 
asymptomatic.  There are 3 types of ASDs:  ASD secundum (ASD2), ASD primum (ASD1), and ASD 
sinus venous.  ASD, primum is categorized as an atrioventricular septal defects since it involves 
the endocardial cushions.  ASD, sinus venous are included in the cell growth grouping of defects.  
ASD, secundum is the most prevalent ASD and is a defect within the middle of the septum, 
where the foramen ovale was located.  They result from inadequate growth of the septum 
secundum or too much reabsorption of the septum primum during development.   ASD, 
Figure 2.3:  Atrial Septal Defects  
http://www.merckmanuals.com/home/s
ec23/ch265/ch265b.html#v815583 
 secundums are not foramen ovales that failed to close after birth.  Those defects, called pat
foramen ovale, are not generally considered an ASD, but a separate defect.    
2.2.4.3 Atrioventricular Septal Defect
Previously known as endocardial cushion defects, 
atrioventricular septal defects arise when the two endocardial 
cushions fail to fuse properly with the atrial septum and/or 
ventricular septum during development.   These defects are 
actually a combination of multiple defects that involve the atrial 
and ventricular septums and the valves at their junctions.  AVSDs 
are further classified as partial, intermediate (or transitional), or complete depending mostly 
upon the degree of ventricular malformation.   
above as a defect in the anterior section of the atrial septum, either with or without a cleft 
located in the mitral valve.  The transitional AVSD also has a minor defect in the ventricular 
septum, while a complete AVSD has an ASD1, a VSD in the inlet, and abnormalities in the valves 
that separate the atria and ventricles.  The combination of an ASD1 and a VSD in the ventricular 
inlet results in a large, centralized defect which causes shunting of the blood that di
volume and pressure in all 4 chambers of the heart, causing the heart to become enlarged 
(Figure 2.4).  Due to abnormalities in the valves, blood can also flow “backwards” through the 
valves, also known as valve regurgitation.  These defects can be 
2.2.4.4 Conotruncal Defects 
Conotruncal defects are malformations concerning the outflow tracts of the heart, the 
portion of the ventricles that connect to the great arteries.  The most common conotruncal 
defect is Tetralogy of Fallot (TOF), a collection of 4 distinct malformations. 
2.5, TOF consists of a narrowing of the pulmonary valve, known as pulmonary stenosis, a 
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s 
A partial AVSD is an ASD primum, described 
corrected with surgery.
 As shown in Figure 
Figure 2.4: Complete 
Atrioventricular Septal Defe
http://www.childrensmn.org/
web/cardiovas/115292.asp
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thickening of the wall of the right ventricle, a displaced aorta that overlaps the right ventricle,  
and a VSD.  The pulmonary stenosis restricts the amount of blood 
that can flow out of the right ventricle, causing this blood to go 
into the left ventricle and into the displaced aorta.  In essence, 
the blood bypasses the pulmonary circulation and fails to become 
oxygenated.  This leads to cyanosis.  TOF requires surgical 
correction.  Transposition of the Great Arteries (TGA) is another 
common conotruncal defect where the placement of the aorta 
and the pulmonary artery are reversed, so oxygenated blood travels back and forth between the 
lungs and the heart, but is never pumped to the body tissues.  TGA must be surgically corrected 
within the first few days of life.   In a Double Outlet Right Ventricle (DORV) defect, the aorta is 
connected to the right ventricle, instead of the left ventricle.  DORV defects always occur with a 
VSD, which allows some oxygenated blood to enter the aorta, but still limits the oxygenation of 
body tissues.  Isolated VSDs of the outlet are also classified as conotruncal defects.   
2.2.4.5 Right Ventricle Outflow Tract Obstructions (RVOTO) 
This grouping contains defects which block or obstruct the boundary between the right 
ventricle and the pulmonary artery.  The defect can occur in the pulmonary valve, the 
supravalvar region, the upper part of the ventricle from which the pulmonary artery arises (the 
conus arteriousus), or in the pulmonary artery.  Described above, valvular pulmonary stenosis 
(PVS), the narrowing of the pulmonary valve, is the most common RVOTO defect. 
2.2.4.6 Left Ventricle Outflow Tract Obstructions (LVOTO) 
Similar to RVOTOS, LVOTOS block or obstruct the movement of blood through the left 
ventricle into the aorta, potentially reducing the oxygenation of the body’s organs and tissues.  
Figure 2.5: Tetralogy of Fallot  
http://www.bluebabysyndrome.org/93
/blue-baby-syndrome-
treatmenttetralogy-of-fallot/ 
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These defects occur in the aortic valve, or in the sub- or supravalvar region.  The most common 
LVOTO is coarctation of the aorta, a narrowing of the aorta at the ductus arteriousus (the fetal 
structure which connected the pulmonary artery to the aorta to bypass pulmonary circulation).  
Severity of this defect depends upon where the narrowing occurs, before or after the ductus 
arteriousus.  Hypoplastic left heart syndrome (HLHS) is a severe LVOTO defect where, because 
the ventricular region of the endocardial tube gets “pinched” during development, the left side 
of the heart is underdeveloped, including the aorta, the aortic valve, the left ventricle, and the 
mitral valve.  This defect causes the right side of the heart to be overworked.  Surgery is 
eventually required or it results in heart failure.  Similar to pulmonary stenosis, aortic stenosis is 
a narrowing of the aortic valve.      
2.2.4.7 Ebstein’s   
Ebstein’s anomaly is given its own category, even though it is one of the more rare 
defects.  Named after the German physician who first described the defect, Ebstein’s anomaly is 
a malformation in the tricuspid valve, the valve that separates the right atrium from the right 
ventricle.  When the valve is open in a normal heart, blood flows from the atrium into the 
ventricle.  The valve closes when the ventricle contracts to pump blood to the rest of the body.  
In Ebstein’s anomaly, the leaflets of the valve are located further in the ventricle, causing the 
atrium to be larger than normal and the ventricle to be smaller.  The malformed leaflets also 
allow blood to travel back from the ventricle into the atrium.  This defect can cause blood/fluid 
build-up in the left atrium and affects oxygenation of the blood and subsequently the body’s 
organs and tissues.  Less severe forms of this defect can be treated with medication, but more 
severe forms require surgery to repair the malformed valve. 
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2.2.4.8 Patent Ductus Arteriousus 
As described in a previous section, the ductus arteriousus is a fetal structure that allows 
the fetal circulation to bypass the lungs by connecting the pulmonary artery directly to the 
aorta.  Once an infant is born and the lungs fill with air, pressure changes cause the ductus 
arteriousus to close, usually within the first few days.  If it fails to close, the defect is known as 
patent ductus arteriousus (PDA) and, depending upon its size, can reduce the amount of blood 
that travels to the lungs to be oxygenated.  PDA is more common among infants born preterm, 
and usually will close on its own within 2 years in these infants.  Among term babies, a PDA that 
fails to close within a few days likely will require intervention if it causes symptoms.  
Medications, such as a specific form of ibuprofen, can cause the PDA to close. Otherwise, 
catheterization and sometimes surgery are required.  PDA that occurs in isolation in preterm 
babies is often excluded from structural defect studies, as it is hypothesized to be a result of 
being born preterm and not a developmental or structural defect in the heart.   
2.2.4.9 Cardiac Looping 
In the initial stages of cardiac development, the heart consists of endocardial tubes 
which fuse and form a single tube which then loops and folds on itself in order to create the 
cardiac structure and the position of the four chambers.  Defects that form as a result of an 
incorrect looping process are grouped together in this category.   The disruptions in looping can 
cause atrioventricular discordance defects, where the right ventricle is on the left side of the 
septum and the left ventricle is on the right.  Incorrect looping can also cause single ventricle 
defects, where only one ventricle is developed correctly. These defects are rare and very 
complex, almost always requiring surgery.  
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2.2.4.10 Heterotaxy  
These defects arise as part of the failure during development to establish typical left-
right differences in anatomy.  For example, one defect in this grouping, dextrocardia, is when 
the heart is located in the right side of the thorax.  The defects in this group are often complex, 
consisting of multiple malformations within the heart. 
2.2.4.11 Abnormal Cell-growth Defects  
Another grouping of rare defects, this group consists primarily of defects in the 
connections between the pulmonary veins and the left atrium.   If all four pulmonary veins are 
connected somewhere besides the left atrium, the defect is referred to as total anomalous 
pulmonary venous return (TAPVR).  If only some of the veins are connected into the wrong 
section of the heart, the defect is known as partial anomalous pulmonary venous return 
(PAPVR).  The result of this defect is a lack of oxygenated blood being distributed to the body.     
2.2.4.12 Cardiomyopathy   
Cardiomyopathy encompasses diseases of the muscle tissue in the heart.  Because it is 
not a structural defect, even though it can be present at birth, it is often not included in studies 
of CHDs. 
There are some individual defects and congenital heart diagnoses which do not fit into the 
above categories.  These defects are either very rare, usually occur in the presence of other defects and 
have little clinical significance when present alone, or include diagnoses, such as arrhythmias or 
aneurisms, that are not typically included in birth defect surveillance and research.     
Infants with CHDs can be further classified according to whether they are found in the presence 
of chromosomal abnormalities, or other non-cardiac defects.  Cases of birth defects can be referred to 
as “multiple” or “isolated” depending on the presence of other defects. The proportions of infants that 
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fall into these different categories tend to vary by study population.  A recent review of metropolitan 
Atlanta’s birth defects surveillance system from 1968-2005 found that, within their system, the majority 
of infants with a cardiac birth defect (71.3%) had no other congenital anomalies, while 13.5% had both 
cardiac and non-cardiac defects.98   Approximately 13% of CHDs occurred in conjunction with either a 
chromosomal abnormality or a recognized syndrome of defects, while 2% occurred in the presence of 
laterality defects, when the left-right orientation of the body is disrupted.98   Additionally, previous 
population-based studies found that even among infants with only CHDs, approximately 22% have more 
than one defect present.97   It should be noted some phenotypes, such as Tetralogy of Fallot or 
Hypoplastic Left Heart Syndrome, are classified as a single phenotype, even though they are a collection 
of different structural anomalies.   These different levels of complexity must be addressed in research of 
CHDs, since the etiology of a single, CHD is probably not the same as the etiology of that same defect, if 
it is accompanied by multiple other cardiac and non-cardiac defects within an infant. 
2.2.5 Risk Factors 
 Approximately 8-10% of all cases of CHDs are associated with a chromosomal abnormality.73  It 
is estimated that almost half of all children with Down syndrome, trisomy 21, have a CHD.99  
Additionally, another 3-5% of cases have single-gene disorders and syndromes.73  The remaining 
majority of cases have an unclear etiology, but previous research has identified certain risk factors for 
having a CHD, although most are not well-established.  Much of the previous research within the US is 
from state surveillance programs, the Baltimore-Washington Infant Study, a case-control study of birth 
defects conducted in the 1980s100, and the National Birth Defects Prevention Study101 (NBDPS), an 
ongoing population-based case-control study that is the source of the data for this proposal. The risk 
factors examined in previous research are summarized in Table 2.3.  Research on exposure to air 
pollutants and CHDs will be described in detail in Section 2.4.  Currently, maternal diabetes mellitus, 
maternal phenylketonuria, thalidomide exposure, exposure to retinoic acids, and maternal rubella are 
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the only well-established risk factors.73  For all other risk factors listed, the results from previous 
research have either been mixed, with some studies observing associations that are not replicated in 
subsequent studies, or have only been examined in one or two studies. 
 In addition to the risk factors listed below, there has been research into the genetic contributors 
to non-syndromic CHDs.  Single gene mutations have been linked to ASDs, TOF, TGS, VSDs, and bicuspid 
aortic valves.73  Researchers have also observed associations between common variants in the 
epidermal growth factor receptor signaling pathway and LVOTO102 defects and genes in the folate-
metabolizing pathway and conotruncal defects.103 
Table 2.3: Summary of Potential Risk Factors for Congenital Heart Defects 
Risk Factors Description of Association 
Demographic Factors  
 Infant Sex
104
 Males more likely to have severe defects such as HLHS, TGA 
 Maternal 
Race/Ethnicity
104,105
 
African-American mothers more likely than Whites to have TOF, PS, but lower 
VSD; Hispanic mothers less likely to have TOF, HLHS, ASD 
 Maternal Age
106,107
 Mothers greater than 39 years more likely to have Ebstein anomaly, VSD, ASD, 
TOF, PS, LVOTO, RVOTO  
 Paternal Age
108
 Older fathers (greater than 35 years) more likely to have RVOTO; among 
younger fathers, increasing risk of APVR, coarctation of the aorta that plateaus 
at older ages  
Socioeconomic Factors
109
 Measured via education and income; Lower SES associated with multiple 
defects; not many studies 
Maternal Diseases and Illnesses 
Diabetes
110,111
 Type 1 diabetes linked to multiple CHDs, strong associations with conotruncal 
defects; type1 or type2 linked with multiple defects 
Phenylketonuria
112
 Uncontrolled phenylketonuria associated with all defects, but most commonly 
with TOF, VSDs, PDA, and SV 
Rubella
73
 Associated with PDA, pulmonary valve abnormalities, VSDs and peripheral 
pulmonary stenosis 
Fever/Influenza
113
 Associations with PS, RVOTO, LVOTO, coarctation of the aorta,  
conotruncal defects, VSDs, and pulmonary atresia  
Epilepsy
114
 Associated with any heart defect; Unclear if it is epilepsy or medications used  
Obesity
115
 Increasing BMI associated with conotruncal and RVOTO  
Medications and Substance Use 
Thalidomide
73
 Known cardiac teratogen; associated with broad spectrum of defects 
 Retinoids
116
 Associated with Outflow Tract Defects 
Ibuprofen
117
 Associations with VSDs 
 Multivitamin w/folic acid
118-
120
 
Association between using multivitamin containing folic acid and lower 
prevalence of all CHDs; Also shown to reduce risk of CHDs in the presence of 
other risk factors 
Lithium
121,122
 Associated with Ebstein’s anomaly 
 SSRIs
123
 Associations with septal defects 
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Table 2.3 (cont.)  
Risk Factors Description of Association 
Tobacco Use
124-126
 Maternal Associated with multiple defects, but larger studies  have observed 
no associations 
Marijuana Use
127
 Associated with VSDs  
Alcohol Use
127,128
 Very high levels of drinking associated with VSDs and ASDs 
Environmental Factors  
Maternal Exposure to 
Solvents
129
 
Associated with multiple defects including conotruncal, HLHS, PS, aortic 
coarctation, TOF, ASD, TAPVR, Ebstein’s anomaly 
Maternal Exposure to 
Herbicides/Pesticides
103,129
 
Associated with conotruncals, TGA, TAPVR, and VSDs 
Air Pollution
5,8,16,22-24
 Associated with multiple defects, sometimes not replicated in subsequent 
studies; See Section 2.4 for more details 
2.2.6 Potential Biological Pathways for Air Pollutants to Contribute to CHDs 
Weeks 3 through 8 of pregnancy are hypothesized to be the relevant time periods of exposure for 
CHDs.   The mechanisms for how exposure to air pollutants during this critical time is not well 
understood.  Animal studies suggest that exposure to pollutants such as ozone, NO2 and CO can be 
embryotoxic, but they haven’t been associated directly with CHDs.23   It is possible that pathways which 
are hypothesized to impact fetal growth, such as pollutants causing increased viscosity of blood plasma 
and affecting maternal/fetal nutrition through the umbilical, could have a role in disrupting the growth 
and development of the cardiac structure.13   
Another potential biological pathway is through epigenetic changes.  Recent research by Chowdhury 
et al found associations between measures of maternal global DNA hypomethylation and CHDs.35  DNA 
methylation refers to the addition of a methyl group to the cytosine base on DNA.  Cells have a specific 
methylation pattern that encodes protein expression and is maintained during cell replication.  DNA 
methylation is associated with repressed gene expression, potentially by blocking promoters were 
transcription factors can bind.   Previous research has found that DNA hypomethylation contributes to 
chromosomal instability, altered gene expression, cellular differentiation, and apoptosis during 
embryogenesis.130  In a mouse model, disruption of DNA methylation was shown to cause exencephaly 
in treated mice131, and a recent epidemiologic study found associations between lower levels of DNA 
methylation and neural tube defects.132  Baccarelli et al have observed DNA hypomethylation after 
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exposure to particulate matter and black carbon, a measure of traffic pollutants.34  Thus, it is possible 
that exposure to pollutants early in pregnancy, may trigger DNA hypomethylation which disrupts normal 
cardiac development.  Because folate acts as a methyl donor, necessary to initiate and regulate DNA 
methylation processes, it is possible that a woman’s folate status at the beginning of her pregnancy may 
modify impacts from air pollution, and that women with low folate levels may be especially vulnerable 
to the impacts of air pollutants if this mechanism is true.36         
2.3 Previous Epidemiological Research on Ambient Air Pollutants and CHDs 
To date, there have been eight previously published studies on exposure to ambient air pollutants 
during pregnancy and CHDs.5,8,16-18,22,24,25  For the purpose of this proposal, only studies which directly 
measured or estimated ambient levels of at least one of the criteria air pollutants were included (i.e., 
proximity studies, biomarker studies, studies of non-criteria pollutants were not included).  These 
studies are presented in Table 2.4. 
2.3.1 Summary of Study Characteristics and Findings 
Study Design and Population: Six of the studies have been case-control designs5,8,16,17,24,25, while two 
were cohorts18,22, analyzed as a time-series design.  Four were within the United Kingdom or England, 
three were conducted in the United States, and one was conducted in Australia.  All but the study in 
Australia utilized population-based birth defect registries and vital records/birth certificates as their 
source of data.  The study in Australia used hospital-based records.  The four studies conducted in the 
UK/England included elective terminations at any gestational age as cases; all other studies included 
only live births and fetal deaths after 20 weeks. 
Outcome Assessment:  There was some heterogeneity in how studies aggregated the CHDs into 
groupings.  The three earlier studies used the same six groupings of CHDs which were not based on a 
specific classification scheme.   The four studies in England used ICD-10 codes to group the CHDs, 
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although the Rankin study had a total of six groups, while the others had 10 groups.  Strickland et al 
used 12 distinct groupings, based on the STS cardiac codes described in section 2.2.4. Many of the 
studies examined groups and individual defects, so the groupings were not mutually exclusive.  Thus, 
there wasn’t much of an improvement in the classification from the original studies that examined 6 
groups, except for studies of more prevalent individual defects such as TOF and TGA.  Two studies, 
Gilboa et al and Hansen et al, did not exclude or stratify by presence of chromosomal anomalies.  
Exposure Assessment:  None of the studies have examined PM2.5.  All other criteria pollutants have been 
examined, although not in every study.  All studies used either local area code (e.g. ZIP Code or 
municipal code) or residential address at the time of delivery to assign exposure.  All but 2 studies used 
an average or weighted average of exposure over weeks 3-8 of pregnancy.  One study used a single 
average over the entire first trimester, while the Ritz et al study calculated averages for each of the first 
3 months of pregnancy, as well as the subsequent two trimesters, and the 3 month period prior to 
pregnancy.  Four studies assigned exposure using the closest, stationary air monitor.  One averaged all 
of the monitors within a specific radius.   One study, Strickland et al, used a single, centralized monitor 
to assign the same exposure to all women who conceived on the same day.  Dolk et al assigned women 
the average exposure from 1996 determined by a prediction model which used monitoring and 
emissions data.  Another study in the UK conducted by Dadvand et al utilized output from a 
spatiotemporal prediction model to assign exposure.  That model was constructed similar to a land-use 
regression model, described in Section 2.1.2.5 as covariates such as traffic, population density, and 
other land use variables were used to predict pollutant levels at maternal postal areas.  The first stage of 
the model utilized meteorological data to quantify the regional, temporal trend in air pollutant 
concentrations, and then used that as an offset in the second stage of the model which used land-use 
variables at the different monitoring sites as predictors of the air pollutant concentrations for the 
different postal areas.   
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Covariate Assessment:  All studies were limited to data from vital records, birth defects registries or 
hospital records for the covariates.  Each study utilized a different adjustment set, except for the two 
studies by Dadvand et al which had the same adjustment set, as seen in Table 2.4.  Almost all studies 
included adjustment for season of conception, and in non-time series analyses, demographic factors  
related to socioeconomic status.  Only one study examined alcohol use.  The Rankin et al study adjusted 
for birth weight.  A number of studies adjusted for infant sex.   
Findings: Each study examined multiple pollutants and multiple windows of exposure, so there were 
many effect estimates reported for each study.  In general, results were inconsistent between studies.  
There was a general lack of precision, which made drawing conclusions about many of the estimates 
difficult.  There were some common associations observed.  Two studies which utilized the same 
outcome classification found elevated odds of pulmonary artery and valve defects with ozone exposure.  
A few studies found associations between SO2 and conotruncal defects, such as TOF, and COA.  The 
analysis in Atlanta which used a time-series analysis did not observe any statistically significant findings, 
except for PM and PDA.  But, they did observe elevated effect estimates for some associations that did 
not reach statistical significance, even though they were greater than effects observed in other studies.  
For example, the rate ratio for TGA and ozone was 1.70, but imprecise with a confidence interval of 
0.83, 3.48.  A recent review and meta-analysis of all the studies above found that relationships between 
SO2 and tetralogy of Fallot and coarctation of the aorta, NO2 and tetralogy of Fallot and coarctation of 
the aorta and PM10 and ASDs were statistically significant although had small effects, with summary 
effect estimates all less than 1.20.23 No other significant associations emerged from their analyses.  
However, because all studies did not examine all pollutants and due to heterogeneity in the defect 
classification, not all relationships could be examined. 
  
Table 2.4: Summary of Previous Epidemiological Research on Exposure to Air Pollutants and Congenital Heart Defects 
Author, Year Geographic 
Area, Years 
Design and 
Analysis method 
Outcome 
Classification 
Exposure 
Assessment 
Adjustment Set Findings 
(ORs/RRs, CIs) 
Misc. 
Ritz et al, 
2002
5
 
California, 4 
counties  
 
1987-1993 
case-control:  
cases include live-
born and fetal 
deaths from birth 
defects registry, 
diagnosis up to 1 
year old 
controls randomly 
selected from birth 
certificates 
must live within 
10km of a monitor 
Analysis: logistic 
regression 
Six groups: aortic 
defects, defects of 
the atrium and 
atrium septum, 
endocardial and 
mitral valve defects, 
pulmonary artery 
and valve defects, 
conotruncal defects, 
and ventricular 
septal defects (not in 
conotruncal) 
Pollutants 
Examined:  
CO, NO2, O3, PM10 
Data Source 
Closest stationary 
monitor 
Exposure Window 
Monthly avg. for 
first 3 months of 
pregnancy; 
averages over 2
nd
 
trimester, 3
rd
 
trimester, and 3 
months prior to 
conception 
maternal age, 
maternal 
race/ethnicity, 
maternal 
education, 
access to 
prenatal care, 
infant gender, 
decade of birth, 
parity, birth 
type, time since 
last pregnancy, 
season of 
conception, and 
other air 
pollutants 
 
2nd month CO VSDs 
2.84 (1.15, 6.99) 
2nd month ozone 
aortic artery and valve 
defects 2.68 (1.19, 
6.05), pulmonary 
artery and valve 2.94 
(1.00, 8.67), 
conotruncal 2.63 
(0.75, 9.24) 
Inverse associations 
between 1st month 
and 3rd month ozone 
and pulmonary artery 
and valve and 3rd 
month ozone and 
aortic artery and valve 
No 
evidence of 
EMM by 
race or age 
Gilboa et al, 
2005
8
 
Texas, 7 
counties 
1997-2000 
case-control: cases 
include live-born 
and fetal deaths 
from birth defects 
registry; controls 
selected from vital 
records,frequency-
matched on vital 
status, year and 
maternal county of 
residence at 
delivery 
restricted to 
parents > 18 
Analysis: logistic 
and polytomous 
logistic regression 
Six groups: similar to 
Ritz et al 
Pollutants 
Examined: 
CO, NO2, O3, PM10, 
SO2 
Data Source 
Closest stationary 
monitor 
Exposure Window 
Average over 
weeks 3-8 of 
pregnancy 
Varied by 
pollutant-defect 
combination; 
included 
maternal 
education, 
race/ethnicity, 
season of 
conception, 
plurality,parity, 
infant sex, 
maternal age, 
marital status, 
prenatal care, 
maternal illness, 
gravidity, 
tobacco use 
CO and conotruncals  
1.46 (1.03, 2.08) 
CO and TOF 
2.04 (1.26, 3.29) 
 
SO2 and VSDs 2.16 
(1.51, 3.09) 
 
PM10 and ASDs 
2.27 (1.43, 3.60) 
 
Inverse associations 
between CO and ASD, 
O3 and VSD, SO2 and 
ASD and conotruncals, 
PM10 and endocardial 
cushion defects  
didn’t 
report 
controlling 
for 
matching 
factors 
 
No 
evidence of 
EMM by 
sex, 
plurality, 
education, 
race, 
season of 
conception 
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Table 2.4 (cont.) 
Author, Year Geographic 
Area, Years 
Design and 
Analysis method 
Outcome 
Classification 
Exposure 
Assessment 
Adjustment Set Findings 
(ORs/RRs, CIs) 
Misc. 
Hansen et al, 
2009
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Brisbane, 
Australia, 
1998-2004 
case-control 
cases and controls 
selected from vital 
records;singleton 
live-births and 
fetal deaths 
matched on 
maternal age, 
marital status, 
indigenous status, 
number of 
previous 
pregnancies, 
month of LMP, 
area-level SES, 
distance to air 
pollution monitor 
Analysis: 
Conditional logistic 
regression in 
Bayesian 
framework 
Six groups similar to 
Ritz et al and Gilboa 
et al 
Pollutants 
Examined 
CO, NO2, O3, PM10, 
SO2 
Data Source 
Closest stationary 
monitor 
Exposure Window 
Average over 
weeks 3-8 of 
pregnancy 
Infant sex Examining all births 
Inverse associations 
between CO and VSDs 
and conotruncals 
 
Births within 6km of a 
monitor 
O3 and pulmonary 
artery and valve 
2.96 (1.34, 7.52) 
 
SO2 aortic artery and 
valve defects 
10.76 (1.50, 179.8) 
 
NO2 and endocardial 
cushion defects 
6.93 (0.93, 114.8) 
 
Inverse between SO2 
and conotruncals 
 
Small 
number of 
cases in 
each group 
Rankin et al, 
2009
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Northern 
United 
Kingdom, 
1985-2000 
case-control: 
population-based 
congenital defect 
registry includes 
livebirths, fetal 
deaths (>20 
weeks), elective 
terminations;   
controls randomly 
selected from birth 
records  
Analysis: logistic 
regression 
Six groups based on 
ICD-10 codes 
Pollutants 
Examined 
Black Smoke (BS),  
SO2 
Data Source 
Average of all 
monitors within 
10km of maternal 
residence 
Exposure Window 
Average over first 
trimester 
birth weight, 
infant sex, 
material 
deprivation 
 
BS 
ORs range from 0.90-
1.03; nothing 
statistically significant 
SO2 
All CHDs 0.82 (0.68, 
0.98) 
AVSD 
1.35 (0.60, 3.05) 
PDA 
0.36 (0.19, 0.69) 
VSD 
0.78 (0.58, 1.04) 
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Table 2.4 (cont.) 
Author, Year Geographic 
Area, Years 
Design and 
Analysis method 
Outcome 
Classification 
Exposure 
Assessment 
Adjustment Set Findings 
(ORs/RRs, CIs) 
Misc. 
Strickland et 
al, 2009
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Atlanta, GA, 5 
counties, 
1986-2003 
cohort, time series 
 
includes all live-
births and fetal-
deaths > 20 weeks 
gestation from 
vital records linked 
to birth defects 
registry 
 
Analysis: Poisson 
regression 
12 groups, some 
individual defects, 
some groupings so 
not mutually 
exclusive 
Pollutants 
Examined 
CO, PM10, O3, NO2  
Data Source 
Stationary monitor 
in Central Atlanta 
Exposure Window 
Weighted average 
of Weeks 3-7 of 
pregnancy; greater 
weight  in center 
weeks 
week of year and 
day of follow-up- 
modeled as 
cubic spline with 
knot every year 
PDA and PM10 
1.60 (1.11, 2.31) 
Only sig. result 
O3: ranged from 0.78-
1.29 (3 below 1.0, 9 
above) 
PM10: ranges from 
0.85, 1.60 (6 below 
1.0, 6 above) 
NO2: ranges from 
0.80-1.27 (4 below, 8 
above) 
CO: ranges from 0.80-
1.16 (7 below, 5 
above) 
SO2: 0.70-1.22 (7 
below, 5 above) 
 
Dolk et al, 
2010
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England, 4 
regions, 1991-
1999 
Cohort 
cases from 
population-based 
congenital defect 
registry includes 
livebirths, fetal 
deaths (>20 
weeks), elective 
terminations;   
controls randomly 
selected from birth 
records  
Analysis: 
Poisson Regression 
10 groups based on 
ICD-10 codes; some 
individual defects, 
some groupings so 
not mutually 
exclusive 
Pollutants 
Examined 
PM10, NO2, SO2 
Data Source 
Estimates for local 
areas from 
prediction models 
which include 
monitoring data 
and emissions data 
Exposure Window 
Annual average for 
1996 
maternal age, 
neighborhood 
socioeconomic 
deprivation, 
hospital 
catchment area 
SO2 and TOF  
1.38 (1.07,1.79) 
 NO2 and TOF  
1.44 (0.71, 2.93)  
PM10 and TOF 
1.48 (0.57,3.84) 
SO2 ranged from 0.94, 
1.15 for other defects 
NO2 ranged from 0.62, 
1.50 for other defects 
PM10 ranged from 
0.49, 1.22 for other 
defects 
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Table 2.4 (cont.) 
Author, Year Geographic 
Area, Years 
Design and 
Analysis method 
Outcome 
Classification 
Exposure 
Assessment 
Adjustment Set Findings 
(ORs/RRs, CIs) 
Misc. 
Dadvand et 
al, 2011
24
 
Northeast 
England, 
1985-1996 
case-control:  
 
cases from 
population-based 
congenital defect 
registry includes 
livebirths, fetal 
deaths (>20 
weeks), elective 
terminations;   
 
controls randomly 
selected from birth 
records  
 
Analysis: logistic 
regression 
10 based on ICD-10 
codes; some 
individual defects, 
some groupings so 
not mutually 
exclusive 
Pollutants 
Examined 
BS, SO2 
Data Source 
Spatiotemporal 
Model 
Exposure Window 
Average of weeks 
3-8 of pregnancy 
birth year, 
socioeconomic 
status, infant 
sex, season of 
conception, and 
degree of 
urbanity 
 
BS 
malformations of 
cardiac chambers and 
connections 
2.00 (1.27, 3.17) 
VSD 
0.73 (0.58, 0.91) 
Others range from 
0.83-1.43; 
SO2 
Malformations of 
great arteries and 
veins 
0.58 (0.40,0.86) 
COA 
0.39 (0.22, 0.70) 
Others range from 
0.75-1.18 
 
Dadvand et 
al, 2011b
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Northeast 
England, 
1993-2003 
Case-control 
cases from 
population-based 
congenital defect 
registry includes 
livebirths, fetal 
deaths (>20 
weeks), elective 
terminations;   
controls randomly 
selected from birth 
records  
frequency-
matched on birth 
year 
Analysis: logistic 
regression 
10 based on ICD-10 
codes; some 
individual defects, 
some groupings so 
not mutually 
exclusive 
Pollutants 
Examined 
O3, CO, PM10, NO2, 
NO, SO2 
Data Source 
Stationary air 
monitor closest to 
maternal residence 
at delivery 
Exposure Window 
Average over 
weeks 3-8 
birth year, 
socioeconomic 
status, infant 
sex, season of 
conception, and 
degree of 
urbanity 
 
Malformations of 
cardiac chambers and 
connections 
1.47 (0.48, 4.37) 
Malformations of 
cardiac septa 
2.33 (1.75, 3.10) 
COA:2.17 (0.54, 8.70) 
PS:2.68 (1.30, 5.53) 
TOF:1.98 (0.53, 7.31) 
VSD:2.63 (1.87, 3.71) 
Malformations of 
great arteries and 
veins 
0.76 (0.32, 1.80) 
All other comparisons 
around 1 
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2.3.2 Methodological Limitations of Previous Studies 
Although there were differences in study design, exposure and outcome assessment and 
subsequent findings from the previous investigations into exposure to air pollutants and CHDs, there 
were some consistent limitations and methodological challenges.  CHDs are an extremely 
heterogeneous outcome, and associations with particular defects may be masked when lumped 
with other CHDs into a single group for analysis.  This is difficult challenge since CHDs are a rare 
occurrence and stratification reduces an already small sample size.  However, more consistent 
findings between the studies were for the larger, individual defects that are relatively homogeneous 
such as TOF and COA.  It is possible that further refinement in outcome aggregations within a larger 
study of birth defects would have an enhanced ability to explore etiologic relationships.31,97 
Additionally, not all studies excluded or stratified by the presence of chromosomal anomalies.  CHDs 
in the presence of chromosomal anomalies may have a different etiology.  This is also true for CHDs 
which are found in combination with other CHDs. Many of the studies, including Strickland et al18, 
included cases with more than one CHD, and either classified them according to the more severe 
defect or counted them twice if the defects were hypothesized to be developmentally independent.   
Misclassification of exposure is another consistent challenge.133  The majority of studies 
used one exposure metric, the average ambient concentration during weeks 3 through 8 of 
pregnancy.  Because of the timing of the development of the cardiac structure, we know that 
exposure during week 8 is not equivalent to exposure in week 3.  Yet, most analytic methods cannot 
handle the correlation in exposure between the different weeks of development if entered 
simultaneously into a standard logistic model like those used in the studies described.  Additionally, 
identifying this relevant time period is highly dependent upon obtaining a correct gestational age.  
Because most studies utilize records from birth certificates, LMP is used to calculate gestational age.  
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Previous research has shown some misclassification in gestational age based on LMP recorded on 
the birth certificate, which could impact identifying the relevant time period.134   
As stated previously, these studies are measuring a proxy for exposure, the ambient 
concentrations of pollutants in the air at the monitor closest to the woman’s residential location, 
often at the time of delivery.  While having personal air monitors to collect exposure is not feasible, 
there needs to be an attempt to minimize the misclassification based on using this proxy for 
exposure.133  Most of the studies relied primarily on monitoring data from stationary monitors, but 
as discussed in Section 2.1.2, there are deterministic models that utilize additional types of data, 
including atmospheric and meteorological data, knowledge about atmospheric chemistry and 
transport, and reported emissions to predict pollutant surfaces over a geographic area that can be 
used to assign exposure at maternal locations.  These models can be also be combined with 
monitoring data using statistical methods to improve estimation of pollutant concentrations.67       
Tracking residential mobility during pregnancy is another way to minimize exposure 
misclassification.  Recent studies on residential mobility during pregnancy within the individual sites 
of the National Birth Defects Prevention Study revealed geographic differences in mobility.  
Approximately 30% of women in Texas moved during pregnancy30, compared to 22% in Atlanta135, 
and 17% in upstate New York29.  Two of these studies found that using residence at delivery did not 
cause considerable misclassification of exposure to ozone and PM10 or benzene due to the relatively 
short distance of the move.  Kappa statistics calculated in these studies ranged from 0.69 to 0.99, 
suggesting agreement between exposures determined using address at delivery and using address 
at birth.29,30  However, it is unclear if these patterns on pregnancy mobility are generalizable to other 
locations.  Additionally, in Texas, cases were more likely to move earlier in pregnancy, which could 
suggest differential misclassification, particularly when the relevant time window of exposure for 
birth defects is limited to the first 8 weeks of pregnancy.30     
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 Residual confounding is another limitation of these studies.133  Available covariates are 
limited to data collected as part of vital records or birth defects registries, excluding factors such as 
illegal substance use, medication use and other variables associated with CHDs that may vary 
spatially like air pollutants.  Additionally, the quality of data collected on administrative forms can be 
highly variable.  Having access to a larger number, and more standardized collection of covariate 
information would be able to reduce some of this confounding.133  Utilizing time-series study 
designs, such as those employed by Strickland et al18 could also reduce the need to collect data on 
spatial confounders, since the relationship is explored within the temporal domain only.  However, 
using a single, central stationary monitor to reflect the exposure at a given time points for an entire 
population may introduce exposure misclassification, particularly for pollutants with considerable 
local spatial variation. 
 
 
  
CHAPTER 3 
 
 
3. METHODOLOGY 
 
3.1 Study Overview 
The study was conducted by linking ambient air pollutant data from different EPA exposure 
assessment methods to birth outcomes and covariate data from the National Birth Defects 
Prevention Study using geocoded maternal residential history during pregnancy.  For Specific Aim 1, 
exposure to the individual criteria air pollutants, except lead, will be assessed using the EPA’s Air 
Quality Systems (AQS) data which is composed of actual monitoring data of ambient concentrations 
of the pollutants collected from stationary air monitors located across the United States, as 
described in Section 2.1.2.3.  In Specific Aim 2, exposure to PM2.5 and ozone will also be assessed 
using output from an EPA product, referred to as downscaler CMAQ, which combines numerical 
output from a deterministic prediction model that predicts air pollutant surfaces based on emissions 
inventories, meteorological factors, atmospheric reactions, and pollutant transport information with 
actual monitoring data.28  Because downscaler CMAQ only started producing these predicted 
surfaces in 2001 and only produced estimates for the eastern US, only births in those geographic 
areas with estimated conception dates after January 1, 2001 will be included in those analyses.  
3.2 Data Sources 
3.2.1 Study Population, the National Birth Defects Prevention Study 
The National Birth Def Defects Prevention Study (NBDPS) is the largest, ongoing, population-
based site case-control study of birth defects within the US.101 Directed by the Centers for Disease 
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Control (CDC), the NBDPS began in 1996 through the establishment of 7 collaborative Centers for 
Birth Defects Research and Prevention.   These centers were based in the CDC’s Metropolitan 
Atlanta Congenital Defects Program, and existing birth defects surveillance programs in Arkansas, 
California, Iowa, Massachusetts, New Jersey, New York, and Texas.   While some centers cover births 
in the entire state, others only monitor specific counties/catchment areas. In 2002, two additional 
centers were added, North Carolina and Utah, while New Jersey’s site ceased data collection 
activities.  Using the infrastructure of their existing surveillance programs, each center aims to 
contribute 300 eligible birth defect cases annually to the NBDPS.  Cases include livebirths and 
stillbirths greater than 20 weeks gestation or at least 500 grams, as well as elective terminations of 
prenatally-diagnosed defects at any gestational age, where available.   Each center also aims to 
recruit 100 controls annually.  Controls are live-births who are randomly selected from either vital 
records (IA, MA, NC, NJ, UT, CDC-MACDP) or hospital records (AR, CA, NY, TX).  The records for 
controls that are randomly selected for participation are also reviewed to ensure the infant was not 
a stillbirth and the infant does not have any congenital defects.  At each center, clinicians review the 
medical records of cases using standardized criteria to ensure eligibility and review and 
appropriately classify or reclassify defects.  Working together by using a clinical database shared 
between the centers, clinicians make individual notes on each case and collectively resolve any 
questions about a case’s classification.136  Overall, there is a 69% participation rate among cases and 
a 65% participation rate among controls.  To date, the NBDPS has recruited over 27,000 cases and 
over 10,000 controls.   
 As part of the NBDPS protocol, mothers complete a detailed, one-hour computer assisted 
telephone interview (CATI) on a wide range of questions on demographics, pregnancy history, 
maternal conditions and illnesses, family history, lifestyle and behavioral factors, maternal nutrition, 
medication use, multivitamin use before and during pregnancy, environmental exposures,  
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occupational history and physical activity.  Participants are also asked to provide complete 
residential history during pregnancy.  The NBDPS also collects biological specimens, in the form of 
buccal cells, for DNA extraction and genetic analysis.  The study has the ability to link participation 
information with the clinical records used to classify defects.  Some centers also link NBDPS 
participants with their original birth certificate information from vital records.  Analytic databases 
are created from the pooled data from each center and made available to all centers periodically.   
 3.2.1.1 Assessing Gestational Age within the NBDPS 
 The NBDPS has a standardized protocol for assessing gestational age at birth of 
participants in the study.  During the maternal interview, mothers are asked about the 
estimated date of delivery (EDD) that was given to them by their clinician while pregnant 
with the enrolled child.  If a mother was given more than one EDD during her pregnancy, she 
is asked to give the last estimate given to her.  This date is used to calculate her estimated 
date of conception (DOC) which in conjunction with the infant’s date of birth, is used to 
calculate gestational age.  If a mother cannot recall the estimated delivery date she was 
given, NBDPS staff can refer to her medical records and use an ultrasound given before 14 
weeks to estimate the EDD.  If no early ultrasound is available, then the NBDPS will look at 
the LMP and if available ultrasound given before 27 weeks or a neonatal exam.  If 2 of the 3 
agree, are within 7 days of each other if assessed during the first trimester and 14 days if 
assessed in the 2nd trimester, that EDD will be used.  If the different sources don’t agree, 
then the NBDPS will use LMP, and if that is not available then ultrasound < 27 weeks, and if 
nothing else is available, neonatal estimate. 
3.2.1.2 Residential History and Geocoding within the NBDPS 
 As part of the maternal interview, participants are asked to provide the addresses of 
all of their residential locations from 3 months prior to the estimated DOC through the 
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infant’s date of birth or date of stillbirth/termination.  The addresses are recorded along 
with the dates the participant resided at each location.  Due to the highly identifiable nature 
of addresses, this data is stored locally at each center.  Periodically, the NBDPS compiles the 
address information from all of the centers and utilizes the Geospatial Research, Analysis 
and Services Program of the Agency for Toxic Substances and Disease Registry (ATSDR) to 
geocode the data using a standardized protocol.  Once geocoded, the data for each center is 
sent back only to that center for storage; a centralized database is not maintained.  Centers 
wishing to utilize geocodes for research studies must obtain each center’s geocodes directly 
from them.  The dates of residence for each geocoded address, as well as the total number 
of addresses for each participant, are maintained in the centralized analytic database.  For 
this study, we will be using geocoded data for participants with EDDs through 12/31/2006.   
3.2.1.3 CHDs within the NBDPS: Exclusion Criteria and Classification 
Not all CHDs are eligible for inclusion in the NBDPS.  Because of the implicit known 
etiology, all defects, cardiac and non-cardiac, associated with chromosomal/microdeletion 
disorders and single-gene deletion disorders are excluded.  Additionally, certain CHDs are 
also excluded, either because they are extremely rare, they are difficult to ascertain during 
infancy, they deal mainly with the vascular system and likely have a different etiology, or 
they are not generally considered a structural defect of clinical importance.  These defects 
are listed in Table 3.1.  It should be noted that the recruitment of VSDs, muscular and not 
specified is no longer being pursued since the higher prevalence of that defect led to a 
sufficient number of cases within the NBDPS.97     
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Table 3.1: Congenital heart defects excluded from the National Birth Defects Prevention Study 
Patent Ductus Arteriosus Bicuspid Aortic Valve 
Patent Foramen Ovale Aortic Dilatation 
Cor Triatrium Right Aortic Arch 
Aortopulmonary windeo Aberrant Subclavian Artery 
Double Outlet Left Ventricle Double Aortic Arch 
Isolated Congenitally Corrected TGA Vascular Ring 
Mitral Stenosis Isolated Valve Dysplasias 
Isolated Congenital Arrhythmias Cardiomyopathy 
Coronary Anomalies  
 
Because specific CHDs are both rare and heterogeneous, the NBDPS developed a 
unique classification scheme, with the specific purpose of balancing the needs between 
aggregation and maintaining relatively homogeneous outcome groups to facilitate etiologic 
research.  Cases are classified according to three axes: cardiac phenotype, cardiac 
complexity, and the presence of other defects.97  Cardiac phenotype refers to the specific 
CHD, or defects a case has had diagnosed.  There are three levels of aggregation for cardiac 
phenotypes: the first is a detailed description of the phenotype, for example transposition 
of the great arteries, atrial septal defect, secundum, and pulmonary stenosis.  The NBDPS 
contains over 85 unique phenotypes, known as Level-1 groups (Table A1).  Level-2 consists 
of 28 cardiac categories, which are relatively homogeneous but still provide adequate 
sample size.  These 28 categories can be collapsed into a third level of aggregation, Level-3, 
which consists of eight heterogeneous groupings with larger sample size.  The 28 categories, 
with their corresponding 8 higher aggregations, are listed in Table 3.2 with estimated 
sample sizes in the most recent analytic database which includes births with estimated 
delivery dates from the start of the study in 1997 through 12/31/2007.   
 Cardiac complexity refers to whether there are one or more CHDs present.  If only a 
single defect, or well-established condition treated like a single defect (such as Tetralogy of 
Fallot), the case is classified as simple.  If the case has two or three fairly simple defects, 
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which are observed together, the case is classified as association.  If there are multiple, 
independent defects, the case is classified as complex.  The third axis refers to whether any 
non-CHDs are present.  If there are no other defects present, the case is classified as 
isolated.   
    
Table 3.2: Classification of Congenital Heart Defects, using 2-level of Aggregations and Corresponding Sample 
Size within the NBDPS most recent analytic database 
Left Ventricular Outflow Tract Obstruction 
(LVOTO) 
 Right Ventricular Outflow Tract 
Obstruction (RVOTO) 
 
Hypoplastic Left Heart Syndrome (HLHS) 475 Pulmonary Atresia 188 
Interrupted Aortic Arch, Type A (IAA-A) 14 Tricuspid Atresia 128 
Coarctation of the Aorta (COA) 839 Ebstein’s Malformation 124 
Aortic Stenosis (AS) 356 Pulmonary Valve Stenosis 1112 
Conotruncal  Septals  
Truncus 90 VSDs, perimembranous 1547 
Interrupted Aortic Arch, Type B (IAA-B) 30 VSDs, muscular 743 
Interrupted Aortic Arch, NOS (IAA-NOS) 8 VSDs, OS/NOS 90 
D-Transposition of the Great Arteries (TGA) 591 Atrial Septal Defect (ASD), 
secundum 
1856 
Tetralogy of Fallot (TOF) 886 ASD, OS/NOS 572 
Double Outlet Right Ventricle (DORV)-TGA 127 Complex  
Double Outlet Right Ventricle (DORV)-other 90 Single Ventricle 265 
Ventricular Septal Defect VSD, conoventricular 126 L-TGA 42 
Atrioventricular Septal Defect (AVSD) 260 Other Association 112 
Anomalous Pulmonary Venous Return (APVR)  Laterality Defects 325 
Total APVR (TAPVR) 224   
Partial APVR (PAPVR) 48   
 
3.2.2 Sources of Air Pollution Data from the Environmental Protection Agency 
3.2.2.1 Ambient Air Monitoring Data 
As described in Section 2.1.2.3, states, local agencies, and tribal agencies within the 
United States maintain a broad network of stationary air monitors in order to comply with 
regulations in the Clean Air Act.  Measurement data from these monitors are provided to 
the Environmental Program Agency, where it is compiled and housed in a repository known 
as the Air Quality System (AQS).  Through collaboration with researchers at the EPA, AQS 
data were obtained for all monitors within the nine states where NBDPS centers are located.  
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The daily average of pollutant concentrations were provided for each pollutant measured at 
each monitoring station, except for ozone where an 8-hour average is used.  Not all 
monitors record measurements on all days.  For example, PM2.5 can be measured daily, 
every 3rd day, or every 6th day depending on the monitor location. 
 3.2.2.2 Downscaler Community Multiscale Air Quality (downscaler CMAQ) Model 
As described 
above, the EPA’s 
Community Multiscale Air 
Quality  (CMAQ) is a 
deterministic prediction 
model that utilizes 
multiple inputs to predict 
air pollutant concentrations 
for PM2.5 and ozone across 
the United States.137  As illustrated in Figure 3.1, weather data is input into the 
meteorological model which simulates atmospheric circulation.  The output of this model is 
then used as the input to MCIP, the meteorological-chemical interface processor, that 
formats/translates the meteorological data so it can be linked to the chemical/emissions 
data and used for air quality simulations.  Separately, data from the EPA Emissions 
Inventory, described in Section 2.1.2.2, is input into the Sparse Matrix Operator Kernel 
Emissions Model (SMOKE), which processes the emissions data in order to create gridded, 
speciated, hourly emissions data that can be input into the CMAQ model.  SMOKE also 
receives inputs from MCIP, in order to use atmospheric data to model emissions.  Both the 
meteorological data and the emissions data is then input into the CMAQ Air Quality model, 
http://www.epa.gov/AMD/ModelDevelopment/index.html 
Figure 3.1: Data Inputs into the Community Multiscale Air Quality (CMAQ) 
Model 
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which contains the chemical-transport processors that simulate chemical transformation 
and fate within the atmosphere.  Processes simulated in this model include gas-phase 
chemical reactions, deposition, horizontal and vertical diffusion, aerosol dynamics and 
thermodynamics, and plume chemistry effects, among others.137  From this model, 
predicted concentrations of pollutants are output as a gridded surface, in grids that vary in 
size.  For the eastern part of the United States, the gridded outputs are 12 km x 12 km.  For 
the west, the output grids are 36 km x 36 km.  Thus, pollutant estimates are obtained for the 
many areas which lack monitoring stations.      
Downscaler CMAQ takes the numerical output from this model and combines it with 
EPA monitoring data using linear regression with spatially- and temporally-varying bias 
coefficients in a Bayesian framework.138 The numerical output is combined with monitoring 
data to improve spatial predication, as output from CMAQ can be biased due to the varying 
quality of the underlying emissions inventories and the many assumptions made throughout 
the modeling process. The resulting model, referred to as downscaler CMAQ because it 
scales gridded CMAQ output down to the point-level monitoring data, provides bias-
corrected, daily predictions of concentrations of 24-hour PM2.5 and 8-hour maximum ozone 
at the centroid of every census tract in the United States.     
 Both sources of exposure data will provide daily estimates of ambient concentrations of the 
pollutants.  However, based on previous work utilizing this data, it was determined that daily 
estimates of pollutant concentrations possess a great amount of random variation that negatively 
impacts estimation and precision of the etiologic relationships of interest from subsequent modeling 
processes.  Using monthly or trimester-specific averages, while reducing the random variation, also 
smoothes over important temporal variation in pollutant concentrations that may lead to 
misclassification of exposure.  It was observed that weekly averages were able to minimize the 
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random variation, while still maintaining the ability to observe relevant trends in air pollutant 
concentrations.139  Therefore, using both data sources, weekly averages will be constructed for each 
pollutant, for every calendar week during the study period 1997-2006.  
3.2.3 Supplemental Sources for Covariate Information 
Road Networks from ESRI StreetMap North America: Some of the pollutants, such as SO2, measured 
by the EPA monitors are a marker of regional pollution.  These pollutants may interact with more 
local sources of pollution, such as living close to a major roadway.  Proximity to a roadway will be 
quantified by calculating the shortest straight-line distance to a major roadway.  The source of the 
roadway network that will be used is the ESRI StreetMap North America dataset.   Using the 
participant’s residential location as the starting point, the distance to the closest major road, 
defined as a highway or major arterial road, will be calculated geodesic distance measurements, 
which avoids distortion due to projection of geographic coordinates.  This was performed in ArcGIS.  
The continuous value of the shortest distance was stored as the exposure metric, although distance 
to a major road will also be examined categorically in the analysis. 
3.3 Methodology for Specific Aim 1 
Specific Aim 1:  To determine whether exposure during pregnancy to individual criteria air 
pollutants, assessed using measurements from stationary air monitors, is associated with CHDs  
Subaim 1a:  To determine if the relationship between exposure to PM2.5 and CHDs is 
modified by use of folic-acid supplements early in pregnancy 
Subaim 1b:  To explore the effect of multiple pollutants on CHDs using principal components 
analysis (PCA) 
Eight sets of analyses will be performed in order to address Specific Aim 1.  They are summarized in 
Table 3.3 and the methodology is described in more detail below. 
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Table 3.3: Summary of Analyses to Address Specific Aim 1 
Specific 
Aim 
Population Outcome 
Grouping 
Exposure 
Source 
Pollutants 
Examined 
EMM/Confounders Model 
1 All 6 categories Monitoring 
Data 
All Identified through 
DAG/Prelim Analysis 
Hierarchical 
Regression 
1 All 28 categories Monitoring 
Data 
All Identified through 
DAG/Prelim Analysis 
Hierarchical 
Regression 
1 <10km to a 
monitor 
6 categories Monitoring 
Data 
All Identified through 
DAG/Prelim Analysis 
Polytomous 
Logistic 
1 <10km to a 
monitor 
28 categories Monitoring 
Data 
All Identified through 
DAG/Prelim Analysis 
Polytomous 
Logistic 
1a <50km to PM 
monitor 
6 categories Monitoring 
Data 
PM2.5  Use of Folic Acid and 
Identified through 
DAG/Prelim Analysis 
Polytomous 
Logistic 
1a <50km to PM 
monitor 
28 categories Monitoring 
Data 
PM2.5 Use of Folic Acid and 
Identified through 
DAG/Prelim Analysis 
Polytomous 
Logistic 
1b Near all 
monitors 
6 categories Monitoring 
Data 
All Identified through 
DAG/Prelim Analysis 
PCA and 
Hierarchical 
Regression 
1b Near all 
monitors 
28 categories Monitoring 
Data 
All Identified through 
DAG/Prelim Analysis 
PCA and 
Hierarchical 
Regression 
 
3.3.1 Study Population 
For this aim, the study population consists of all participants in the NBDPS with at least one 
diagnosed CHD and all controls who are included in the most recent version of the NBDPS analytic 
database who have estimated date of delivery (EDDs) from the start of the study in 1997 through 
12/31/2006.  These dates were selected because geocoded residential addresses are not yet 
available for participants with EDDs after 12/31/2006.  Additionally, women who reported having 
non-gestational diabetes during their pregnancy will be excluded from this aim because of the 
strong association between maternal diabetes and CHDs.110  For specific aim 1a, the analysis will be 
restricted to women who live within 50 km of an air pollution monitor measuring PM2.5.  Due to 
changes in pollutant monitoring, this effectively limits the population to women with EDDs from 
1/1/1999-12/31/2006.  For specific aim 1b, the analysis is limited to women who live within 50 km 
of each type of air pollutant monitor.  Again, due to the monitoring of PM2.5, this limits to women 
with EDDs from 1/1/1999-12/31/2006. 
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3.3.2 Outcome Assessment 
 The classification scheme for CHDs utilized by the NBDPS was described above in Section 
3.2.1.  For the primary analyses of this specific aim, cases will be limited to participants who have a 
simple, isolated defect.  This translates to each having a single CHD or well-defined pattern of CHDs 
without any concurrent non-CHDs.  In a previous version of the data, it was calculated that 65% of 
cardiac cases were simple and isolated.  These groupings are considered to be the most etiologically 
pure and are able to be classified into mutually exclusive groups.  Subsequent analyses may include 
cases classified as association and isolated, those who have two or three simple CHDs only.  Before 
these analyses are pursued, we will consult with the collaborating NBDPS cardiologist to determine 
appropriate classification. 
 Among the simple, isolated cases, the cases will be aggregated into groups using the 28 
categories defined in the Level-2 aggregation and the 8 Level-3 aggregations as recommended by 
NBDPS cardiologists.  Because we are limiting to simple, isolated CHDs, only six of the level-3 
aggregations are represented in our sample.  The Level-3 aggregations will be for instances when 
the sample size of the Level-2 aggregation is too small for analytic purposes.  Additionally, some 
Level-2 categories within the same Level-3 heading may be collapsed to improve sample size, for 
example Truncus, Interrupted Aortic Arch, Type B and Interrupted Aortic Arch, NOS could be 
collapsed into an Other Conotruncals category, which would maintain the homogeneity of larger 
conotruncal categories, such as d-TOF and TGA.   
3.3.3 Exposure Assessment 
 Specific aim 1 will utilize monitoring data to assign exposure for the individual criteria air 
pollutants.  As written in section 3.2.2, weekly averages for all pollutants will be constructed for the 
entire study period, 1997-2006.  Using ArcGIS, for each case and control, all residential locations 
throughout pregnancy will be linked to the closest air monitor.  Additionally, the distance to the 
57 
 
closest air monitor will be stored in order to calculate an indicator for women who live within 10 km 
of a monitor.  Subsequent subanalyses will be restricted to those women as it is expected that the 
exposure classification will be better for women who live closer to the air monitors.  Once the cases 
and controls are linked to a source of pollutant data, exposure metrics will be constructed for weeks 
2 through 8, to correspond to the critical period of exposure for cardiac development.   In addition 
to assigning average exposures for the individual weeks, each participant will be assigned a single 
average of weeks 2 through 8, in order to compare to previous studies which utilized a single metric. 
 3.3.3.1 Constructing source-factors for Specific Aim 1b 
 In order to obtain the source factors used to assess the relationship between air 
pollutants and CHDs in a multipollutant context, principal component analysis (PCA) was 
conducted among the subset of participants who lived within 50 km of each type of 
pollutant and had pollutant concentrations for all six pollutants.  PCA is a dimension-
reduction technique that is used to reduce the number of correlated variables, which you 
believe may be measuring the same construct, into a smaller number of artificial variables 
that capture most of the variance of the original variables while being uncorrelated with 
each other.140  Using this method, we avoid the issue of multicollinearity that would arise if 
we tried to simultaneously enter each pollutant in a regression model.141    We standardized 
the exposure data to prepare the data for PCA.  Using SAS v9.2 to run the PCA, we retained 
components with an eigenvalue at or greater than 1, which indicates that the component 
accounts for at least the same or more variance than one of the original pollutant variables.  
We then applied a varimax rotation and calculated factor scores for each participant. 
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3.3.4 Covariate Selection  
 The directed acyclic graph (DAG) describing the potential relationship between exposure to 
air pollutants during pregnancy, CHDs and potential confounders and effect measure modifiers is 
illustrated in Figure 3.2.  DAGs graphically describe the relationships between variables and provide 
a systematic method to assess a variable’s potential for confounding.  Based on the previous 
literature, there are a number of variables that could confound the association between air 
pollutants and birth defects.  It should be noted that this DAG is meant to be a general 
representation of the relationship between air pollutants and CHDs.  It is possible that some aspects 
could be different for specific pollutants and/or specific defects.   
Exposure to air pollution is assessed by residential exposure.  “Choice” of geographic 
residence is affected by many demographic factors, which in turn can be associated with behaviors 
that could increase the risk for CHDs.  For example, behavioral risk factors for CHDs, such as tobacco 
and alcohol use during pregnancy124,128, are also associated with exposure to air pollution through 
demographic variables and socioeconomic status.142   There are also direct pathways from 
race/ethnicity, paternal/maternal age and socioeconomic status to both CHDs and choice of 
geographic residence.  These paths suggest that controlling for the demographic factors would block 
both sets of pathways. Maternal fever/influenza during pregnancy is also not a direct cause of air 
pollution, but it does vary by season, which is associated with air pollution through temperature and 
other weather conditions.  This suggests that controlling for season would block the entire pathway.  
Living near a roadway is also included in this DAG, as they represent a much more local exposure to 
air pollutants.  The exposure being assessed in this study is over a considerable amount of space and 
it is possible that living near a roadway has an effect on CHDs, separate from the air pollutant 
exposures we are measuring.  However, it is possible that controlling for this variable will adjust 
away some of the relationship between exposure to air pollution and CHDs.    Use of folic-acid 
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supplements is another behavioral factor that is affected by SES and associated with CHDs.118  
However, due to the previous research on DNA methylation34,36, folic-acid supplementation will be 
assessed for effect measure modification as the primary analysis of Specific Aim 1a.   
The DAG doesn’t show  family history because while having a family history of CHDs is a risk 
factor for having an infant with a CHD, but there is not clear association with exposure to air 
pollution.  However, it is possible that family history may be associated with increased susceptibility 
to insults to cardiac development.73  Therefore, we will assess family history for effect measure 
modification (EMM). Previous studies have also adjusted for infant sex, but there isn’t a direct path 
connecting it to air pollution and CHDs.  Previous research suggests that exposure to some 
environmental toxins could be able to affect the sex ratio143, although this is not well established for 
air pollutants.  That would put infant sex on the causal pathway, and thus it should not be controlled 
for in the analysis.  It’s also possible that infant sex could impact susceptibility to air pollution, and 
therefore it could be assessed for EMM.  A summary of the variables described above are presented 
 Use of Folic 
Acid 
Paternal Age 
Season 
Temperature 
Proximity to 
Roadway 
Maternal 
Medication 
Maternal 
Fever/Influenza 
Pre-pregnancy 
BMI 
Maternal Age 
at Conception 
Maternal 
Race/Ethnicity 
Tobacco Use 
Alcohol Use Socioeconomic 
Status (SES) 
“Choice” of 
Geography 
Cardiac Birth 
Defects 
Exposure to Air 
Pollution 
Figure 3.2: Directed Acyclic Graph (DAG) of the relationship between Exposure to Air Pollutants and Congenital Heart 
Defects 
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in Table 3.4, including whether the DAG suggests it should be controlled for, the source of data, and 
how it is originally coded.  There are a number of variables within the NBDPS dataset that could 
reflect socioeconomic status. They will be examined individually and in combination to see the 
impact they have on the estimates.  Some variables listed have more detailed coding available 
within the CATI.  This may be examined if deemed appropriate during analyses. 
 
Table 3.4: Summary of Potential Confounders and Effect Measure Modifiers for Specific Aim 1 
Variable Data Source Original Coding Identified by DAG as 
Needing Adjustment 
Maternal Age CATI Continuous, years Yes 
Paternal Age CATI Continuous, years Yes 
Maternal Race/Ethnicity CATI Non-Hispanic White 
Non-Hispanic Black  
Hispanic  
Asian/Pacific Islander  
Native American/ Alaskan Native  
Other 
Yes 
Alcohol Use CATI Yes/No OR 
Binge drinking/Non-binge 
drinking/ No drinking OR 
Yes/No by each of the first 3 
months of pregnancy, each 
trimester, and 3 mos. Prior to 
conception 
No 
Tobacco Use CATI Yes/No Ever OR Yes/No by each of 
the first 3 months of pregnancy, 
each trimester, and 3 mos. Prior to 
conception 
No 
Infant Sex CATI Male/Female No 
Proximity to a Roadway Calculated 
using geocoded 
residence and 
road networks 
Continuous distance Yes 
Use of Folic-Acid 
Supplementation 
CATI Yes/No by month from 3 mos. 
Before conception to birth 
No 
Season of Conception CATI Four seasons Yes 
Fever/Influenza CATI Yes/No and month during 
pregnancy if Yes 
No 
Maternal Medication Use CATI Yes/No, type of medication and 
month during pregnancy 
No 
Socioeconomic Status    
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3.3.5 Data Exploration and Coding 
 Descriptive, univariate analysis on the variables discussed above using the original coding 
will be performed and outliers and prevalence of missing data will be identified.  We will also 
examine the number of geocoded cases within each of the 28 categories of CHDs and collapse as 
necessary to ensure that each analytic group has a minimum of 100 cases.  Following univariate 
analysis, we will conduct bivariate analysis between each pollutant and any CHD as an outcome to 
explore the general shape of the relationship between exposure and outcome.  This will be 
examined using both continuous measures of exposure and multiple categorizations to best capture 
the relationship.  We will start by examining exposure contrasts that were used in previous research.  
The choice of exposure coding will also be reassessed during the modeling process.  As illustrated in 
the DAG, there are complex relationships between the multiple demographic and socioeconomic 
factors.  In order to prevent collinearity in our models, we will assess associations between the 
demographic and various measures of socioeconomic status.  Additionally, we will explore the 
distribution of covariates between cases and controls and explore the distributions of exposure at 
Table 3.4 (cont.)    
Variable Data Source Original Coding Identified by DAG as 
Needing Adjustment 
  Maternal Education CATI No formal schooling 
1-6 years 
7-8 years 
9-11 years 
12 years, completed high school or 
equivalent 
1-3 years of college 
Completed technical college 
4 years college/bachelor’s degree 
Master’s degree 
Advanced degree (MD, PhD, JD) 
 
Yes 
  Paternal Education CATI Same as above  
  Household Income CATI Categorical: 10,000-50,000 in 
10,000 increments 
 
Pre-pregnancy BMI CATI Continuous and Categorical No 
Family History of Birth 
Defects 
CATI Yes/No for each parent and Y/N 
for extended family 
No/ Potential EMM 
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the different levels of each of the covariates.  At this point, we will explore different coding options 
for the covariates.  For continuous variables such as age, we will determine if the relationship with 
the odds of having a defect is approximately linear, or if we need to construct indicator variables to 
accommodate a non-linear relationship.  For categorical variables, we will explore collapsing levels 
within variables if sample size is small.  As shown in the table above, use of folic-acid 
supplementation was originally collected for each month of pregnancy and the 3 months prior to 
conception.  Because we are interested in early folic-acid supplementation use for specific aim 1a, 
we will focus on use during the month prior and two months after conception.  We will explore 
different combinations, such as only examining one month prior (as a proxy for the very beginning 
of pregnancy), one month after conception and two months after conception separately, combining 
one month prior and one month after, and then aggregating all three.      
After exploring variable coding, we will explore preliminary EMM and confounding by all of 
the covariates by constructing simple, logistic regression models of the disease-exposure 
relationship.  This will be done since exposure will be assessed continuously or with multiple 
categorical indicators, and tabular analyses are not feasible.  In order to assess EMM by each 
covariate, likelihood ratio tests will compare models which include interaction terms between the 
exposure and covariate of interest and those that do not, using an α-level of 0.2 to indicate the 
potential for EMM.  If a variable is not determined to be a potential modifier, it will then be assessed 
for confounding by comparing the change-in-estimate from models which do and do not contain the 
individual covariates .  If the change-in-estimate is greater than 0.05, it will be considered a potential 
confounder.  Because the effect estimates from these models tend to be small, I have chosen to use 
a smaller change-in-estimate criterion than typical.  These analyses will be done individually for the 
6 larger aggregations.   
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The results from these analyses will be examined, in combination with the DAG and 
information on potential biological mechanisms and relationships to make a decision about which 
covariates will be assessed for EMM and confounding in the final modeling strategy.  In general, if a 
covariate is identified as a potential modifier by the preliminary data analysis, it will be explored as a 
modifier in the multivariable analysis.  For variables not identified as modifiers, if the DAG indicates 
a need for adjustment, the covariate will be considered a potential confounder and assessed during 
modeling, in the presence of other covariates.  If the DAG doesn’t indicate a need for adjustment, 
but analysis of the data indicate the potential for EMM or confounding, it will also be assessed in the 
presence of other covariates.  Otherwise, the variable will not be assessed in the final strategy.   
3.3.6 Modeling Strategy 
 A two-stage hierarchical regression model will be utilized for the primary analyses and for 
aim 1b.  For sensitivity analyses and aim 1a, only the first-stage model, the polytomous logistic 
regression model will be used due to reduced sample size. 
 3.3.6.1 Polytomous Logistic Regression 
 As shown in Table 3.3, there will be eight sets of models using a polytomous logistic 
regression model.  The outcome will be defined using either the 6 level-3 groupings or the 
individual CHDs.  Exposure will be a single average for weeks 2 through 8 or simultaneously 
modeling each week of exposure.  Exposure will be examined both continuously and 
categorically, based on results from the data exploration analyses described above.  For 
specific aim 1b, the factor scores will be used to assign exposure.   
 The models will be constructed using a backward elimination strategy, starting with 
a full model that contains all covariates that were identified as potential modifiers and 
confounders in the data exploration analyses.  EMM will be assessed first, by comparing the 
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full model which includes the interaction term(s) to a model that does not.  This will be done 
for each potential modifier, and if one drops out, the new full model will not contain that 
interaction term.  Likelihood ratio tests will be performed to determine which modifiers will 
remain using an α-level of 0.20.  Any variables not identified as modifiers will be assessed 
for confounding by individually removing covariates and comparing stratum-specific 
estimates (if modifiers are present) for all cardiac levels back to the full model. We will 
examine the change-in-estimate and change-in-precision for each calculated estimate.  
Because we are using polytomous models, the models result in multiple estimates, one for 
each CHD grouping (i.e. outcome level).  Therefore, there is only one adjustment set for all 
of the different categories of defects.  If the change-in-estimate for at least one defect 
category is greater than 0.05, the covariate being examined will be retained in the model.  If 
the change-in-estimate for some defect categories caused by adjusting for a variable 
corresponds to a greater loss of precision in others, we will evaluate running separate 
models for the different cardiac outcomes as opposed to running polytomous models.  This 
will be done for all covariates.  The order of removal will be covariates that were identified 
through data exploration and then covariates that were identified by the DAG only and then 
covariates that were identified by the DAG and through data exploration.  The final 
determination of the model will consider the results of this strategy along with the DAG and 
the adjustment sets in previous research. 
As a sensitivity analysis, the models will be conducted by restricting to women who 
live within 10 km of a monitor.  We hypothesize that we may reduce exposure 
misclassification by limiting the population to women whose assigned exposure may be 
more reliable.  For aim 1a, if folic acid-containing supplement use was not determined to be 
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a modifier through the modeling building process, it will be put back in to the final model 
and reassessed using likelihood ratio tests.   
 3.3.6.2 Hierarchical Model 
Because we simultaneously assessed multiple weeks of exposure and multiple 
defects/groupings, we constructed two-stage hierarchical regression models, using a 
software program adapted from Witte et al, to account for the correlation between 
estimates and partially address multiple inference. For the primary analyses and aim 1b, the 
polytomous logistic regression described above represents the first-stage model.  Equation 1 
represents the unconditional, polytomous logistic regression model containing all individual 
weeks of exposure, or the single 7-week average, and the full adjustment set determined by 
the process described above.  
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 x represents either the seven-week average or the vector of weekly pollutant 
concentrations, βd is the vector of regression coefficients corresponding to pollutant 
exposure for a specific CHD (d), w represents the covariates and γd is the vector of 
regression coefficients corresponding to the covariates for that specific CHD.  The second-
stage model is given in equation 2   
                 (2) 
where Zi is a row in the design matrix that includes an intercept term and then indicator 
variables for type of defect, broader defect grouping, and exposure week/level for the i-th β, 
π is the vector of coefficients estimated from the data and δi are independent normal 
random variables with a mean of zero and a variance of τ2 that describe the residual 
variation in βi, not captured by the design matrix.  The obtained second-stage coefficients 
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are used to estimate the means toward which the first-stage coefficients will be shrunk 
towards, with the magnitude of the shrinkage depending upon the precision of the 
maximum likelihood estimate obtained in stage 1 and the value of the second stage 
variance, τ2. 144,145  We fixed τ2 at 0.5, corresponding to a prior belief with 95% certainty that 
the residual odds ratio will fall within a 16-fold span.   
This model was implemented using Proc IML in SAS v9.2.  To assess whether our 
results were robust to changes in model specification we explored setting the value of τ2 to 
0.25, corresponding to a 7-fold odds ratio span as well as to a value of 1, corresponding to a 
50-fold span.   Additionally, we explored different specifications for the design matrix which 
would define the prior mean as either a common mean for all defects, a common mean for 
each defect, or a common mean for each exposure week/level, across defects.  
3.3.7 Minimum Effect Size Analysis 
The minimum effect size is calculated based on a previous version of the analytic dataset.  
We will gain additional cases by using the new dataset for this proposed study which will add an 
extra year of data.  Based on a previous study by Gilboa et al, we estimated that 86% of cases and 
80% of controls, across all study centers, would be successfully geocoded.8  Based on this, analyses 
would be conducted using 5,445 controls.  The table below lists the minimum detectable effect 
estimate for all of the 28 CHD groupings with more than 100 geocoded cases.  For this analysis, we 
consider those who have exposure greater than the 75th percentile of each pollutant distribution in 
the controls as “exposed”.  Using that definition of exposed and assuming unadjusted logistic 
regression and 80% power, the effect estimate detectable for a subgroup of 100 would be 1.83.  The 
proposed analysis will be more complex than the assumptions of this effect size analysis.  This will 
impact the minimum detectable estimate that our study will be able to detect.  However, if we 
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conclude that there not enough cases within a subgroup to obtain a reliable estimate, we will use 
the greater level aggregations for the analysis.       
 
Table 3.5: Minimum Effect Size Analysis for Different Congenital Heart Defects 
CHD Groupings Total Geocoded 
Cases (estimated) 
Minimum Detectable Effect 
Estimate 
Hypoplastic Left Heart Syndrome (HLHS) 475 1.35 
Coarctation of the Aorta (COA) 839 1.27 
Aortic Stenosis (AS) 356 1.41 
D-Transposition of the Great Arteries (TGA) 591 1.31 
Tetralogy of Fallot (TOF) 886 1.26 
Double Outlet Right Ventricle (DORV)-TGA 127 1.75 
Ventricular Septal Defect VSD, conoventricular 126 1.75 
Atrioventricular Septal Defect (AVSD) 260 1.50 
Total APVR (TAPVR) 224 1.53 
Pulmonary Atresia 188 1.60 
Tricuspid Atresia 128 1.75 
Ebstein’s Malformation 124 1.76 
Pulmonary Valve Stenosis 1112 1.23 
VSDs, perimembranous 1547 1.20 
VSDs, muscular 743 1.29 
Atrial Septal Defect (ASD), secundum 1856 1.19 
ASD, OS/NOS 572 1.32 
Single Ventricle 265 1.49 
Other Association 112 1.78 
Laterality Defects 325 1.43 
 
3.4 Methodology for Specific Aim 2 
Specific Aim 2:  To utilize the greater spatial and temporal resolution of exposure estimates derived 
from deterministic pollutant simulation models to investigate the association between select criteria 
air pollutants and CHDs 
Subaim 2a: To compare effect estimates and model fit when using monitoring data and 
output from a statistical model which combines the two in order to assign women’s 
exposure during pregnancy 
Subaim 2b: To determine if the addition of rural populations, who are often excluded from 
studies due to large distance from monitoring sites, affects the observed relationship 
between exposure to criteria air pollutants and CHDs 
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3.4.1 Study Population 
For this aim, the study population consists of all participants in the NBDPS with at least one 
diagnosed CHD and all controls who are included in the most recent version of the NBDPS analytic 
database who have EDDs from the start of downscaler CMAQ predictions in 1/1/2001 through 
12/31/2006.  This effectively excludes women from the California and Utah sites as no predictions 
were made for the western United States until 2007.  It also excludes women from the Texas site 
with EDDs prior to 1/1/2002, when downscaler CMAQ predictions began for that state. As for 
specific aim 1, women who reported having non-gestational diabetes during their pregnancy will be 
excluded from this aim because of the strong association between maternal diabetes and CHDs.110  
To address subaim 2a, the population will be limited to women who have AQS measurements 
available, i.e. live within 50 km of an air pollutant monitor for PM2.5 or ozone.  For subaim 2b, the full 
population will be compared to the population used in subaim 2a. 
3.4.2 Outcome Assessment 
 Outcome assessment for this aim is the same as for Specific Aim 1.  Due to smaller sample 
sizes, some individual defects will only be able to be analyzed as part of the larger defect-groupings.   
3.4.3 Exposure Assessment 
 Specific aim 2 will utilize model-based data from the downscaler CMAQ model to assign 
exposure for PM2.5 and ozone.  Using ArcGIS, for each case and control, all residential locations 
throughout pregnancy will be linked to the closest centroid of a census tract, where downscaler 
CMAQ predictions were made. Once the cases and controls are linked to a census-tract centroid, 
exposure metrics will be constructed for weeks 2 through 8, to correspond to the critical period of 
exposure for cardiac development.   In addition to assigning average exposures for the individual 
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weeks, each participant will be assigned a single average of weeks 2 through 8, in order to compare 
to previous studies which utilized a single metric. 
3.4.4 Covariate Assessment 
 Covariate assessment and DAG analysis were the same as for specific aim 1.  Because of 
limited sample size, effect measure modification of folic-acid will not be assessed in this aim. 
3.4.5 Data Exploration and Coding 
 Data exploration and coding will be the same as outlined for specific aim 1.  In addition, to 
compare pollutant concentrations obtained from the downscaler CMAQ model to those obtained 
from AQS air monitors, distributions of pollutant concentrations from each source for the 
population that lived within 50 km of an air monitor were compared.  Then, distributions of 
downscaler CMAQ values among those who do and do not live within 50 km of a stationary air 
monitor were compared to determine the impact of including populations that do not live near 
regulatory monitors as detailed in subaim 2b.  The pollutant concentrations were also compared 
categorically, as these types of metrics are often utilized in epidemiologic studies.   
3.4.6 Modeling Strategy 
For this aim, two-stage hierarchical regression models, as detailed for specific aim 1, were 
constructed.  The procedure for constructing the first-stage polytomous models was also the same.  
Three sets of models were constructed for comparison purposes.  For aim 2a, models using AQS 
measurements to assign exposure for those living within 50 km of an air monitor were compared to 
those using CMAQ predictions to assign exposure for those living within 50 km of an air monitor.  
For aim 2b, the models using downscaler CMAQ predictions constructed above were compared to a 
model using downscaler CMAQ predictions for the full population.  Both the seven-week summary 
measure and individual weekly averages were assessed.   
  
CHAPTER 4 
 
4. MATERNAL EXPOSURE TO CRITERIA AIR POLLUTANTS DURING EARLY PREGNANCY AND 
CONGENITAL HEART DEFECTS IN OFFSPRING: RESULTS FROM THE NATIONAL BIRTH DEFECTS 
PREVENTION STUDY 
 
4.1 Introduction 
Epidemiologic studies provide inconsistent evidence of an association between exposure to 
air pollutants and CHDs. 5,8,16-18,22-25  A recent meta-analysis identified two associations: nitrogen 
dioxide (NO2) exposure and tetralogy of Fallot (TOF) and sulfur dioxide (SO2) exposure and 
coarctation of the aorta (COA).23  However, each meta-analysis was based on only four studies and 
only able to explore five defects/defect groupings.  Moreover, to date, no studies have explored the 
relationship between particulate matter with aerodynamic diameter less than 2.5 micrometers 
(PM2.5) and CHDs.          
Most previous studies utilized monitoring data and assigned exposure by averaging daily 
pollutant averages over post-conception weeks three through eight.  This method misses short-term 
temporal variability in pollutant concentrations and higher, acute exposures.  Consequently, it does 
not capture the temporal variability in exposure across windows with greater impact on cardiac 
development, which could mask or attenuate associations.  Utilizing daily maximum concentrations, 
as opposed to averages, to calculate exposure would better capture daily exposure peaks and more 
closely parallel regulatory standards issued by the Environmental Protection Agency (EPA). 40  
Separating a single overall average into weekly averages would also allow for the exploration of 
specific windows of susceptibility and reduce potential misclassification of exposure.  
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This study utilizes data from the National Birth Defects Prevention Study (NBDPS), a large 
population-based case-control study of birth defects to investigate the association between CHDs in 
offspring and maximum ambient levels of the following criteria air pollutants during early 
pregnancy: carbon monoxide (CO), NO2, ozone, particulate matter with aerodynamic diameter less 
than 10 micrometers (PM10), PM2.5, and SO2.  Although a criteria air pollutant, lead was not included 
in this study as the primary route of exposure to lead is through dust and soils, and not inhalation of 
ambient air.   
4.2 Methodology 
4.2.1 Study Population 
The NBDPS has been approved by the institutional review boards (IRBs) of all participating 
centers.  These analyses were reviewed and approved by the University of North Carolina IRB. The 
design of the NBDPS has been described previously. 101  Cases include livebirths and stillbirths 
greater than 20 weeks gestation or at least 500 grams, as well as elective terminations of prenatally-
diagnosed defects when available, at nine US study sites.  The NBDPS excludes cases with 
chromosomal/microdeletion disorders and disorders of known single-gene deletion causation.  
Controls are unaffected livebirths who are randomly selected from either vital records or hospital 
records, depending upon study center.  The participation response was 69% among all cases and 
65% for controls.   
For this analysis, the study population consisted of all controls and eligible cases with a 
simple, isolated CHD (ie a single CHD with no extra-cardiac birth defects present) and had an 
estimated date of delivery (EDD) from the start of the study in 1997 through 12/31/2006.  Women 
who reported having pregestational diabetes (Types I and II) during their pregnancy were excluded 
owing to the  established association with CHD. 110  The NBDPS classification methodology called for 
a team of clinicians with expertise in pediatric cardiology to assign a single, detailed cardiac 
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phenotype to each case based on a review of information abstracted from the medical record and 
then aggregate them into individual CHDs and defect-groupings. 97  Our isolated CHD cases fell into 
24 individual defects and six broader groupings (Table 4.1).  The following additional groups were 
created due to limited sample size of individual defects:  1)other conotruncal defects, which 
included common truncus, interrupted aortic arch-type b, interrupted aortic arch-not otherwise 
specified (iaa-typeb, iaa-nos), double outlet right ventricle associated with transposition of the great 
arteries (DORV-TGA) and not associated with TGA (DORV-other)  and conoventricular septal defects 
(VSD-conoventricular); and 2) atresias that included both pulmonary and tricuspid atresia.   
 As part of the NBDPS protocol, mothers completed a computer assisted telephone 
interview, which included a residential history during the pregnancy. These addresses were centrally 
geocoded to ensure consistency across study centers.  Each geocoded residential address during the 
first eight weeks of pregnancy was matched to the closest stationary air monitor with more than 
50% of data available, for each pollutant using ArcGISv10 and monitor locations obtained using data 
from EPA’s Air Quality System.  If a woman lived more than 50 km away from the closest pollutant-
specific air monitor, she was excluded from that analysis.  PM2.5 measurements first became 
available in 1999, so participants from 1996-1998 were excluded from that analysis.     
4.2.2 Exposure Assignment and Covariates 
Pollutant concentrations from the closest monitor were assigned to the woman’s 
corresponding pregnancy period for each address reported during the first eight weeks of 
pregnancy.  For CO, NO2, and SO2, we used the daily maximum hourly measurement, while we used 
the daily maximum 8-hour average for ozone to parallel the EPA regulatory standards and capture 
daily variability in ambient concentrations. 40  Concentrations of PM2.5 and PM10 are based on 24-
hour measurements, but were often measured only on every 3rd or 6th day.  For the present analysis, 
we averaged over the daily maximum or 24-hour measurements for weeks two through eight of 
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pregnancy, measured from the estimated date of conception, to assign a seven-week  and also one-
week averages of the maximum daily values.  Per NBDPS protocols, estimated date of conception 
was obtained by calculating backwards from the estimated date of delivery each woman reported 
being given by her clinician during pregnancy.  We included week two in addition to the standard 
window of cardiac development, as previous literature suggests the potential for lag effects of air 
pollution. 3,146  Ambient levels of each pollutant except ozone were categorized using the 
distribution of pollutant concentration among the controls into the following categories: less than 
the 10th centile (referent), 10th centile to the median, median to the 90th centile and greater than or 
equal to the 90th centile.  These categories captured the departure from linearity observed in initial, 
exploratory analyses.  Ozone was categorized into quartiles for the same reason.  Centiles were 
calculated separately for the seven-week and one-week measures of exposure, although the values 
were very similar.         
Potential confounders were identified through review of the literature and directed acyclic 
graph analysis.147  The following variables obtained from the maternal interview were included in 
the final adjustment set for all statistical models:  age, race/ethnicity, educational attainment, 
household income, tobacco smoking in the first month of pregnancy, alcohol consumption during 
the first trimester, and maternal birth outside of the US.  Educational attainment was collapsed into 
the following categories: 0-6 years, 7-11 years, completed high school or equivalency, 1-3 years 
college or completed technical school, bachelor’s degree, and masters or advanced degree.  In order 
to account for potential differences in case ascertainment by study center, final models were also 
adjusted for the center-specific ratio of septal defects to total heart defects.  This adjustment for 
center was chosen to account for differences in the types of cardiac cases that were recruited at 
each site, without controlling away effects due to spatial variability in pollutant concentrations that 
could occur when using a crude indicator for site.  Distance to the closest major road, defined as an 
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interstate, US highway, state or larger county highway was constructed using ArcGISv10 and then 
dichotomized first at 200 meters and then at 50 meters, consistent with previous research which 
suggests that pollutant levels drop-off more than 200 meters from a roadway. 148   All potential 
confounders, as well as pre-pregnancy body mass index, maternal occupation status during 
pregnancy (defined dichotomously), and distance to a major roadway were assessed for effect 
measure modification using likelihood ratio tests with an a priori alpha level of 0.1.       
4.2.3 Statistical Analysis 
For each pollutant, models were constructed to explore individual defects and defect-
groupings.  Because we simultaneously assessed multiple weeks of exposure and multiple 
defects/groupings, we constructed two-stage hierarchical regression models, using a SAS/IML 
software program adapted from Witte et al, to account for the correlation between estimates and 
partially address multiple inference. 144,149 The first-stage, represented in Equation 1, was an 
unconditional, polytomous logistic regression model of individual CHDs on exposure (X) defined as 
either all one-week averages of maximum or 24-hour pollutant values or the single 7-week average, 
and the full adjustment set (w) detailed above.  
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βd is the vector of regression coefficients corresponding to pollutant exposure for an individual CHD 
(d), while γd is the vector of regression coefficients corresponding to the covariates for a given 
defect, and m is the total number of individual types of CHDs.  The second-stage model is given in 
Equation 2   
              (2) 
where Zi is a row in the design matrix that includes an intercept term and then indicator variables for 
type of defect, broader defect grouping, and exposure week/level for the i-th β, π is the vector of 
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coefficients corresponding to the variables included in the design matrix and δi are independent 
normal random variables with a mean of zero and a variance of τ2 that describe the residual 
variation in βi.  The obtained second-stage coefficients,π, are used to estimate the means toward 
which the first-stage coefficients will be shrunk, with the magnitude of the shrinkage depending 
upon the precision of the maximum likelihood estimate obtained in stage 1 and the value of the 
second stage variance, τ2. 144,145  We fixed τ2 at 0.5, corresponding to a prior belief with 95% certainty 
that the residual odds ratio will fall within a 16-fold span.   
To assess whether our results were robust to changes in model specification we conducted 
sensitivity analyses by setting the value of τ2 to 0.25, corresponding to a 7-fold odds ratio span, as 
well as to a value of 1, corresponding to a 50-fold span.   We also explored different specifications 
for the design matrix, in turn defining the prior mean as a common mean for all defects, a common 
mean for each defect, or a common mean for each exposure week/level, across defects.  Defects 
with fewer than 100 cases were excluded from hierarchical models and explored using Firth’s 
penalized maximum likelihood method to address the quasi-complete separation that occurred due 
to small sample size. 150   
In order to explore associations with CHDs within a multipollutant context, a principal 
component analysis (PCA) was conducted among the subset of participants who lived within 50 km 
of each type of monitor and had pollutant concentrations for all six pollutants.  PCA is used to 
reduce the number of correlated variables, which are believed to be measuring the same construct 
or source, into a smaller number of artificial variables that capture most of the variance of the 
original variables while being uncorrelated with each other. 140 This allows the resulting source-
factors to be included within the same model, reducing issues of multicollinearity.  From this 
analysis, we retained components with an eigenvalue at or greater than 1, which indicates that the 
component accounts for at least the same or more variance than one of the original pollutant 
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variables.  We then applied a varimax rotation and calculated factor scores for each participant.  
These factor-scores were subsequently categorized using the 10th, 50th and 90th centiles and used to 
assign exposure in hierarchical models.   
4.3 Results 
Characteristics of the study population are detailed in Table 4.1.  Approximately 90% of both 
cases and controls had a successfully geocoded residential address during the first 8 weeks of 
pregnancy.  Women with successfully geocoded addresses delivered infants with a similar case 
phenotype and had a racial, educational, and behavioral profile similar to the full study population.  
There were site-related differences in both geocoding success and proximity to pollutant monitors 
with more rural sites making up a smaller percentage of the analytic samples.  Additionally, women 
who lived within 50 km of a SO2 monitor were slightly older, more likely to be White or African-
American, work outside the home, have higher household income and report alcohol consumption 
during pregnancy.  The majority of women had daily exposure levels below EPA’s regulatory 
standards.   
4.3.1 Exposure assigned as a single 7-week average of daily maximums or 24-hour measurements 
Figure 4.1 shows the estimated adjusted odds ratios (OR) and 95% confidence intervals (CI) 
resulting from the hierarchical regression models of the 7-week average exposure to individual 
pollutants and CHDs.  Crude estimates were similar to estimates adjusted for confounders, so only 
adjusted estimates are shown.  Larger ORs were observed for both left and right ventricular outflow 
tract obstruction defects (LVOTO, RVOTO) than other defect groups.  For example, women with the 
highest average daily maximum exposure to NO2 (greater than 45.5 ppb) had more than two times 
the odds of both COA (OR 2.5 95% CI 1.21, 5.18) and PVS (OR 2.03 95%CI 1.23, 3.33) as women with 
the lowest exposure (less than 18.9 ppb).   We observed a similar relationship between SO2 exposure 
and PVS, although it was attenuated at the highest exposure level (OR 10-50/10 centile contrast 
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2.34 95% CI 1.33, 4.14; OR 50-90/10 centile contrast 2.06 95% CI 1.16, 3.67; OR 90/10 centile 
contrast 1.48 95% CI 0.74, 2.97). The odds of the conotruncal and septal groups were elevated with 
exposure to NO2 and PM10 although to a lesser magnitude than observed for the outflow tract 
defects.  There was some evidence of heterogeneity within the LVOTO defects as hypoplastic left 
heart syndrome (HLHS) was associated with exposure to PM2.5 (90/10 centile contrast: OR 2.04 95% 
CI 1.07, 3.89) but not NO2.    There was also some evidence of heterogeneity within septals related 
to SO2 exposure, as we observed increased odds of VSDs (OR 90/10 centile contrast 1.48 95% CI 0.91 
2.42) and reduced odds of atrial septal defects (ASD) (OR 90/10 centile contrast 0.67 95% CI 0.41, 
1.09).  Although imprecise, the effect estimates for anomalous pulmonary venous return (APVR) and 
CO and NO2 exposures indicated lower odds with greater exposure, although this was somewhat 
attenuated at the highest level of exposure.  Complete estimated ORs and 95% CIs are listed in Table 
A2.1. For both PM10 and NO2, we found evidence of effect measure modification by distance to a 
major road in first-stage maximum likelihood models (PM10 likelihood ratio test: χ
2 =30.5, p=0.03; 
NO2 likelihood ratio test: χ
2=34.5, p=0.01).  In both cases, odds ratios were generally greater for 
women who lived within 50 meters of a roadway (Table A2.2).   
4.3.2 Exposure assigned as one-week average of daily maximums or 24-hour measurements 
Examining the individual weeks of exposure did not identify periods of susceptibility that 
were consistent across pollutants.  For example, Figure 4.2 shows the weekly odds of PVS, a defect 
where elevated effect estimates were observed when using the seven-week summary measure of 
exposure.  As illustrated in the figure, there was no consistent window across pollutants, but both 
CO and ozone have individual weeks where the estimates were larger in magnitude than estimates 
obtained using the summary exposure and where the other weeks were closer to null, suggesting a 
period of greater susceptibility (CO-week 2: 90/10 centile comparison: OR 0.37 95% CI 0.19,0.7; 
ozone-week 3 75/25 centile comparison: OR 2.15 95% CI 1.22, 3.78).  Additionally, when exploring 
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PM2.5, a pollutant that had no association with PVS when using a summary measure of exposure, 
there was an almost doubling of odds in week 5 when comparing women with exposure greater 
than the 90th centile to women with exposure less than the 10th centile (OR 1.83 95% CI 1.08, 3.12) 
that was similarly observed in week 8.   
Weekly analysis of PM2.5 revealed more potential windows of susceptibility, particularly 
week 2 of pregnancy.  For example, women having a child with TOF have almost twice the odds of 
being above the 90th centile versus below the 10th centile for PM2.5 exposure in week 2 of pregnancy 
as controls (OR 1.96, 95% CI 1.11, 3.46) while women with a baby with atrioventricular septal defect 
(AVSD) have more than three times the odds (OR 3.43 95% CI 1.36,8.66).  Women with offspring 
with other septal defects, such as ASDs and perimembranous VSDs were less likely to have higher 
exposure during this time (OR 0.6, 95% CI 0.4, 0.9).  Another potential window was observed  when 
exploring SO2 and VSDs, where the summary exposure revealed a slightly elevated odds ratio among 
women with exposure greater than the 90th centile, but weekly analysis revealed this effect was 
limited to week 3 and the magnitude increased (OR 1.98 95% CI 1.1, 3.56). Drastic weekly 
fluctuations in odds were also observed, for example reduced odds for women with PM2.5 exposure 
above the 90th centile observed for aortic stenosis, COA, and dTGA in week 3 followed by elevated 
odds in week 4.  Full results for the weekly exposure analyses are provided in Tables A2.3 and A2.4.     
4.3.3 Principal Component Analysis 
Only 26% of the geocoded population lived within 50km of each type of pollutant monitor 
and had exposure data for all pollutants (Table 4.1).  These women were primarily from the 
Massachusetts and Atlanta sites, African-American, living in a higher income household, and non-
smokers during pregnancy, and they were more likely to be born outside the US.  Using this 
subsample, three source-factors emerged from the principal component analysis.  The factor that 
explained the largest amount of total variance was loaded primarily by CO and NO2 and is likely 
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related to motor vehicle traffic.  The second factor, driven by PM10,
 PM2.5 and ozone likely represents 
multiple sources as PM is a mixture itself and both PM2.5 and ozone are secondary pollutants.  The 
third factor was loaded by SO2 and most likely represents pollution from coal combustion.  Within 
this multipollutant context, we again observed elevated odds of multiple types of defects with 
greater exposure (Table 4.2).  Findings were less precise due to the reduced sample size, but 
elevated effect estimates between the NO2 loaded factor and LVOTO defects, as well as TOF, were 
seen although there was greater attenuation of odds at the highest exposure level in the source 
factor model than we observed in the single pollutant models.  In contrast, we did not observe a 
strong relationship between the NO2-loaded factor and PVS, although we did observe greater odds 
of PVS among women exposed to higher levels of the PM10/PM2.5/ozone factor.  Within the 
multipollutant context, the SO2 source factor was no longer associated with elevated odds of 
defects, and we observed an inverse relationship between that factor and septal defects.   
We did not observe a considerable difference in results obtained when using different 
values of second-stage variance or different design matrices. In order to explore our choice of 
including all women living within 50 km of a monitor, we reran our first-stage maximum likelihood 
single-pollutant analyses limiting subjects to women who lived within 10 km of a monitor.  This 
reduced the sample to 27.5-48.1% of the original study population depending upon pollutant.  
Despite the greater imprecision, we observed that estimates were generally similar or larger in 
magnitude in this subpopulation when examining the larger defect-groupings.  The exception to this 
was for SO2, where estimates were lower although very imprecise (Table A2.5). 
  
Table 4.1: Demographic comparison of NBDPS congenital heart cases and controls, 1997-2006, for full study and each pollutant examined 
a
 
 
 
 
 
N % N % N % N % N % N % N % N % N %
TOTAL POPULATION 12383 11144 7458 6849 7636 8077 7827 6205
  Excluded Diabetes 185 1.5 170 1.5 98 1.3 89 1.3 126 1.7 117 1.4 113 1.4 85 1.4
ANALYTIC POPULATION 12198 10974 7360 6760 7510 7960 7714 6120 2914
CONTROLS 7056 57.9 6328 57.7 4349 59.1 3968 58.7 4422 58.9 4632 58.2 4407 57.1 3508 57.3 1652 56.7
TOTAL CASES 5142 42.2 4646 42.3 3011 40.9 2792 41.3 3088 41.1 3328 41.8 3307 42.9 2612 42.7 1262 43.3
Left Ventricular Outflow Tract Obstructions 902 7.4 829 7.6 580 7.9 545 8.1 566 7.5 611 7.7 596 7.7 462 7.5 233 8
   Aortic Stenosis 200 1.6 182 1.7 117 1.6 110 1.6 112 1.5 137 1.7 135 1.8 87 1.4 47 1.6
   Coarctation of the Aorta 338 2.8 312 2.8 229 3.1 215 3.2 223 3 231 2.9 233 3 195 3.2 97 3.3
   Interrupted Aortic Arch-
   Type A
   Hypoplastic Left Heart  
   Syndrome
Conotruncals 1099 9 1004 9.2 753 10.2 691 10.2 736 9.8 757 9.5 736 9.5 587 9.6 315 10.8
   Common Truncus 46 0.4 44 0.4 33 0.5 30 0.4 24 0.3 32 0.4 32 0.4 26 0.4 16 0.5
   Interrupted Aortic Arch –
   Type B/NOS
   d-Transposition of the 
   Great Arteries
   Tetralogy of Fallot 571 4.7 520 4.7 399 5.4 355 5.3 386 5.1 401 5 396 5.1 307 5 168 5.8
   Double Outlet Right 
   Ventricle
   Conoventricular septal 
   defect
Atrioventricular Septal Defects 97 0.8 82 0.8 53 0.7 53 0.8 49 0.7 55 0.7 62 0.8 46 0.8 20 0.7
Anomalous Pulmonary Venous Return 171 1.4 155 1.4 105 1.4 100 1.5 112 1.5 118 1.5 114 1.5 84 1.4 46 1.6
   Total 147 1.2 135 1.2 96 1.3 93 1.4 104 1.4 105 1.3 101 1.3 74 1.2 42 1.4
   Partial 24 0.2 20 0.2 9 0.1 7 0.1 8 0.1 13 0.2 13 0.2 10 0.2 4 0.1
Full Sample of 
Controls and 
Simple 
Population 
with 
Geocoded 
Population 
living within 
50km from a 
Population 
living within 
50km from an 
Population 
living within 
50km from an 
Population 
living within 
50km from a 
Population 
living within 
50km from a 
Population 
living within 
50km from an 
Population 
living within 
50km from all 
0.1 3 0.16 0.1 7 0.1 7 0.1
353 2.9 326 3 228 3.1
8 0.1 611 0.1 9 0.1 6 0.1
220 2.9 174 2.8 86 3214 3.2 224 3 236 3
0.1 2 0.19 0.1 9 0.1 8 0.1
368 3 339 3.1 247 3.4
9 0.1 614 0.1 14 0.1 10 0.1
235 3.1 200 3.3 100 3.4238 3.5 254 3.4 252 3.2
0.4 12 0.428 0.4 30 0.4 34 0.4
50 0.4 46 0.4 32 0.4
30 0.4 2250 0.4 41 0.4 32 0.4
34 0.4 26 0.4 17 0.631 0.5 33 0.4 30 0.4
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Right Ventricular Outflow Tract Obstructions 811 6.7 728 6.6 502 6.8 459 6.8 487 6.5 522 6.6 540 7 443 7.2 211 7.2
   Pulmonary Atresia 100 0.8 92 0.8 69 0.9 60 0.9 65 0.9 72 0.9 71 0.9 59 1 29 1
   Tricuspid Atresia 45 0.4 41 0.4 32 0.4 30 0.4 33 0.4 36 0.5 34 0.4 26 0.4 15 0.5
   Ebstein's Anomaly 58 0.5 53 0.5 34 0.5 33 0.5 37 0.5 35 0.4 38 0.5 31 0.5 12 0.4
   Pulmonary Valve Stenosis 606 5 540 4.9 365 5 334 4.9 350 4.7 377 4.7 395 5.1 327 5.3 155 5.3
Septals 2062 16.9 1848 16.8 1018 13.8 944 14 1138 15.2 1265 15.9 1259 16.3 990 16.2 437 15
   Perimembranous 
   ventricular septal defects
   Muscular ventricular septal 
   defects
b
   Ventricular septal 
   defects,NOS
   Atrial septal defects 1057 8.7 936 8.5 416 5.7 395 5.8 550 7.3 617 7.8 709 9.2 452 7.4 204 7
Live Birth 12153 99.6 10935 99.6 7331 99.6 6735 99.6 7480 99.6 7930 99.6 7684 99.6 6096 99.6 2899 99.5
Fetal Death 31 0.3 26 0.2 18 0.2 17 0.3 19 0.3 21 0.3 18 0.2 18 0.3 11 0.4
Induced Abortion 7 0.1 7 0.1 5 0.1 3 <0.1 5 0.1 5 0.1 6 0.1 4 0.1 2 0.1
Arkansas 1835 15 1225 11.2 328 4.5 337 5 406 5.4 401 5 650 8.4 388 6.3 217 7.5
California 1471 12.1 1343 12.2 1237 16.8 1299 19.2 1302 17.3 1281 16.1 1068 13.8 253 4.1 209 7.2
Iowa 1390 11.4 1333 12.2 502 6.8 236 3.5 532 7.1 857 10.8 734 9.5 430 7 42 1.4
Massachusetts 1673 13.7 1624 14.8 1459 19.8 1485 22 1412 18.8 1398 17.6 1190 15.4 1479 24.2 858 29.4
New York 1095 9 1046 9.5 715 9.7 686 10.2 956 12.7 565 7.1 681 8.8 884 14.4 250 8.6
Texas 1665 13.7 1550 14.1 598 8.1 484 7.2 966 12.9 841 10.6 917 11.9 385 6.3 170 5.8
Metropolitan Atlanta 1460 12 1342 12.2 1314 17.9 1326 19.6 980 13.1 1329 16.7 1076 14 1276 20.9 790 27.1
North Carolina 715 5.9 654 6 495 6.7 177 2.6 507 6.8 513 6.4 633 8.2 448 7.3 68 2.3
Utah 894 7.3 857 7.8 712 9.7 730 10.8 449 6 775 9.7 765 9.9 577 9.4 310 10.6
MATERNAL AGE(avg,sd)
Born Outside United States 2212 18.5 1972 18 1546 21.1 1411 20.9 1558 20.9 1616 20.4 1514 19.7 1117 18.3 620 21.4
846 6.9 765 7 501 6.8
TABLE 4.1: (cont.)
Full Sample of 
Controls and 
Simple 
Population 
with 
Geocoded 
Population 
living within 
50km from a 
Population 
living within 
50km from an 
Population 
living within 
50km from an 
Population 
living within 
50km from a 
Population 
living within 
50km from a 
Population 
living within 
50km from an 
Population 
living within 
50km from all 
538 7 438 7.2 230 7.9461 6.8 495 6.6 522 6.6
1.4 0 074 1.1 79 1.1 109 1.4
26 0.2 24 0.2 16 0.2
0 0 86130 1.1 123 1.1 85 1.2
12 0.2 14 0.2 3 0.114 0.2 14 0.2 17 0.2
BIRTH OUTCOME
STUDY SITE
28.4 (6.18)
MATERNAL NATIVITY
26.9 (6.18) 27.1 (6.16) 27.8 (6.08) 27.7 (6.12) 27.5 (6.22) 27.5 (6.1) 27.5 (6.11) 28.2 (6.05)
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White, non-Latino 7331 60.1 6658 60.7 4263 57.9 3896 57.7 4227 56.3 4625 58.1 4507 58.4 3855 63 1668 57.3
Black, non-Latino 1380 11.3 1189 10.8 913 12.4 864 12.8 861 11.5 931 11.7 886 11.5 905 14.8 506 17.4
Latino 2755 22.6 2471 22.5 1659 22.6 1523 22.5 1909 25.4 1851 23.3 1783 23.1 924 15.1 502 17.2
Asian/ Pacific Islander 324 2.7 292 2.7 262 3.6 246 3.6 238 3.2 265 3.3 229 3 216 3.5 130 4.5
Other 405 3.3 362 3.3 261 3.6 229 3.4 273 3.6 286 3.6 307 4 219 3.6 107 3.7
White, non-Latino 6986 59 6424 59.5 4155 57.4 3796 57 4089 55.4 4493 57.4 4338 57.3 3757 62.3 1634 57.1
Black, non-Latino 1483 12.5 1305 12.1 982 13.6 920 13.8 940 12.7 1009 12.9 972 12.8 972 16.1 523 18.3
Latino 2714 22.9 2459 22.8 1635 22.6 1504 22.6 1885 25.5 1829 23.4 1774 23.4 924 15.3 495 17.3
Asian/ Pacific Islander 282 2.4 263 2.4 235 3.2 220 3.3 214 2.9 237 3 204 2.7 189 3.1 111 3.9
Other 370 3.1 342 3.2 236 3.3 218 3.3 252 3.4 261 3.3 282 3.7 193 3.2 101 3.5
0-6 years 422 3.5 362 3.3 249 3.4 228 3.4 270 3.6 267 3.4 264 3.4 140 2.3 78 2.7
7-8 years 228 1.9 206 1.9 128 1.8 110 1.6 145 1.9 146 1.8 141 1.8 96 1.6 45 1.6
9-11 years 1427 11.9 1263 11.6 767 10.5 716 10.6 852 11.4 851 10.7 865 11.3 542 8.9 259 8.9
Completed HS/Equiv. 2959 24.7 2646 24.2 1574 21.5 1468 21.8 1681 22.5 1769 22.3 1721 22.4 1263 20.7 575 19.8
1-3 years College 2925 24.4 2671 24.4 1745 23.8 1613 24 1748 23.4 1913 24.1 1853 24.1 1453 23.8 632 21.8
Completed Technical School 410 3.4 376 3.4 225 3.1 214 3.2 245 3.3 239 3 250 3.3 198 3.2 69 2.4
4 Years College/Bachelor's Degree 2610 21.8 2457 22.5 1869 25.5 1690 25.1 1774 23.7 1966 24.8 1844 24 1662 27.2 830 28.6
Master's Degree 779 6.5 732 6.7 591 8.1 539 8 587 7.9 589 7.4 577 7.5 581 9.5 317 10.9
Advanced Degree 226 1.9 216 2 181 2.5 157 2.3 171 2.3 185 2.3 165 2.2 167 2.7 97 3.3
0-6 years 471 4.1 411 3.9 290 4.1 266 4.1 314 4.3 315 4.1 307 4.1 163 2.7 81 2.9
7-8 years 221 1.9 196 1.8 122 1.7 113 1.7 138 1.9 130 1.7 133 1.8 85 1.4 39 1.4
9-11 years 1300 11.2 1162 10.9 680 9.5 637 9.7 765 10.5 775 10 804 10.8 494 8.3 221 7.8
Completed HS/Equiv. 3568 30.7 3203 30.1 1928 27 1786 27.2 2076 28.6 2121 27.5 2115 28.3 1617 27.1 748 26.4
1-3 years College 2241 19.3 2044 19.2 1349 18.9 1246 19 1339 18.5 1471 19.1 1425 19.1 1084 18.2 503 17.7
Completed Technical School 369 3.2 338 3.2 215 3 187 2.9 224 3.1 238 3.1 229 3.1 198 3.3 82 2.9
4 Years College/Bachelor's Degree 2414 20.8 2271 21.4 1721 24.1 1577 24 1621 22.3 1814 23.5 1688 22.6 1545 25.9 757 26.7
Master's Degree 689 5.9 654 6.1 536 7.5 490 7.5 504 6.9 543 7 506 6.8 509 8.5 249 8.8
Advanced Degree 363 3.1 350 3.3 300 4.2 258 3.9 277 3.8 309 4 269 3.6 277 4.6 159 5.6
TABLE 4.1: (cont.)
Full Sample of 
Controls and 
Simple 
Population 
with 
Geocoded 
Population 
living within 
50km from a 
Population 
living within 
50km from an 
Population 
living within 
50km from an 
Population 
living within 
50km from a 
Population 
living within 
50km from a 
MATERNAL RACE
PATERNAL RACE
MATERAL EDUCATION
Population 
living within 
50km from an 
Population 
living within 
50km from all 
PATERNAL EDUCATION
8
2
 
  
<10,000 2146 19.4 1837 18.2 1118 16.5 1028 16.5 1282 18.6 1249 17.2 1289 17.6 805 14.3 391 14.1
>50,000 3671 33.3 3513 34.8 2756 40.7 2513 40.4 2630 38.2 2811 38.7 2796 38.1 2506 44.5 1312 47.3
In Between 5223 47.3 4757 47.1 2899 42.8 2685 43.1 2964 43.1 3213 44.2 3258 44.4 2321 41.2 1072 38.6
Underweight 613 5.3 534 5 339 4.8 313 4.8 356 4.9 362 4.7 364 4.9 278 4.7 142 5
Normal Weight 6234 53.5 5683 53.8 3951 55.7 3635 55.8 3923 54.4 4234 55.2 3945 53.2 3340 56.3 1592 56.4
Overweight 2717 23.3 2471 23.4 1610 22.7 1469 22.6 1680 23.3 1761 23 1764 23.8 1330 22.4 634 22.4
Obese 2091 17.9 1877 17.8 1188 16.8 1097 16.8 1251 17.4 1309 17.1 1347 18.2 989 16.7 457 16.2
Reported Ever Smoking 4044 33.6 3637 33.2 2299 31.3 2097 31.1 2426 32.4 2508 31.6 2419 31.4 2031 33.2 901 31
Reported Smoking in 1st month of pregnancy 2012 16.7 1768 16.2 976 13.3 904 13.4 1082 14.5 1115 14 1104 14.4 886 14.5 372 12.8
None 7709 64.7 6968 64.2 4593 63 4243 63.2 4666 62.8 4991 63.3 4944 64.8 3708 61.1 1782 61.7
Less than 4 drinks per week 2749 23.1 2544 23.4 1858 25.5 1700 25.3 1885 25.4 1946 24.7 1822 23.9 1651 27.2 828 28.7
Binge drinking (4+ drinks per week) 1459 12.2 1345 12.4 844 11.6 766 11.4 879 11.8 947 12 869 11.4 710 11.7 277 9.6
Did not work outside home 3416 28.5 3059 28 2024 27.6 1883 27.9 2147 28.7 2207 27.8 2208 28.7 1567 25.7 803 27.6
Within 50 km n/a 2012 18.3 1330 18.1 1232 18.2 1397 18.6 1449 18.2 1412 18.3 1155 18.9 570 19.6
14.8 13.7 12.8 13.5 10.4 18.8
0 0 251 3.7 2908 38.7 76 1 1735 22.5 803 13.1
TABLE 4.1 (cont)
MATERNAL HOUSEHOLD INCOME
MATERNAL BODY MASS INDEX
Full Sample of 
Controls and 
Simple 
Population 
with 
Geocoded 
Population 
living within 
50km from a 
Population 
living within 
50km from an 
Population 
living within 
50km from an 
Population 
living within 
50km from a 
MATERNAL SMOKING
MATERNAL ALCOHOL CONSUMPTION
Reported month prior through first trimester
MATERNAL OCCUPATIONAL STATUS
PROXIMITY OF MATERNAL RESIDENCE TO MAJOR ROADWAY
MONITOR-RELATED CHARACTERISTICS
Population 
living within 
50km from a 
Population 
living within 
50km from an 
Population 
living within 
50km from all 
35 μg/m
3
,24hr 75 ppb,1hr
At least one day of exposure greater than regulatory standard
a
 Does not include missing data so not all variables will sum to the total sample size
b
 PM2.5 data was only available after 1999 and NBDPS stopped recruiting simple, isolated muscular VSDs after the first year of data collection.
Median distance to monitor (km)
EPA Regulatory Standard, averaging time 35ppm,1hr 100 ppb,1hr 75 ppb,8hr 150 μg/m
3
,24hr
8
3
 
  
Figure 4.1: Estimated adjusted odds ratios and 95% confidence intervals between congenital heart defects 
average of daily maximums/24 hour measures of criteria air pollutants, NBDPS 1997
For all pollutants except ozone, the three categories of exposure are: 10
centile, at or greater than the 90
th
 centile, with the referent level being less than the 10
ozone, the three categories of exposure were 25
75
th
 centile, with the referent grouping being below the 25
while squares indicate individual defects.  A double arrow indicates the confidence interval went beyond the 
boundary of the figure. 
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Figure 4.2: Estimated adjusted odds ratios and 95% confidence intervals of pulmonary valve stenosis (PVS) for categorical 
measures of one-week averages of daily maximums/24 hour measures of criteria air pollutants, plotted for weeks 2 
through 8 of pregnancy NBDPS 1997-2006.
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Table 4.2: Estimated adjusted odds ratios and 95% confidence intervals between pollutant factors identified through 
principal components analysis and cardiac birth defects within NBDPS 1999-2006 
 
 
 
 
  
Factor 1
Loadings CO: 85 NO2: 71 OZ:-39
PM10: 40 PM2.5: 21 SO2:5
<10th 
percentile 
(Referent)
10th percentile to 
median
median to 90th 
percentile >90th percentile
LVOTO
a
1 1.57 (0.93,2.63) 1.62 (0.96,2.74) 1.04 (0.51,2.1)
Aortic Stenosis
b
1 2.31 (0.76,6.98) 2.34 (0.76,7.15) 1.88 (0.31,11.21)
Coarctation of the Aorta
b
1 1.25 (0.61,2.57) 1.47 (0.71,3.03) 1.22 (0.49,3.02)
Hypoplastic Left Heart Syndrome
b
1 1.59 (0.77,3.28) 1.58 (0.75,3.3) 1.21 (0.46,3.22)
CONOTRUNCALS
a
1 1.18 (0.75,1.84) 1.35 (0.86,2.12) 1.24 (0.71,2.17)
d-TGA
b
1 1.09 (0.57,2.1) 1.17 (0.6,2.27) 1.17 (0.52,2.66)
Tetralogy of Fallot
b
1 1.33 (0.74,2.4) 1.64 (0.91,2.97) 1.27 (0.6,2.69)
Other Conotruncals
b
1 1.08 (0.44,2.63) 1.08 (0.43,2.69) 1.23 (0.41,3.65)
APVR
a
1 0.52 (0.23,1.2) 0.66 (0.29,1.5) 0.83 (0.3,2.3)
AVSD
c
1 0.40 (0.13, 1.36) 0.87 (0.28, 2.68) 0.51 (0.10, 2.70)
RVOTO
a
1 1.13 (0.68,1.86) 1.27 (0.77,2.11) 1.4 (0.75,2.62)
Pulmonary/Tricuspid Atresia
b
1 1.37 (0.59,3.21) 0.85 (0.34,2.14) 1.26 (0.43,3.68)
Pulmonary Valve Stenosis
b
1 1.06 (0.6,1.85) 1.41 (0.8,2.48) 1.41 (0.69,2.89)
SEPTALS
a
1 1.03 (0.69,1.52) 1.2 (0.81,1.78) 1.12 (0.69,1.81)
VSD-perimembranous
b
1 0.8 (0.5,1.27) 0.97 (0.6,1.56) 0.95 (0.53,1.71)
ASDs
b
1 1.36 (0.77,2.39) 1.49 (0.84,2.64) 1.32 (0.67,2.62)
a
Estimates results from a hierarchical regression model.  First stage was polytomous logistic model with 
defect groupings as outcomes and adjusted for maternal race, maternal age, maternal educational 
attainment, maternal household income, maternal smoking status and alcohol consumption during early 
pregnancy, nativity, and site-specific heart defect ratio. Second stage was a linear model with indicator 
variables for defect grouping and level of exposure.
b
Estimates result from a hierarchical regression model, same as above but with individual defects as 
outcomes.
c
Estimates result from model utilizing Firth's penalized maximum likelihood regression to deal with quasi-
separation of points due to small sample size in certain cells.  Model adjusted for variables listed above.
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Table 4.2 (cont.)
Factor 2
Loadings CO: 11 NO2: 6 OZ: 66
PM10: 68 PM2.5: 71 SO2: -3
<10th 
percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile >90th percentile
LVOTO
a
1 1.42 (0.86,2.36) 1.26 (0.75,2.12) 1.33 (0.69,2.53)
Aortic Stenosis
b
1 2.15 (0.72,6.45) 1.89 (0.62,5.72) 1.93 (0.5,7.36)
Coarctation of the Aorta
b
1 0.99 (0.52,1.87) 0.82 (0.42,1.59) 1.37 (0.62,3)
Hypoplastic Left Heart Syndrome
b
1 2.04 (0.88,4.73) 1.94 (0.82,4.56) 1.26 (0.44,3.63)
CONOTRUNCALS
a
1 1.11 (0.72,1.69) 1.15 (0.74,1.77) 1.19 (0.69,2.04)
d-TGA
b
1 1.04 (0.55,1.96) 1.03 (0.54,1.99) 1.29 (0.58,2.86)
Tetralogy of Fallot
b
1 1.15 (0.66,2) 1.33 (0.76,2.33) 1.27 (0.63,2.55)
Other Conotruncals
b
1 1.23 (0.5,3.02) 0.96 (0.38,2.44) 0.99 (0.32,3.06)
APVR
a
1 0.84 (0.37,1.91) 0.72 (0.3,1.69) 0.59 (0.19,1.85)
AVSD
c
1 1.32 (0.38, 4.59) 0.67 (0.17, 2.62) 1.20 (0.25, 5.91)
RVOTO
a
1 1.32 (0.78,2.24) 1.24 (0.72,2.14) 1.85 (0.99,3.46)
Pulmonary/Tricuspid Atresia
b
1 1.49 (0.57,3.87) 0.99 (0.36,2.73) 1.7 (0.56,5.13)
Pulmonary Valve Stenosis
b
1 1.2 (0.66,2.18) 1.28 (0.7,2.34) 1.89 (0.94,3.79)
SEPTALS
a
1 1.06 (0.74,1.52) 0.89 (0.61,1.3) 0.73 (0.44,1.19)
VSD-perimembranous
b
1 1.47 (0.89,2.43) 1.09 (0.65,1.84) 0.95 (0.5,1.83)
ASDs
b
1 0.8 (0.51,1.27) 0.78 (0.49,1.25) 0.62 (0.32,1.17)
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4.4 Discussion 
In this analysis, we found the odds of several CHDs were higher among women with greater 
exposures to criteria air pollutants.  Evaluating individual weeks of exposure revealed some 
potential windows of susceptibility for individual defect-pollutant relationships.  This is the first 
study to examine PM2.5 exposure and CHDs, and we found elevated odds of AVSD, HLHS, PVS, and 
TOF within the period of cardiac development. The toxicology of the criteria pollutants suggest that 
maternal exposure early in pregnancy may play a role in altered cardiac development, potentially 
through mechanisms such as inflammatory processes in the mother, altered DNA methylation, and 
increased viscosity of blood plasma affecting blood flow and maternal/fetal nutrition.13,151    
Table 4.2 (cont.)
Factor 3
Loadings CO: -11 NO2:25 OZ: -20
PM10: -18 PM2.5: 32 SO2: 94
<10th 
percentile 
(Referent)
10th percentile to 
median
median to 90th 
percentile >90th percentile
LVOTO
a
1 1.02 (0.58,1.77) 1.01 (0.58,1.77) 0.86 (0.44,1.7)
Aortic Stenosis
b
1 1.58 (0.56,4.52) 1 (0.35,2.9) 0.69 (0.16,3.1)
Coarctation of the Aorta
b
1 0.81 (0.38,1.73) 1.28 (0.61,2.67) 0.67 (0.26,1.72)
Hypoplastic Left Heart Syndrome
b
1 1.1 (0.5,2.43) 0.88 (0.4,1.96) 1.15 (0.46,2.86)
CONOTRUNCALS
a
1 0.79 (0.48,1.28) 1.05 (0.64,1.7) 0.8 (0.44,1.44)
d-TGA
b
1 0.68 (0.32,1.44) 1.15 (0.55,2.39) 1.05 (0.45,2.43)
Tetralogy of Fallot
b
1 0.85 (0.45,1.61) 1.01 (0.54,1.89) 0.72 (0.34,1.56)
Other Conotruncals
b
1 0.78 (0.31,1.94) 0.97 (0.39,2.39) 0.48 (0.14,1.7)
APVR
a
1 0.58 (0.23,1.49) 0.92 (0.37,2.3) 0.47 (0.14,1.53)
AVSD
c
1 2.84 (0.28, 28.9) 2.18 (0.21, 22.7) 2.59 (0.21, 32.7)
RVOTO
a
1 1.35 (0.74,2.45) 1.1 (0.6,2.02) 1.18 (0.58,2.38)
Pulmonary/Tricuspid Atresia
b
1 0.97 (0.36,2.63) 1.05 (0.39,2.82) 0.87 (0.27,2.81)
Pulmonary Valve Stenosis
b
1 1.51 (0.76,3) 1.08 (0.54,2.18) 1.03 (0.46,2.31)
SEPTALS
a
1 0.69 (0.47,1.03) 0.64 (0.43,0.97) 0.54 (0.32,0.9)
VSD-perimembranous
b
1 0.65 (0.4,1.07) 0.59 (0.36,0.98) 0.67 (0.37,1.23)
ASDs
b
1 0.76 (0.45,1.29) 0.7 (0.41,1.19) 0.4 (0.19,0.83)
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Utilizing one-week averages, we observed temporal variability in odds of certain CHDs 
within the window of cardiac development, including elevated odds of COA with week 3 ozone 
exposure and elevated odds of TOF and AVSD, but reduced odds of septal defects, with greater 
exposure to PM2.5 during week 2 of pregnancy.  It is possible that environmental insults early in 
cardiac development could result in more complex defects, thus reducing the risk of a single, 
isolated septal defect associated with PM2,5 exposure.  One limitation of using multiple weeks of 
exposure in a single model is the multicollinearity which arises due to the high correlation between 
individual weeks of exposure.  Although utilizing hierarchical regression partially addressed multiple 
inference and accounted for some of the correlation between effect estimates, more sophisticated 
models which utilize Bayesian shrinkage to a greater degree may better account for the correlation 
between time periods of exposure and improve. 33       
Our main analysis explored each pollutant individually, potentially confounding effects of 
the different pollutants.  The PCA-based analysis that we used to explore the odds of defects in a 
multipollutant context continued to show greater odds of certain CHDs with increasing pollutant 
exposure.  Many of the associations with SO2 found in the single-pollutant analysis, however, were 
not observed when the SO2 loaded component was examined simultaneously with other pollutant 
components.  These differences could be due to co-pollutants not accounted for in the single-
pollutant models or to the smaller size and different demographics of the subsample of women with 
data on all pollutants.  In single-pollutant analyses, we observed greater odds ratios among women 
living close to major roadways for both exposure to NO2 and PM10.  As these pollutants are known to 
arise from motor vehicle traffic and distance to a monitor was highly correlated to distance to a 
major roadway, it seems likely that living near a roadway was a marker for more accurate exposure 
classification rather than an interaction between different sources of pollutants.            
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When using the single 7-week summary exposure, we observed the primary associations 
reported in the previous meta-analysis, NO2 and TOF and SO2 exposure and COA. 
23  The meta-
analysis also suggested associations between NO2 and COA, SO2 and TOF, and PM10 and ASDs, 
although these were no longer significant once the largest study was excluded. Of these, we only 
observed the association between NO2 and COA.  Our results were consistent with some of the 
findings from individual studies that were not identified in the meta-analysis.  We observed the 
association between SO2 and VSDs observed in Gilboa et al. (2005) and, had we collapsed the 
different VSD categories, we would have seen the increased odds of VSDs with CO exposure 
observed by Ritz et al. (2002).  We did not observe the inverse associations between SO2 and 
conotruncal defects reported by both Gilboa et al and Hansen et al 8,16 but in our source-factor 
analysis, there was a suggestion of an inverse relationship between conotruncal defects and the 
factor driven by SO2.   
As the largest, ongoing case-control study of birth defects in the United States, the NBDPS 
has a large sample size that allows analysis of systematically classified CHDs.  We limited our 
analyses to simple, isolated defects to avoid heterogeneity from etiologies of multiple defects.  The 
variation observed within larger groupings of CHDs illustrates the importance of examining 
individual CHDs, as aggregations based on different classification schemes would impact observed 
estimates.  We had complete residential history, avoiding the misclassification of exposure that 
occurs when using residence at delivery. 135  We also explored how timing of exposure within the 
critical window of heart development impacted the odds of different defects and utilized daily 
maximums so as not to smooth over potentially relevant variability in exposure.  Utilizing 
hierarchical regression allowed us to improve estimation and partially address the issue of multiple 
testing.  Finally, this was the first study to explore associations between PM2.5 and CHDs and to 
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utilize principal component analysis to assess the relationship between air pollutants and CHDs in a 
multipollutant context. 
Assigning ambient concentrations of pollutants at their residential location as an individual’s 
exposure does not account for time-activity patterns such as time spent indoors and pollutant 
concentrations at other relevant locations.  This potential for exposure misclassification could 
impact our effect estimates if there are differences in these factors between cases and controls, 
which could occur if women of case offspring had more difficult pregnancies, limiting their outdoor 
movement.  
The NBDPS had a response slightly lower than 70% and like many studies is subject to 
potential selection bias based on who agrees to participate.  Additionally, there is the potential for 
selection bias if the factors that contribute to women living near a pollutant monitor are also 
associated with pollutant exposure and CHDs.  While monitors are often sited based on population 
density and suspected pollutant exposure 152, we did not observe strong associations between 
maternal demographic factors that could influence residential location and the presence of CHDs 
within our full population.  However, our results may not be generalizable to rural populations that 
live more than 50 km from an air monitor.  Our source-factor analysis was based on small numbers 
of a highly select population who live near multiple pollutant monitors and may not be generalizable 
to the larger population.  We conducted many analytic contrasts, and although hierarchical 
regression partially addresses multiple comparisons, it is possible that some of our findings are due 
to chance.     
In this study, we observed associations between several CHDs and greater pollutant 
exposure, even at ambient levels below current EPA regulatory standards.  Some of these elevated 
effects were observed only during specific weeks within the window of cardiac development, 
suggesting that accounting for temporal variability in pollutant concentrations and developmental 
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susceptibility can improve effect estimation. Future research should focus on further exploration of 
temporal windows of susceptibility and examining the risk of CHDs within a multipollutant context, 
in order to gain understanding of the contribution of the different air pollutants and their sources.
  
 
CHAPTER 5 
5. COMPARING THE IMPACT OF MONITOR-BASED VERSUS MODEL-BASED ESTIMATES OF 
POLLUTANT EXPOSURE ON THE RELATIONSHIP BETWEEN MATERNAL EXPOSURE TO PM2.5 AND 
OZONE URING PREGNANCY AND CONGENITAL HEART DEFECTS IN OFFSPRING  
 
5.1 Introduction 
 Epidemiologic studies of the health effects of air pollutants often take advantage of existing 
stationary air monitoring networks to provide air pollutant information over large spatial areas.13,153  
Measurements from these networks, intended to assure compliance with the Environmental 
Protection Agency’s (EPA) regulatory standards, are compiled into a publicly available, repository 
known as the Air Quality System (AQS).57  The AQS can then be used to provide historical 
measurements of multiple air pollutants in order to assign exposure at a relatively low-cost to 
researchers.  However, the density of these air monitoring networks is not consistent across space 
or time, as most monitors are located in urban areas and for some pollutants, including fine 
particulate matter (PM2.5), measurements are not taken daily or in the case of ozone, are not 
measured during colder months.  This lack of spatial and temporal resolution can impact the effect 
estimates of epidemiologic studies by excluding rural populations who do not live in proximity to air 
monitors as well as excluding those individuals whose period of exposure occurs when monitors are 
non-operational.  
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Spatiotemporal deterministic air pollutant prediction models, such as the EPA’s Community 
Multiscale Air Quality (CMAQ) model have the capability of predicting air pollutant concentrations 
consistently across large spatial areas, by utilizing multiple sources of data, including emissions and 
meteorological data, to simulate chemical transformation and fate within the atmosphere.137  The 
resulting output, a 12 km x 12 km gridded pollutant surface, can be used to assign daily exposures 
for the entire population, including those living far from air monitoring networks.  However, these 
outputs can be subject to some bias due to the varying quality of the underlying emissions 
inventories and the many assumptions made throughout the modeling process.  For example, a 
recent study by Bravo et al compared estimates from AQS and CMAQ and found that for short-term 
metrics of exposure (i.e. daily or weekly) there were seasonal, as well as spatial variations in how 
well the CMAQ predictions matched AQS measurements.154 
Methods have been developed which calibrate the CMAQ predictions using monitoring 
measurements where they are available, to take advantage of the greater temporal and spatial 
resolution of predictive models, while improving these predictions by incorporating information 
from the presumably unbiased measurements.  One such method, described by Berrocal et al, 
combines these two sources of data using linear regression with spatially- and temporally-varying 
bias coefficients in a Bayesian framework.138 The resulting model, referred to as downscaler CMAQ 
because it scales gridded CMAQ output down to the point-level monitoring data, provides bias-
corrected, daily concentrations of 24-hour PM2.5 and 8-hour maximum ozone at the centroid of 
every census tract in the United States.  One previous study has compared estimates obtained using 
output from the downscaler CMAQ numerical model to those obtained from AQS measurements, 
but the study focused only on ozone and was limited to a single state.155  Exploring a larger 
geographic area could provide details on how agreement between AQS measurements and 
downscaler CMAQ model estimates vary spatially.   
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The goal of this analysis was to compare the use of pollutant concentration measurements 
from the AQS monitoring network to calibrated pollutant predictions from the downscaler CMAQ 
model to assign exposure in a study of the relationship between maternal air pollutant exposure 
during pregnancy and congenital heart defects (CHDs) in offspring.  We explored whether there 
were differences in the magnitude of the assigned exposure, as well as whether differences in study 
population due to the greater spatial and temporal resolution of the downscaler CMAQ model 
impacted effect estimates.    
5.2 Methodology 
This study was reviewed and approved by the University of North Carolina, Chapel Hill 
Institutional Review Board.   
5.2.1 Study Population 
 The National Birth Defects Prevention Study, a large multisite, population-based case-
control study begun in 1997, has been described previously.101  Cases include livebirths and 
stillbirths greater than 20 weeks gestation or at least 500 grams, as well as elective terminations of 
prenatally-diagnosed defects at any gestational age.  Because of their known etiology, cases with 
chromosomal/microdeletion disorders and single-gene deletion disorders are excluded.  Controls 
are livebirths who are randomly selected from either vital records or hospital records, depending 
upon study center.  There is a 69% response among cases and a 65% response for controls.  Because 
downscaler CMAQ predictions were only available starting in 2001, we restricted to participants 
who had estimated dates of conception from 2001 through 2006, the last year for which geocoded 
residential information was available for NBDPS participants at the time of this study.  Additionally 
because downscaler CMAQ predictions were not available for the entire US during this time period, 
if a woman resided in a geographic location where downscaler predictions were not created, she 
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was excluded from this analysis.  This restriction resulted in excluding women from the California 
and Utah study centers, and women from the Texas study center with estimated dates of 
conception prior to 2002.   
The NBDPS case-classification scheme for CHDs has been described previously 97.  A team of 
reviewers assign a single, detailed cardiac phenotype to each case based on medical record review.  
These phenotypes are then aggregated into 27 main individual defects and then again into eight 
broader groupings of defects.  To create a homogeneous case group, cases with multiple CHDs or a 
simultaneous non-CHD were excluded from this analysis, as were cases with mothers who had non-
gestational diabetes due to its strong association with CHDs in offspring.110 The resulting single, 
isolated CHDs fell into 23 individual defects and six broader groupings (Table 5.1).  Due to sample 
size limitations, only aortic stenosis, coarctation of the aorta (COA), hypoplastic left heart syndrome 
(HLHS), tetralogy of Fallot (TOF), transposition of the great arteries (dTGA), pulmonary valve stenosis 
(PVS), perimembranous ventricular septal defects(VSDpm) and atrial septal defects (ASD) were 
examined as individual defects.  Common truncus, interrupted aortic arch-type b, interrupted aortic 
arch-not otherwise specified (iaa-typeb, iaa-nos), double outlet right ventricle associated with 
transposition of the great arteries (DORV-TGA) and not (DORV-other)  and conoventricular septal 
defects (VSDcono) were aggregated into a new category, ‘Other Conotruncals’.  All other individual 
defects were explored only as part of the larger, broader categories.   
5.2.2 Exposure Assignment and Confounder Selection 
NBDPS participants complete a computer-assisted telephone interview and provide their 
complete residential history during pregnancy.  Because the downscaler CMAQ predicts pollutant 
concentrations at the centroid of every census tract, women were matched to the closest centroid 
of a census tract, using ArcGIS v10, starting with their residence at conception.  In some cases, the 
closest centroid was not the centroid of the census tract the woman lived within.  If a woman had 
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additional residences during the first eight weeks of pregnancy, she was matched to the centroids 
closest to those residences as well, corresponding to the time of pregnancy that she lived there.  For 
both PM2.5 and ozone, daily predictions at that centroid from the downscaler CMAQ model were 
assigned to each woman and then averaged over weeks two through eight of pregnancy, the 
window of cardiac development, to create a single 7-week measure of exposure.  Individual weekly 
averages were also constructed to explore the effects of the greater temporal resolution of 
downscaler CMAQ predictions.  In order to compare the downscaler CMAQ predictions to 
measurements from AQS monitors, women whose residential addresses were within 50 km of a 
stationary air monitor were assigned exposure from that source in the same manner as above.  At 
many monitoring sites, PM2.5 measurements were only taken every 3
rd or 6th day.   
To compare pollutant predictions obtained from the downscaler CMAQ model to 
concentrations obtained from AQS air monitors, we compared the distributions of pollutant 
predictions and concentrations from each source for the population that lived within 50 km of an air 
monitor.  We then compared the distributions of downscaler CMAQ predictions among those who 
do and do not live within 50 km of a stationary air monitor to determine the impact of including 
populations that do not live near regulatory monitors.  We also explored the pollutant predictions 
and concentrations categorically, as this form of an exposure metric  is often utilized in 
epidemiologic studies.  Accounting for departures of linearity observed in exploratory analyses, we 
categorized PM2.5 using the pollutant prediction or concentration among the controls into the 
following categories: Low- less than the 10th percentile (referent), Low-middle-10th percentile to the 
median, Middle-high median to the 90th percentile and High- greater than or equal to the 90th 
percentile.  These percentile cut-offs were calculated separately for the following three measures: 
CMAQ predictions for the full population, AQS concentrations for the population within 50 km of a 
monitor and CMAQ predictions for the population within 50 km of a monitor. Percentiles were 
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calculated separately for the seven-week average and the individual weeks of exposure, although 
the values were very similar.  Ozone was categorized into quartiles in a similar manner.  We used 
percentile based cut-offs to accommodate the differences in distribution between the different 
exposure metrics.  We also explored using constant numeric cutoffs to create our categories but did 
not observe substantial difference in the resulting categorizations and continued to use the 
percentile-based cut-offs.  In addition, we explored factors which we hypothesized could impact 
agreement between the two metrics constructed for the same population (i.e. those living within 50 
km of a monitor), including season of exposure and closer proximity to the stationary air monitor. 
Potential confounders were identified through review of the literature and directed acyclic 
graph analysis.  The following variables obtained from the maternal interview were included in the 
final adjustment set:  age, race/ethnicity, educational attainment, household income, tobacco 
smoking in the first month of pregnancy, and alcohol consumption during the first 3 months of 
pregnancy.  Additionally, in order to account for potential differences in case ascertainment by 
study center, final models were adjusted for the center-specific ratio of septal defects to total CHDs.  
This adjustment for center was chosen to account for differences in the types of cardiac cases that 
were recruited at each site, as single-isolated setpal defects are often the most sensitive markers of 
differences in case ascertainment.  Maternal birth outside the US was identified as a potential 
confounder through review of the literature but did not affect the estimates obtained upon 
adjustment, and was not included in the final model.  A potential effect measure modifier, distance 
to the closest major road, defined as an interstate, US highway, state or larger county highway (FCC 
code A10-A39), was constructed using ArcGISv10 and then dichotomized at 50 meters.   That 
distance variable, as well as pre-pregnancy body mass index, maternal occupation status, and the 
confounders listed above were assessed for effect measure modification using likelihood ratio tests 
with an a priori alpha level of 0.1.         
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5.2.3 Statistical Analysis 
In order to contrast how changing the source of exposure assignment and/or changing the 
population included impacts the estimate of the relationship between each pollutant and CHDs, we 
constructed the following three sets of models: 1) using CMAQ predictions to assign exposure for 
the full population 2) using AQS measurements to assign exposure for those living within 50 km of 
an air monitor 3) using CMAQ predictions to assign exposure for those living within 50 km of an air 
monitor.  Because each model simultaneously assessed multiple weeks of exposure and multiple 
defects/groupings, we constructed two-stage hierarchical regression models, using a software 
program adapted from Witte et al, to account for the correlation between estimates and partially 
address multiple inference. 144,149 The first-stage was an unconditional, polytomous logistic 
regression model containing all individual weeks of exposure, or the single 7-week average, and the 
full adjustment set detailed above. The resulting coefficients for the pollutant-defect relationships 
from that model were then regressed on a linear combination of indicator variables that defined the 
exposure week/level, the type of individual defect, and the broader defect-grouping of each 
coefficient in a second-stage model.  The obtained second-stage coefficients are used to estimate 
the values toward which the first-stage coefficients will be shrunk towards, with the magnitude of 
the shrinkage depending upon the precision of the maximum likelihood estimate obtained in stage 1 
and the value of the second stage variance, τ2. 144,145  We fixed τ2 at 0.5, corresponding to a prior 
belief with 95% certainty that the residual odds ratio (i.e. not defined by the second stage) will fall 
within a 16-fold span.  To assess whether our results were robust to changes in model specification 
we explored setting the value of τ2 to 0.25, corresponding to a 7-fold odds ratio span as well as to a 
value of 1, corresponding to a 50-fold span.  Since there were fewer than 50 cases, the defect 
grouping of atrioventricular septal defects (AVSD) was explored separately using Firth’s penalized 
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maximum likelihood method to address the quasi-complete separation that occurred due to small 
sample size. 150   
5.3 Results 
 After the study exclusions, 2,051 cases and 2,791 controls were included in our full study 
population (Table 5.1).  Approximately 88.1% of these women lived within 50 km of an operational 
stationary air monitor for PM2.5 and 69.5% lived within 50 km of an operational stationary air 
monitor for ozone.  The lower percentage of women with ozone measurements from an AQS 
monitor is partly due to location and partly due to the lack of monitoring in many locations during 
the fall/winter months.  As shown in Table 5.1, despite reducing sample size, the profile of different 
CHDs does not vary greatly in the limited populations, although women whose offspring had septal 
defects made up a slightly lower percentage of women living near an ozone monitor.  There was a 
considerable difference in the breakdown of study sites as women from Arkansas and Iowa were 
less likely to live near either type of AQS monitor.  Demographically, women living near AQS 
monitors were slightly older, more likely to be Black or Latino, have an advanced educational 
degree, have a household income greater than $50,000 and be born outside of the United States.  
These women were slightly less likely to smoke during pregnancy and more likely to work outside 
the home.  While many of these differences were more pronounced for women living near ozone 
monitors, there was not a considerable difference in the make-up of the populations.       
 Figure 5.1a shows the population distribution of the seven-week average PM2.5 
concentration when using downscaler CMAQ predictions to assign exposure for the full population, 
downscaler CMAQ predictions for the population living within 50 km of an air monitor and the AQS 
measurements for the population living within 50 km of an air monitor. Comparing the distributions 
of AQS measurements and downscaler CMAQ predictions for the population living within 50 km of 
an air monitor, we observe that using the AQS measurements yields a distribution with a slightly 
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larger range and slightly greater density in the tails of the distribution than when using the 
downscaler CMAQ predictions, although the mean is slightly lower.  The Spearman correlation 
coefficient between the AQS measurements and the downscaler predictions for the population with 
both measurements is 0.88.  When contrasting the distributions of downscaler CMAQ predictions 
for the full population vs. the population that lives within 50 km of an air monitor, it appears that 
including the full population shifts the curve slightly to the left, but the shape doesn’t change 
considerably.  All three distributions have a relatively similar shape.  Figure 5.1b shows similar 
results for the population distributions of the seven-week average ozone concentration.  Again, 
using the AQS measurements provides a distribution with a lower mean, greater range and heavier 
tails, particularly the lower tail, although the Spearman correlation coefficient between the AQS 
measurements and the downscaler predictions is higher at 0.95.  However, the AQS and downscaler 
CMAQ distributions for the limited populations still have a relatively similar shape. Including the full 
population does not just shift the curve left, as it did for PM2.5, but instead increases the proportion 
of lower-middle values, changing the shape of the distribution from the other two.     
 The categorical exposure metrics based on these distributions also revealed differences that 
could impact the estimates obtained from epidemiologic studies.   Because the AQS and downscaler 
CMAQ distributions are different, the percentile cut-off values used to create the categorical 
exposure metrics, as described in the methods, vary slightly, although we observed similar results 
when using constant numeric cutoffs.  Approximately 72.2% of participants maintained the same 
exposure classification for both exposure metrics for PM2.5 and 79.5% of participants maintained 
consistent classification for ozone.  For PM2.5, the remaining 27.8% were split in half as to whether 
their categorization increased or decreased when using the downscaler CMAQ predictions as 
opposed to AQS measurements.  Similarly, equal percentages of participants saw their 
categorization of ozone exposure increase or decrease.  When restricting to participants who lived 
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within 10 km of a stationary air monitor, the percentages of agreement increased very slightly, to 
74.6% for PM2.5 and 81.1% for ozone.   
These findings did not change considerably based on case/control status.  However, 
agreement between AQS-derived and downscaler CMAQ-derived PM2.5 exposure categorizations 
varied considerably by site, with Texas, Massachusetts and New York having lower levels of 
agreement than other sites.   There was less variability by site for agreement in ozone exposure, 
although Massachusetts had lower agreement than other sites.  When dichotomizing the exposure 
metrics by season of conception (winter/fall vs. spring/summer), we did not observe differences in 
categorization for PM2.5 when compared to the full sample, but we did for ozone.  While the amount 
of agreement was consistent for both seasons (78.9% spring/summer vs. 80% winter/fall), in 
spring/summer months, a larger percentage of participants had higher categorization based on the 
downscaler CMAQ predictions than the categorization obtained using AQS measurements (14.3% vs. 
6.7%).  This was reversed in winter months (4.9% vs. 14.8%).   
Figures 5.2 and 5.3 compare adjusted estimates obtained from the hierarchical analysis 
when using the three different exposure metrics.  Estimates and 95% CIs are presented in Table 
A3.1.  Comparing estimates obtained using AQS vs. downscaler CMAQ for the population living 
within 50 km of a stationary air monitor, we observed that for some defects there are considerable 
differences in estimates obtained.  For example, using AQS measurements to assign exposure, the 
odds of left ventricular outflow tract obstruction (LVOTO) defects are 1.57 times as high in the 
highest decile of PM2.5 exposure compared to the lowest decile (95% CI 0.88, 2.78).  When using the 
downscaler CMAQ to assign exposure, the odds ratio is 0.86 (95% CI 0.46, 1.6).  A similar discrepancy 
was observed for COA, an individual LVOTO defect.  Other smaller differences between the two are 
observed for individual defects TOF and PVS.  When we compare to the estimates obtained from 
using downscaler CMAQ predictions for the full population, we see that adding in the additional 
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participants didn’t considerably alter estimates from what was obtained for the limited population, 
although there are still considerable differences from the AQS-based estimates.   
For ozone, there are stronger similarities between the three different estimates across 
defects, with greater precision of the protective effect of the highest quartile of ozone exposure on 
ASDs and a greater magnitude of the relationship between the highest level of exposure and PVS 
when using downscaler CMAQ estimates on the full population as the notable exceptions.  We reran 
the models using constant numeric cutoffs across the three different metrics to create the 
categorical values and continued to find differences in the resulting effect estimates, although in 
some cases these differences were attenuated (Table A3. 2).  When examining PM2.5 and ozone 
among the population living within 50 km of an air monitor, the AIC values from the first-stage 
logistic models were slightly lower when using AQS-derived estimates of exposure than when using 
downscaler CMAQ-derived estimates, suggesting slightly better model fit (PM2.5: 11635 vs. 11647; 
ozone: 9052 v 9057). 
Generally, adjusted estimates were closer to the null than crude estimates and only 
adjusted estimates are presented.  Adjusting for site-related differences in case phenotypes, as 
represented by the percent of cases that were septal defects, in models using AQS-based exposures 
and CMAQ-based exposures of ozone had little effect beyond moving the estimates of ASDs closer 
to the null, after simultaneous adjustment of demographic factors.  However, adjusting for this 
factor in the models of downscaler-CMAQ based estimates of PM2.5 resulted in larger movement 
toward the null for multiple defects and movement away from the null for PVS.  When comparing 
estimates unadjusted for site-related case ascertainment differences, the odds of PVS with greater 
PM2.5 exposure obtained from the downscaler CMAQ-based models were similar to those from the 
AQS-based models.  Differences in other defect estimates persisted.  
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Assessing the odds of CHDs by weekly averages revealed elevated odds ratios that were not 
observed when utilizing the seven-week average.  This was true across all three metrics.  In some 
cases, estimates from the three metrics were in agreement, for example elevated odds of PVS with 
greater exposure to PM2.5 during week 8 of pregnancy (Table A3.3).  There were also examples of 
discrepancies in estimates obtained using the different exposure metrics.  For example, using AQS-
derived measurements to assign exposure, there is more than a doubling of the odds of PVS when 
comparing the highest to lowest quartiles of ozone exposure (OR 2.22 95% CI 1.06, 4.67).  When this 
is explored in the full population using the downscaler CMAQ predictions to assign exposure, the 
odds ratio is only equal to 1.21 (95% CI 0.68, 2.17).  Often, when the difference between estimates 
was greater than expected given the precision of the estimates, the AQS-derived estimate was 
greater in magnitude.  Full weekly results are provided in Tables A3.3 and A3.4. 
Because we observed slight differences in classification of ozone by season of 
conception/exposure, we reran the first-stage, maximum likelihood models with an interaction term 
between seven-week exposure and season to obtain season-specific estimates and observed the 
differences between the AQS-based and downscaler CMAQ-based estimates were relatively 
consistent given the reduced precision.  Additionally, we reran the hierarchical models using 
different values of tau-squared and found our results were robust to these changes in model 
specification. 
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Table 5.1: Case phenotypes, demographic and behavioral characteristics of NBDPS participants with single, isolated 
congenital heart defects and controls with estimated dates of delivery from 2001-2006
a
 
N % N % N %
Total N 4842 4264 3364
Case Phenotypes
Controls 2791 57.6 2451 57.5 1970 58.6
LVOTO 327 6.8 284 6.7 225 6.7
    Aortic Stenosis 74 1.5 60 1.4 44 1.31
    Coarctation of the Aorta 134 2.8 121 2.8 90 2.68
    IAA-Type A 4 0.1 4 0.1 3 0.09
    Hypoplastic Left Heart Syndrome 115 2.4 99 2.3 88 2.62
CONOTRUNCAL 437 9 393 9.2 311 9.2
    Common Truncus 20 0.4 17 0.4 10 0.3
    IAA-Type B/NOS 6 0.1 6 0.1 6 0.2
    d-TGA 143 3 131 3.1 104 3.1
    Tetralogy of Fallot 237 4.9 213 5 171 5.1
    DORV-TGA/DORV-Other 14 0.3 11 0.3 9 0.3
    VSD-conoventricular 18 0.4 15 0.4 11 0.3
AVSD 39 0.8 36 0.8 26 0.8
APVR 71 1.5 64 1.5 55 1.6
    Total-APVR (TAPVR) 61 1.3 56 1.3 49 1.5
    Partial APVR (PAPVR) 10 0.2 8 0.2 6 0.2
RVOTO 313 6.5 280 6.6 209 6.2
    Pulmonary Atresia 36 0.7 34 0.8 28 0.8
    Tricuspid Atresia 17 0.4 17 0.4 13 0.4
    Ebstein's Anomaly 26 0.5 22 0.5 17 0.5
    Pulmonary Valve Stenosis 234 4.8 207 4.9 151 4.5
SEPTALS 864 17.8 756 17.7 568 16.9
    VSD-perimembranous 361 7.5 313 7.3 234 7
    VSD-NOS/OS/multiple 6 0.1 6 0.1 3 0.1
    ASDs, all 497 10.3 437 10.3 331 9.8
Birth Outcome
Live Birth 4825 99.7 4248 99.6 3350 99.6
Fetal Death 8 0.2 7 0.2 6 0.2
Induced Abortion 4 0.1 4 0.1 3 0.1
Study Site
Arkansas 567 11.7 447 10.5 197 5.9
Iowa 751 15.5 543 12.7 308 9.2
Massachusetts 940 19.4 912 21.4 807 24
New York 476 9.9 443 10.4 435 12.9
Texas 686 14.2 526 12.3 516 15.3
Metropolitan Atlanta 755 15.6 752 17.6 589 17.5
North Carolina 649 13.4 628 14.7 502 14.9
Utah 18 0.4 13 0.3 10 0.3
Maternal Age at conception, avg (sd) 27.7 (6.2) 28.0 (6.2) 28.2 (6.3)
Maternal Race
NH White 2911 60.1 2533 59.4 1888 56.1
NH Black 652 13.5 615 14.4 505 15
Latino 940 19.4 791 18.6 710 21.1
Other 338 7 324 7.6 260 7.7
Full Population
Population living 
within 50km of a  
PM2.5 air monitor
Population living 
within 50km of an 
ozone air monitor
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N % N % N %
Maternal Education
0-8 years 245 5.1 210 5 172 5.1
9-11 years 528 11 456 10.7 360 10.8
12 years, Completed High School or Equivalent 1078 22.4 889 21 671 20.1
Some College/Completed Trade School 1205 25 1034 24.4 792 23.7
4 Years College or Bachelors Degree 1218 25.3 1140 26.9 909 27.2
Masters Degree/Advanced Degree 541 11.2 515 12.1 440 13.2
Maternal Household Income
<=50,000 2768 60.3 2329 57.5 1804 56.6
>50,000 1822 39.7 1720 42.5 1384 43.4
Maternal BMI
Underweight 206 4.4 177 4.3 142 4.4
Normal Weight 2431 52.3 2170 53 1712 53.2
Overweight 1146 24.7 1004 24.5 790 24.5
Obese 867 18.7 745 18.2 577 17.9
Maternal Birth in the United States
No 920 19.1 845 19.9 721 21.6
Maternal Smoking first month of pregnancy
Yes 786 16.3 658 15.5 498 14
Alcohol Consumption anytime in the month before to 3rd month of pregnancy
None 2939 61.5 2553 60.6 2011 60.6
Less than 4 drinks per week 1270 26.6 1170 27.8 939 28.3
Binge drinking (4+ drinks per week) 568 11.9 493 11.7 368 11.1
Maternal Occupational Status
Did not work outside the home 1343 27.9 1175 27.7 979 29.3
a
 Does not include missing data so not all variables will sum to the total sample size
Full Population Population living Population living 
TABLE 5.1 (cont.)
 Figure 5.1: Population distribution of 7-week average of 24
metric; Red line indicates AQS-derived exposure, Green line indicates downscaler
of a monitor, Blue line indicates downscaler-CMAQ for full population (a): PM
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-hr measurements or 8 hour maximums, by source of exposure 
-CMAQ for population living within 50 km 
2.5 (b): ozone 
(a)
(b)
 
 
 
  
Figure 5.2: Adjusted odds ratios and 95% confidence intervals for the relationship between maternal exposure to PM
and congenital heart defects, by source of exposure metric
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2.5 
 Figure 5.3: Adjusted odds ratios and 95% confidence intervals for the 
and congenital heart defects, by source of exposure metric
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relationship between maternal exposure to ozone 
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5.4 Discussion 
 In summary, we observed differences in both the population included and the magnitude of 
the pollutant concentrations assigned when using AQS-derived and downscaler CMAQ-derived 
exposure estimates.  These differences contributed to slightly differing estimates of the effect of 
pollutant exposure during pregnancy and CHDs in offspring, whether using a seven-week average 
measure of exposure or individual weekly averages.  For example, based on AQS-derived estimates 
of exposure, we observed greater odds of LVOTO defects, particularly COA, with greater exposure to 
PM2.5 and greater odds of PVS with exposure to ozone in week 3 of pregnancy.  These associations 
were not observed when using downscaler CMAQ-derived estimates of exposure.  Other observed 
associations, such as between PM2.5 and TOF, were observed for the three different metrics with 
differing magnitudes.   In general, differences between estimates using the different metrics were 
more pronounced in models of PM2.5 when compared to ozone, and the PM2.5-related differences 
were most notable when comparing AQS-derived estimates among populations living within 50 km 
of an air monitor to downscaler-CMAQ derived estimates among the full population. 
 Previous research on the CMAQ model found spatial differences in agreement with AQS 
measurements for both PM2.5 and ozone.
154 Our study also found spatial differences in agreement, 
particularly for PM2.5. In the previous study examining differences in estimates obtained from the 
different exposure metrics for ozone, there did not appear to be a large difference in estimates 
obtained from AQS measurements versus those obtained from downscaler CMAQ, beyond greater 
precision due to increased sample size.155  Yet, we observed greater spatial variability in agreement 
for PM2.5 and composition of PM2.5 varies spatially, while ozone does not.
156  When exploring the 
association between PM2.5 and CHDs across a large spatial gradient, the resulting effect estimate 
mixes the effects of the different components. Previous research suggests that the different 
components of particulate matter can impact different biological systems.157,158  Therefore, it is 
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possible that the relationship between exposure to PM2.5 and risk of CHDs may vary by composition. 
Thus not only can inclusion of rural populations, where the composition may be different from those 
who live close to monitoring networks impact effect estimates related to PM2.5 exposure, but if the 
agreement between AQS and downscaler CMAQ varies in a spatial process that coincides with 
differences in composition, the resulting effect estimates related to PM2.5 exposure would be 
different between the two models.  This could also explain why adjusting for site-related 
characteristics had a larger impact on models using downscaler-CMAQ derived estimates of 
exposure to PM2.5 than either models using AQS-derived estimates or models exploring ozone 
exposure.   Given the agreement between estimates from models using downscaler-CMAQ derived 
exposures for the full and limited populations, it does not appear that adding in the rural 
populations has much of an impact, aside from spatial differences in agreement between 
downscaler-CMAQ and AQS measurements and increase in sample size.     
 Limiting to women within 10 km of a monitor did not greatly improve the agreement 
between the AQS and downscaler CMAQ exposure distributions, suggesting that it is not a matter of 
misclassification of exposure due to distance from the monitor.  Because we assigned downscaler-
CMAQ exposures by matching to the closest census tract centroid in the same process as matching 
to the closest air monitor, both metrics were subject to misclassification due to topography, wind 
direction etc. although the distance to a census tract centroid are generally shorter than to an air 
monitor.  Some differences in effect estimates were attenuated when using constant numeric cut-
offs to create the categorical variables.  This could be because the distribution of downscaler CMAQ 
predictions had lighter tails than the AQS distribution, causing discrepancies in percentile-based 
cutoffs.      
 We observed seasonal differences in agreement between monitor-based and model-based 
estimates of ozone exposure.  This did not have an impact on our estimates because CHDs do not 
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vary seasonally, nor do the relationships between ozone exposure and CHDs.  However, in a study of 
a seasonally-varying outcome, such as preterm birth, these differences could have a large impact on 
study results and should be accounted for in the analysis.   
 Using a multisite study, such as the NBDPS, provided a favorable study population with large 
spatial and temporal variability in order to compare the different exposure metrics as well as 
examine the impact of inclusion of more rural populations.  We observed that agreement between 
AQS concentrations and downscaler-CMAQ predictions vary spatially.  Due to the time period of the 
study, we were limited to participants who lived in the eastern and central US.  Agreement between 
AQS measurements and downscaler CMAQ predictions may be different in Western states.  
Additionally, we tried to control for site-related differences in case ascertainment using the variable 
containing the percentage of septal cases at each site.  It is unclear what is driving these site-related 
differences in case phenotype.  If these differences are due to spatial variability in pollutant 
concentrations, we are overadjusting our models and true effect estimates would be further from 
the null.  However, as stated previously, the impact of site-adjustment was not very large for the 
AQS-derived model estimates apart from attenuating the protective effect of pollutant exposure on 
ASDs.     
  Differences in effect estimates obtained from using downscaler CMAQ predictions to assign 
exposure versus AQS measurements were larger when investigating PM2.5 compared to ozone, 
potentially due to the spatially varying composition of the particles causing spatial variability in the 
effect of PM2.5 on risk of CHDs.   The seasonal variation in agreement between AQS and downscaler 
CMAQ ozone predictions could have had a larger impact on effect estimates if our outcome of 
interest had also varied seasonally.  Further application of using downscaler CMAQ predictions to 
assign exposure in epidemiologic studies should carefully assess the spatial and seasonal variability 
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in both the outcome itself and the relationship of interest to determine if there is a potential for 
biased estimates.
  
CHAPTER 6 
6. INVESTIGATING THE IMPACT OF FOLIC-ACID SUPPLEMENT USE ON THE RELATIONSHIP BETWEEN 
EXPOSURE TO PM2.5 DURING PREGNANCY AND CONGENITAL HEART DEFECTS  
 
6.1 Introduction 
 One of the potential biological pathways through which air pollutants could cause 
congenital heart defects (CHDs) is through epigenetic changes.36  Research by Chowdhury et al 
found associations between measures of maternal global DNA hypomethylation and CHDs, while 
research by Sheng et al found lower levels of methylation in children with tetralogy of Fallot, a 
conotruncal CHD.35,159  DNA methylation refers to the addition of a methyl group to the cytosine 
base on DNA.  Cells have a specific methylation pattern that encodes protein expression and is 
maintained during cell replication.  DNA methylation is associated with repressed gene expression, 
potentially by blocking promoters were transcription factors can bind.   Previous research has found 
that DNA hypomethylation contributes to chromosomal instability, altered gene expression, cellular 
differentiation, and apoptosis during embryogenesis.130  In a mouse model, disruption of DNA 
methylation was shown to cause exencephaly in treated mice131, and a recent epidemiologic study 
found associations between lower levels of DNA methylation and neural tube defects.132  Baccarelli 
et al have observed DNA hypomethylation after exposure to particulate matter and black carbon, a 
measure of traffic pollutants.34  Thus, it is possible that exposure to pollutants early in pregnancy, 
may trigger DNA hypomethylation which disrupts normal cardiac development.  Because folate acts 
as a methyl donor, necessary to initiate and regulate DNA methylation processes, it is possible that a 
woman’s folate status at the beginning of her pregnancy may modify impacts from air pollution, and
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that women with low folate levels may be especially vulnerable to the impacts of air pollutants if 
this mechanism is true.36    The goal of this subanalysis was to investigate whether use of folic-acid 
supplements modifies the relationship between exposure to fine particulate matter (PM2.5) during 
pregnancy and CHDs within the National Birth Defects Prevention Study (NBDPS).   
6.2 Methods      
 The population for this subanalysis were all controls and cases with a single, isolated CHD, 
with no non-CHDs present who had an estimated date of delivery (EDD) from 1999, when PM2.5 
monitoring began through 12/31/2006 and lived within 50 kilometers of a PM2.5 stationary air 
monitor. Women with non-gestational diabetes were excluded.  Cases were classified according to 
standardized NBDPS criteria.97   
Pollutant concentrations from the closest monitor were assigned to the woman’s 
corresponding pregnancy period.  If a woman had more than one residential address, daily 
exposures were assigned using the monitors closest to the residence that corresponded to that day 
of pregnancy.  Concentrations of PM2.5 are based on 24-hour measurements, but were often 
measured only on every 3rd or 6th day.  For the present analysis, we explored exposure using 
individual weekly averages.  We included week two in addition to the standard window of cardiac 
development, as previous literature suggests the potential for lag effects of air pollution 3,146.  
Ambient levels were categorized using the distribution of pollutant concentration among the 
controls into the following categories: less than the 10th percentile (referent), 10th percentile to the 
median, median to the 90th percentile and greater than or equal to the 90th percentile.  These 
categories captured the departure from linearity observed in initial, exploratory analyses. 
Folic-acid use was categorized in two ways: as a dichotomous ever/never variable and a 
multilevel variable incorporating information on both supplement use and dietary intake of folate 
and folic-acid.  Because the use of folic-acid supplements varies during pregnancy, women reported 
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their supplement use on a monthly basis for the duration of pregnancy.  Because defects are 
triggered very early in pregnancy, we explored supplement use in the month prior to conception 
and then explored supplement use in the first month of pregnancy.  Dietary folate was assessed 
using a shorted version of the Willett food frequency questionnaire and transformed into dietary 
folate equivalents (DFE) which allows for the combination of naturally occurring folate in foods and 
folic-acid supplementation of foods, such as grains.160  Because it is semi-quantitative, the food 
frequency questionnaire often does not provide an exact intake of DFE, but instead provides a 
relative measure that can be used to accurately rank women’s intake.  Therefore, we dichotomized 
women at the median level of DFE’s among controls.  This measure was then combined with 
supplement use in the month prior to conception to form a multilevel variable with the following 
categories: 1-No supplementation and dietary folate less than the median, 2- No supplementation 
and dietary folate greater than or equal to the median , 3-  Supplementation and dietary folate less 
than the median, 4- Supplementation and dietary folate greater than or equal to the median.  We 
also created a similar variable using supplement use in the first month of pregnancy. 
Potential confounders were identified through review of the literature and directed acyclic 
graph analysis.  The following variables obtained from the maternal interview were included in the 
final adjustment set:  age, race/ethnicity, educational attainment, household income, tobacco 
smoking in the first month of pregnancy, alcohol consumption during the first 3 months of 
pregnancy, and maternal birth outside of the US.  Additionally, in order to account for potential 
differences in case ascertainment by study center, final models were adjusted for the center-specific 
ratio of septal defects to total CHDs.  This adjustment for center was chosen to account for 
differences in the types of cardiac cases that were recruited at each site, controlling away effects 
due to spatial variability in pollutant concentrations.     
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Main effects of use of folic-acid supplements, dietary intake of DFEs, and PM2.5 exposure 
were assessed using polytomous logistic regression models adjusted for the set of confounders 
defined above.  Effect measure modification was assessed by using likelihood ratio tests comparing 
logistic regression models with and without interaction terms between PM2.5 exposure and 
supplement use, defined dichotomously or as the multi-level variable.  An a priori α-level was set at 
0.2 to indicate the presence of effect measure modification, given the small sample size for 
individual defects.  When we explored PM2.5 exposure during weeks 5-8, we only explored folic-acid 
supplement use in the first month of pregnancy, and not the month prior to conception, due to the 
short amount of time folate is available in the body.    
6.3 Results   
 Demographics of the study population are provided in Table 6.1.  Approximately 35% of 
women reported taking a folic-acid containing supplement one month prior to pregnancy, while 
53.9% reported taking supplements by the first month of pregnancy.  Approximately 32% of women 
had lower dietary intake of folate and did not report taking a folic-acid supplement while 16% had 
high dietary intake and reported taking a supplement in the month prior to conception.  
6.3.1 Main Effects 
 Results from the main effect analyses of folic-acid use are shown in Table 6.2.  Generally, 
odds of CHDs associated with not taking a folic-acid supplement were slightly greater when 
exploring use in the month prior to conception than when exploring use in the first month of 
pregnancy.  Greater odds of ASDs were observed among the offspring of women who did not report 
taking supplements in the month prior to pregnancy as well as among women with lower dietary 
intake of folate.  Women with lower dietary intake also had greater odds of offspring with d-
transposition of the great arteries and total anomalous pulmonary venous return.  Women with 
higher dietary intake who also reported taking a supplement had lower odds of many individual 
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defects when compared to women with lower intake who did not take a supplement.  In previous 
analyses of the main effects of PM2.5, we observed elevated odds of tetralogy of fallot (TOF) with 
greater exposure in week 2 of pregnancy and elevated odds of pulmonary valve stenosis were 
observed in weeks 5 and 8.   
6.3.2 Effect Measure Modification 
 We found evidence that the odds of TOF with greater exposure to week 2 exposure of PM2.5 
were modified by use of folic-acid supplements in the month prior to pregnancy.  Looking at the 
stratum-specific estimates, we observed that women who did not take supplements had larger odds 
ratios, but this became attenuated at the higher pollutant levels (Table 6.3).  We observed a similar 
pattern when using the combination folic-acid variable (Table 6.4). Women who had higher amounts 
of dietary intake and took a folic-acid supplement before pregnancy had lower odds of offspring 
with TOF until the highest decile of PM2.5 exposure.   Unlike for TOF, there was no evidence of 
modification of the relationship between PM2.5 exposure and coarctation of the aorta using the 
likelihood ratio test, although the stratums-specific estiamtes were on opposite sides of the null.   
When we examined supplement use in the first month of pregnancy, the likelihood ratio test gave a 
p-value of 0.08, suggesting the presence of modification.  The stratum-specific estimates remained 
on opposite sides of the null, through imprecise.  In contrast with the findings observed for TOF, 
when we examined the combination variable, women who took a supplement but had low dietary 
folate intake had the lowest odds ratios describing the association between PM2.5 exposure and 
COA.    
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Table 6.1:  Demographic characteristics of NBDPS study population living within 50km of a PM2.5 monitor 
 
Characteristic N % Characteristic N %
Maternal Age (avg, sd) 27.5 (6.11) Maternal Race
White, non-Latino 4507 58.4
Controls 4407 57.1 Black, non-Latino 886 11.5
Cases Latino 1784 23.1
LVOTO 596 7.7 Asian/ Pacific Islander 229 3
   Aortic Stenosis 135 1.8 Other 307 4
   Coarctation of the Aorta 233 3
   IAA-Type A 8 0.1 Maternal Education
   Hypoplastic Left Heart Syn. 220 2.9 0-6 years 264 3.4
CONOTRUNCAL 736 9.5 7-8 years 141 1.8
   Common Truncus 32 0.4 9-11 years 865 11.3
   IAA-Type B/NOS 9 0.1 12 Years, Completed HS or Equiv. 1721 22.4
   d-TGA 235 3 1-3 years College 1854 24.1
   Tetralogy of Fallot 397 5.1 Completed Technical School 250 3.3
   DORV-TGA/DORV-Other 30 0.4 4 Years College/Bachelor's Degree 1844 24
   VSD-conoventricular 34 0.4 Master's Degree 577 7.5
AVSD 63 0.8 Advanced Degree 165 2.2
APVR 114 1.5
   Total-APVR (TAPVR) 101 1.3 Maternal Household Income
   Partial APVR (PAPVR) 13 0.2 <10,000 1289 17.6
RVOTO 540 7 >50,000 2796 38.1
   Pulmonary Atresia 71 0.9 In Between 3259 44.4
   Tricuspid Atresia 34 0.4
   Ebstein's Anomaly 38 0.5 Maternal BMI
   Pulmonary Valve Stenosis 395 5.1 Underweight 364 4.9
SEPTALS 1259 16.3 Normal Weight 3946 53.2
   VSD-perimembranous 538 7 Overweight 1764 23.8
   VSD-NOS/OS 12 0.2 Obese 1347 18.2
   ASDs, all 709 9.2
Maternal Smoking first month of pregnancy
Study Site Yes 1104 14.4
Arkansas 650 8.4
California 1069 13.9 Alcohol Consumption, month prior-first trimester
Iowa 734 9.5 None 4945 64.8
Massachusetts 1190 15.4 Less than 4 drinks per week 1822 23.9
New York 681 8.8 Binge drinking (4+ drinks per week) 869 11.4
Texas 917 11.9
Metropolitan Atlanta 1076 14 Use of Folic Acid Supplements
North Carolina 633 8.2 One month prior to conception 2697 35.3
Utah 765 9.9 First month of pregnancy 4118 53.9
No Supplement  and low DFE
a
2473 32.4
Supplement and low DFE 1461 19.2
No Supplement and high DFE 2461 32.3
Supplement and high DFE 1236 16.2
a
DFE, dietary folate equivalents-categories created by dichotomizing at the median
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Table 6.2: Adjusted
a
 main effects of folic-acid supplement use and dietary folate on congenital heart defects 
 
 
Table 6.3: Adjusted
a
 odds ratios and 95% confidence intervals of PM 2.5 and selected CHDs, by folic acid supplement use 
 
Use of Folic Acid Supplement Dietary Folate Equivalents, DFE
Used 
Supplement 
(referent)
b
No use one 
month prior to 
pregnancy
No use during 
first month of 
pregnancy
At or 
above the 
median 
Below the 
median 
LVOTO 1 1.06 (0.87, 1.30) 0.89 (0.73, 1.09) 1 1.15 (0.96, 1.37)
   Aortic Stenosis 1 1.05 (0.71, 1.56) 1.00 (0.67, 1.48) 1 1.06 (0.74, 1.52)
   Coarctation of the Aorta 1 1.18 (0.86, 1.61) 0.88 (0.64, 1.20) 1 1.16 (0.88, 1.53)
   Hypoplastic Left Heart Syn. 1 0.96 (0.69, 1.33) 0.83 (0.61, 1.15) 1 1.20 (0.90, 1.60)
CONOTRUNCALS 1 0.93 (0.77, 1.12) 0.90 (0.75, 1.08) 1 1.12 (0.95, 1.32)
   d-TGA 1 0.98 (0.72, 1.34) 0.91 (0.67, 1.23) 1 1.32 (1.00, 1.74)
   Tetralogy of Fallot 1 0.85 (0.66, 1.08) 0.87 (0.68, 1.11) 1 1.11 (0.90, 1.38)
   Other Conotruncals 1 1.19 (0.73, 1.95) 1.04 (0.66, 1.63) 1 0.81 (0.54, 1.22)
APVR 1 1.20 (0.74, 1.94) 1.02 (0.66, 1.58) 1 1.51 (1.00, 2.27)
AVSD 1 0.87 (0.49, 1.54) 0.78 (0.45, 1.37) 1 1.45 (0.86, 2.45)
RVOTO 1 1.07 (0.86, 1.33) 0.96 (0.78, 1.18) 1 1.02 (0.85, 1.24)
   Pulmonary/Tricuspid Atresia 1 1.03 (0.63, 1.67) 0.93 (0.59, 1.46) 1 1.12 (0.74, 1.69)
   Pulmonary Valve Stenosis 1 1.02 (0.79, 1.30) 0.95 (0.74, 1.20) 1 1.02 (0.82, 1.26)
SEPTALS 1 1.19 (1.01, 1.39) 1.07 (0.93, 1.24) 1 1.16 (1.02, 1.33)
   VSD-perimembranous 1 1.11 (0.89, 1.38) 1.07 (0.87, 1.32) 1 1.09 (0.91, 1.32)
   ASD-all 1 1.23 (1.00, 1.51) 1.04 (0.87, 1.26) 1 1.23 (1.03, 1.45)
a 
Models adjusted for maternal race, age, educational attainment, birth outside the US, tobacco, alcohol use, and site-
specific septal case ratio.
b
 Referent group changes depeding upon time period explored; when comparing to no use one month prior to pregnancy, it 
consists of women who used a supplment one month prior to pregnancy; when comparing to women with no use in the 
first month of pregnancy, it consists of women who used a supplement during the first month of pregnancy
<10th 
percentile 
(Referent)
10th percentile to 
median
median to 90th 
percentile >90th percentile
X
2
 from 
likelihood 
ratio test p-value
Tetralogy of Fallot, week 2 exposure
Supplement use month prior to conception 1 1.36 (0.64, 2.91) 1.63 (0.76, 3.47) 2.11 (0.86, 5.14) 4.83 0.18
No supplement use month prior to conception 1 2.37 (1.11, 5.02) 1.60 (0.73, 3.50) 2.57 (1.09, 6.10)
Supplement use first month of pregancy 1 1.66 (0.85, 3.24) 1.78 (0.90, 3.52) 2.07 (0.93, 4.61) 4.83 0.18
No supplement use first month of pregnancy 1 2.14 (0.90, 5.11) 1.33 (0.54, 3.28) 2.68 (1.01, 7.12)
Coarctation of the aorta, week 2 exposure
Supplement use month prior to conception 1 0.80 (0.37, 1.72) 0.83 (0.38, 1.83) 0.89 (0.30, 2.70) 1.86 0.6
No supplement use month prior to conception 1 1.55 (0.71, 3.41) 1.60 (0.71, 3.63) 2.10 (0.78, 5.60)
Supplement use first month of pregancy 1 0.84 (0.46, 1.56) 0.78 (0.41, 1.49) 0.89 (0.36, 2.17) 6.833 0.08
No supplement use first month of pregnancy 1 3.47 (0.80, 15.0) 4.28 (0.98, 18.7) 5.75 (1.17, 28.4)
a 
Models adjusted for maternal race, age, educational attainment, birth outside the US, tobacco, alcohol use, and site-specific 
septal case ratio.
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Table 6.4: Adjusted
a
 odds ratios and 95% confidence intervals of week 2 exposure to PM 2.5 and tetralogy of Fallot and 
coarctation of the aorta, by folic-acid supplement use 
 
6.4 Discussion 
 Our findings suggest use of a folic-acid supplement may reduce the risk of CHDs associated 
with PM2.5 exposure during early pregnancy.  These findings were primarily limited to PM2.5 
exposure very early in pregnancy and were observed for only TOF and COA.  It is well established 
that folic-acid intake reduces the odds of neural tube defects161, and literature suggests that it also 
reduces the odds of other birth defects, including CHDs, although mechanisms are unclear.162,163  
However, to our knowledge, this is the first study to show that folic-acid supplement use modifies 
the odds of CHDs associated with maternal exposure to PM2.5 in early pregnancy.  The differences in 
results when incorporating dietary folate intake could be a result of the imprecision of the estimates 
given the small sample size, or it could suggest the potential for hypermethylation to play a role in 
the development of COA from too much folic-acid.164 
A recent study found lower methylation levels in the cardiac tissue of infants with TOF.159  In 
conjunction with previous research associating maternal levels of DNA methylation with CHDs in 
offspring35, this suggests that altered DNA methylation processes could play a role in the 
<10th 
percentile 
(Referent)
10th percentile to 
median
median to 90th 
percentile >90th percentile
Tetralogy of Fallot
No supplement use, Low DFE 1 2.38 (0.83, 6.85) 1.71 (0.58, 5.04) 3.06 (0.95, 9.88)
Supplement use, Low DFE 1 2.75 (0.80, 9.40) 2.71 (0.80, 9.26) 2.34 (0.56, 9.72)
No supplement use, High DFE 1 1.91 (0.73, 5.00) 1.37 (0.51, 3.68) 1.74 (0.57, 5.29)
Supplement use, High DFE 1 0.73 (0.27, 1.96) 1.28 (0.50, 3.27) 2.31 (0.75, 7.10)
Coarctation of the aorta
No supplement use, Low DFE 1 2.80 (0.35, 22.0) 4.71 (0.60, 37) 7.56 (0.84, 68)
Supplement use, Low DFE 1 0.5 (0.24, 1.04) 0.6 (0.29, 1.26) 0.56 (0.19, 1.64)
No supplement use, High DFE 1 4.30 (0.55, 33.5) 3.67 (0.46, 29) 3.74 (0.39, 36)
Supplement use, High DFE 1 2.43 (0.71, 8.36) 1.56 (0.43, 5.65) 2.17 (0.44, 10.6)
a 
Models adjusted for maternal race, age, educational attainment, birth outside the US, tobacco, alcohol 
use, and site-specific septal case ratio.
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development of CHDs.  Toxiciological and epidemiologic literature suggest that exposure to PM2.5 
can impact methylation processes34,36, suggesting a potential pathway between associations 
observed between maternal exposure to air pollutants and CHDs in offspring.  It is possible that 
folic-acid taken very early in pregnancy counteracts the detrimental effects of particulates on 
methylation processes during development.  Our findings for TOF suggest that there could be a 
threshold of particulate exposure, after which folic-acid can no longer prevent disruption of the DNA 
methylation processes.  This did not appear to be the case for COA, however, and further research is 
necessary to determine not only if our findings can be replicated, but if there are different 
mechanisms at play for the different defects. 
This study relied on maternal report of folic acid supplement use and maternal reports of 
food intake to calculate dietary folate intake, and so is subject to the same potential for recall bias 
as other case-control studies with retrospective exposure ascertainment.  Additionally, the food 
frequency questionnaire used was only semi-quantitiative, and we could only account for dietary 
intake using a crude dichotomy at the median level.  Similarly, although we were able to explore 
folic-acid use monthly, we used an ever/never categorization within that time period and did not 
differentiate by when during the month a woman initiated use, how often she took the supplement, 
and what other nutrients were contained in the supplement.  More refined categorizations could 
potentially improve effect estimation and help determine at what point folic-acid may modify the 
effects of PM2.5.  It is possible that unmeasured characteristics of women who are more likely to 
take folic-acid supplements early in pregnancy are confounding this observed interaction.  For 
example, women who report taking folic-acid in the month prior to conception may have healthier 
habits or may have been more likely to have planned the pregnancy.  We adjusted our models for 
many demographic factors that are associated with choosing to use folic-acid supplements but 
residual confounding is a possibility.  It is also possible that other nutrients within supplements or 
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within foods that contain folate are responsible for our results.  This could potentially explain why 
women who didn’t take a supplement but had higher dietary folate levels showed a larger effect of 
PM2.5 on COA.  Finally, this study did not have any information on genetic factors that could 
influence this relationship, for example an individual’s ability to metabolize folate and other methyl 
donors.  This lack of information would potentially attenuate the true modification by folic-acid, as it 
would allow us to get a better measure of the amount of methyl groups truly available for the 
methylation processes within the body.      
In summary, we found that use of a folic-acid supplement reduced the association between 
maternal PM2.5 exposure and CHDs in offspring.  Future research could focus on better 
characterization of folic-acid use and dietary intake of folate and other nutrients, as well as 
incorporating measures of maternal DNA methylation within analyses.  
  
CHAPTER 7 
7. CONCLUSIONS  
 
7.1 Summary of Findings 
The purpose of this dissertation was to utilize the NBDPS, a large population-based multi-
site case-control study of birth defects with large geographic variability, complete residential history 
during pregnancy and detailed nutrition and other covariate information in order to investigate the 
relationships between maternal exposure to criteria air pollutants during pregnancy and CHDs.  The 
detailed covariate information allowed for the exploration of potential effect measure modification 
by use of folic-acid during pregnancy, and the large geographic extent of the study population 
allowed for a meaningful comparison of monitor-based versus model-based estimates of exposure 
to air pollutants.   
This study found greater odds of multiple types of CHDs with greater exposure to criteria air 
pollutants.  Consistent with a previous meta-analysis, the main analyses revealed a greater risk of 
COA and TOF with greater exposure to NO2 and greater risk of COA with exposure to SO2.
23  The 
odds of outflow tract obstruction defects, both left and right, were elevated with greater exposure 
to multiple individual air pollutants, with odds ratios often around 2 when comparing the highest to 
lowest decile of exposure.  The similarity in findings for the outflow tract defects across different 
pollutants suggests the potential for outflow tract development to be particularly susceptible to 
environmental insult. 
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This study also revealed evidence of both temporal and spatial variability in these 
relationships, which had not been examined in previous studies.  Utilizing hierarchical regression to 
account for the association between individual weeks of exposure, this study identified potential 
temporal windows of susceptibility within the typical window of cardiac development, for example 
week 3 ozone exposure and PVS and week 2 PM2.5 exposure and TOF.  Findings in week 2 support 
the occurrence of lagged effects of air pollutants, suggested in previous studies146, as cardiac 
development doesn’t typically begin until week 3 of pregnancy.   
The potential for spatial differences were revealed by comparing the findings reported in 
Chapter 4 which used AQS measurements to assign exposure to the NBDPS population to Chapter 5 
which used different exposure metrics to assign exposure to the subpopulation that had downscaler 
CMAQ data available.  The primary difference between these two populations was the exclusion of 
western states from analyses reported in Chapter 5. The results for ozone between the two AQS-
based analyses are consistent, even showing similar temporal variability and elevated odds of PVS in 
week 3.  However, the PM2.5 analyses were not consistent, most notably the elevated odds of HLHS 
are only observed when the western states are included.  It is known that the composition of PM2.5 
varies spatially, as previous research suggests PM2.5 in the western states is more likely to be 
composed of organic carbon and nitrates as opposed to greater sulfate composition in the eastern 
states. 156  Thus, it is possible the discrepancy in the findings between the two analyses suggests that 
the relationship between particulates and CHDs varies by the composition of PM2.5.  The lack of 
difference in the ozone results makes it unlikely that a difference in model construction or temporal 
differences in the population (i.e. excluding women from 1999-2001 when downscaler CMAQ 
estimates became available) are responsible for the discrepancy.    
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This study also explored the variability in effect by maternal use of folic-acid very early in 
pregnancy.  Although estimates were imprecise, there was evidence of effect measure modification 
as assessed by likelihood ratio tests and when examining estimates of the odds of TOF and COA with 
increasing PM2.5 exposure stratified by maternal use of folic-acid supplements.  This suggests that 
folic-acid may modify the air pollutant-CHD association, potentially by disrupting DNA methylation 
processes.  The differences in results when incorporating dietary folate intake could be a result of 
the imprecision of the estimates given the small sample size, or it could suggest the potential for 
hypermethylation to modify the relationship between air pollutants and CHDs.164 
In addition to investigating the etiologic relationship between maternal air pollutant 
exposure and CHDs in offspring, this study also explored how differences in exposure assessment 
can impact the observed relationships.   By comparing the distribution of monitor-based exposure 
estimates to model-based estimates for the same population, it was observed that, for both PM2.5 
and ozone,  the magnitude of the estimate assigned to an individual, although highly correlated, 
changes, resulting in a model-based distribution that has thinner tails and a slightly narrower range 
than the monitor-based distribution.  The statistical analyses using the model-based exposure 
estimates resulted in lower effect estimates for some defects when comparing the highest and 
lowest deciles of exposure and slightly worse model fit than the models which used monitor-based 
measurements.  Including the population living far from monitors that would typically be excluded 
from these analyses caused estimates to be even more divergent from the AQS findings.  
Differences were greater for PM2.5 than ozone.  Again, this potentially suggests that the relationship 
between PM2.5 exposure and CHDs varies by the composition of the particulate.  If different 
components of PM drive the relationship with CHD development and using model-based estimates 
allows for the inclusion of populations from a greater spatial area, it is possible that those additional 
populations are exposed to a particulate with a different composition, mixing effects of the different 
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components and causing the effect estimate to vary from that obtained when using the monitor 
based measure for a more narrowly-defined geographic population.   
7.2 Strengths and Limitations 
This was the first study to explore the relationship between exposure to PM2.5 and CHDs and 
how this relationship may be modified by use of folic-acid early in pregnancy.   This was also the first 
study to explore temporal variability in the associations between criteria air pollutants and CHDs 
within the window of cardiac development and the first to use PCA to explore how source-factors of 
pollutants are associated with CHDs in a multipollutant context.  
One of the most prominent strengths of this dissertation is the use of the study population 
from the NBDPS.  As the largest, ongoing case-control study of birth defects in the United States, it 
has a large sample size that allows analysis of systematically classified CHDs within etiologically 
relevant subgroups as opposed to larger, more heterogeneous aggregations.  The study collected a 
large amount of information on relevant covariates, including nutritional factors, which allowed the 
exploration of biologically-relevant interactions between air pollution and use of folic-acid, as well 
as reduce residual confounding that may have affected previous research in this field that depended 
upon administrative data sources.  As a multi-site study, the NBDPS has a large amount of 
geographic diversity in the study population, which provided a greater exposure gradient than 
previous single-site studies may have been able to observe.  The large geographic extent of the 
study participants also allowed for a meaningful comparison of two different sources of exposure 
data and how agreement varies in time and space for each pollutant. Additionally, the hierarchical 
models we propose using will enable us to investigate multiple windows of exposure 
simultaneously, rather than having to average over multiple weeks, potentially smoothing over 
relevant temporal fluctuations.  We also had complete residential history for the 3 months prior to 
conception and throughout pregnancy.  This reduced exposure misclassification that can occur when 
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only residence at delivery is used to assign exposure.   Additionally, we averaged over daily 
maximums to assign exposure, the metric used by the EPA to regulate these pollutants, as opposed 
to daily averages.  This reduced the possibility that we would smoother over potentially important 
temporal variability in ambient pollutant concentrations. 
Despite the large sample size, some defects are so rare that estimates were very imprecise 
and often could only be studied as part of a larger defect-grouping.  Additionally, the subsample that 
lived within 50 km of all types of air pollutant monitors was small, and may not be generalizable to 
the larger population.  Although this study compared two different sources of data to estimate 
exposure during pregnancy, they are both proxies for an individual woman’s actual exposure to air 
pollutants.  We also don’t have any measures of time spent outdoors, time spent at locations other 
than the primary residence, or physical activity performed outdoors, which would all impact an 
individual’s exposure to the ambient air.  It is possible that the attenuated odds we observed at the 
highest exposure levels for certain pollutants was due to women avoiding the outdoors in highly 
polluted areas.  Additionally, in our models which utilize air monitoring data, we are simply 
matching women to the closest monitor within 50 km, which is a rather large distance.  Our 
sensitivity analysis restricting to women who lived within 10kilometers of an air monitor found that 
most estimates were larger in magnitude when compared to the primary analyses, but this 
subsample was much smaller causing imprecise estimates.  It is also possible that the closest 
monitor is not the most relevant, for example if the monitor is down-wind from the home.  The 
participation rates of the NBDPS are relatively high, but they do vary slightly by racial group.  There 
may be other difference between those who agree to participate and those who do not.  This 
potential selection bias could impact our study results.  There is the possibility of recall bias affecting 
our estimates for the folic-acid subanalysis, as mothers of case births might be more likely to recall 
their supplement and diet information than a control mother. 
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7.3 Public Health Impact and Avenues for Further Research 
 This study further adds to the literature on exposure to air pollutants during pregnancy and 
CHDs by providing evidence suggesting that these relationships can vary in time, space and by 
maternal nutrition factors.  It also helps advance risk assessment, by identifying potentially 
susceptible windows during cardiac development when the fetus is more susceptible to 
environmental insult.  These more refined effect estimates can be used when determining the risk 
to a population that accompanies an increase in ambient air pollutant concentrations.  This is 
facilitated by the use of daily maximums to assign exposure, as that is the metric used by the EPA to 
regulate pollutants.  Exploring the source-factors of the pollutants in a multipollutant context also 
advances risk assessment, as populations are rarely exposed to one pollutant at a time.  Identifying 
the potential modification of the relationship between PM2.5 exposure and CHDs by use of folic-acid 
could inform mechanistic research aimed at investigating the role of DNA methylation in these 
associations.  Additionally, it points to the possibility of a potential future intervention aimed at 
increasing supplement use among women of reproductive age, particularly in developing countries 
which are just now beginning to see increases in air pollutants due to increased industrialization but 
lack the dietary supplementation programs for folic-acid. 
There are multiple avenues for further research.  First, as these individual pollutants are 
highly correlated with each other and other hazardous air pollutants, continuing to explore their 
relationship with CHDs in a multipollutant context will help to determine which pollutants and which 
sources may be driving the associations with CHDs.  There are multiple statistical techniques to 
explore multipollutant contexts165, but it will also require finding populations where multiple types 
of monitors are co-located or taking advantage of model-based estimates to fill in the gaps of the 
monitoring networks.     
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As many of the findings in this study pointed toward the potential for the relationship 
between PM2.5 and CHDs to vary by the composition of PM2.5, future studies should explore the 
speciated components of PM2.5 as different, correlated measure of exposure.  This can be done 
using the hierarchical regression methods utilized in the current study.  Exploring these 
components, including how they vary geographically, could further refine some of the effect 
estimates we observed between particulate exposure and CHDs. 
Finally, it is possible that other maternal dietary factors could modify the relationship 
between pollutant exposure and disrupted fetal development.166  For example, DNA methylation is 
only one potential mechanism which could underly the relationship between air pollutant exposure 
and CHDs.  Oxidative stress is another potential mechanism, which has been discussed with respect 
to other adverse birth outcomes resulting from pollutant exposure such as preterm birth.13  
Exploring whether a mother’s antioxidant intake modifies the impact of pollutant exposure could 
provide evidence supporting a hypothesis of that mechanism. 
In conclusion, this study was able to determine that the odds of multiple individual CHDs are 
associated with greater pollutant exposure, in both single-pollutant and source-factor models.  
There is some evidence that these relationships vary within the window of cardiac development, 
suggesting potential windows of increased susceptibility. These estimates can be used to enhance 
risk assessment and determine how changes in ambient air pollutant concentrations can impact 
human health.  Future research should focus on further exploring the simultaneous effects of 
multiple pollutants, refining exposure assessment to focus on individual components of PM2.5 to 
improve effect estimation and continuing to explore the potential for maternal dietary factors to 
modify the relationship between pollutant exposure and CHDs in offspring.   
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APPENDIX 1 
LIST OF CONGENITAL HEART DEFECT CLASSIFICATIONS IN NATIONAL  
BIRTH DEFECTS PREVENTION STUDY 
 
Conotruncal 
Truncus Truncus arteriosus with or without atrial septal defect 
IAA, B Interrupted aortic arch type B, with or without atrial septal defect 
IAA, nos Interrupted aortic arch, type not specified but presumed to be type B, with or without atrial 
septal defect 
d-TGA-IVS d-transposition of the great arteries with intact ventricular septum, with or without atrial 
septal defect 
d-TGA-IVS 1 LVOTO (PS) d-transposition of the great arteries with intact ventricular septum, plus 
pulmonary stenosis or other left ventricular outflow tract obstruction 
d-TGA-IVS 1 RVOTO (AS, COA) d-transposition of the great arteries with intact ventricular septum, 
plus aortic stenosis or coarctation or other right ventricular outflow tract obstruction 
TGA nos d-transposition of the great arteries, not otherwise specified, but presumed to be with intact 
ventricular septum, with or without atrial septal defect 
TGA os d-transposition of the great arteries, otherwise specified. Usually with other defects 
d-TGA-VSD d-transposition of the great arteries with noninlet ventricular septal defect, with or without 
atrial septal defect 
d-TGA-VSD 1 LVOTO (PS) d-transposition of the great arteries with noninlet ventricular septal defect, 
plus pulmonary stenosis or other left ventricular outflow tract obstruction 
d-TGA-VSD 1 RVOTO (AS, COA) d-transposition of the great arteries with noninlet ventricular septal 
defect, plus aortic stenosis or coarctation or other right ventricular outflow tract obstruction 
TOF Tetralogy of Fallot with or without atrial septal defect; NOT pulmonary atresia with ventricular 
septal defect 
TOF, absent pulmonary valve Tetralogy of Fallot with absent pulmonary valve 
PA-VSD (TOF anatomy) Pulmonary atresia with ventricular septal defect, tetralogy of Fallot variant, with 
or without atrial septal defect 
DORV-TOF type Double outlet right ventricle (tetralogy of Fallot type anatomy) with normally positioned 
great arteries, with or without atrial septal defect 
DORV-TGA type Double outlet right ventricle with malposed great vessels or d-transposed great artery 
type, with or without atrial septal defect 
DORV, os Double outlet right ventricle, other specified type (NOT tetralogy type or malposed great 
arteries), with or without atrial septal defect 
DORV, nos Double outlet right ventricle, type not otherwise specified, with or without atrial septal defect 
VSD conov Ventricular septal defect reported as conoventricular, malalignment-type, or subaortic (not 
otherwise specified) 
IAA, B 1 Truncus Interrupted aortic arch, Type B plus truncus arteriosus, with or without atrial septal 
defect 
Atrioventricular Septal Defect (AVSD) 
AVSD, unspecified Unspecified type of atrioventricular septal defect, with or without other atrial or 
ventricular septal defects 
ASD-1 Primum type atrial septal defect (isolated atrial component of atrioventricular septal defect) 
VSD, inlet-type Inlet type ventricular septal defect (isolated ventricular component of atrioventricular 
septal defect) 
AVSD, complete Complete atrioventricular septal defect, with both atrial and ventricular septal defects 
AVSD, transitional Transitional type atrioventricular defect (endocardial cushion defect, otherwise 
specified) 
AVSD 1 LVOTO Atrioventricular septal defect plus left ventricular outflow tract obstruction (includes 
unbalanced defects with left ventricular dominance) 
AVSD 1 RVOTO Atrioventricular septal defect plus right ventricular outflow tract obstruction (includes 
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unbalanced defects with right ventricular dominance) 
Anomalous-Pulmonary Venous Return (APVR) 
TAPVR Total anomalous pulmonary venous return 
TAPVR 1 RVOTO Total anomalous pulmonary venous return, plus pulmonary stenosis 
TAPVR 1 LVOTO Total anomalous pulmonary venous return, plus aortic stenosis or coarctation 
PAPVR Partial anomalous pulmonary venous return 
PAPVR 1 RVOTO Partial anomalous pulmonary venous return, plus pulmonary stenosis 
PAPVR 1 LVOTO Partial anomalous pulmonary venous return, plus aortic stenosis or coarctation 
Left Ventricular Outflow Tract Obstruction (LVOTO) 
HLHS, IVS Hypoplastic left heart syndrome with intact ventricular septum, with or without atrial septal 
defect 
HLHS 1 VSD Hypoplastic left heart syndrome with ventricular septal defect, with or without atrial septal 
defect 
HLHS 1 APVR Hypoplastic left heart syndrome plus total or partial anomalous pulmonary venous return 
IAA, A Interrupted aortic arch type A, with or without atrial septal defect 
COA-IVS Coarctation of aorta with intact ventricular septum, with or without atrial septal defect 
AS Aortic stenosis with or without atrial septal defect 
AS 1 COA Aortic stenosis with or without atrial septal defect, plus coarctation 
Right Ventricular Outflow Tract Obstruction (RVOTO) 
PVS Pulmonary valve stenosis 
PVS, nos Pulmonary stenosis not otherwise specified but presumed to be valvar 
Tricuspid atresia, IVS Tricuspid atresia with intact ventricular septum, with or without atrial septal defect 
Tricuspid atresia 1 VSD Tricuspid atresia with ventricular septal defect, with or without atrial septal 
defect 
Ebstein Ebstein malformation or anomaly 
PA-IVS Pulmonary atresia with intact ventricular septum, with or without atrial septal defect 
PA, nos Pulmonary atresia not otherwise specified but presumed to be with intact ventricular septum 
PA-VSD (not TOF anatomy) Pulmonary atresia with ventricular septal defect, not tetralogy of Fallot 
variant, with or without atrial septal defect 
PA-VSD, nos Pulmonary atresia with ventricular septal defect, not stated if tetralogy variant 
PA-IVS 1 Ebstein Pulmonary atresia with intact ventricular septum, plus Ebstein’s malformation 
Tricuspid atresia 1 PA-IVS Pulmonary atresia with intact ventricular septum, plus tricuspid atresia 
Septal Defects 
VSD pm Perimembranous ventricular septal defect 
VSD musc Muscular ventricular septal defect 
VSD nos Ventricular septal defect, type not specified 
VSD os Ventricular septal defect, otherwise specified 
ASD2 Secundum atrial septal defect 
ASD, nos Atrial septal defect, not otherwise specified, but presumed secundum type 
ASD, os Other specified type atrial septal defect (i.e., sinus venosus, coronary sinus) 
VSDs multiple (pm, musc, or nos) Combination of perimembranous, muscular, or not otherwise 
specified types of ventricular septal defects 
VSD (non-inlet) 1 ASD2/ASD nos Any non-inlet ventricular septal defect plus atrial septal defect 
Heterotaxy 
Heterotaxy or S.I.totalis: simple CVM Laterality defects (heterotaxy, situs inversus totalis) with simple 
cardiovascular malformation 
Heterotaxy or S.I.totalis: complex CVM Laterality defects (heterotaxy, situs inversus totalis) with 
complex cardiovascular malformation 
Heterotaxy or S.I.totalis: no CVM Laterality defects (heterotaxy, situs inversus totalis) with no cardiac 
malformations 
Single Ventricle/Complex 
Multiple, complex heart anomaly In general, three or more defects (in addition to simple atrial septal 
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defect, ventricular septal defect) 
SV Single (univentricular) heart, excludes functional single ventricle such as HLHS, DORV with 
malaligned AVSD. Typically associated with several other defects 
SV, DILV, nos Single ventricle, double-inlet left ventricle type with great artery position not specified 
SV, DILV, l-malposition Single ventricle, double-inlet left ventricle type with l-malposed great arteries 
SV, DILV, d-malposition Single ventricle, double-inlet left ventricle type with d-malposed great arteries 
SV, DIRV Single ventricle, double-inlet right ventricle 
SV, os Single ventricle, other specified type 
SV, nos Single ventricle, not otherwise specified type 
L-TGA L-transposition of the great arteries with or without atrial or ventricular septal defects 
L-TGA 1 RVOTO (AS, COA) L-transposition of the great arteries plus aortic stenosis or coarctation 
(morphological right ventricular outflow obstruction) 
L-TGA 1 LVOTO (PS) L-transposition of the great arteries plus pulmonic stenosis (morphological left 
ventricular outflow obstruction) 
ASSOCIATIONS 
Conotruncal + AVSD 
d-TGA-IVS + AVSD d-Transposition of the great arteries with intact ventricular septum, plus 
atrioventricular septal defect 
d-TGA-VSD + AVSD d-Transposition of the great arteries with noninlet of ventricular septal defect plus 
atrioventricular septal defect 
TOF + AVSD Tetralogy of Fallot plus atrioventricular septal defect 
PA-VSD (TOF anatomy) + AVSD Pulmonary atresia with ventricular septal defect, tetralogy of Fallot 
variant, plus atrioventricular septal defect 
APVR + AVSD 
TAVPR + AVSD Total anomalous pulmonary venous return, plus atrioventricular septal defect 
PAVPR + AVSD Partial anomalous pulmonary venous return, plus atrioventricular septal defect 
Septal + LVOTO 
VSD (non-inlet) + COA Coarctation of aorta with noninlet ventricular septal defect, with or without atrial 
septal defect 
VSD (non-inlet) + ASD2/nos + AS Any non-inlet ventricular septal defect plus atrial septal defect plus 
aortic valve stenosis 
VSD (non-inlet) + ASD2/nos + COA Any non-inlet ventricular septal defect plus atrial septal defect plus 
coarctation 
Septal + RVOTO 
ASD + PVS Pulmonary valve stenosis plus atrial septal defect 
VSD (non-inlet) + PVS Pulmonic valve stenosis plus noninlet ventricular septal defect, with or without 
atrial septal defect 
VSD (non-inlet) + ASD2/nos + PVS Any non-inlet ventricular septal defect plus atrial septal defect plus 
pulmonary valve stenosis 
Other Associations Two (occasionally three) major defects not specified elsewhere 
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Table A2.1: Odds Ratios and 95% Confidence Intervals between CHDs and 7-week average exposure to air pollutants 
 
<10th 
percentile 
(Referent)
10th percentile to 
median
median to 90th 
percentile >90th percentile
Pollutant concentrations < 0.58 0.58-1.16 1.16-2.13 >2.13
LVOTO
a
1 1.11 (0.8,1.53) 1.11 (0.8,1.55) 0.95 (0.62,1.45)
Aortic Stenosis
b
1 0.93 (0.49,1.79) 0.94 (0.49,1.81) 0.76 (0.32,1.79)
Coarctation of the Aorta
b
1 1.13 (0.7,1.82) 0.93 (0.57,1.52) 0.98 (0.53,1.82)
Hypoplastic Left Heart Syndrome
b
1 1.22 (0.71,2.12) 1.5 (0.87,2.6) 1.07 (0.53,2.14)
CONOTRUNCALS
a
1 1.21 (0.9,1.64) 1.28 (0.94,1.73) 1.22 (0.84,1.79)
d-TGA
b
1 1.34 (0.81,2.22) 1.34 (0.8,2.23) 1.15 (0.61,2.19)
Tetralogy of Fallot
b
1 1.22 (0.81,1.83) 1.35 (0.9,2.03) 1.29 (0.78,2.14)
Other Conotruncals
b
1 0.96 (0.48,1.95) 0.92 (0.45,1.88) 1.08 (0.46,2.56)
Common Truncus
c
1 1.03 (0.35,3.99) 0.7 (0.22,2.82) 0.33 (0.03,2.06)
DORV-TGA and DORV-Other
c
1 1.03 (0.3,5.35) 0.88 (0.25,4.6) 1.34 (0.29,7.82)
IAA TypeB/NOS
c
1 0.34 (0.07,2.03) 0.17 (0.02,1.27) 1.72 (0.32,10.56)
VSD-Conoventricular
c
1 0.8 (0.26,3.18) 1.33 (0.45,5.15) 1.32 (0.28,6.33)
APVR
a
1 0.46 (0.25,0.84) 0.48 (0.26,0.88) 0.59 (0.27,1.28)
TAPVR
b
1 0.53 (0.28,1) 0.43 (0.22,0.84) 0.67 (0.3,1.5)
AVSD
a
1 0.95 (0.35,2.56) 1.11 (0.41,2.98) 0.75 (0.2,2.83)
RVOTO
a
1 0.94 (0.67,1.33) 0.97 (0.69,1.37) 0.89 (0.57,1.39)
Pulmonary/Tricuspid Atresia
b
1 0.77 (0.4,1.5) 0.75 (0.38,1.47) 0.72 (0.3,1.73)
Pulmonary Atresia
c
1 0.68 (0.33,1.53) 0.55 (0.26,1.27) 0.68 (0.24,1.87)
Tricuspid Atresia
c
1 0.81 (0.26,3.25) 1.12 (0.38,4.4) 0.79 (0.13,4.11)
Pulmonary Valve Stenosis
b
1 0.92 (0.61,1.37) 1 (0.67,1.49) 0.92 (0.56,1.53)
Ebstein's Anomaly
c
1 8.46 (1.15,1081) 5.25 (0.67,678) 4.4 (0.35,612)
SEPTALS
a
1 1.01 (0.78,1.33) 1.13 (0.86,1.47) 1.3 (0.95,1.8)
VSD-perimembranous
b
1 0.87 (0.62,1.23) 1.04 (0.74,1.47) 1.01 (0.66,1.56)
VSD-muscular
c
1 2.13 (0.22,272) 2.37 (0.27,297) 2.78 (0.3,354)
ASD-all
b
1 1.08 (0.74,1.59) 0.99 (0.67,1.46) 1.13 (0.71,1.8)
a
Estimates results from a hierarchical regression model.  First stage was polytomous logistic model with 
defect groupings and adjusted for maternal race, maternal age, maternal educational attainment, 
maternal household income, maternal smoking status and alcohol consumption during early pregnancy, 
nativity, and site-specific heart defect ratio. Second stage was a linear model with indicator variables for 
defect grouping and level of exposure.
b
Estimates result from a hierarchical regression model, same as above but used individual defects as 
outcomes.
c
Estimates result from model utilizing Firth's penalized maximum likelihood regression to deal with quasi-
separation of points due to small sample size in certain cells.  Model adjusted for same variables as 
above.
Carbon Monoxide, ppm
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Table A2.1 (cont.)
<10th 
percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile
>90th 
percentile
Pollutant concentrations <18.9 18.9-33.3 33.3-45.5 >45.5
LVOTO
a
1 1.44 (1,2.08) 1.49 (1.03,2.15) 1.53 (0.98,2.39)
Aortic Stenosis
b
1 2.22 (0.94,5.26) 1.66 (0.69,3.99) 2.22 (0.83,5.97)
Coarctation of the Aorta
b
1 1.74 (0.91,3.32) 2.34 (1.24,4.42) 2.5 (1.21,5.18)
Hypoplastic Left Heart Syndrome
b
1 1.07 (0.65,1.78) 1.04 (0.62,1.72) 0.85 (0.43,1.68)
CONOTRUNCALS
a
1 1.36 (0.99,1.88) 1.32 (0.96,1.82) 1.42 (0.96,2.11)
d-TGA
b
1 1.18 (0.71,1.95) 1.24 (0.75,2.04) 1.29 (0.69,2.38)
Tetralogy of Fallot
b
1 1.51 (0.98,2.34) 1.27 (0.82,1.97) 1.51 (0.89,2.57)
Other Conotruncals
b
1 1.33 (0.55,3.22) 1.81 (0.76,4.31) 1.49 (0.52,4.24)
Common Truncus
c
1 5.6 (0.7,724.31) 9.65 (1.29,1233.7) 3.46 (0.18,507.59)
DORV-TGA and DORV-Other
c
1 1.1 (0.24,10.38) 1.57 (0.37,14.56) 1.25 (0.16,13.91)
IAA TypeB/NOS
c
1 0.68 (0.12,6.89) 0.21 (0.02,2.61) 1.36 (0.16,15.75)
VSD-Conoventricular
c
1 0.6 (0.21,2.05) 0.76 (0.28,2.54) 0.87 (0.19,3.65)
APVR
a
1 0.54 (0.28,1.03) 0.57 (0.3,1.09) 0.89 (0.41,1.94)
TAPVR
b
1 0.51 (0.26,1.01) 0.54 (0.28,1.06) 0.92 (0.42,2.03)
AVSD
a
1 0.63 (0.27,1.47) 0.66 (0.29,1.54) 0.64 (0.2,1.98)
RVOTO
a
1 1.32 (0.88,1.97) 1.5 (1.01,2.24) 2.22 (1.4,3.52)
Pulmonary/Tricuspid Atresia
b
1 2.45 (0.86,6.95) 2.02 (0.71,5.79) 2.33 (0.71,7.68)
Pulmonary Atresia
c
1 1.76 (0.64,6.64) 1.58 (0.57,5.96) 2.1 (0.59,8.97)
Tricuspid Atresia
c
1 2.81 (0.68,25.85) 1.88 (0.43,17.67) 2.07 (0.27,22.91)
Pulmonary Valve Stenosis
b
1 1.02 (0.66,1.59) 1.3 (0.85,2) 2.03 (1.23,3.33)
Ebstein's Anomaly
c
1 6.17 (0.79,795) 8.39 (1.12,1075) 11.88 (1.25,1582)
SEPTALS
a
1 1.24 (0.94,1.64) 1.23 (0.94,1.63) 1.44 (1.02,2.03)
VSD-perimembranous
b
1 1.13 (0.78,1.64) 1.18 (0.82,1.71) 1.47 (0.94,2.3)
VSD-muscular
c
1 0.75 (0.17,3.7) 0.56 (0.13,2.84) 0.46 (0.08,2.85)
ASD-all
b
1 1.29 (0.87,1.91) 1.25 (0.84,1.86) 1.23 (0.74,2.04)
Nitrogen Dioxide, ppb
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Table A2.1 (cont.)
<25th percentile 
(Referent)
25th percentile 
to median
median to 75th 
percentile >75th percentile
Pollutant concentrations <32.2 32.2-42.9 42.9-51.8 >51.8
LVOTO
a
1 0.96 (0.74,1.25) 0.95 (0.73,1.23) 0.94 (0.73,1.22)
Aortic Stenosis
b
1 1.21 (0.7,2.11) 0.95 (0.53,1.67) 1.07 (0.61,1.87)
Coarctation of the Aorta
b
1 0.74 (0.49,1.11) 0.94 (0.64,1.38) 0.97 (0.67,1.42)
Hypoplastic Left Heart Syndrome
b
1 1.07 (0.72,1.58) 0.95 (0.64,1.41) 0.86 (0.58,1.29)
CONOTRUNCALS
a
1 1.16 (0.92,1.45) 0.97 (0.76,1.22) 1 (0.79,1.26)
d-TGA
b
1 0.82 (0.56,1.21) 1.08 (0.76,1.53) 0.81 (0.56,1.19)
Tetralogy of Fallot
b
1 1.34 (0.99,1.81) 0.86 (0.62,1.19) 1.11 (0.82,1.51)
Other Conotruncals
b
1 1.44 (0.79,2.62) 1.07 (0.56,2.02) 1.15 (0.62,2.13)
Common Truncus
c
1 1.73 (0.48,7.32) 1.64(0.43,7.12) 2.40 (0.70, 9.98)
DORV-TGA and DORV-Other
c
1 1.26 (0.41,4.09) 1.34 (0.44,4.32) 0.97 (0.31,3.23)
IAA TypeB/NOS
c
1 1.10 (0.23,5.25) 0.15 (0.01,1.58) 0.85 (0.14,4.40)
VSD-Conoventricular
c
1 1.53 (0.61,3.95) 0.98 (0.35,2.67) 0.89 (0.32,2.42)
APVR
a
1 0.95 (0.53,1.71) 1.11 (0.63,1.94) 0.95 (0.54,1.7)
TAPVR
b
1 1.22 (0.65,2.27) 1.35 (0.74,2.46) 1.09 (0.59,2.04)
AVSD
a
1 1.22 (0.53,2.81) 1.18 (0.51,2.72) 1.24 (0.54,2.85)
RVOTO
a
1 1.21 (0.91,1.61) 1.07 (0.8,1.44) 1.26 (0.95,1.67)
Pulmonary/Tricuspid Atresia
b
1 1.25 (0.67,2.32) 0.92 (0.48,1.79) 1.31 (0.72,2.39)
Pulmonary Atresia
c
1 1.23 (0.55,2.78) 1.06 (0.46,2.45) 1.87 (0.91,4.01)
Tricuspid Atresia
c
1 1.27 (0.49,3.34) 0.71 (0.22,2.06) 0.59 (0.19,1.72)
Pulmonary Valve Stenosis
b
1 1.27 (0.91,1.78) 1.17 (0.84,1.64) 1.27 (0.91,1.77)
Ebstein's Anomaly
c
1 0.74 (0.29,1.85) 0.68 (0.25,1.74) 0.88 (0.34,2.22)
SEPTALS
a
1 1.03 (0.85,1.25) 0.94 (0.77,1.14) 0.89 (0.72,1.09)
VSD-perimembranous
b
1 0.96 (0.73,1.26) 0.93 (0.7,1.23) 1.06 (0.81,1.39)
VSD-muscular
c
1 0.91 (0.36,2.19) 1.28 (0.45,3.41) 1.08 (0.47,2.42)
ASD-all
b
1 1.25 (0.97,1.61) 1.1 (0.84,1.44) 0.85 (0.63,1.14)
Ozone, ppb
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Table A2.1 (cont.)
<10th percentile 
(Referent)
10th percentile to 
median
median to 90th 
percentile
>90th 
percentile
Pollutant concentrations <14.9 14.9-24.2 24.2-40.6 >40.6
LVOTO
a
1 1.1 (0.79,1.55) 1.37 (0.99,1.91) 1.12 (0.72,1.72)
Aortic Stenosis
b
1 1.24 (0.62,2.46) 1.51 (0.76,2.98) 0.92 (0.36,2.32)
Coarctation of the Aorta
b
1 1.71 (0.95,3.09) 1.77 (0.98,3.2) 1.68 (0.82,3.45)
Hypoplastic Left Heart Syndrome
b
1 0.79 (0.48,1.31) 1.24 (0.76,2.01) 0.98 (0.52,1.87)
CONOTRUNCALS
a
1 1.21 (0.89,1.64) 1.31 (0.96,1.78) 1.44 (0.99,2.1)
d-TGA
b
1 1.1 (0.67,1.81) 1.16 (0.71,1.92) 1.45 (0.8,2.64)
Tetralogy of Fallot
b
1 1.14 (0.76,1.7) 1.35 (0.91,2.02) 1.3 (0.79,2.16)
Other Conotruncals
b
1 2.12 (0.84,5.39) 1.68 (0.65,4.34) 2.07 (0.71,6.02)
Common Truncus
c
1 2.79 (0.68,25.68) 2.34 (0.55,21.79) 1.75 (0.22,19.95)
DORV-TGA and DORV-Other
c
1 1.21 (0.36,6.2) 0.94 (0.27,4.93) 1.41 (0.29,8.49)
IAA TypeB/NOS
c
1 2.58 (0.27,341.64) 1.01 (0.05,147.07) 8.75 (0.6,1249.69)
VSD-Conoventricular
c
1 1.29 (0.38,6.6) 1.12 (0.32,5.82) 1.25 (0.25,7.71)
APVR
a
1 1.49 (0.66,3.33) 1.34 (0.59,3.03) 1.44 (0.55,3.79)
TAPVR
b
1 1.28 (0.57,2.89) 1.12 (0.49,2.55) 1.36 (0.52,3.6)
AVSD
a
1 6.25 (0.84,46.26) 6.7 (0.9,49.66) 4.8 (0.53,43.41)
RVOTO
a
1 1 (0.71,1.41) 1.18 (0.84,1.66) 0.98 (0.62,1.55)
Pulmonary/Tricuspid Atresia
b
1 0.75 (0.38,1.49) 0.91 (0.46,1.8) 0.43 (0.16,1.21)
Pulmonary Atresia
c
1 0.68 (0.32,1.59) 0.82 (0.39,1.9) 0.48 (0.13,1.51)
Tricuspid Atresia
c
1 0.84 (0.28,3.32) 1.04 (0.35,4.02) 0.32 (0.03,2.07)
Pulmonary Valve Stenosis
b
1 1.13 (0.75,1.7) 1.31 (0.87,1.98) 1.17 (0.68,2)
Ebstein's Anomaly
c
1 0.6 (0.21,2.01) 0.73 (0.26,2.43) 1.26 (0.31,5.07)
SEPTALS
a
1 1.23 (0.97,1.57) 1.21 (0.95,1.55) 0.91 (0.65,1.28)
VSD-perimembranous
b
1 1.42 (0.98,2.05) 1.42 (0.98,2.05) 1.18 (0.73,1.92)
VSD-muscular
c
1 1.18 (0.52,2.88) 1.68 (0.73,4.13) 0.69 (0.12,3.06)
ASD-all
b
1 1.14 (0.83,1.57) 1.09 (0.79,1.51) 0.81 (0.51,1.28)
PM10, micrometers/cubic meter
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Table A2.1 (cont.)
<10th 
percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile >90th percentile
Pollutant concentrations <7.77 7.77-12.1 12.1-19.7 >19.7
LVOTO
a
1 1.03 (0.76,1.39) 0.85 (0.62,1.15) 1.25 (0.86,1.82)
Aortic Stenosis
b
1 0.9 (0.53,1.51) 0.59 (0.33,1.03) 0.96 (0.47,1.94)
Coarctation of the Aorta
b
1 0.88 (0.56,1.37) 0.85 (0.54,1.35) 1.06 (0.6,1.87)
Hypoplastic Left Heart Syndrome
b
1 1.59 (0.91,2.79) 1.25 (0.7,2.21) 2.04 (1.07,3.89)
CONOTRUNCALS
a
1 0.97 (0.73,1.29) 0.98 (0.73,1.31) 1.2 (0.84,1.72)
d-TGA
b
1 0.96 (0.6,1.53) 1.03 (0.65,1.65) 1.07 (0.59,1.93)
Tetralogy of Fallot
b
1 0.97 (0.66,1.44) 1.02 (0.69,1.51) 1.32 (0.83,2.12)
Other Conotruncals
b
1 1.02 (0.5,2.05) 0.75 (0.36,1.57) 1.05 (0.45,2.49)
Common Truncus
c
1 1.2 (0.35,6.16) 0.97 (0.27,5.13) 2.54 (0.58,14.64)
DORV-TGA and DORV-Other
c
1 0.54 (0.2,1.64) 0.4 (0.13,1.31) 0.22 (0.02,1.22)
IAA TypeB/NOS
c
1 0.56 (0.09,5.69) 0.32 (0.04,3.53) 2.35 (0.36,25.05)
VSD-Conoventricular
c
1 1.52 (0.47,7.7) 1.03 (0.3,5.35) 0.97 (0.18,6)
APVR
a
1 0.91 (0.48,1.71) 0.68 (0.35,1.32) 1.1 (0.5,2.44)
TAPVR
b
1 0.95 (0.48,1.87) 0.68 (0.33,1.39) 1.04 (0.44,2.44)
AVSD
a
1 2.36 (0.71,7.85) 2.27 (0.68,7.59) 2.67 (0.67,10.53)
RVOTO
a
1 0.92 (0.67,1.27) 0.96 (0.69,1.32) 0.93 (0.6,1.42)
Pulmonary/Tricuspid Atresia
b
1 0.89 (0.46,1.7) 0.62 (0.31,1.23) 0.74 (0.32,1.73)
Pulmonary Atresia
c
1 0.68 (0.33,1.52) 0.61 (0.29,1.4) 0.69 (0.25,1.86)
Tricuspid Atresia
c
1 1.37 (0.49,5.21) 0.53 (0.15,2.27) 0.9 (0.18,4.45)
Pulmonary Valve Stenosis
b
1 0.93 (0.64,1.36) 1.09 (0.74,1.58) 1.05 (0.64,1.72)
Ebstein's Anomaly
c
1 0.8 (0.32,2.36) 0.7 (0.27,2.13) 0.45 (0.04,2.34)
SEPTALS
a
1 0.89 (0.72,1.1) 0.66 (0.53,0.83) 0.62 (0.45,0.85)
VSD-perimembranous
b
1 1.17 (0.83,1.64) 1.06 (0.75,1.5) 0.85 (0.54,1.35)
VSD-muscular
c
1 n/a n/a n/a
ASD-all
b
1 0.8 (0.63,1.03) 0.5 (0.38,0.65) 0.54 (0.35,0.81)
PM2.5 micrometers/cubic meter
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Table A2.1 (cont.)
<10th 
percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile >90th percentile
Pollutant concentrations <3.45 3.45-9.70 9.70-19.9 >19.9
LVOTO
a
1 1.32 (0.88,1.98) 1.49 (0.99,2.24) 1.07 (0.64,1.79)
Aortic Stenosis
b
1 0.93 (0.44,1.97) 0.84 (0.39,1.83) 0.58 (0.2,1.65)
Coarctation of the Aorta
b
1 1.21 (0.65,2.24) 1.74 (0.95,3.2) 1.62 (0.79,3.3)
Hypoplastic Left Heart Syndrome
b
1 1.98 (0.97,4.04) 1.84 (0.89,3.78) 0.96 (0.37,2.47)
CONOTRUNCALS
a
1 1.12 (0.78,1.6) 1.35 (0.95,1.92) 1.22 (0.79,1.88)
d-TGA
b
1 1.32 (0.72,2.43) 1.61 (0.88,2.96) 1.46 (0.71,2.98)
Tetralogy of Fallot
b
1 1.08 (0.67,1.73) 1.2 (0.74,1.92) 1.17 (0.66,2.07)
Other Conotruncals
b
1 0.9 (0.37,2.16) 1.5 (0.64,3.53) 0.91 (0.3,2.79)
Common Truncus
c
1 0.74 (0.21,3.17) 1.19 (0.35,5.14) 1.58 (0.31,8.16)
DORV-TGA and DORV-Other
c
1 0.79 (0.18,4.66) 1.71 (0.42,10.11) 0.41 (0,5.48)
IAA TypeB/NOS
c
1 n/a n/a n/a
VSD-Conoventricular
c
1 0.82 (0.22,4.4) 1.27 (0.35,6.91) 0.5 (0.04,3.88)
APVR
a
1 1.33 (0.54,3.3) 1.65 (0.67,4.09) 1.02 (0.32,3.28)
TAPVR
b
1 1.03 (0.41,2.61) 1.46 (0.58,3.62) 0.93 (0.29,2.99)
AVSD
a
1 0.82 (0.28,3.2) 1.1 (0.39,4.23) 1.54 (0.45,6.46)
RVOTO
a
1 1.81 (1.15,2.83) 1.65 (1.04,2.6) 1.24 (0.7,2.18)
Pulmonary/Tricuspid Atresia
b
1 1.13 (0.49,2.61) 1.17 (0.5,2.73) 0.76 (0.25,2.31)
Pulmonary Atresia
c
1 1.22 (0.47,3.94) 1.31 (0.5,4.23) 0.74 (0.16,3.09)
Tricuspid Atresia
c
1 0.81 (0.25,3.34) 0.66 (0.19,2.82) 0.78 (0.13,4.17)
Pulmonary Valve Stenosis
b
1 2.34 (1.33,4.14) 2.06 (1.16,3.67) 1.48 (0.74,2.97)
Ebstein's Anomaly
c
1 0.75 (0.24,3.01) 0.76 (0.23,3.15) 1.45 (0.34,6.72)
SEPTALS
a
1 1.06 (0.82,1.38) 1.09 (0.84,1.43) 1.12 (0.8,1.58)
VSD-perimembranous
b
1 1.26 (0.84,1.89) 1.36 (0.9,2.05) 1.48 (0.91,2.42)
VSD-muscular
c
1 n/a n/a n/a
ASD-all
b
1 0.93 (0.68,1.28) 0.83 (0.59,1.16) 0.67 (0.41,1.09)
Sulfur Dioxide, ppb
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Table A2.2: Adjusted Odds Ratios and 95% Confidence Intervals between Cardiac Birth Defects and 7-week average 
exposure to nitrogen dioxide andPM10, by distance to major road
a
 
 
<10th 
percentile
10th percentile to 
median
median to 90th 
percentile >90th percentile
Pollutant concentrations <18.9 18.9-33.3 33.3-45.5 >45.5
LVOTO 1 1.01 (0.45,2.26) 1.31 (0.6,2.85) 2.11 (0.82,5.45)
Aortic Stenosis 1 3.29 (0.4,26.86) 1.42 (0.16,13.01) 7.52 (0.81,69.88)
Coarctation of the Aorta 1 0.23 (0.05,0.98) 1.22 (0.44,3.4) 1.69 (0.47,6.16)
Hypoplastic Left Heart Syndrome 1 1.6 (0.44,5.78) 1.41 (0.39,5.14) 1.12 (0.18,6.97)
CONOTRUNCALS 1 3.17 (1.21,8.26) 3.8 (1.47,9.8) 7.12 (2.53,19.99)
d-TGA 1 2.68 (0.59,12.04) 3.54 (0.81,15.57) 6.23 (1.24,31.19)
Tetralogy of Fallot 1 4.66 (1.08,20.11) 4.53 (1.05,19.47) 11.05 (2.39,51)
Other Conotruncals 1 1.34 (0.15,12.2) 3.06 (0.38,24.63) 1.49 (0.09,24.47)
APVR 1 1.01 (0.26,3.92) 1.18 (0.31,4.42) 1.1 (0.18,6.85)
RVOTO 1 1.56 (0.62,3.95) 1.14 (0.44,2.97) 3.55 (1.25,10.06)
Pulmonary/Tricuspid Atresia 1 1.4 (0.28,6.92) 0.96 (0.18,5.1) 1.83 (0.25,13.43)
Pulmonary Valve Stenosis 1 1.48 (0.48,4.58) 1.09 (0.34,3.47) 3.11 (0.86,11.18)
SEPTALS 1 1.74 (0.93,3.26) 1.41 (0.74,2.66) 1.8 (0.8,4.03)
VSD-perimembranous 1 2.68 (1.02,7.05) 1.98 (0.74,5.27) 2.87 (0.91,9.06)
ASD-all 1 1.07 (0.48,2.38) 0.96 (0.43,2.17) 0.97 (0.31,3.05)
<10th 
percentile 
10th percentile to 
median
median to 90th 
percentile >90th percentile
Pollutant concentrations <14.9 14.9-24.2 24.2-40.6 >40.6
LVOTO 1 1.21 (0.56,2.6) 1.33 (0.62,2.86) 2.2 (0.85,5.71)
Aortic Stenosis 1 1.49 (0.32,6.98) 1.15 (0.23,5.69) 3.9 (0.68,22.49)
Coarctation of the Aorta 1 0.56 (0.16,1.9) 1.34 (0.44,4.09) 1.76 (0.42,7.42)
Hypoplastic Left Heart Syndrome 1 1.89 (0.55,6.5) 1.43 (0.4,5.11) 1.76 (0.34,9.13)
CONOTRUNCALS 1 1.19 (0.59,2.4) 1.55 (0.78,3.09) 2.63 (1.14,6.06)
d-TGA 1 0.97 (0.31,3.06) 1.46 (0.48,4.44) 2.04 (0.52,8)
Tetralogy of Fallot 1 1.14 (0.45,2.89) 1.61 (0.65,4) 2.86 (0.98,8.42)
Other Conotruncals 1 2.34 (0.29,18.99) 1.54 (0.18,13.38) 3.13 (0.27,35.94)
APVR 1 b b b
RVOTO 1 1.74 (0.66,4.63) 1.99 (0.75,5.28) 3.59 (1.14,11.38)
Pulmonary/Tricuspid Atresia 1 2.72 (0.34,21.81) 2.49 (0.31,20.25) 1.49 (0.09,24.62)
Pulmonary Valve Stenosis 1 1.29 (0.43,3.93) 1.71 (0.57,5.12) 3.25 (0.87,12.15)
SEPTALS 1 1.51 (0.86,2.64) 1.43 (0.81,2.52) 1.36 (0.6,3.1)
VSD-perimembranous 1 1.68 (0.73,3.89) 1.59 (0.68,3.7) 1.77 (0.56,5.57)
ASD-all 1 1.37 (0.66,2.83) 1.24 (0.59,2.61) 0.96 (0.3,3.06)
b
 Could not be estimated due to small sample size
a
Estimates result from maximum-likelihood, polytomous logistic model includes an interaction term between exposure and  distance to 
roadway and adjusted for maternal race, maternal age, maternal educational attainment, maternal household income, maternal 
smoking status and alcohol consumption during early pregnancy, nativity, and site-specific heart defect ratio. 
Nitrogen Dioxide, ppb
PM10, micrometers/cubic meter
Living within 50 meters of a major roadway
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<10th percentile
10th percentile 
to median
median to 90th 
percentile >90th percentile
Pollutant concentrations <18.9 18.9-33.3 33.3-45.5 >45.5
LVOTO 1 1.54 (1.01,2.33) 1.53 (1.01,2.33) 1.41 (0.85,2.34)
Aortic Stenosis 1 2.03 (0.79,5.25) 1.63 (0.63,4.25) 1.57 (0.5,4.93)
Coarctation of the Aorta 1 2.79 (1.19,6.52) 3.28 (1.41,7.61) 3.32 (1.3,8.43)
Hypoplastic Left Heart Syndrome 1 0.97 (0.56,1.7) 0.95 (0.55,1.66) 0.76 (0.36,1.6)
CONOTRUNCALS 1 1.16 (0.82,1.64) 1.07 (0.76,1.52) 0.96 (0.62,1.5)
d-TGA 1 1 (0.58,1.71) 1 (0.58,1.71) 0.88 (0.43,1.77)
Tetralogy of Fallot 1 1.26 (0.79,1.99) 1.01 (0.63,1.61) 0.92 (0.5,1.69)
Other Conotruncals 1 1.28 (0.49,3.38) 1.6 (0.62,4.17) 1.4 (0.43,4.5)
APVR 1 0.45 (0.21,0.95) 0.45 (0.21,0.95) 0.88 (0.36,2.14)
RVOTO 1 1.25 (0.8,1.95) 1.53 (0.99,2.38) 1.98 (1.19,3.31)
Pulmonary/Tricuspid Atresia 1 3.6 (0.85,15.26) 3.04 (0.71,12.97) 3.07 (0.61,15.48)
Pulmonary Valve Stenosis 1 0.93 (0.58,1.5) 1.28 (0.8,2.04) 1.85 (1.08,3.18)
SEPTALS 1 1.14 (0.84,1.55) 1.18 (0.87,1.61) 1.35 (0.93,1.98)
VSD-perimembranous 1 0.93 (0.62,1.4) 1.05 (0.71,1.57) 1.28 (0.78,2.09)
ASD-all 1 1.36 (0.87,2.14) 1.34 (0.85,2.11) 1.3 (0.73,2.3)
<10th percentile 
10th percentile 
to median
median to 90th 
percentile >90th percentile
Pollutant concentrations <14.9 14.9-24.2 24.2-40.6 >40.6
LVOTO 1 1.08 (0.74,1.57) 1.37 (0.95,1.98) 0.96 (0.59,1.57)
Aortic Stenosis 1 1.18 (0.54,2.55) 1.57 (0.73,3.35) 0.49 (0.14,1.67)
Coarctation of the Aorta 1 2.18 (1.08,4.39) 1.97 (0.97,3.98) 1.78 (0.76,4.12)
Hypoplastic Left Heart Syndrome 1 0.63 (0.36,1.09) 1.19 (0.71,2.01) 0.88 (0.44,1.78)
CONOTRUNCALS 1 1.2 (0.85,1.69) 1.25 (0.89,1.76) 1.27 (0.84,1.94)
d-TGA 1 1.12 (0.64,1.94) 1.1 (0.63,1.92) 1.38 (0.71,2.68)
Tetralogy of Fallot 1 1.13 (0.72,1.77) 1.3 (0.83,2.04) 1.08 (0.61,1.92)
Other Conotruncals 1 2.07 (0.73,5.88) 1.67 (0.58,4.81) 1.96 (0.59,6.5)
APVR 1 b b b
RVOTO 1 0.9 (0.62,1.3) 1.07 (0.74,1.54) 0.75 (0.45,1.25)
Pulmonary/Tricuspid Atresia 1 0.58 (0.27,1.22) 0.77 (0.37,1.58) 0.29 (0.09,0.96)
Pulmonary Valve Stenosis 1 1.09 (0.7,1.69) 1.24 (0.8,1.93) 0.95 (0.52,1.72)
SEPTALS 1 1.17 (0.89,1.53) 1.16 (0.88,1.52) 0.83 (0.57,1.21)
VSD-perimembranous 1 1.36 (0.9,2.04) 1.38 (0.91,2.08) 1.08 (0.63,1.86)
ASD-all 1 1.1 (0.77,1.56) 1.06 (0.74,1.51) 0.77 (0.47,1.28)
Nitrogen Dioxide, ppb
PM10, micrometers/cubic meter
Table A2.2 (cont.)
Living beyond 50 meters of a major roadway
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Table A2.3: Adjusted Odds Ratios and 95% Confidence Intervals between cardiac defect-groupings and weekly exposure to 
criteria air pollutants from hierarchical models 
 
Week of Pregnancy
Cardiac Defect Pollutant
<10th 
percentile 
10th percentile 
to median
median to 90th 
percentile >90th percentile
LVOTO Carbon Monoxide 1 0.99 (0.67,1.47) 0.99 (0.63,1.55) 0.98 (0.56,1.7)
Nitrogen Dioxide 1 0.92 (0.57,1.47) 0.94 (0.56,1.56) 1.1 (0.62,1.97)
Ozone
a
1 0.83 (0.59,1.18) 0.96 (0.65,1.44) 0.88 (0.57,1.37)
PM 10 1 0.98 (0.66,1.43) 1.1 (0.74,1.63) 0.91 (0.55,1.51)
PM 2.5 1 1.11 (0.79,1.55) 1.1 (0.77,1.57) 1.48 (0.94,2.33)
Sulfur Dioxide 1 0.79 (0.52,1.2) 0.65 (0.41,1.02) 0.7 (0.4,1.24)
CONOTRUNCALS Carbon Monoxide 1 1.17 (0.81,1.69) 1.04 (0.69,1.57) 0.93 (0.56,1.56)
Nitrogen Dioxide 1 0.95 (0.61,1.46) 1.11 (0.7,1.77) 1.15 (0.67,1.96)
Ozone
a
1 1.03 (0.76,1.39) 0.73 (0.51,1.05) 0.99 (0.67,1.46)
PM 10 1 1.01 (0.7,1.46) 1.12 (0.77,1.62) 1 (0.63,1.59)
PM 2.5 1 1.39 (0.98,1.97) 1.29 (0.9,1.86) 1.5 (0.96,2.35)
Sulfur Dioxide 1 0.83 (0.55,1.25) 1.12 (0.72,1.73) 1 (0.58,1.72)
APVR Carbon Monoxide 1 0.67 (0.35,1.3) 0.84 (0.4,1.77) 1.16 (0.47,2.87)
Nitrogen Dioxide 1 0.77 (0.36,1.66) 0.65 (0.29,1.47) 1.5 (0.61,3.71)
Ozone
a
1 0.77 (0.38,1.56) 1.01 (0.48,2.1) 1.19 (0.54,2.59)
PM 10 1 1.19 (0.51,2.77) 1.77 (0.78,4.05) 0.93 (0.34,2.54)
PM 2.5 1 1.57 (0.79,3.16) 1.14 (0.55,2.35) 1.79 (0.76,4.22)
Sulfur Dioxide 1 0.87 (0.42,1.83) 0.81 (0.38,1.77) 0.66 (0.24,1.82)
AVSD Carbon Monoxide 1 0.73 (0.31,1.7) 0.76 (0.31,1.86) 2 (0.74,5.45)
Nitrogen Dioxide 1 0.64 (0.26,1.52) 0.8 (0.33,1.95) 1.35 (0.49,3.71)
Ozone
a
1 1.17 (0.51,2.68) 1.03 (0.42,2.51) 1.36 (0.53,3.49)
PM 10 1 0.98 (0.38,2.53) 0.97 (0.38,2.51) 1.76 (0.61,5.08)
PM 2.5 1 1.27 (0.54,2.98) 0.82 (0.34,1.99) 3.43 (1.36,8.66)
RVOTO Carbon Monoxide 1 0.61 (0.42,0.91) 0.64 (0.41,1) 0.45 (0.25,0.8)
Nitrogen Dioxide 1 1.02 (0.62,1.7) 0.85 (0.49,1.48) 0.71 (0.38,1.34)
Ozone
a
1 0.87 (0.59,1.28) 0.61 (0.39,0.95) 0.72 (0.45,1.14)
PM 10 1 1.1 (0.72,1.67) 1.16 (0.76,1.79) 0.83 (0.47,1.45)
PM 2.5 1 1.2 (0.84,1.71) 0.92 (0.63,1.35) 0.95 (0.57,1.57)
Sulfur Dioxide 1 0.81 (0.53,1.25) 0.78 (0.49,1.24) 1.05 (0.59,1.87)
SEPTALS Carbon Monoxide 1 1.07 (0.76,1.5) 1.03 (0.7,1.5) 0.9 (0.57,1.42)
Nitrogen Dioxide 1 0.99 (0.67,1.44) 0.92 (0.61,1.39) 0.8 (0.49,1.3)
Ozone
a
1 1.02 (0.79,1.31) 0.72 (0.53,0.97) 0.83 (0.6,1.16)
PM 10 1 0.87 (0.66,1.16) 0.9 (0.67,1.21) 0.75 (0.5,1.12)
PM 2.5 1 1.02 (0.8,1.31) 0.92 (0.71,1.2) 0.6 (0.4,0.9)
Sulfur Dioxide 1 0.75 (0.55,1.01) 0.63 (0.45,0.88) 0.79 (0.52,1.2)
a
Ozone exposure was categorized as follows:  Less than the 25th percentile (referent), 25th percentile to 
median, median to 75th percentile and 75th percentile and greater
Week 2
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Table A2.3 (cont.)
Week of Pregnancy
Cardiac Defect Pollutant
<10th percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile >90th percentile
LVOTO Carbon Monoxide 1 1.06 (0.69,1.62) 1.21 (0.75,1.95) 1.15 (0.64,2.08)
Nitrogen Dioxide 1 1.22 (0.74,2.03) 1.37 (0.8,2.36) 0.79 (0.41,1.52)
Ozone
a
1 1.13 (0.79,1.63) 0.99 (0.64,1.52) 1.12 (0.69,1.8)
PM 10 1 0.89 (0.61,1.28) 0.89 (0.61,1.3) 0.85 (0.52,1.39)
PM 2.5 1 0.69 (0.51,0.94) 0.54 (0.38,0.75) 0.52 (0.33,0.83)
Sulfur Dioxide 1 1.11 (0.69,1.78) 1.42 (0.86,2.36) 1.66 (0.91,3.05)
CONOTRUNCALS Carbon Monoxide 1 0.93 (0.63,1.36) 0.95 (0.62,1.47) 0.75 (0.43,1.29)
Nitrogen Dioxide 1 1.87 (1.14,3.08) 1.63 (0.96,2.79) 1.6 (0.88,2.93)
Ozone
a
1 1.26 (0.91,1.75) 1.27 (0.87,1.86) 1.19 (0.77,1.82)
PM 10 1 1.02 (0.71,1.46) 1 (0.69,1.44) 1.11 (0.7,1.75)
PM 2.5 1 0.8 (0.59,1.09) 0.72 (0.52,0.99) 0.58 (0.38,0.9)
Sulfur Dioxide 1 0.89 (0.58,1.35) 0.99 (0.63,1.55) 1.1 (0.64,1.89)
APVR Carbon Monoxide 1 1.03 (0.52,2.04) 1.23 (0.56,2.67) 1.12 (0.43,2.92)
Nitrogen Dioxide 1 1.33 (0.6,2.95) 0.98 (0.42,2.31) 1.02 (0.38,2.72)
Ozone
a
1 0.97 (0.48,1.96) 1.44 (0.69,3.02) 0.94 (0.41,2.17)
PM 10 1 0.97 (0.45,2.07) 1.02 (0.48,2.18) 1.56 (0.64,3.77)
PM 2.5 1 0.61 (0.34,1.09) 0.65 (0.35,1.22) 0.77 (0.34,1.74)
Sulfur Dioxide 1 1.35 (0.6,3.02) 1.34 (0.58,3.1) 1.08 (0.38,3.04)
AVSD Carbon Monoxide 1 1.14 (0.48,2.74) 1.43 (0.57,3.56) 0.77 (0.23,2.58)
Nitrogen Dioxide 1 0.98 (0.39,2.43) 1.33 (0.53,3.37) 1.22 (0.41,3.57)
Ozone
a
1 1.03 (0.45,2.37) 0.92 (0.37,2.28) 1.34 (0.51,3.5)
PM 10 1 0.74 (0.28,1.95) 1.83 (0.73,4.55) 1.19 (0.23,6.12)
PM 2.5 1 0.71 (0.31,1.65) 1.44 (0.65,3.22) 0.69 (0.24,2)
RVOTO Carbon Monoxide 1 1.33 (0.85,2.1) 1.15 (0.69,1.92) 1.03 (0.55,1.93)
Nitrogen Dioxide 1 0.94 (0.55,1.6) 1.29 (0.73,2.29) 1.23 (0.64,2.36)
Ozone
a
1 1.18 (0.78,1.8) 1.86 (1.16,2.98) 2.01 (1.21,3.36)
PM 10 1 1.48 (0.95,2.3) 1.28 (0.81,2.02) 1.46 (0.83,2.55)
PM 2.5 1 0.74 (0.53,1.04) 0.76 (0.53,1.09) 0.71 (0.43,1.16)
Sulfur Dioxide 1 1.31 (0.82,2.1) 1.07 (0.65,1.77) 0.96 (0.51,1.79)
SEPTALS Carbon Monoxide 1 0.93 (0.65,1.33) 1.07 (0.72,1.61) 1.2 (0.74,1.95)
Nitrogen Dioxide 1 1.11 (0.74,1.67) 1.05 (0.67,1.63) 0.84 (0.5,1.41)
Ozone
a
1 1 (0.77,1.3) 0.9 (0.66,1.24) 0.95 (0.67,1.36)
PM 10 1 1.18 (0.88,1.57) 1.03 (0.76,1.39) 1 (0.66,1.49)
PM 2.5 1 0.86 (0.68,1.1) 0.78 (0.6,1.02) 0.84 (0.58,1.23)
Sulfur Dioxide 1 0.9 (0.66,1.23) 1.05 (0.74,1.49) 1.24 (0.8,1.91)
Week 3
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Table A2.3 (cont.)
Week of Pregnancy
Cardiac Defect Pollutant
<10th 
percentile 
10th percentile to 
median
median to 90th 
percentile
>90th 
percentile
LVOTO Carbon Monoxide 1 0.76 (0.51,1.13) 0.6 (0.38,0.95) 0.76 (0.43,1.34)
Nitrogen Dioxide 1 1.34 (0.82,2.21) 1.1 (0.64,1.89) 1.2 (0.64,2.23)
Ozone
a
1 0.98 (0.68,1.42) 0.95 (0.61,1.47) 0.85 (0.52,1.38)
PM 10 1 0.95 (0.65,1.39) 1 (0.68,1.48) 1.09 (0.66,1.77)
PM 2.5 1 1.37 (0.96,1.96) 1.28 (0.87,1.87) 1.56 (0.97,2.51)
Sulfur Dioxide 1 1.01 (0.63,1.61) 1.36 (0.82,2.24) 0.71 (0.37,1.35)
CONOTRUNCALS Carbon Monoxide 1 1.12 (0.76,1.65) 1.27 (0.82,1.95) 0.96 (0.56,1.65)
Nitrogen Dioxide 1 1.57 (0.98,2.5) 1.39 (0.84,2.3) 1.45 (0.81,2.59)
Ozone
a
1 1.13 (0.81,1.57) 0.85 (0.58,1.26) 0.86 (0.56,1.33)
PM 10 1 0.76 (0.54,1.08) 0.83 (0.58,1.18) 0.98 (0.63,1.53)
PM 2.5 1 0.95 (0.69,1.32) 1.1 (0.78,1.55) 1.11 (0.71,1.71)
Sulfur Dioxide 1 1.33 (0.86,2.05) 1.06 (0.66,1.69) 0.97 (0.55,1.72)
APVR Carbon Monoxide 1 0.79 (0.4,1.55) 0.88 (0.41,1.9) 0.96 (0.37,2.48)
Nitrogen Dioxide 1 1.01 (0.47,2.16) 0.9 (0.39,2.06) 1.15 (0.44,3)
Ozone
a
1 1.04 (0.52,2.1) 0.9 (0.41,1.95) 0.99 (0.43,2.31)
PM 10 1 1.01 (0.49,2.11) 1.09 (0.53,2.24) 0.65 (0.25,1.68)
PM 2.5 1 1.32 (0.67,2.59) 1.28 (0.63,2.58) 1.28 (0.53,3.08)
Sulfur Dioxide 1 1.4 (0.59,3.29) 1.52 (0.64,3.63) 1.05 (0.36,3.04)
AVSD Carbon Monoxide 1 1.24 (0.51,3.04) 1.13 (0.44,2.87) 0.94 (0.3,2.98)
Nitrogen Dioxide 1 0.94 (0.39,2.24) 1 (0.4,2.51) 0.95 (0.32,2.84)
Ozone
a
1 1.38 (0.6,3.17) 0.91 (0.35,2.37) 1.6 (0.6,4.23)
PM 10 1 1.52 (0.52,4.39) 1.3 (0.46,3.69) 0.75 (0.19,2.96)
PM 2.5 1 1.56 (0.67,3.64) 1.23 (0.52,2.92) 1.19 (0.42,3.36)
RVOTO Carbon Monoxide 1 0.92 (0.6,1.42) 0.81 (0.49,1.31) 0.94 (0.52,1.71)
Nitrogen Dioxide 1 1.29 (0.76,2.2) 0.9 (0.5,1.6) 1.02 (0.53,1.95)
Ozone
a
1 0.91 (0.59,1.38) 1.06 (0.66,1.71) 0.84 (0.5,1.42)
PM 10 1 1.12 (0.75,1.69) 0.8 (0.52,1.22) 1.04 (0.61,1.76)
PM 2.5 1 0.96 (0.68,1.37) 0.98 (0.67,1.43) 0.94 (0.57,1.54)
Sulfur Dioxide 1 0.98 (0.62,1.55) 0.87 (0.53,1.43) 0.95 (0.52,1.76)
SEPTALS Carbon Monoxide 1 1.16 (0.81,1.65) 1.16 (0.78,1.74) 1.1 (0.68,1.78)
Nitrogen Dioxide 1 1.52 (1,2.32) 1.51 (0.96,2.39) 1.48 (0.88,2.51)
Ozone
a
1 1.1 (0.84,1.45) 1.07 (0.77,1.49) 1 (0.69,1.45)
PM 10 1 1.02 (0.76,1.35) 0.98 (0.73,1.33) 0.86 (0.57,1.29)
PM 2.5 1 1 (0.78,1.3) 0.92 (0.7,1.22) 0.95 (0.65,1.39)
Sulfur Dioxide 1 1.19 (0.86,1.64) 1.03 (0.71,1.48) 0.87 (0.55,1.38)
Week 4
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Table A2.3 (cont.)
Week of Pregnancy
Cardiac Defect Pollutant
<10th 
percentile 
10th percentile 
to median
median to 90th 
percentile >90th percentile
LVOTO Carbon Monoxide 1 1.13 (0.75,1.73) 1.07 (0.67,1.72) 0.79 (0.43,1.44)
Nitrogen Dioxide 1 1.03 (0.62,1.7) 1.08 (0.63,1.86) 0.98 (0.52,1.85)
Ozone
a
1 0.65 (0.46,0.94) 0.69 (0.45,1.06) 0.73 (0.45,1.17)
PM 10 1 1.1 (0.75,1.63) 1.25 (0.84,1.86) 0.88 (0.52,1.49)
PM 2.5 1 1.01 (0.73,1.41) 0.95 (0.67,1.36) 1.12 (0.7,1.79)
Sulfur Dioxide 1 1.02 (0.64,1.63) 1.04 (0.63,1.72) 1.16 (0.64,2.12)
CONOTRUNCALS Carbon Monoxide 1 0.83 (0.57,1.22) 0.85 (0.55,1.31) 0.91 (0.53,1.55)
Nitrogen Dioxide 1 0.51 (0.34,0.76) 0.49 (0.31,0.77) 0.48 (0.28,0.83)
Ozone
a
1 1.14 (0.82,1.58) 1.36 (0.92,2.01) 1.38 (0.89,2.15)
PM 10 1 1.12 (0.78,1.62) 1.19 (0.82,1.74) 1.22 (0.76,1.95)
PM 2.5 1 1.01 (0.73,1.39) 0.91 (0.65,1.28) 0.91 (0.58,1.42)
Sulfur Dioxide 1 0.8 (0.54,1.2) 0.77 (0.49,1.19) 0.77 (0.45,1.31)
APVR Carbon Monoxide 1 1.27 (0.64,2.51) 0.81 (0.37,1.81) 1.17 (0.45,3.05)
Nitrogen Dioxide 1 0.53 (0.24,1.16) 0.94 (0.42,2.15) 1.53 (0.59,3.97)
Ozone
a
1 1.18 (0.59,2.36) 1.19 (0.55,2.58) 0.96 (0.41,2.25)
PM 10 1 0.73 (0.34,1.55) 1.23 (0.6,2.52) 1.58 (0.66,3.78)
PM 2.5 1 1.46 (0.7,3.04) 1.78 (0.85,3.75) 1.6 (0.64,3.98)
Sulfur Dioxide 1 1.25 (0.55,2.83) 1.66 (0.72,3.83) 0.76 (0.25,2.36)
AVSD Carbon Monoxide 1 1.05 (0.45,2.46) 1.07 (0.43,2.69) 0.57 (0.15,2.13)
Nitrogen Dioxide 1 0.63 (0.27,1.48) 0.67 (0.27,1.66) 0.64 (0.2,1.98)
Ozone
a
1 0.61 (0.27,1.39) 0.62 (0.25,1.55) 0.81 (0.31,2.16)
PM 10 1 0.75 (0.29,1.95) 1.63 (0.65,4.05) 1.18 (0.23,6.11)
PM 2.5 1 1.37 (0.61,3.07) 1.19 (0.52,2.72) 1.29 (0.47,3.57)
RVOTO Carbon Monoxide 1 1.11 (0.71,1.74) 1.26 (0.76,2.09) 1.37 (0.73,2.55)
Nitrogen Dioxide 1 0.72 (0.43,1.21) 1.04 (0.59,1.82) 1.13 (0.59,2.16)
Ozone
a
1 1.01 (0.67,1.52) 1.02 (0.63,1.64) 1.07 (0.64,1.8)
PM 10 1 0.81 (0.55,1.18) 0.84 (0.56,1.24) 0.86 (0.51,1.45)
PM 2.5 1 1.09 (0.75,1.56) 1.17 (0.79,1.72) 1.74 (1.07,2.83)
Sulfur Dioxide 1 1.19 (0.73,1.94) 1.45 (0.86,2.44) 1.34 (0.71,2.51)
SEPTALS Carbon Monoxide 1 0.99 (0.69,1.42) 1.04 (0.69,1.57) 1.23 (0.75,2)
Nitrogen Dioxide 1 0.99 (0.66,1.49) 1.15 (0.74,1.8) 1.56 (0.93,2.6)
Ozone
a
1 1.16 (0.88,1.53) 1.4 (1.01,1.95) 1.58 (1.09,2.29)
PM 10 1 1.2 (0.88,1.61) 1.31 (0.96,1.78) 1.46 (0.98,2.19)
PM 2.5 1 1.12 (0.87,1.45) 0.95 (0.72,1.26) 1.2 (0.82,1.75)
Sulfur Dioxide 1 1.2 (0.86,1.68) 1.3 (0.9,1.88) 1.34 (0.86,2.1)
Week 5
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Table A2.3 (cont.)
Week of Pregnancy
Cardiac Defect Pollutant
<10th 
percentile 
10th percentile 
to median
median to 90th 
percentile
>90th 
percentile
LVOTO Carbon Monoxide 1 1.16 (0.76,1.76) 1.28 (0.8,2.05) 0.88 (0.48,1.6)
Nitrogen Dioxide 1 1.03 (0.63,1.69) 1.08 (0.63,1.85) 1 (0.53,1.87)
Ozone
a
1 1.52 (1.05,2.2) 1.34 (0.86,2.1) 1.22 (0.74,2.01)
PM 10 1 0.98 (0.67,1.43) 0.98 (0.66,1.44) 0.86 (0.51,1.45)
PM 2.5 1 1.04 (0.74,1.47) 1.09 (0.75,1.57) 0.95 (0.58,1.55)
Sulfur Dioxide 1 1.3 (0.79,2.13) 1.03 (0.61,1.74) 1.02 (0.54,1.91)
CONOTRUNCALS Carbon Monoxide 1 1.26 (0.85,1.87) 1.32 (0.85,2.05) 1.53 (0.9,2.61)
Nitrogen Dioxide 1 1.14 (0.72,1.8) 1.4 (0.85,2.29) 1.21 (0.68,2.17)
Ozone
a
1 1 (0.73,1.38) 1.04 (0.71,1.52) 0.83 (0.53,1.29)
PM 10 1 0.89 (0.63,1.26) 0.72 (0.5,1.03) 0.9 (0.57,1.42)
PM 2.5 1 1.02 (0.73,1.42) 1 (0.7,1.42) 0.89 (0.57,1.41)
Sulfur Dioxide 1 1.03 (0.66,1.59) 1.17 (0.73,1.88) 1.15 (0.65,2.02)
APVR Carbon Monoxide 1 1.09 (0.56,2.13) 0.93 (0.43,2.03) 0.49 (0.18,1.34)
Nitrogen Dioxide 1 0.94 (0.44,2.03) 0.85 (0.37,1.96) 0.64 (0.23,1.75)
Ozone
a
1 0.9 (0.45,1.78) 0.91 (0.42,1.96) 1.07 (0.46,2.48)
PM 10 1 1.19 (0.56,2.54) 0.96 (0.45,2.04) 0.89 (0.35,2.31)
PM 2.5 1 0.79 (0.44,1.42) 0.48 (0.25,0.94) 1 (0.45,2.24)
Sulfur Dioxide 1 1.28 (0.55,3.01) 1.06 (0.45,2.54) 2.34 (0.89,6.17)
AVSD Carbon Monoxide 1 1.05 (0.45,2.4) 0.97 (0.39,2.36) 0.87 (0.28,2.72)
Nitrogen Dioxide 1 1.43 (0.58,3.54) 1.11 (0.43,2.9) 0.59 (0.17,1.99)
Ozone
a
1 1.69 (0.77,3.71) 0.88 (0.36,2.18) 0.41 (0.14,1.17)
PM 10 1 1.46 (0.56,3.79) 0.95 (0.36,2.5) 0.85 (0.25,2.91)
PM 2.5 1 1.23 (0.57,2.67) 0.89 (0.4,1.99) 0.48 (0.15,1.57)
RVOTO Carbon Monoxide 1 1.45 (0.93,2.28) 1.18 (0.71,1.95) 1.46 (0.79,2.7)
Nitrogen Dioxide 1 0.74 (0.44,1.23) 0.96 (0.55,1.68) 1.02 (0.54,1.93)
Ozone
a
1 1.07 (0.71,1.6) 1.22 (0.76,1.95) 1.13 (0.67,1.89)
PM 10 1 0.97 (0.65,1.45) 0.98 (0.65,1.48) 0.94 (0.54,1.63)
PM 2.5 1 0.82 (0.58,1.17) 0.84 (0.58,1.22) 0.76 (0.46,1.26)
Sulfur Dioxide 1 1.16 (0.71,1.89) 1.06 (0.63,1.78) 1.09 (0.58,2.06)
SEPTALS Carbon Monoxide 1 1 (0.71,1.42) 0.84 (0.56,1.24) 0.92 (0.57,1.48)
Nitrogen Dioxide 1 0.68 (0.46,0.99) 0.74 (0.49,1.13) 0.63 (0.38,1.05)
Ozone
a
1 1.09 (0.83,1.42) 1.09 (0.79,1.51) 0.87 (0.6,1.26)
PM 10 1 0.98 (0.74,1.29) 0.9 (0.67,1.2) 0.92 (0.62,1.38)
PM 2.5 1 0.97 (0.76,1.26) 0.89 (0.68,1.18) 0.81 (0.55,1.2)
Sulfur Dioxide 1 0.97 (0.7,1.34) 1.11 (0.77,1.59) 1.12 (0.71,1.75)
Week 6
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Table A2.3 (cont.)
Week of Pregnancy
Cardiac Defect Pollutant
<10th 
percentile 
10th percentile 
to median
median to 90th 
percentile >90th percentile
LVOTO Carbon Monoxide 1 1.03 (0.69,1.56) 1.25 (0.79,1.99) 1.45 (0.82,2.59)
Nitrogen Dioxide 1 1.24 (0.75,2.02) 1.34 (0.78,2.29) 1.58 (0.86,2.92)
Ozone
a
1 1.18 (0.82,1.69) 1.03 (0.67,1.58) 1.24 (0.78,1.99)
PM 10 1 1.43 (0.94,2.18) 1.38 (0.9,2.12) 1.53 (0.9,2.6)
PM 2.5 1 1.16 (0.82,1.64) 1.2 (0.84,1.73) 1.23 (0.75,2.01)
Sulfur Dioxide 1 1.28 (0.78,2.09) 1.38 (0.82,2.33) 0.94 (0.5,1.8)
CONOTRUNCALS Carbon Monoxide 1 1.13 (0.77,1.67) 1.16 (0.75,1.78) 1.59 (0.94,2.69)
Nitrogen Dioxide 1 1.06 (0.69,1.63) 0.83 (0.51,1.33) 0.91 (0.52,1.58)
Ozone
a
1 0.84 (0.61,1.15) 0.75 (0.52,1.09) 0.75 (0.49,1.14)
PM 10 1 1.04 (0.73,1.5) 1.11 (0.77,1.62) 1.14 (0.72,1.82)
PM 2.5 1 1.28 (0.91,1.82) 1.4 (0.97,2.01) 1.52 (0.97,2.4)
Sulfur Dioxide 1 1.09 (0.71,1.67) 1.18 (0.74,1.88) 0.94 (0.53,1.67)
APVR Carbon Monoxide 1 0.51 (0.27,0.98) 0.47 (0.22,0.99) 0.93 (0.37,2.35)
Nitrogen Dioxide 1 1.37 (0.63,3.02) 1.26 (0.54,2.93) 0.63 (0.22,1.81)
Ozone
a
1 0.98 (0.5,1.91) 0.71 (0.33,1.53) 0.87 (0.38,1.99)
PM 10 1 1.78 (0.78,4.08) 1.22 (0.53,2.82) 1.28 (0.49,3.38)
PM 2.5 1 1.27 (0.68,2.39) 0.97 (0.49,1.9) 1.02 (0.42,2.49)
Sulfur Dioxide 1 1.29 (0.58,2.89) 0.9 (0.39,2.1) 1.38 (0.52,3.64)
AVSD Carbon Monoxide 1 0.88 (0.38,2.05) 1.02 (0.42,2.49) 1 (0.32,3.12)
Nitrogen Dioxide 1 0.96 (0.41,2.26) 0.76 (0.3,1.89) 1.05 (0.37,3.02)
Ozone
a
1 0.92 (0.42,2.03) 0.53 (0.21,1.34) 0.85 (0.33,2.2)
PM 10 1 1.25 (0.54,2.9) 0.58 (0.23,1.46) 1.92 (0.71,5.24)
PM 2.5 1 1.14 (0.48,2.71) 1.32 (0.56,3.1) 2.45 (0.92,6.5)
RVOTO Carbon Monoxide 1 0.83 (0.54,1.28) 0.95 (0.59,1.55) 1.48 (0.83,2.67)
Nitrogen Dioxide 1 1.38 (0.81,2.37) 1.33 (0.74,2.39) 1.27 (0.66,2.45)
Ozone
a
1 0.74 (0.5,1.1) 0.64 (0.41,1) 0.67 (0.41,1.09)
PM 10 1 1.34 (0.86,2.1) 1.49 (0.94,2.34) 1.6 (0.92,2.81)
PM 2.5 1 1.05 (0.74,1.5) 1 (0.69,1.45) 0.81 (0.48,1.37)
Sulfur Dioxide 1 1.27 (0.78,2.07) 1.31 (0.78,2.21) 0.81 (0.42,1.56)
SEPTALS Carbon Monoxide 1 1.24 (0.87,1.77) 1.25 (0.84,1.87) 1.31 (0.81,2.13)
Nitrogen Dioxide 1 1.15 (0.78,1.69) 0.88 (0.57,1.35) 0.92 (0.56,1.52)
Ozone
a
1 0.73 (0.56,0.95) 0.57 (0.42,0.77) 0.68 (0.48,0.96)
PM 10 1 0.94 (0.71,1.24) 0.95 (0.71,1.27) 0.88 (0.59,1.31)
PM 2.5 1 1.17 (0.9,1.51) 1.14 (0.86,1.51) 0.98 (0.65,1.47)
Sulfur Dioxide 1 1.1 (0.8,1.52) 1.01 (0.7,1.46) 0.89 (0.56,1.4)
Week 7
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Table A2.3 (cont.)
Week of Pregnancy
Cardiac Defect Pollutant
<10th 
percentile 
10th percentile 
to median
median to 90th 
percentile >90th percentile
LVOTO Carbon Monoxide 1 1.13 (0.76,1.69) 1.09 (0.7,1.71) 0.91 (0.52,1.62)
Nitrogen Dioxide 1 0.68 (0.44,1.06) 0.68 (0.42,1.09) 0.76 (0.43,1.33)
Ozone
a
1 0.99 (0.7,1.38) 1.1 (0.75,1.62) 1.08 (0.7,1.67)
PM 10 1 0.63 (0.44,0.91) 0.81 (0.56,1.16) 1.05 (0.66,1.65)
PM 2.5 1 1.18 (0.85,1.64) 1.01 (0.71,1.44) 0.95 (0.59,1.53)
Sulfur Dioxide 1 1.57 (0.98,2.53) 1.39 (0.84,2.32) 1.7 (0.93,3.1)
CONOTRUNCALS Carbon Monoxide 1 0.96 (0.67,1.38) 0.94 (0.63,1.41) 0.84 (0.51,1.4)
Nitrogen Dioxide 1 0.9 (0.59,1.37) 1.13 (0.71,1.77) 1.19 (0.7,2.03)
Ozone
a
1 1.05 (0.78,1.41) 1.01 (0.71,1.42) 1.11 (0.75,1.63)
PM 10 1 0.71 (0.5,1.01) 1.01 (0.71,1.43) 1.06 (0.69,1.65)
PM 2.5 1 0.9 (0.65,1.25) 1.19 (0.85,1.66) 1.23 (0.8,1.87)
Sulfur Dioxide 1 1.23 (0.81,1.86) 1.24 (0.79,1.94) 1.14 (0.66,1.96)
APVR Carbon Monoxide 1 0.81 (0.42,1.56) 0.83 (0.39,1.77) 0.97 (0.39,2.45)
Nitrogen Dioxide 1 0.93 (0.44,1.96) 0.53 (0.23,1.22) 1.51 (0.61,3.71)
Ozone
a
1 1.05 (0.55,2) 0.95 (0.46,1.95) 1.04 (0.47,2.28)
PM 10 1 0.45 (0.23,0.85) 0.46 (0.25,0.88) 0.93 (0.43,2.02)
PM 2.5 1 1.36 (0.7,2.66) 1.03 (0.51,2.1) 1.33 (0.56,3.16)
Sulfur Dioxide 1 1.96 (0.79,4.85) 2.16 (0.87,5.37) 1.39 (0.47,4.1)
AVSD Carbon Monoxide 1 0.97 (0.43,2.2) 0.77 (0.32,1.86) 0.75 (0.24,2.3)
Nitrogen Dioxide 1 0.8 (0.34,1.91) 1 (0.41,2.45) 0.68 (0.21,2.24)
Ozone
a
1 0.85 (0.36,2) 1.61 (0.69,3.72) 1.39 (0.54,3.57)
PM 10 1 0.52 (0.23,1.2) 0.79 (0.36,1.72) 0.6 (0.18,1.94)
PM 2.5 1 0.96 (0.47,1.98) 0.67 (0.31,1.44) 1.07 (0.41,2.75)
RVOTO Carbon Monoxide 1 1.15 (0.75,1.77) 1.31 (0.81,2.12) 0.81 (0.44,1.5)
Nitrogen Dioxide 1 1.04 (0.62,1.75) 0.97 (0.55,1.68) 1.53 (0.83,2.83)
Ozone
a
1 1.17 (0.81,1.69) 1.08 (0.71,1.65) 1.24 (0.78,1.96)
PM 10 1 0.86 (0.56,1.31) 1.19 (0.78,1.82) 1.27 (0.75,2.15)
PM 2.5 1 1.15 (0.8,1.65) 1.06 (0.72,1.56) 1.38 (0.85,2.24)
Sulfur Dioxide 1 1.29 (0.81,2.04) 1.4 (0.86,2.3) 1.31 (0.71,2.41)
SEPTALS Carbon Monoxide 1 0.75 (0.54,1.03) 0.85 (0.59,1.22) 0.79 (0.5,1.25)
Nitrogen Dioxide 1 1.06 (0.72,1.56) 1.18 (0.77,1.8) 1.82 (1.13,2.94)
Ozone
a
1 1.17 (0.91,1.51) 1.13 (0.84,1.52) 1.33 (0.95,1.86)
PM 10 1 0.96 (0.72,1.28) 1.05 (0.78,1.41) 1.05 (0.71,1.55)
PM 2.5 1 0.88 (0.69,1.13) 0.99 (0.76,1.29) 1.02 (0.71,1.48)
Sulfur Dioxide 1 0.99 (0.72,1.34) 1.07 (0.76,1.51) 1.09 (0.71,1.68)
Week 8
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Table A2.4: Odds Ratios and 95% Confidence Intervals between individual cardiac birth defects and weekly exposure to 
criteria air pollutants from hierarchical models 
 
Cardiac Defect Pollutant
<10th 
percentile 
(Referent)
10th percentile to 
median
median to 90th 
percentile >90th percentile
Aortic Stenosis
Carbon Monoxide 1 0.88 (0.46,1.68) 0.95 (0.46,1.93) 0.9 (0.37,2.18)
Nitrogen Dioxide 1 0.89 (0.44,1.8) 0.72 (0.34,1.53) 1.14 (0.48,2.72)
Ozone
a
1 0.96 (0.52,1.78) 1.3 (0.68,2.52) 0.98 (0.46,2.06)
PM 10 1 1.02 (0.51,2.05) 1.54 (0.77,3.07) 1 (0.41,2.41)
PM 2.5 1 1.09 (0.61,1.94) 1.18 (0.65,2.16) 1.7 (0.78,3.69)
Sulfur Dioxide 1 0.37 (0.19,0.74) 0.74 (0.37,1.5) 0.68 (0.27,1.73)
Coarctation of the Aorta
Carbon Monoxide 1 0.9 (0.54,1.52) 0.93 (0.52,1.65) 0.83 (0.4,1.74)
Nitrogen Dioxide 1 1.1 (0.57,2.13) 0.92 (0.46,1.84) 1.35 (0.63,2.89)
Ozone
a
1 0.64 (0.38,1.07) 0.79 (0.45,1.4) 0.81 (0.44,1.49)
PM 10 1 1.24 (0.7,2.19) 1.19 (0.67,2.12) 0.81 (0.38,1.73)
PM 2.5 1 1.18 (0.73,1.92) 1.19 (0.71,1.98) 1.4 (0.73,2.69)
Sulfur Dioxide 1 1.03 (0.57,1.85) 0.68 (0.37,1.27) 0.72 (0.34,1.52)
Hypoplastic Left Heart 
Syndrome
Carbon Monoxide 1 1.13 (0.64,1.99) 1.01 (0.54,1.89) 1.01 (0.48,2.15)
Nitrogen Dioxide 1 0.87 (0.47,1.6) 1.17 (0.61,2.23) 0.85 (0.38,1.86)
Ozone
a
1 0.89 (0.55,1.43) 0.85 (0.49,1.47) 0.78 (0.43,1.44)
PM 10 1 0.76 (0.45,1.29) 0.84 (0.5,1.43) 0.91 (0.47,1.77)
PM 2.5 1 1.01 (0.62,1.64) 0.87 (0.52,1.46) 1.18 (0.62,2.25)
Sulfur Dioxide 1 0.96 (0.53,1.73) 0.71 (0.38,1.33) 0.95 (0.44,2.07)
d-TGA
Carbon Monoxide 1 0.98 (0.59,1.64) 0.73 (0.41,1.29) 0.64 (0.31,1.33)
Nitrogen Dioxide 1 0.88 (0.49,1.56) 0.97 (0.52,1.8) 0.87 (0.41,1.82)
Ozone
a
1 0.92 (0.58,1.47) 1.01 (0.6,1.71) 0.89 (0.5,1.59)
PM 10 1 1.04 (0.61,1.8) 0.93 (0.53,1.64) 1 (0.5,1.97)
PM 2.5 1 1.2 (0.73,1.97) 1.09 (0.65,1.83) 0.96 (0.49,1.89)
Sulfur Dioxide 1 0.81 (0.44,1.47) 1.25 (0.67,2.32) 0.86 (0.4,1.86)
Tetralogy of Fallot
Carbon Monoxide 1 1.3 (0.8,2.09) 1.36 (0.81,2.31) 1.29 (0.68,2.44)
Nitrogen Dioxide 1 0.97 (0.57,1.65) 1.11 (0.63,1.94) 1.37 (0.72,2.6)
Ozone
a
1 1.11 (0.76,1.63) 0.6 (0.37,0.96) 1.13 (0.7,1.84)
PM 10 1 1.09 (0.68,1.74) 1.26 (0.78,2.04) 1.14 (0.63,2.05)
PM 2.5 1 1.64 (1.02,2.63) 1.41 (0.87,2.31) 1.96 (1.11,3.46)
Sulfur Dioxide 1 0.84 (0.51,1.39) 0.95 (0.56,1.62) 0.99 (0.51,1.91)
Week 2
a
Ozone exposure was categorized using the following categories:  Less than the 25th percentile (referent), 25th percentile to 
median, median to 75th percentile and 75th percentile and greater
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Cardiac Defect Pollutant
<10th 
percentile 
10th percentile to 
median
median to 90th 
percentile >90th percentile
Other Conotruncals
Carbon Monoxide 1 1.15 (0.58,2.29) 0.84 (0.4,1.76) 0.7 (0.28,1.76)
Nitrogen Dioxide 1 0.99 (0.43,2.24) 1.43 (0.63,3.27) 1 (0.38,2.64)
Ozone
a
1 1.03 (0.55,1.93) 0.62 (0.3,1.29) 0.89 (0.42,1.91)
PM 10 1 0.7 (0.35,1.4) 1.03 (0.53,2.02) 0.63 (0.25,1.57)
PM 2.5 1 0.99 (0.5,1.95) 1.23 (0.62,2.45) 1.13 (0.46,2.8)
Sulfur Dioxide 1 0.56 (0.26,1.21) 1 (0.46,2.14) 0.96 (0.38,2.44)
TAPVR
Carbon Monoxide 1 0.71 (0.37,1.38) 0.91 (0.43,1.92) 1.02 (0.4,2.58)
Nitrogen Dioxide 1 0.71 (0.34,1.52) 0.6 (0.26,1.36) 1.43 (0.58,3.53)
Ozone
a
1 0.71 (0.34,1.5) 1.18 (0.56,2.48) 1.36 (0.62,2.97)
PM 10 1 1.05 (0.46,2.42) 1.57 (0.7,3.53) 0.88 (0.33,2.36)
PM 2.5 1 1.43 (0.72,2.86) 0.98 (0.47,2.04) 1.67 (0.71,3.95)
Sulfur Dioxide 1 0.89 (0.42,1.9) 0.87 (0.4,1.91) 0.76 (0.28,2.07)
Carbon Monoxide 1 0.92 (0.48,1.78) 0.78 (0.37,1.62) 0.92 (0.37,2.31)
Nitrogen Dioxide 1 0.93 (0.43,1.99) 0.98 (0.44,2.18) 1.03 (0.4,2.63)
Ozone
a
1 1.05 (0.52,2.08) 0.63 (0.29,1.36) 1.15 (0.53,2.49)
PM 10 1 0.88 (0.44,1.75) 0.9 (0.45,1.81) 1.08 (0.46,2.57)
PM 2.5 1 1.6 (0.83,3.09) 0.99 (0.48,2) 1.12 (0.46,2.7)
Sulfur Dioxide 1 0.79 (0.37,1.67) 1.32 (0.61,2.87) 0.59 (0.2,1.74)
Carbon Monoxide 1 0.53 (0.34,0.81) 0.63 (0.39,1.02) 0.37 (0.19,0.7)
Nitrogen Dioxide 1 0.95 (0.55,1.65) 0.76 (0.42,1.37) 0.66 (0.33,1.29)
Ozone
a
1 0.78 (0.51,1.2) 0.6 (0.37,0.97) 0.59 (0.35,0.99)
PM 10 1 1.25 (0.77,2.04) 1.3 (0.79,2.14) 0.76 (0.39,1.46)
PM 2.5 1 1.17 (0.78,1.75) 0.89 (0.58,1.37) 0.94 (0.54,1.65)
Sulfur Dioxide 1 0.85 (0.53,1.36) 0.7 (0.42,1.16) 1.08 (0.58,2.01)
VSD-perimembranous
Carbon Monoxide 1 1.08 (0.71,1.65) 1.05 (0.65,1.68) 0.95 (0.54,1.69)
Nitrogen Dioxide 1 1.09 (0.67,1.78) 0.95 (0.56,1.61) 0.94 (0.51,1.73)
Ozone
a
1 0.92 (0.64,1.32) 0.86 (0.57,1.31) 0.97 (0.61,1.52)
PM 10 1 0.84 (0.57,1.24) 0.92 (0.62,1.36) 0.87 (0.52,1.47)
PM 2.5 1 0.97 (0.68,1.38) 1.05 (0.72,1.51) 0.6 (0.34,1.04)
Sulfur Dioxide 1 0.76 (0.5,1.15) 0.65 (0.41,1.02) 1.08 (0.63,1.85)
ASD-all
Carbon Monoxide 1 1.07 (0.69,1.67) 0.94 (0.57,1.54) 0.67 (0.36,1.25)
Nitrogen Dioxide 1 0.94 (0.58,1.52) 0.9 (0.54,1.52) 0.65 (0.34,1.22)
Ozone
a
1 1.18 (0.87,1.61) 0.64 (0.44,0.94) 0.77 (0.5,1.18)
PM 10 1 0.98 (0.67,1.41) 0.98 (0.67,1.44) 0.66 (0.38,1.15)
PM 2.5 1 1.07 (0.8,1.45) 0.84 (0.6,1.17) 0.66 (0.4,1.11)
Sulfur Dioxide 1 0.7 (0.48,1) 0.63 (0.41,0.95) 0.64 (0.37,1.12)
Table A2.4 (cont.)
Week 2
Pulmonary/Tricuspid Atresia
Pulmonary Valve Stenosis
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Table A2.4 (cont.)
Week 3
Cardiac Defect Pollutant
<10th 
percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile >90th percentile
Aortic Stenosis
Carbon Monoxide 1 0.93 (0.47,1.82) 1.06 (0.51,2.2) 0.66 (0.25,1.74)
Nitrogen Dioxide 1 1.73 (0.78,3.88) 2.38 (1.03,5.46) 0.63 (0.21,1.89)
Ozone
a
1 1.58 (0.85,2.96) 1.13 (0.55,2.32) 1.45 (0.66,3.16)
PM 10 1 1.35 (0.71,2.57) 1.03 (0.53,2) 0.51 (0.18,1.42)
PM 2.5 1 0.55 (0.33,0.89) 0.42 (0.24,0.73) 0.39 (0.17,0.88)
Sulfur Dioxide 1 1.49 (0.7,3.18) 1.23 (0.55,2.76) 1.18 (0.45,3.15)
Coarctation of the 
Aorta
Carbon Monoxide 1 1.2 (0.68,2.12) 1.21 (0.65,2.27) 1.11 (0.5,2.42)
Nitrogen Dioxide 1 1.16 (0.6,2.24) 1.36 (0.68,2.7) 0.74 (0.33,1.68)
Ozone
a
1 1.1 (0.64,1.87) 1.16 (0.63,2.11) 1.22 (0.63,2.36)
PM 10 1 0.91 (0.54,1.53) 0.87 (0.51,1.49) 1.12 (0.57,2.22)
PM 2.5 1 0.82 (0.53,1.27) 0.59 (0.36,0.95) 0.52 (0.27,1.01)
Sulfur Dioxide 1 0.97 (0.51,1.86) 1.74 (0.9,3.39) 1.96 (0.9,4.25)
Hypoplastic Left Heart 
Syndrome
Carbon Monoxide 1 0.94 (0.52,1.7) 1.13 (0.59,2.14) 1.27 (0.58,2.76)
Nitrogen Dioxide 1 1.09 (0.58,2.05) 1.09 (0.55,2.15) 1.07 (0.48,2.38)
Ozone
a
1 1.07 (0.65,1.77) 0.85 (0.47,1.52) 0.97 (0.51,1.84)
PM 10 1 0.66 (0.39,1.1) 0.91 (0.54,1.51) 0.9 (0.47,1.75)
PM 2.5 1 0.79 (0.49,1.27) 0.71 (0.43,1.18) 0.79 (0.41,1.51)
Sulfur Dioxide 1 1.05 (0.57,1.95) 1.09 (0.57,2.08) 1.35 (0.6,3.02)
d-TGA
Carbon Monoxide 1 1.07 (0.61,1.86) 1 (0.54,1.84) 0.94 (0.44,2.01)
Nitrogen Dioxide 1 1.73 (0.91,3.31) 1.23 (0.62,2.47) 1.24 (0.56,2.73)
Ozone
a
1 1.33 (0.82,2.16) 1.25 (0.72,2.18) 1.18 (0.64,2.2)
PM 10 1 0.79 (0.47,1.32) 0.76 (0.45,1.29) 1.05 (0.55,2.01)
PM 2.5 1 0.79 (0.5,1.26) 0.77 (0.47,1.26) 0.47 (0.23,0.95)
Sulfur Dioxide 1 1.21 (0.67,2.22) 0.94 (0.5,1.79) 0.96 (0.45,2.06)
Tetralogy of Fallot
Carbon Monoxide 1 0.84 (0.53,1.35) 0.82 (0.48,1.38) 0.56 (0.29,1.09)
Nitrogen Dioxide 1 1.65 (0.91,2.99) 1.6 (0.85,2.99) 1.4 (0.68,2.86)
Ozone
a
1 1.25 (0.83,1.89) 1.26 (0.78,2.02) 1.13 (0.66,1.94)
PM 10 1 1.18 (0.74,1.88) 1.1 (0.68,1.76) 1.1 (0.61,1.98)
PM 2.5 1 0.78 (0.53,1.16) 0.7 (0.46,1.06) 0.73 (0.43,1.24)
Sulfur Dioxide 1 0.76 (0.46,1.26) 1.06 (0.63,1.81) 1.14 (0.59,2.2)
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Week 3
Cardiac Defect Pollutant
<10th 
percentile 
10th percentile 
to median
median to 90th 
percentile >90th percentile
Other Conotruncals
Carbon Monoxide 1 0.94 (0.45,1.96) 1.49 (0.69,3.21) 1.31 (0.51,3.34)
Nitrogen Dioxide 1 1.45 (0.61,3.45) 1.33 (0.55,3.19) 1.58 (0.6,4.16)
Ozone
a
1 1.12 (0.57,2.18) 1.27 (0.61,2.64) 1.32 (0.59,2.99)
PM 10 1 0.99 (0.47,2.1) 1.19 (0.57,2.48) 1.12 (0.46,2.74)
PM 2.5 1 0.95 (0.5,1.79) 0.73 (0.37,1.43) 0.36 (0.13,1.01)
Sulfur Dioxide 1 0.99 (0.45,2.19) 1.16 (0.52,2.61) 1.74 (0.68,4.42)
TAPVR
Carbon Monoxide 1 1.05 (0.52,2.11) 1.06 (0.48,2.33) 1.16 (0.44,3.05)
Nitrogen Dioxide 1 1.3 (0.59,2.87) 0.79 (0.34,1.86) 1.01 (0.38,2.64)
Ozone
a
1 0.95 (0.46,1.97) 1.42 (0.68,2.97) 0.85 (0.37,1.96)
PM 10 1 0.82 (0.38,1.76) 0.92 (0.43,1.95) 1.52 (0.64,3.63)
PM 2.5 1 0.5 (0.27,0.91) 0.62 (0.33,1.16) 0.72 (0.31,1.64)
Sulfur Dioxide 1 1.34 (0.6,2.99) 1.34 (0.59,3.05) 0.99 (0.35,2.84)
Carbon Monoxide 1 0.91 (0.47,1.78) 0.58 (0.27,1.24) 0.81 (0.32,2.09)
Nitrogen Dioxide 1 0.72 (0.34,1.52) 1.08 (0.49,2.36) 0.96 (0.36,2.53)
Ozone
a
1 1.06 (0.51,2.19) 1.66 (0.78,3.52) 1.27 (0.55,2.91)
PM 10 1 1.5 (0.69,3.23) 1.35 (0.62,2.93) 0.79 (0.28,2.2)
PM 2.5 1 0.97 (0.52,1.83) 0.73 (0.37,1.44) 0.83 (0.35,1.95)
Sulfur Dioxide 1 1.61 (0.66,3.91) 1.6 (0.65,3.91) 1.48 (0.53,4.17)
Carbon Monoxide 1 1.42 (0.86,2.37) 1.38 (0.78,2.42) 1.07 (0.54,2.14)
Nitrogen Dioxide 1 1.02 (0.56,1.85) 1.33 (0.71,2.49) 1.22 (0.6,2.48)
Ozone
a
1 1.3 (0.81,2.08) 1.93 (1.15,3.25) 2.15 (1.22,3.78)
PM 10 1 1.34 (0.82,2.17) 1.14 (0.7,1.88) 1.4 (0.76,2.58)
PM 2.5 1 0.65 (0.44,0.95) 0.7 (0.47,1.05) 0.6 (0.35,1.05)
Sulfur Dioxide 1 1.14 (0.7,1.87) 0.88 (0.52,1.49) 0.81 (0.42,1.57)
VSD-perimembranous
Carbon Monoxide 1 0.93 (0.6,1.46) 1.09 (0.67,1.8) 1.07 (0.59,1.96)
Nitrogen Dioxide 1 1.14 (0.68,1.91) 1.18 (0.68,2.06) 0.89 (0.47,1.71)
Ozone
a
1 1.11 (0.76,1.62) 1.07 (0.69,1.66) 1.02 (0.63,1.66)
PM 10 1 1.3 (0.86,1.96) 1.16 (0.76,1.77) 0.86 (0.48,1.52)
PM 2.5 1 1.06 (0.74,1.51) 0.88 (0.6,1.3) 0.73 (0.43,1.24)
Sulfur Dioxide 1 1.32 (0.82,2.11) 1.5 (0.91,2.48) 1.98 (1.1,3.56)
ASD-all
Carbon Monoxide 1 0.88 (0.55,1.41) 1 (0.59,1.69) 1.04 (0.55,1.98)
Nitrogen Dioxide 1 1.06 (0.63,1.77) 0.99 (0.57,1.73) 0.8 (0.41,1.55)
Ozone
a
1 0.94 (0.68,1.29) 0.82 (0.56,1.21) 0.92 (0.59,1.43)
PM 10 1 1.16 (0.8,1.68) 1.02 (0.69,1.5) 1.13 (0.67,1.91)
PM 2.5 1 0.74 (0.55,0.98) 0.72 (0.52,0.99) 0.95 (0.6,1.49)
Sulfur Dioxide 1 0.75 (0.52,1.1) 0.84 (0.55,1.28) 0.79 (0.44,1.39)
Pulmonary Valve Stenosis
Pulmonary/Tricuspid Atresia
Table A2.4 (cont.)
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Week 4
Cardiac Defect Pollutant
<10th 
percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile
>90th 
percentile
Aortic Stenosis
Carbon Monoxide 1 0.65 (0.34,1.22) 0.59 (0.29,1.2) 0.68 (0.27,1.7)
Nitrogen Dioxide 1 1.27 (0.59,2.71) 1.11 (0.5,2.48) 1.94 (0.78,4.81)
Ozone
a
1 1.16 (0.62,2.15) 0.91 (0.44,1.85) 1.16 (0.53,2.54)
PM 10 1 0.94 (0.49,1.81) 1.12 (0.58,2.14) 0.96 (0.41,2.23)
PM 2.5 1 1.42 (0.77,2.62) 1.3 (0.68,2.48) 1.67 (0.75,3.72)
Sulfur Dioxide 1 0.84 (0.4,1.77) 1.43 (0.66,3.1) 0.73 (0.27,2.02)
Coarctation of the 
Aorta
Carbon Monoxide 1 0.81 (0.48,1.37) 0.62 (0.34,1.12) 0.91 (0.43,1.9)
Nitrogen Dioxide 1 1.65 (0.82,3.32) 1.53 (0.74,3.19) 1.48 (0.65,3.37)
Ozone
a
1 1.03 (0.6,1.77) 1.07 (0.58,1.97) 0.85 (0.43,1.66)
PM 10 1 1.02 (0.58,1.78) 1.07 (0.61,1.87) 1.1 (0.54,2.22)
PM 2.5 1 1.37 (0.82,2.29) 1.45 (0.85,2.48) 1.61 (0.82,3.14)
Sulfur Dioxide 1 1.38 (0.71,2.67) 1.63 (0.82,3.23) 0.93 (0.41,2.14)
Hypoplastic Left 
Heart Syndrome
Carbon Monoxide 1 1.12 (0.63,2) 0.91 (0.48,1.72) 1.05 (0.49,2.27)
Nitrogen Dioxide 1 1.27 (0.69,2.36) 0.9 (0.46,1.77) 0.83 (0.37,1.88)
Ozone
a
1 0.86 (0.52,1.42) 0.89 (0.5,1.59) 0.77 (0.4,1.47)
PM 10 1 0.92 (0.54,1.58) 0.89 (0.52,1.54) 1.01 (0.52,1.98)
PM 2.5 1 1.11 (0.67,1.84) 0.92 (0.54,1.56) 1.13 (0.58,2.21)
Sulfur Dioxide 1 0.83 (0.46,1.51) 1.14 (0.61,2.15) 0.6 (0.25,1.44)
d-TGA
Carbon Monoxide 1 1.15 (0.65,2.03) 1.65 (0.89,3.07) 1.01 (0.46,2.2)
Nitrogen Dioxide 1 1.56 (0.82,2.94) 1.37 (0.69,2.72) 1.67 (0.76,3.64)
Ozone
a
1 0.88 (0.54,1.43) 0.76 (0.44,1.34) 0.83 (0.45,1.54)
PM 10 1 0.78 (0.46,1.31) 0.84 (0.49,1.43) 1.07 (0.56,2.06)
PM 2.5 1 1.04 (0.62,1.73) 1.43 (0.85,2.43) 1.31 (0.67,2.57)
Sulfur Dioxide 1 0.9 (0.49,1.66) 1.09 (0.57,2.07) 1.16 (0.54,2.5)
Tetralogy of Fallot
Carbon Monoxide 1 0.94 (0.59,1.51) 0.95 (0.57,1.6) 0.73 (0.38,1.4)
Nitrogen Dioxide 1 1.77 (0.99,3.14) 1.51 (0.81,2.8) 1.46 (0.72,2.96)
Ozone
a
1 1.21 (0.8,1.83) 0.88 (0.54,1.45) 0.81 (0.47,1.4)
PM 10 1 0.69 (0.45,1.05) 0.82 (0.53,1.26) 0.87 (0.5,1.51)
PM 2.5 1 0.87 (0.58,1.31) 0.96 (0.63,1.46) 1.06 (0.63,1.81)
Sulfur Dioxide 1 1.43 (0.84,2.44) 0.91 (0.51,1.61) 0.94 (0.47,1.87)
Table A2.4 (cont.)
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Week 4
Cardiac Defect Pollutant
<10th 
percentile 
10th percentile 
to median
median to 90th 
percentile
>90th 
percentile
Other Conotruncals
Carbon Monoxide 1 1.31 (0.63,2.74) 1.15 (0.53,2.54) 1.32 (0.52,3.32)
Nitrogen Dioxide 1 1.01 (0.47,2.16) 1.02 (0.46,2.28) 1.01 (0.39,2.61)
Ozone
a
1 1.63 (0.83,3.21) 1.01 (0.46,2.21) 1.2 (0.52,2.78)
PM 10 1 1.1 (0.53,2.28) 0.82 (0.39,1.73) 1.12 (0.47,2.68)
PM 2.5 1 1.17 (0.59,2.29) 1.09 (0.54,2.19) 0.83 (0.32,2.14)
Sulfur Dioxide 1 1.82 (0.8,4.14) 1.4 (0.6,3.29) 0.53 (0.16,1.69)
TAPVR
Carbon Monoxide 1 0.84 (0.42,1.65) 0.79 (0.36,1.73) 1.04 (0.4,2.7)
Nitrogen Dioxide 1 0.98 (0.46,2.1) 0.85 (0.37,1.95) 1.1 (0.42,2.88)
Ozone
a
1 0.98 (0.48,2) 0.8 (0.37,1.75) 0.98 (0.43,2.24)
PM 10 1 0.85 (0.41,1.78) 1.06 (0.52,2.17) 0.65 (0.25,1.67)
PM 2.5 1 1.11 (0.56,2.18) 1.17 (0.58,2.35) 1.39 (0.59,3.3)
Sulfur Dioxide 1 1.32 (0.57,3.06) 1.39 (0.59,3.28) 1.06 (0.38,3)
Carbon Monoxide 1 1.47 (0.71,3.02) 0.99 (0.45,2.17) 0.99 (0.38,2.6)
Nitrogen Dioxide 1 1.43 (0.65,3.15) 1.52 (0.66,3.51) 0.94 (0.33,2.69)
Ozone
a
1 0.88 (0.42,1.81) 1.02 (0.48,2.18) 0.83 (0.36,1.92)
PM 10 1 0.98 (0.53,1.83) 0.5 (0.25,0.99) 0.45 (0.17,1.21)
PM 2.5 1 1.09 (0.59,2.02) 0.8 (0.41,1.57) 1.06 (0.45,2.49)
Sulfur Dioxide 1 1.59 (0.72,3.52) 0.87 (0.38,2.02) 0.96 (0.35,2.62)
Carbon Monoxide 1 0.84 (0.53,1.35) 0.72 (0.42,1.22) 0.82 (0.43,1.56)
Nitrogen Dioxide 1 1.34 (0.75,2.39) 0.82 (0.44,1.53) 0.97 (0.48,1.95)
Ozone
a
1 1.08 (0.67,1.73) 1.16 (0.69,1.98) 0.94 (0.53,1.68)
PM 10 1 1.35 (0.82,2.2) 1.02 (0.61,1.69) 1.4 (0.76,2.56)
PM 2.5 1 0.9 (0.6,1.35) 1.05 (0.69,1.61) 0.88 (0.5,1.54)
Sulfur Dioxide 1 0.92 (0.56,1.51) 0.88 (0.52,1.51) 0.97 (0.5,1.87)
VSD-perimembranous
Carbon Monoxide 1 0.91 (0.59,1.4) 0.98 (0.6,1.59) 0.9 (0.5,1.62)
Nitrogen Dioxide 1 1.24 (0.74,2.06) 1.31 (0.75,2.28) 1.09 (0.57,2.09)
Ozone
a
1 1.15 (0.78,1.71) 1.05 (0.66,1.66) 1.15 (0.7,1.9)
PM 10 1 1.13 (0.75,1.71) 1.06 (0.7,1.62) 0.9 (0.52,1.57)
PM 2.5 1 1.02 (0.7,1.47) 1.06 (0.72,1.56) 1.14 (0.68,1.89)
Sulfur Dioxide 1 1.36 (0.86,2.15) 0.94 (0.57,1.55) 0.77 (0.42,1.42)
ASD-all
Carbon Monoxide 1 1.42 (0.88,2.3) 1.3 (0.76,2.21) 1.19 (0.62,2.29)
Nitrogen Dioxide 1 1.6 (0.93,2.77) 1.52 (0.85,2.75) 1.6 (0.81,3.14)
Ozone
a
1 1.17 (0.83,1.63) 1.16 (0.78,1.72) 0.9 (0.56,1.44)
PM 10 1 0.99 (0.68,1.42) 0.95 (0.65,1.39) 0.8 (0.48,1.36)
PM 2.5 1 1.01 (0.75,1.37) 0.83 (0.59,1.16) 0.83 (0.51,1.35)
Sulfur Dioxide 1 1.01 (0.68,1.49) 1.11 (0.71,1.73) 0.9 (0.49,1.63)
Pulmonary Valve Stenosis
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Week 5
Cardiac Defect Pollutant
<10th percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile
>90th 
percentile
Aortic Stenosis
Carbon Monoxide 1 1.48 (0.73,2.99) 1.38 (0.64,2.96) 0.95 (0.36,2.5)
Nitrogen Dioxide 1 0.96 (0.46,1.98) 0.79 (0.36,1.72) 0.67 (0.26,1.75)
Ozone
a
1 0.97 (0.53,1.78) 0.72 (0.35,1.46) 0.77 (0.35,1.71)
PM 10 1 0.9 (0.49,1.64) 0.88 (0.47,1.63) 0.72 (0.3,1.73)
PM 2.5 1 0.83 (0.48,1.45) 1.28 (0.72,2.26) 1 (0.43,2.31)
Sulfur Dioxide 1 0.69 (0.34,1.39) 0.63 (0.29,1.34) 1.11 (0.45,2.72)
Coarctation of the 
Aorta
Carbon Monoxide 1 0.94 (0.55,1.62) 0.88 (0.48,1.62) 0.78 (0.35,1.71)
Nitrogen Dioxide 1 1.22 (0.58,2.54) 1.28 (0.6,2.73) 1.55 (0.68,3.58)
Ozone
a
1 0.55 (0.32,0.94) 0.72 (0.39,1.31) 0.94 (0.49,1.8)
PM 10 1 1.78 (0.94,3.38) 1.71 (0.9,3.26) 1.13 (0.51,2.54)
PM 2.5 1 0.99 (0.63,1.57) 0.9 (0.55,1.46) 0.98 (0.51,1.89)
Sulfur Dioxide 1 1.06 (0.57,1.97) 1.01 (0.53,1.94) 1.08 (0.5,2.32)
Hypoplastic Left 
Heart Syndrome
Carbon Monoxide 1 1.09 (0.6,1.97) 1.13 (0.59,2.15) 0.79 (0.35,1.78)
Nitrogen Dioxide 1 0.86 (0.46,1.61) 0.99 (0.51,1.94) 0.63 (0.27,1.47)
Ozone
a
1 0.76 (0.46,1.26) 0.93 (0.52,1.66) 0.79 (0.41,1.52)
PM 10 1 0.89 (0.51,1.55) 1.32 (0.77,2.29) 0.97 (0.47,1.98)
PM 2.5 1 1.24 (0.75,2.05) 0.87 (0.5,1.51) 1.52 (0.79,2.94)
Sulfur Dioxide 1 1.35 (0.68,2.66) 1.53 (0.75,3.1) 1.29 (0.55,3.04)
d-TGA
Carbon Monoxide 1 0.83 (0.48,1.43) 0.99 (0.54,1.82) 0.87 (0.4,1.85)
Nitrogen Dioxide 1 0.6 (0.34,1.04) 0.54 (0.29,0.99) 0.64 (0.3,1.34)
Ozone
a
1 1.29 (0.8,2.09) 1.53 (0.86,2.69) 1.27 (0.67,2.41)
PM 10 1 0.81 (0.48,1.35) 0.88 (0.52,1.49) 0.92 (0.47,1.8)
PM 2.5 1 0.92 (0.57,1.47) 0.92 (0.56,1.51) 0.97 (0.5,1.87)
Sulfur Dioxide 1 0.86 (0.48,1.54) 0.74 (0.4,1.39) 0.95 (0.45,1.98)
Tetralogy of Fallot
Carbon Monoxide 1 1.09 (0.67,1.77) 0.94 (0.55,1.63) 1.24 (0.64,2.39)
Nitrogen Dioxide 1 0.53 (0.33,0.86) 0.55 (0.32,0.93) 0.47 (0.24,0.92)
Ozone
a
1 1.03 (0.68,1.56) 1.16 (0.71,1.9) 1.31 (0.76,2.26)
PM 10 1 1.62 (0.96,2.74) 1.66 (0.97,2.83) 1.62 (0.86,3.05)
PM 2.5 1 1.11 (0.73,1.68) 1.05 (0.68,1.63) 0.9 (0.51,1.58)
Sulfur Dioxide 1 0.93 (0.56,1.53) 0.86 (0.5,1.48) 0.76 (0.39,1.49)
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Week 5
Cardiac Defect Pollutant
<10th percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile
>90th 
percentile
Other Conotruncals
Carbon Monoxide 1 0.57 (0.29,1.13) 0.81 (0.39,1.69) 0.68 (0.27,1.74)
Nitrogen Dioxide 1 0.72 (0.33,1.56) 0.78 (0.35,1.76) 0.86 (0.34,2.21)
Ozone
a
1 0.89 (0.45,1.74) 1.16 (0.55,2.44) 1.36 (0.59,3.11)
PM 10 1 0.76 (0.38,1.49) 0.86 (0.43,1.69) 1.02 (0.43,2.39)
PM 2.5 1 1.13 (0.59,2.16) 0.65 (0.32,1.31) 1.29 (0.55,3.02)
Sulfur Dioxide 1 0.62 (0.29,1.29) 0.91 (0.42,1.94) 0.87 (0.34,2.27)
TAPVR
Carbon Monoxide 1 1.36 (0.68,2.72) 0.8 (0.36,1.8) 1.15 (0.44,3.04)
Nitrogen Dioxide 1 0.54 (0.24,1.2) 1.09 (0.48,2.49) 1.38 (0.52,3.62)
Ozone
a
1 1.55 (0.77,3.14) 1.38 (0.63,3.02) 1 (0.42,2.38)
PM 10 1 0.69 (0.33,1.47) 1.07 (0.52,2.2) 1.58 (0.67,3.74)
PM 2.5 1 1.53 (0.68,3.4) 1.7 (0.76,3.79) 1.91 (0.75,4.84)
Sulfur Dioxide 1 1.25 (0.54,2.93) 1.74 (0.74,4.11) 0.86 (0.28,2.61)
Carbon Monoxide 1 1.39 (0.66,2.93) 1.56 (0.7,3.46) 1.1 (0.4,2.97)
Nitrogen Dioxide 1 1.16 (0.51,2.64) 1.32 (0.56,3.1) 0.76 (0.26,2.2)
Ozone
a
1 0.78 (0.38,1.62) 1.24 (0.58,2.62) 1.02 (0.44,2.33)
PM 10 1 1.27 (0.61,2.64) 1.07 (0.5,2.25) 1.23 (0.49,3.1)
PM 2.5 1 1.23 (0.64,2.35) 1.2 (0.6,2.39) 1.53 (0.65,3.6)
Sulfur Dioxide 1 0.77 (0.37,1.59) 0.8 (0.37,1.73) 1.23 (0.49,3.12)
Carbon Monoxide 1 0.94 (0.57,1.53) 1 (0.58,1.72) 1.3 (0.67,2.53)
Nitrogen Dioxide 1 0.55 (0.31,0.96) 0.85 (0.47,1.54) 1.14 (0.57,2.24)
Ozone
a
1 1.08 (0.68,1.71) 1.02 (0.6,1.73) 1.11 (0.63,1.98)
PM 10 1 0.7 (0.46,1.07) 0.8 (0.52,1.23) 0.8 (0.44,1.42)
PM 2.5 1 1 (0.66,1.51) 1.12 (0.72,1.72) 1.83 (1.08,3.12)
Sulfur Dioxide 1 1.33 (0.76,2.31) 1.71 (0.95,3.06) 1.39 (0.69,2.81)
VSD-perimembranous
Carbon Monoxide 1 0.87 (0.56,1.36) 0.99 (0.6,1.64) 0.97 (0.53,1.77)
Nitrogen Dioxide 1 1.03 (0.61,1.75) 1.23 (0.7,2.16) 1.75 (0.92,3.33)
Ozone
a
1 1.21 (0.82,1.78) 1.22 (0.77,1.93) 1.33 (0.8,2.2)
PM 10 1 1.3 (0.84,2) 1.3 (0.84,2.03) 1.76 (1.02,3.03)
PM 2.5 1 1.34 (0.92,1.95) 1 (0.67,1.5) 1.34 (0.8,2.23)
Sulfur Dioxide 1 0.97 (0.61,1.53) 1.23 (0.75,2.02) 1.13 (0.62,2.04)
ASD-all
Carbon Monoxide 1 1.14 (0.71,1.85) 1.03 (0.6,1.77) 1.58 (0.83,3.02)
Nitrogen Dioxide 1 0.74 (0.45,1.22) 0.87 (0.5,1.5) 1.05 (0.55,2.01)
Ozone
a
1 1.09 (0.78,1.54) 1.4 (0.93,2.1) 1.76 (1.11,2.8)
PM 10 1 1.04 (0.71,1.51) 1.18 (0.8,1.73) 1.13 (0.67,1.91)
PM 2.5 1 0.97 (0.71,1.31) 0.93 (0.67,1.31) 1.13 (0.71,1.82)
Sulfur Dioxide 1 1.37 (0.92,2.05) 1.23 (0.78,1.95) 1.37 (0.77,2.44)
Pulmonary/Tricuspid Atresia
Pulmonary Valve Stenosis
Table A2.4 (cont.)
158 
 
 
Week 6
Cardiac Defect Pollutant
<10th 
percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile
>90th 
percentile
Aortic Stenosis
Carbon Monoxide 1 1.14 (0.58,2.24) 1.18 (0.57,2.47) 0.74 (0.28,1.94)
Nitrogen Dioxide 1 0.95 (0.47,1.92) 0.68 (0.32,1.48) 0.57 (0.22,1.47)
Ozone
a
1 1.38 (0.75,2.54) 0.9 (0.44,1.84) 0.74 (0.33,1.66)
PM 10 1 0.73 (0.41,1.31) 0.64 (0.35,1.17) 0.77 (0.34,1.76)
PM 2.5 1 1.59 (0.86,2.93) 1.06 (0.55,2.05) 0.81 (0.33,2)
Sulfur Dioxide 1 1.43 (0.67,3.07) 0.78 (0.35,1.76) 1.3 (0.51,3.33)
Coarctation of the 
Aorta
Carbon Monoxide 1 1.48 (0.83,2.64) 1.39 (0.74,2.61) 1.19 (0.54,2.62)
Nitrogen Dioxide 1 0.92 (0.47,1.8) 1.23 (0.61,2.48) 1.32 (0.6,2.91)
Ozone
a
1 1.38 (0.82,2.33) 1.34 (0.72,2.49) 1.37 (0.7,2.7)
PM 10 1 1.03 (0.59,1.77) 0.93 (0.53,1.63) 0.99 (0.48,2.04)
PM 2.5 1 0.71 (0.45,1.13) 0.92 (0.57,1.49) 0.96 (0.5,1.82)
Sulfur Dioxide 1 1.39 (0.72,2.69) 1.05 (0.53,2.08) 1.32 (0.6,2.9)
Hypoplastic Left Heart 
Syndrome
Carbon Monoxide 1 0.97 (0.55,1.71) 1.3 (0.7,2.43) 0.82 (0.36,1.83)
Nitrogen Dioxide 1 1.1 (0.58,2.09) 1.11 (0.56,2.2) 0.89 (0.39,2.04)
Ozone
a
1 1.57 (0.94,2.62) 1.47 (0.81,2.68) 1.3 (0.66,2.54)
PM 10 1 1.12 (0.63,1.98) 1.31 (0.74,2.34) 0.89 (0.42,1.88)
PM 2.5 1 1.11 (0.65,1.88) 1.22 (0.71,2.12) 0.91 (0.44,1.85)
Sulfur Dioxide 1 1.24 (0.65,2.37) 1.27 (0.65,2.5) 0.68 (0.27,1.71)
d-TGA
Carbon Monoxide 1 1.12 (0.64,1.94) 1.16 (0.63,2.14) 1.34 (0.63,2.81)
Nitrogen Dioxide 1 0.97 (0.52,1.82) 1.21 (0.62,2.36) 1.55 (0.72,3.34)
Ozone
a
1 0.86 (0.53,1.39) 1.13 (0.65,1.95) 0.91 (0.48,1.7)
PM 10 1 1.25 (0.71,2.21) 0.89 (0.5,1.61) 1.1 (0.54,2.24)
PM 2.5 1 0.82 (0.5,1.34) 0.88 (0.53,1.46) 1.15 (0.61,2.17)
Sulfur Dioxide 1 1 (0.54,1.87) 1.08 (0.56,2.07) 1.31 (0.61,2.81)
Tetralogy of Fallot
Carbon Monoxide 1 1.24 (0.76,2.03) 1.39 (0.81,2.39) 1.6 (0.83,3.1)
Nitrogen Dioxide 1 1.22 (0.7,2.14) 1.42 (0.78,2.58) 0.97 (0.47,1.98)
Ozone
a
1 1.09 (0.72,1.65) 1.09 (0.67,1.77) 0.88 (0.5,1.52)
PM 10 1 0.84 (0.55,1.28) 0.71 (0.46,1.1) 0.81 (0.46,1.43)
PM 2.5 1 1.19 (0.77,1.84) 1.09 (0.69,1.72) 0.79 (0.44,1.41)
Sulfur Dioxide 1 1 (0.59,1.71) 1.15 (0.66,2.03) 0.91 (0.45,1.84)
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Week 6
Cardiac Defect Pollutant
<10th 
percentile 
10th percentile 
to median
median to 90th 
percentile
>90th 
percentile
Other Conotruncals
Carbon Monoxide 1 1.39 (0.68,2.85) 1.07 (0.49,2.33) 1.18 (0.47,2.99)
Nitrogen Dioxide 1 0.79 (0.36,1.71) 1.02 (0.46,2.28) 0.69 (0.26,1.86)
Ozone
a
1 1.28 (0.67,2.47) 0.9 (0.43,1.91) 0.72 (0.31,1.7)
PM 10 1 0.65 (0.34,1.27) 0.61 (0.31,1.2) 1 (0.44,2.29)
PM 2.5 1 0.93 (0.47,1.83) 0.97 (0.48,1.94) 0.82 (0.33,2.03)
Sulfur Dioxide 1 1.05 (0.47,2.32) 1.19 (0.53,2.68) 1.3 (0.5,3.42)
TAPVR
Carbon Monoxide 1 1.15 (0.59,2.27) 0.94 (0.43,2.07) 0.53 (0.19,1.45)
Nitrogen Dioxide 1 1.09 (0.5,2.39) 0.79 (0.34,1.82) 0.57 (0.21,1.59)
Ozone
a
1 0.8 (0.39,1.62) 0.95 (0.44,2.04) 1.05 (0.45,2.42)
PM 10 1 1.19 (0.57,2.52) 0.84 (0.39,1.8) 0.76 (0.29,1.99)
PM 2.5 1 0.88 (0.47,1.62) 0.54 (0.27,1.07) 0.93 (0.4,2.15)
Sulfur Dioxide 1 1.19 (0.51,2.75) 1.1 (0.47,2.58) 1.95 (0.74,5.11)
Carbon Monoxide 1 0.97 (0.48,1.93) 0.97 (0.45,2.08) 1.61 (0.64,4.06)
Nitrogen Dioxide 1 0.62 (0.3,1.27) 0.7 (0.32,1.52) 0.59 (0.22,1.59)
Ozone
a
1 1.06 (0.53,2.15) 1.17 (0.55,2.51) 1.17 (0.51,2.69)
PM 10 1 1.09 (0.52,2.29) 1.11 (0.53,2.33) 0.88 (0.34,2.27)
PM 2.5 1 0.73 (0.4,1.31) 0.66 (0.35,1.25) 0.95 (0.41,2.18)
Sulfur Dioxide 1 1.21 (0.55,2.67) 1 (0.44,2.27) 1.12 (0.42,3.02)
Carbon Monoxide 1 1.57 (0.95,2.6) 1.31 (0.75,2.29) 1.5 (0.77,2.94)
Nitrogen Dioxide 1 0.9 (0.5,1.63) 1.22 (0.65,2.28) 1.38 (0.69,2.8)
Ozone
a
1 1.14 (0.73,1.81) 1.32 (0.78,2.22) 1.24 (0.7,2.22)
PM 10 1 1.07 (0.67,1.71) 1.11 (0.69,1.78) 1.15 (0.62,2.12)
PM 2.5 1 0.97 (0.64,1.47) 0.97 (0.63,1.49) 0.82 (0.46,1.46)
Sulfur Dioxide 1 1.14 (0.67,1.95) 1.07 (0.61,1.88) 1.09 (0.55,2.17)
VSD-perimembranous
Carbon Monoxide 1 1.04 (0.68,1.61) 0.86 (0.53,1.4) 0.76 (0.42,1.38)
Nitrogen Dioxide 1 0.7 (0.43,1.12) 0.79 (0.47,1.34) 0.63 (0.34,1.18)
Ozone
a
1 1.09 (0.75,1.6) 1.16 (0.74,1.81) 1.08 (0.65,1.79)
PM 10 1 0.87 (0.59,1.27) 0.81 (0.55,1.2) 0.75 (0.44,1.29)
PM 2.5 1 0.88 (0.61,1.26) 0.95 (0.65,1.38) 0.72 (0.42,1.23)
Sulfur Dioxide 1 0.95 (0.6,1.51) 1.13 (0.69,1.85) 1.02 (0.56,1.86)
ASD-all
Carbon Monoxide 1 0.97 (0.61,1.52) 0.9 (0.54,1.49) 1.13 (0.6,2.13)
Nitrogen Dioxide 1 0.77 (0.47,1.26) 0.81 (0.47,1.39) 0.76 (0.4,1.45)
Ozone
a
1 1.04 (0.75,1.45) 1.02 (0.69,1.52) 0.72 (0.45,1.16)
PM 10 1 1.21 (0.83,1.76) 1.03 (0.7,1.53) 1.23 (0.73,2.08)
PM 2.5 1 1.05 (0.78,1.43) 0.84 (0.6,1.18) 0.87 (0.53,1.42)
Sulfur Dioxide 1 0.95 (0.64,1.4) 1.1 (0.71,1.71) 1.07 (0.6,1.92)
Pulmonary/Tricuspid Atresia
Pulmonary Valve Stenosis
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Week 7
Cardiac Defect Pollutant
<10th 
percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile >90th percentile
Aortic Stenosis
Carbon Monoxide 1 0.77 (0.4,1.5) 1.11 (0.54,2.28) 1.35 (0.55,3.29)
Nitrogen Dioxide 1 0.96 (0.47,1.95) 0.9 (0.42,1.94) 0.98 (0.4,2.43)
Ozone
a
1 0.89 (0.49,1.63) 0.71 (0.36,1.44) 1.27 (0.6,2.69)
PM 10 1 0.89 (0.48,1.66) 1.06 (0.57,1.98) 0.82 (0.35,1.96)
PM 2.5 1 1.03 (0.6,1.76) 0.87 (0.48,1.56) 0.95 (0.41,2.21)
Sulfur Dioxide 1 1.23 (0.59,2.53) 0.98 (0.45,2.14) 0.52 (0.18,1.46)
Coarctation of the 
Aorta
Carbon Monoxide 1 1.44 (0.81,2.58) 1.6 (0.85,3.01) 1.7 (0.78,3.71)
Nitrogen Dioxide 1 1.31 (0.66,2.6) 1.4 (0.68,2.86) 1.79 (0.81,3.96)
Ozone
a
1 1.11 (0.66,1.87) 0.97 (0.53,1.77) 1.27 (0.66,2.44)
PM 10 1 1.4 (0.75,2.6) 1.54 (0.83,2.87) 1.82 (0.86,3.82)
PM 2.5 1 1.23 (0.76,2.01) 1.2 (0.72,2) 1.15 (0.58,2.28)
Sulfur Dioxide 1 1.37 (0.69,2.72) 1.49 (0.74,3.02) 1.3 (0.57,2.93)
Hypoplastic Left Heart 
Syndrome
Carbon Monoxide 1 0.79 (0.45,1.37) 0.96 (0.52,1.77) 1.26 (0.59,2.67)
Nitrogen Dioxide 1 1.21 (0.64,2.28) 1.37 (0.69,2.7) 1.34 (0.6,2.98)
Ozone
a
1 1.2 (0.73,1.99) 1.03 (0.58,1.83) 0.9 (0.47,1.72)
PM 10 1 1.97 (1.02,3.82) 1.46 (0.75,2.86) 1.69 (0.78,3.64)
PM 2.5 1 1.25 (0.73,2.15) 1.51 (0.86,2.63) 1.62 (0.81,3.27)
Sulfur Dioxide 1 1.31 (0.67,2.53) 1.53 (0.77,3.04) 0.87 (0.36,2.13)
d-TGA
Carbon Monoxide 1 1.12 (0.64,1.94) 1.08 (0.59,1.99) 1.42 (0.68,2.97)
Nitrogen Dioxide 1 1.15 (0.64,2.06) 0.94 (0.49,1.77) 0.74 (0.34,1.61)
Ozone
a
1 0.59 (0.37,0.95) 0.66 (0.39,1.12) 0.64 (0.35,1.17)
PM 10 1 1.16 (0.66,2.04) 1.3 (0.74,2.3) 1.07 (0.53,2.19)
PM 2.5 1 1.18 (0.71,1.95) 1.19 (0.7,2.01) 1.32 (0.68,2.58)
Sulfur Dioxide 1 0.93 (0.5,1.71) 1.19 (0.63,2.27) 0.98 (0.45,2.12)
Tetralogy of Fallot
Carbon Monoxide 1 1.24 (0.76,2.01) 1.32 (0.77,2.25) 1.73 (0.91,3.32)
Nitrogen Dioxide 1 1 (0.6,1.68) 0.79 (0.45,1.39) 1.19 (0.62,2.27)
Ozone
a
1 1.02 (0.68,1.53) 0.84 (0.52,1.35) 0.89 (0.53,1.51)
PM 10 1 0.92 (0.59,1.43) 0.93 (0.59,1.46) 1.09 (0.62,1.92)
PM 2.5 1 1.16 (0.75,1.8) 1.41 (0.9,2.2) 1.37 (0.79,2.4)
Sulfur Dioxide 1 1.35 (0.78,2.33) 1.4 (0.78,2.51) 1.13 (0.56,2.31)
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Week 7
Cardiac Defect Pollutant
<10th 
percentile 
10th percentile 
to median
median to 90th 
percentile >90th percentile
Other Conotruncals
Carbon Monoxide 1 0.88 (0.44,1.75) 0.88 (0.42,1.87) 1.61 (0.66,3.93)
Nitrogen Dioxide 1 1.67 (0.73,3.81) 1.21 (0.52,2.83) 0.88 (0.32,2.41)
Ozone
a
1 0.98 (0.52,1.88) 0.74 (0.36,1.53) 0.64 (0.28,1.46)
PM 10 1 1.17 (0.54,2.54) 1.31 (0.61,2.83) 1.41 (0.57,3.49)
PM 2.5 1 1.54 (0.7,3.41) 1.27 (0.57,2.84) 1.96 (0.78,4.9)
Sulfur Dioxide 1 0.89 (0.43,1.86) 0.78 (0.36,1.68) 0.55 (0.2,1.54)
TAPVR
Carbon Monoxide 1 0.57 (0.3,1.1) 0.53 (0.25,1.15) 1.25 (0.49,3.16)
Nitrogen Dioxide 1 1.37 (0.61,3.04) 1.44 (0.62,3.34) 0.72 (0.25,2.05)
Ozone
a
1 1.07 (0.54,2.11) 0.72 (0.33,1.57) 0.85 (0.37,1.93)
PM 10 1 1.64 (0.72,3.7) 1.17 (0.51,2.67) 1.12 (0.42,2.93)
PM 2.5 1 1.47 (0.75,2.87) 1.14 (0.56,2.31) 0.87 (0.33,2.27)
Sulfur Dioxide 1 1.39 (0.6,3.21) 0.99 (0.42,2.34) 1.37 (0.51,3.66)
Carbon Monoxide 1 0.99 (0.49,1.97) 1.14 (0.54,2.44) 1.45 (0.57,3.73)
Nitrogen Dioxide 1 1.77 (0.81,3.87) 0.93 (0.4,2.16) 0.93 (0.35,2.52)
Ozone
a
1 0.69 (0.35,1.37) 0.71 (0.34,1.49) 0.76 (0.34,1.7)
PM 10 1 0.82 (0.4,1.65) 1.24 (0.62,2.46) 1.25 (0.52,3.01)
PM 2.5 1 0.95 (0.52,1.73) 1.02 (0.54,1.92) 0.83 (0.34,2.03)
Sulfur Dioxide 1 0.83 (0.4,1.71) 1.02 (0.47,2.2) 0.52 (0.18,1.55)
Carbon Monoxide 1 0.78 (0.49,1.25) 0.88 (0.52,1.49) 1.52 (0.81,2.87)
Nitrogen Dioxide 1 1.15 (0.64,2.05) 1.32 (0.71,2.46) 1.31 (0.65,2.63)
Ozone
a
1 0.75 (0.48,1.16) 0.59 (0.36,0.97) 0.66 (0.38,1.14)
PM 10 1 1.45 (0.88,2.41) 1.41 (0.85,2.37) 1.57 (0.84,2.95)
PM 2.5 1 1.12 (0.74,1.69) 1.1 (0.72,1.7) 0.91 (0.5,1.64)
Sulfur Dioxide 1 1.53 (0.87,2.69) 1.61 (0.89,2.91) 0.96 (0.46,2)
VSD-perimembranous
Carbon Monoxide 1 1.2 (0.77,1.88) 1.35 (0.82,2.21) 1.79 (0.99,3.23)
Nitrogen Dioxide 1 1.23 (0.75,2.01) 0.77 (0.45,1.32) 0.95 (0.51,1.77)
Ozone
a
1 0.74 (0.51,1.06) 0.49 (0.32,0.75) 0.56 (0.35,0.89)
PM 10 1 0.96 (0.65,1.42) 0.91 (0.61,1.35) 0.98 (0.58,1.66)
PM 2.5 1 1.21 (0.83,1.75) 1.13 (0.77,1.68) 0.9 (0.52,1.56)
Sulfur Dioxide 1 1.22 (0.77,1.93) 1.03 (0.62,1.69) 0.98 (0.54,1.78)
ASD-all
Carbon Monoxide 1 1.26 (0.79,2.01) 1.13 (0.67,1.91) 0.99 (0.52,1.9)
Nitrogen Dioxide 1 1.26 (0.75,2.11) 1.18 (0.67,2.07) 1.12 (0.58,2.16)
Ozone
a
1 0.79 (0.57,1.09) 0.71 (0.48,1.05) 0.94 (0.6,1.45)
PM 10 1 1 (0.7,1.44) 1.02 (0.7,1.49) 0.91 (0.53,1.54)
PM 2.5 1 1.19 (0.87,1.64) 1.19 (0.84,1.68) 1.12 (0.67,1.86)
Sulfur Dioxide 1 1.04 (0.7,1.53) 1.05 (0.67,1.64) 0.79 (0.43,1.43)
Pulmonary/Tricuspid Atresia
Pulmonary Valve Stenosis
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Week 8
Cardiac Defect Pollutant
<10th 
percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile >90th percentile
Aortic Stenosis
Carbon Monoxide 1 0.93 (0.48,1.79) 0.94 (0.46,1.92) 0.9 (0.37,2.18)
Nitrogen Dioxide 1 0.72 (0.35,1.48) 0.96 (0.45,2.03) 1.72 (0.73,4.04)
Ozone
a
1 1.29 (0.72,2.34) 1.48 (0.77,2.84) 1 (0.47,2.13)
PM 10 1 0.46 (0.25,0.85) 0.82 (0.46,1.46) 1.02 (0.48,2.17)
PM 2.5 1 1.18 (0.67,2.06) 0.95 (0.52,1.73) 1.04 (0.46,2.35)
Sulfur Dioxide 1 1.45 (0.67,3.11) 1.26 (0.56,2.82) 1.83 (0.71,4.71)
Coarctation of the 
Aorta
Carbon Monoxide 1 1.13 (0.65,1.94) 1.12 (0.62,2.03) 1.06 (0.5,2.25)
Nitrogen Dioxide 1 0.74 (0.41,1.34) 0.67 (0.36,1.25) 0.62 (0.3,1.31)
Ozone
a
1 0.81 (0.5,1.31) 0.83 (0.48,1.42) 0.75 (0.41,1.36)
PM 10 1 1.05 (0.58,1.89) 1.22 (0.68,2.18) 1.44 (0.71,2.9)
PM 2.5 1 1.47 (0.9,2.4) 1.09 (0.64,1.83) 1.15 (0.59,2.24)
Sulfur Dioxide 1 1.08 (0.59,1.97) 1.35 (0.72,2.51) 1.31 (0.62,2.78)
Hypoplastic Left 
Heart Syndrome
Carbon Monoxide 1 1.11 (0.63,1.93) 0.98 (0.53,1.81) 0.6 (0.27,1.33)
Nitrogen Dioxide 1 0.67 (0.38,1.18) 0.67 (0.37,1.24) 0.76 (0.36,1.61)
Ozone
a
1 1.1 (0.68,1.79) 1.25 (0.73,2.14) 1.65 (0.91,2.99)
PM 10 1 0.62 (0.37,1.03) 0.72 (0.43,1.19) 0.98 (0.52,1.85)
PM 2.5 1 0.85 (0.53,1.37) 0.93 (0.57,1.54) 0.72 (0.36,1.42)
Sulfur Dioxide 1 1.99 (1.01,3.95) 1.18 (0.57,2.42) 1.74 (0.76,3.98)
d-TGA
Carbon Monoxide 1 1 (0.59,1.71) 0.94 (0.52,1.69) 1.08 (0.53,2.21)
Nitrogen Dioxide 1 0.9 (0.5,1.62) 1.21 (0.65,2.26) 1.23 (0.59,2.59)
Ozone
a
1 1.48 (0.96,2.29) 0.91 (0.53,1.54) 1.18 (0.67,2.09)
PM 10 1 0.92 (0.5,1.66) 1.44 (0.8,2.58) 1.52 (0.76,3.03)
PM 2.5 1 1.28 (0.76,2.16) 1.33 (0.77,2.28) 1.17 (0.59,2.3)
Sulfur Dioxide 1 1.13 (0.63,2.03) 1.15 (0.62,2.13) 0.86 (0.4,1.86)
Tetralogy of Fallot
Carbon Monoxide 1 0.91 (0.58,1.43) 0.92 (0.56,1.52) 0.71 (0.38,1.35)
Nitrogen Dioxide 1 0.91 (0.55,1.52) 1.04 (0.6,1.8) 1.1 (0.58,2.11)
Ozone
a
1 0.9 (0.61,1.32) 1.01 (0.66,1.56) 1.03 (0.63,1.68)
PM 10 1 0.58 (0.38,0.89) 0.87 (0.57,1.31) 0.95 (0.56,1.62)
PM 2.5 1 0.82 (0.54,1.23) 1.14 (0.75,1.74) 1.42 (0.85,2.37)
Sulfur Dioxide 1 1.17 (0.71,1.95) 1.15 (0.67,1.98) 1.29 (0.67,2.5)
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Week 8
Cardiac Defect Pollutant
<10th 
percentile 
10th percentile 
to median
median to 90th 
percentile >90th percentile
Other Conotruncals
Carbon Monoxide 1 0.96 (0.49,1.91) 0.91 (0.43,1.9) 0.74 (0.29,1.85)
Nitrogen Dioxide 1 0.71 (0.33,1.51) 0.99 (0.45,2.17) 1.17 (0.47,2.92)
Ozone
a
1 0.71 (0.37,1.39) 1.23 (0.63,2.4) 1.19 (0.56,2.57)
PM 10 1 0.86 (0.43,1.72) 0.83 (0.42,1.66) 0.77 (0.32,1.84)
PM 2.5 1 0.6 (0.32,1.14) 1.07 (0.57,1.99) 0.63 (0.25,1.59)
Sulfur Dioxide 1 1.49 (0.66,3.35) 1.54 (0.67,3.51) 1.15 (0.42,3.15)
TAPVR
Carbon Monoxide 1 0.82 (0.43,1.59) 0.76 (0.36,1.63) 1.04 (0.41,2.63)
Nitrogen Dioxide 1 0.77 (0.37,1.62) 0.5 (0.22,1.14) 1.65 (0.68,4.01)
Ozone
a
1 1.09 (0.56,2.11) 1 (0.48,2.09) 1.14 (0.52,2.53)
PM 10 1 0.48 (0.25,0.92) 0.47 (0.24,0.91) 0.99 (0.45,2.17)
PM 2.5 1 1.54 (0.75,3.15) 1.05 (0.5,2.23) 1.27 (0.51,3.14)
Sulfur Dioxide 1 1.72 (0.71,4.2) 1.88 (0.77,4.57) 1.38 (0.48,3.97)
Carbon Monoxide 1 0.72 (0.38,1.38) 0.89 (0.44,1.82) 0.51 (0.19,1.36)
Nitrogen Dioxide 1 0.68 (0.33,1.4) 0.68 (0.31,1.47) 1.19 (0.48,2.92)
Ozone
a
1 1.98 (1.03,3.82) 1.29 (0.61,2.72) 1.22 (0.55,2.7)
PM 10 1 0.9 (0.44,1.84) 0.83 (0.41,1.7) 1.16 (0.49,2.74)
PM 2.5 1 0.59 (0.34,1.01) 0.45 (0.24,0.83) 0.7 (0.31,1.57)
Sulfur Dioxide 1 0.84 (0.42,1.66) 0.74 (0.35,1.56) 0.93 (0.36,2.38)
Carbon Monoxide 1 1.43 (0.87,2.35) 1.58 (0.91,2.73) 1.01 (0.51,1.98)
Nitrogen Dioxide 1 1.1 (0.62,1.96) 1.05 (0.57,1.93) 1.53 (0.78,3)
Ozone
a
1 0.9 (0.6,1.37) 0.94 (0.59,1.5) 1.14 (0.69,1.9)
PM 10 1 0.83 (0.51,1.36) 1.27 (0.79,2.05) 1.43 (0.8,2.57)
PM 2.5 1 1.43 (0.91,2.24) 1.37 (0.86,2.19) 1.71 (0.97,3)
Sulfur Dioxide 1 1.49 (0.87,2.53) 1.68 (0.96,2.95) 1.42 (0.71,2.81)
VSD-perimembranous
Carbon Monoxide 1 0.84 (0.55,1.27) 0.83 (0.53,1.32) 0.87 (0.49,1.53)
Nitrogen Dioxide 1 0.94 (0.58,1.53) 1.05 (0.62,1.78) 1.88 (1.04,3.4)
Ozone
a
1 1.13 (0.79,1.6) 0.98 (0.65,1.48) 1.43 (0.91,2.24)
PM 10 1 1.01 (0.66,1.56) 1.48 (0.96,2.28) 1.24 (0.72,2.16)
PM 2.5 1 0.93 (0.65,1.32) 1.08 (0.74,1.56) 1.25 (0.77,2.04)
Sulfur Dioxide 1 0.82 (0.54,1.25) 1 (0.63,1.57) 0.93 (0.53,1.63)
ASD-all
Carbon Monoxide 1 0.68 (0.44,1.04) 0.83 (0.52,1.33) 0.6 (0.33,1.12)
Nitrogen Dioxide 1 1.14 (0.68,1.9) 1.24 (0.71,2.14) 1.49 (0.79,2.81)
Ozone
a
1 1.27 (0.92,1.74) 1.24 (0.86,1.8) 1.17 (0.76,1.81)
PM 10 1 0.99 (0.69,1.43) 0.9 (0.62,1.32) 0.99 (0.6,1.64)
PM 2.5 1 0.87 (0.65,1.18) 0.96 (0.69,1.33) 0.87 (0.54,1.4)
Sulfur Dioxide 1 1.13 (0.78,1.66) 1.03 (0.67,1.59) 1.1 (0.62,1.93)
Pulmonary/Tricuspid Atresia
Pulmonary Valve Stenosis
Table A2.4 (cont.)
164 
 
Table A2.5: Adjusted Odds Ratios and 95% Confidence Intervals between Cardiac Birth Defects and 7-week average 
exposure to criteria air pollutants among participants who lived within 10 km of a stationary air monitor
a
 
 
 
 
 
 
<10th 
percentile 
10th percentile to 
median
median to 90th 
percentile >90th percentile
Carbon Monoxide, ppm
LVOTO 1 1.38 (0.78,2.45) 1.39 (0.78,2.47) 1.25 (0.62,2.53)
CONOTRUNCALS 1 1.19 (0.74,1.94) 1.13 (0.69,1.85) 1.43 (0.8,2.57)
APVR 1 0.51 (0.18,1.42) 0.56 (0.2,1.57) 0.59 (0.16,2.18)
RVOTO 1 0.99 (0.57,1.74) 0.89 (0.5,1.57) 0.7 (0.33,1.47)
SEPTALS 1 0.89 (0.59,1.36) 1.03 (0.68,1.56) 1.1 (0.66,1.82)
Nitrogen Dioxide, ppb
LVOTO 1 1.25 (0.54,2.88) 1.37 (0.6,3.13) 1.44 (0.58,3.61)
CONOTRUNCALS 1 1 (0.49,2.04) 1.2 (0.59,2.43) 1.1 (0.49,2.48)
APVR 1 0.22 (0.07,0.69) 0.27 (0.09,0.81) 0.56 (0.16,1.99)
RVOTO 1 1.5 (0.52,4.34) 1.39 (0.48,4) 2.33 (0.75,7.22)
SEPTALS 1 1.01 (0.55,1.86) 0.91 (0.5,1.67) 1.12 (0.56,2.24)
Ozone, ppb
LVOTO 1 1.47 (0.81,2.67) 1.41 (0.78,2.56) 1.62 (0.84,3.13)
CONOTRUNCALS 1 1.18 (0.76,1.84) 1.04 (0.67,1.63) 0.88 (0.51,1.52)
APVR 1 0.65 (0.21,2.02) 1.2 (0.43,3.39) 1.13 (0.33,3.84)
RVOTO 1 1.61 (0.81,3.21) 2 (1.02,3.91) 1.52 (0.7,3.31)
SEPTALS 1 1.35 (0.87,2.09) 1.25 (0.81,1.95) 1.07 (0.63,1.85)
PM10, micrometers/cubic meter
LVOTO 1 0.87 (0.48,1.57) 1.13 (0.63,2.03) 1.02 (0.51,2.03)
CONOTRUNCALS 1 0.95 (0.54,1.66) 1.09 (0.63,1.89) 1.05 (0.56,1.97)
APVR 1 1.37 (0.31,6.08) 1.26 (0.28,5.57) 1.2 (0.23,6.31)
RVOTO 1 1.12 (0.72,1.76) 1.01 (0.65,1.58) 0.89 (0.52,1.53)
SEPTALS 1 1.26 (0.28,5.57) 1.2 (0.23,6.31) 1.2 (0.23,6.15)
LVOTO 1 1.18 (0.78,1.78) 1.1 (0.71,1.68) 1.57 (0.93,2.66)
CONOTRUNCALS 1 0.95 (0.65,1.4) 0.96 (0.65,1.43) 1.43 (0.88,2.3)
APVR 1 0.95 (0.41,2.19) 0.87 (0.36,2.09) 1.55 (0.54,4.46)
RVOTO 1 1.17 (0.72,1.88) 1.35 (0.84,2.18) 1.21 (0.65,2.28)
SEPTALS 1 0.91 (0.68,1.22) 0.67 (0.49,0.91) 0.71 (0.45,1.1)
LVOTO 1 1.18 (0.58,2.4) 1.29 (0.63,2.65) 0.74 (0.3,1.83)
CONOTRUNCALS 1 0.75 (0.4,1.42) 0.75 (0.4,1.42) 0.61 (0.29,1.31)
APVR 1 1.95 (0.21,17.97) 4.01 (0.45,35.46) 1 (0.05,18.29)
RVOTO 1 1.46 (0.7,3.04) 0.93 (0.43,1.99) 0.69 (0.27,1.74)
SEPTALS 1 1.75 (1.07,2.85) 1.34 (0.8,2.25) 1.52 (0.83,2.76)
PM2.5 micrometers/cubic meter
Sulfur Dioxide, ppb
a
Estimates result from first stage maximum-likelihood, polytomous logistic model with defect groupings as outcomes and 
adjusted for maternal race, maternal age, maternal educational attainment, maternal household income, maternal smoking 
status and alcohol consumption during early pregnancy, nativity, and site-specific heart defect ratio. 
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Table A3.1: Adjusted odds ratios and 95% confidence intervals for CHDs and 7-week average exposure to PM2.5 and ozone 
 
AQS , population within 50km of an air monitor
PM2.5
<10th 
percentile 
10th percentile to 
median
median to 90th 
percentile
>90th 
percentile
Pollutant concentration cut-off values <8.47 μg/m3 8.47-12.2 μg/m3 12.2-17.5 μg/m3 >=17.5 μg/m3
LVOTO
a
1 1.37 (0.85,2.19) 1.02 (0.62,1.66) 1.57 (0.88,2.78)
Aortic Stenosis
b
1 1.11 (0.48,2.59) 0.75 (0.31,1.84) 1.24 (0.42,3.61)
Coarctation of the Aorta
b
1 1.91 (0.85,4.26) 1.45 (0.64,3.31) 2.37 (0.94,5.93)
Hypoplastic Left Heart Syndrome
b
1 1.45 (0.64,3.29) 1.11 (0.48,2.58) 1.55 (0.59,4.08)
CONOTRUNCALS
a
1 1.17 (0.78,1.75) 0.98 (0.65,1.47) 1.19 (0.73,1.96)
d-TGA
b
1 0.83 (0.47,1.47) 0.62 (0.34,1.12) 0.75 (0.35,1.63)
Tetralogy of Fallot
b
1 1.72 (0.92,3.21) 1.65 (0.88,3.1) 1.87 (0.91,3.85)
Other Conotruncals
b
1 1.03 (0.38,2.76) 0.58 (0.2,1.69) 1.02 (0.31,3.36)
APVR
a
1 1.34 (0.55,3.25) 0.73 (0.28,1.9) 1.11 (0.36,3.41)
AVSD
c
1 1.13 (0.40, 4.36) 0.79 (0.26, 3.10) 1.33 (0.34, 5.88)
RVOTO
a
1 1.01 (0.63,1.61) 1.19 (0.74,1.91) 0.82 (0.44,1.54)
Pulmonary Valve Stenosis
b
1 1.19 (0.67,2.13) 1.46 (0.82,2.59) 0.97 (0.46,2.04)
SEPTALS
a
1 1.06 (0.8,1.4) 0.74 (0.55,0.99) 0.72 (0.48,1.08)
VSD-perimembranous
b
1 1.14 (0.74,1.75) 0.86 (0.55,1.35) 0.88 (0.5,1.55)
ASD-all
b
1 1.06 (0.76,1.48) 0.72 (0.49,1.04) 0.65 (0.38,1.12)
Ozone
<25th 
percentile
25th percentile to 
median
median to 75th 
percentile
>75th 
percentile
Pollutant concentration cut-off values <32.4 ppb 32.4-41.4 ppb 41.4-49.8 ppb >=49.8 ppb
LVOTO
a
1 0.95 (0.64,1.42) 0.89 (0.6,1.32) 0.74 (0.49,1.12)
Aortic Stenosis
b
1 1.22 (0.54,2.76) 1.14 (0.52,2.53) 0.47 (0.16,1.36)
Coarctation of the Aorta
b
1 0.63 (0.33,1.2) 0.83 (0.47,1.48) 0.75 (0.41,1.36)
Hypoplastic Left Heart Syndrome
b
1 1.05 (0.58,1.92) 0.8 (0.43,1.51) 0.82 (0.44,1.53)
CONOTRUNCALS
a
1 1.01 (0.72,1.43) 0.95 (0.67,1.34) 0.8 (0.56,1.14)
d-TGA
b
1 0.79 (0.44,1.44) 1.09 (0.64,1.86) 0.76 (0.42,1.36)
Tetralogy of Fallot
b
1 1.19 (0.75,1.86) 0.96 (0.61,1.52) 0.92 (0.58,1.47)
Other Conotruncals
b
1 0.91 (0.39,2.1) 0.59 (0.23,1.53) 0.47 (0.17,1.29)
APVR
a
1 0.5 (0.21,1.19) 1.11 (0.57,2.19) 0.46 (0.19,1.09)
AVSD
a
1 0.90 (0.30, 2.64) 0.91 (0.32, 2.57) 0.75 (0.25, 2.20)
RVOTO
a
1 1.03 (0.67,1.58) 0.75 (0.48,1.18) 1.13 (0.75,1.7)
Pulmonary Valve Stenosis
b
1 1.19 (0.72,1.95) 0.89 (0.53,1.48) 1.18 (0.73,1.91)
SEPTALS
a
1 1.09 (0.83,1.43) 1.04 (0.78,1.38) 0.9 (0.66,1.21)
VSD-perimembranous
b
1 0.91 (0.62,1.36) 0.76 (0.5,1.14) 0.93 (0.63,1.37)
ASD-all
b
1 1.29 (0.92,1.82) 1.4 (0.96,2.02) 0.89 (0.59,1.36)
a Models constructed using two-stage hierarchical regression models of defect-groupings, adjusted for maternal age, race, 
educational level, household income, tobacco use during the first month of pregnancy, alcohol consumption during the first 
three months of pregnancy, and site-specific percentage of septal defects
b Models constructed using two-stage hierarchical regression models of individual defects, adjusted for maternal age, race, 
educational level, household income, tobacco use during the first month of pregnancy, alcohol consumption during the first 
three months of pregnancy, and site-specific percentage of septal defects
c Models constructed using Firth-adjusted logistic regression model, adjusted for maternal age, race, educational level, 
household income, tobacco use during the first month of pregnancy, alcohol consumption during the first three months of 
pregnancy, and site-specific percentage of septal defects
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Table A3.1 (cont.)
downscaler CMAQ , population within 50km of an air monitor
PM2.5 <10th percentile 
10th percentile to 
median
median to 90th 
percentile >90th percentile
Pollutant concentration cut-off values < 9.03 μg/m3 9.03-12.4 μg/m3 12.4-17.1 μg/m3 >= 17.1 μg/m3
LVOTO
a
1 0.87 (0.54,1.42) 0.92 (0.56,1.51) 0.86 (0.46,1.6)
Aortic Stenosis
b
1 0.77 (0.33,1.84) 0.64 (0.26,1.59) 0.54 (0.16,1.91)
Coarctation of the Aorta
b
1 0.98 (0.46,2.1) 1.06 (0.49,2.29) 1.21 (0.49,2.97)
Hypoplastic Left Heart Syndrome
b
1 0.81 (0.36,1.83) 0.93 (0.41,2.13) 0.8 (0.29,2.21)
CONOTRUNCALS
a
1 1.12 (0.71,1.75) 0.96 (0.6,1.52) 1.33 (0.78,2.26)
d-TGA
b
1 0.99 (0.5,1.95) 0.68 (0.33,1.39) 1.01 (0.44,2.31)
Tetralogy of Fallot
b
1 1.34 (0.7,2.55) 1.26 (0.66,2.44) 1.69 (0.82,3.5)
Other Conotruncals
b
1 0.9 (0.29,2.77) 0.9 (0.28,2.88) 1.17 (0.32,4.32)
APVR
a
1 1.27 (0.48,3.35) 0.76 (0.27,2.16) 1.09 (0.33,3.59)
AVSD
c
1 0.65 (0.20, 2.73) 0.79 (0.25, 3.33) 0.62 (0.12, 3.22)
RVOTO
a
1 1.39 (0.79,2.44) 1.42 (0.8,2.52) 1.03 (0.51,2.08)
Pulmonary Valve Stenosis
b
1 1.69 (0.82,3.46) 2 (0.96,4.13) 1.42 (0.6,3.34)
SEPTALS
a
1 0.98 (0.73,1.3) 0.78 (0.57,1.07) 0.77 (0.51,1.16)
VSD-perimembranous
b
1 1.59 (0.94,2.7) 1.31 (0.76,2.26) 1.38 (0.73,2.6)
ASD-all
b
1 0.87 (0.63,1.2) 0.68 (0.46,1) 0.68 (0.4,1.15)
Ozone <25th percentile
25th percentile to 
median
median to 75th 
percentile >75th percentile
Pollutant concentration cut-off values <33.4 ppb 33.4-42.1 ppb 42.1-49.6 ppb >= 49.6 ppb
LVOTO
a
1 1.07 (0.72,1.6) 1.07 (0.72,1.58) 0.77 (0.5,1.18)
Aortic Stenosis
b
1 1.32 (0.59,2.93) 1.04 (0.46,2.35) 0.52 (0.19,1.43)
Coarctation of the Aorta
b
1 0.63 (0.33,1.2) 0.87 (0.49,1.54) 0.72 (0.39,1.31)
Hypoplastic Left Heart Syndrome
b
1 1.42 (0.75,2.68) 1.36 (0.72,2.57) 0.97 (0.49,1.92)
CONOTRUNCALS
a
1 1.06 (0.75,1.51) 1.05 (0.74,1.47) 0.8 (0.56,1.15)
d-TGA
b
1 1.05 (0.59,1.88) 1.23 (0.72,2.09) 0.67 (0.36,1.26)
Tetralogy of Fallot
b
1 1.13 (0.71,1.8) 1.07 (0.68,1.68) 0.96 (0.6,1.53)
Other Conotruncals
b
1 0.84 (0.36,1.98) 0.6 (0.23,1.56) 0.55 (0.21,1.44)
APVR
a
1 0.36 (0.14,0.92) 1.08 (0.56,2.08) 0.42 (0.18,1)
AVSD
a
1 0.77 (0.24, 2.33) 1.16 (0.44, 3.17) 0.64 (0.20, 1.95)
RVOTO
a
1 0.94 (0.61,1.44) 0.88 (0.58,1.34) 0.95 (0.63,1.44)
Pulmonary Valve Stenosis
b
1 1.05 (0.64,1.73) 0.96 (0.59,1.57) 1.03 (0.63,1.66)
SEPTALS
a
1 0.95 (0.73,1.25) 1 (0.75,1.33) 0.84 (0.62,1.13)
VSD-perimembranous
b
1 0.81 (0.55,1.22) 0.84 (0.57,1.25) 0.84 (0.57,1.25)
ASD-all
b
1 1.09 (0.78,1.53) 1.17 (0.81,1.7) 0.87 (0.58,1.31)
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Table A3.1 (cont.)
downscaler CMAQ, full population
PM2.5 <10th percentile 
10th percentile to 
median
median to 90th 
percentile >90th percentile
Pollutant concentration cut-off values < 8.61 μg/m3 8.61-12.1  μg/m3 12.1-16.9 μg/m3 >= 16.9  μg/m3
LVOTO
a
1 1 (0.63,1.61) 1.04 (0.64,1.69) 1.03 (0.57,1.86)
Aortic Stenosis
b
1 1.18 (0.49,2.85) 0.82 (0.32,2.1) 0.77 (0.23,2.59)
Coarctation of the Aorta
b
1 0.8 (0.4,1.61) 0.84 (0.41,1.72) 1.09 (0.47,2.5)
Hypoplastic Left Heart Syndrome
b
1 1.11 (0.5,2.48) 1.47 (0.65,3.35) 1.15 (0.42,3.13)
CONOTRUNCALS
a
1 1.17 (0.75,1.82) 1.06 (0.67,1.68) 1.32 (0.78,2.24)
d-TGA
b
1 1.42 (0.67,3.03) 0.99 (0.45,2.19) 1.29 (0.52,3.19)
Tetralogy of Fallot
b
1 1.08 (0.59,1.95) 1.14 (0.62,2.11) 1.39 (0.7,2.78)
Other Conotruncals
b
1 1.07 (0.39,2.95) 0.93 (0.31,2.73) 1.12 (0.32,3.9)
APVR
a
1 4.71 (1.06,20.91) 2.84 (0.6,13.34) 3.5 (0.66,18.44)
AVSD
c
1 0.60 (0.19, 2.49) 0.66 (0.21, 2.81) 0.50 (0.10, 2.64)
RVOTO
a
1 1.1 (0.66,1.83) 1.25 (0.74,2.12) 0.93 (0.49,1.78)
Pulmonary Valve Stenosis
b
1 1.41 (0.74,2.69) 1.81 (0.94,3.5) 1.38 (0.63,3)
SEPTALS
a
1 0.98 (0.75,1.28) 0.86 (0.64,1.16) 0.81 (0.55,1.2)
VSD-perimembranous
b
1 1.26 (0.79,2.01) 1.14 (0.7,1.86) 1.09 (0.61,1.96)
ASD-all
b
1 0.94 (0.69,1.27) 0.83 (0.57,1.19) 0.79 (0.47,1.31)
Ozone <25th percentile
25th percentile to 
median
median to 75th 
percentile >75th percentile
Pollutant concentration cut-off values <30.5 ppb 30.5-39.6 ppb 39.6-48.2 ppb >= 48.2 ppb
LVOTO
a
1 1.02 (0.73,1.42) 0.98 (0.71,1.36) 0.84 (0.59,1.18)
Aortic Stenosis
b
1 1.36 (0.71,2.61) 1.26 (0.66,2.4) 0.74 (0.35,1.56)
Coarctation of the Aorta
b
1 0.86 (0.53,1.42) 0.77 (0.47,1.26) 0.74 (0.45,1.23)
Hypoplastic Left Heart Syndrome
b
1 0.95 (0.54,1.68) 1.11 (0.65,1.9) 1.03 (0.6,1.79)
CONOTRUNCALS
a
1 1 (0.75,1.35) 0.97 (0.72,1.29) 0.81 (0.6,1.1)
d-TGA
b
1 0.86 (0.52,1.41) 1.02 (0.64,1.63) 0.79 (0.48,1.3)
Tetralogy of Fallot
b
1 1.13 (0.77,1.65) 0.96 (0.66,1.41) 0.87 (0.59,1.29)
Other Conotruncals
b
1 0.89 (0.42,1.87) 0.91 (0.44,1.89) 0.66 (0.3,1.46)
APVR
a
1 0.57 (0.27,1.23) 1.01 (0.54,1.92) 0.75 (0.38,1.5)
AVSD
a
1 1.09 (0.44, 2.68) 1.31 (0.58, 3.04) 0.71 (0.27, 1.82)
RVOTO
a
1 0.98 (0.68,1.41) 0.97 (0.68,1.38) 1.19 (0.85,1.67)
Pulmonary Valve Stenosis
b
1 1.03 (0.68,1.58) 1.09 (0.73,1.64) 1.38 (0.94,2.03)
SEPTALS
a
1 0.86 (0.68,1.09) 0.9 (0.72,1.14) 0.75 (0.59,0.95)
VSD-perimembranous
b
1 0.89 (0.64,1.23) 0.9 (0.66,1.24) 0.84 (0.61,1.17)
ASD-all
b
1 0.84 (0.63,1.14) 0.9 (0.67,1.22) 0.69 (0.5,0.95)
169 
 
Table A3.2: Adjusted odds ratios and 95% confidence intervals between CHDs and 7-week average exposure to PM2.5 and 
Ozone using constant numeric cutoffs 
PM2.5 AQS , population within 50km of an air monitor
Pollutant concentration cut-off values <8.47 μg/m3 8.47-12.2 μg/m3 12.2-17.5 μg/m3 >=17.5 μg/m3
LVOTO
a
1 1.37 (0.85,2.19) 1.02 (0.62,1.66) 1.57 (0.88,2.78)
Aortic Stenosis
b
1 1.11 (0.48,2.59) 0.75 (0.31,1.84) 1.24 (0.42,3.61)
Coarctation of the Aorta
b
1 1.91 (0.85,4.26) 1.45 (0.64,3.31) 2.37 (0.94,5.93)
Hypoplastic Left Heart Syndrome
b
1 1.45 (0.64,3.29) 1.11 (0.48,2.58) 1.55 (0.59,4.08)
CONOTRUNCALS
a
1 1.17 (0.78,1.75) 0.98 (0.65,1.47) 1.19 (0.73,1.96)
d-TGA
b
1 0.83 (0.47,1.47) 0.62 (0.34,1.12) 0.75 (0.35,1.63)
Tetralogy of Fallot
b
1 1.72 (0.92,3.21) 1.65 (0.88,3.1) 1.87 (0.91,3.85)
Other Conotruncals
b
1 1.03 (0.38,2.76) 0.58 (0.2,1.69) 1.02 (0.31,3.36)
APVR
a
1 1.34 (0.55,3.25) 0.73 (0.28,1.9) 1.11 (0.36,3.41)
AVSD
c
1 1.13 (0.40, 4.36) 0.79 (0.26, 3.10) 1.33 (0.34, 5.88)
RVOTO
a
1 1.01 (0.63,1.61) 1.19 (0.74,1.91) 0.82 (0.44,1.54)
Pulmonary Valve Stenosis
b
1 1.19 (0.67,2.13) 1.46 (0.82,2.59) 0.97 (0.46,2.04)
SEPTALS
a
1 1.06 (0.8,1.4) 0.74 (0.55,0.99) 0.72 (0.48,1.08)
VSD-perimembranous
b
1 1.14 (0.74,1.75) 0.86 (0.55,1.35) 0.88 (0.5,1.55)
ASD-all
b
1 1.06 (0.76,1.48) 0.72 (0.49,1.04) 0.65 (0.38,1.12)
Ozone AQS , population within 50km of an air monitor
Pollutant concentration cut-off values <32.4 ppb 32.4-41.4 ppb 41.4-49.8 ppb >=49.8 ppb
LVOTO
a
1 0.95 (0.64,1.42) 0.89 (0.6,1.32) 0.74 (0.49,1.12)
Aortic Stenosis
b
1 1.22 (0.54,2.76) 1.14 (0.52,2.53) 0.47 (0.16,1.36)
Coarctation of the Aorta
b
1 0.63 (0.33,1.2) 0.83 (0.47,1.48) 0.75 (0.41,1.36)
Hypoplastic Left Heart Syndrome
b
1 1.05 (0.58,1.92) 0.8 (0.43,1.51) 0.82 (0.44,1.53)
CONOTRUNCALS
a
1 1.01 (0.72,1.43) 0.95 (0.67,1.34) 0.8 (0.56,1.14)
d-TGA
b
1 0.79 (0.44,1.44) 1.09 (0.64,1.86) 0.76 (0.42,1.36)
Tetralogy of Fallot
b
1 1.19 (0.75,1.86) 0.96 (0.61,1.52) 0.92 (0.58,1.47)
Other Conotruncals
b
1 0.91 (0.39,2.1) 0.59 (0.23,1.53) 0.47 (0.17,1.29)
APVR
a
1 0.5 (0.21,1.19) 1.11 (0.57,2.19) 0.46 (0.19,1.09)
AVSD
a
1 0.90 (0.30, 2.64) 0.91 (0.32, 2.57) 0.75 (0.25, 2.20)
RVOTO
a
1 1.03 (0.67,1.58) 0.75 (0.48,1.18) 1.13 (0.75,1.7)
Pulmonary Valve Stenosis
b
1 1.19 (0.72,1.95) 0.89 (0.53,1.48) 1.18 (0.73,1.91)
SEPTALS
a
1 1.09 (0.83,1.43) 1.04 (0.78,1.38) 0.9 (0.66,1.21)
VSD-perimembranous
b
1 0.91 (0.62,1.36) 0.76 (0.5,1.14) 0.93 (0.63,1.37)
ASD-all
b
1 1.29 (0.92,1.82) 1.4 (0.96,2.02) 0.89 (0.59,1.36)
b Models constructed using two-stage hierarchical regression models of individual defects, adjusted for maternal age, race, 
educational level, household income, tobacco use during the first month of pregnancy, alcohol consumption during the first 
three months of pregnancy, and site-specific percentage of septal defects
c Models constructed using Firth-adjusted logistic regression model, adjusted for maternal age, race, educational level, 
household income, tobacco use during the first month of pregnancy, alcohol consumption during the first three months of 
pregnancy, and site-specific percentage of septal defects
a Models constructed using two-stage hierarchical regression models of defect-groupings, adjusted for maternal age, race, 
educational level, household income, tobacco use during the first month of pregnancy, alcohol consumption during the first 
three months of pregnancy, and site-specific percentage of septal defects
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Table A3.2 (cont.)
PM2.5 downscaler CMAQ , population within 50km of an air monitor
Pollutant concentration cut-off values <8.47 μg/m3 8.47-12.2 μg/m3 12.2-17.5 μg/m3 >=17.5 μg/m3
LVOTO
a
1 0.75 (0.43,1.34) 0.83 (0.46,1.48) 0.74 (0.36,1.51)
Aortic Stenosis
b
1 0.56 (0.21,1.48) 0.48 (0.17,1.33) 0.35 (0.08,1.47)
Coarctation of the Aorta
b
1 1 (0.4,2.52) 1.06 (0.41,2.7) 1.17 (0.4,3.42)
Hypoplastic Left Heart Syndrome
b
1 0.67 (0.26,1.76) 0.9 (0.34,2.37) 0.74 (0.23,2.35)
CONOTRUNCALS
a
1 1.03 (0.59,1.79) 0.96 (0.55,1.7) 1.15 (0.6,2.19)
d-TGA
b
1 0.83 (0.37,1.86) 0.57 (0.25,1.31) 0.77 (0.29,2.04)
Tetralogy of Fallot
b
1 1.58 (0.65,3.84) 1.72 (0.7,4.21) 2.08 (0.79,5.5)
Other Conotruncals
b
1 0.65 (0.19,2.18) 0.72 (0.2,2.51) 0.55 (0.12,2.54)
APVR
a
1 2.44 (0.54,11) 1.67 (0.35,7.87) 1.73 (0.31,9.77)
AVSD
c
1 0.51 (0.14, 2.82) 0.57 (0.15, 3.22) 0.57 (0.10, 3.86)
RVOTO
a
1 0.81 (0.44,1.51) 1.01 (0.54,1.89) 0.5 (0.22,1.14)
Pulmonary Valve Stenosis
b
1 1.04 (0.47,2.32) 1.48 (0.66,3.31) 0.76 (0.28,2.04)
SEPTALS
a
1 0.75 (0.55,1.03) 0.63 (0.44,0.88) 0.61 (0.39,0.95)
VSD-perimembranous
b
1 1.44 (0.77,2.72) 1.3 (0.68,2.5) 1.34 (0.64,2.83)
ASD-all
b
1 0.67 (0.48,0.95) 0.52 (0.35,0.78) 0.51 (0.29,0.91)
Ozone downscaler CMAQ , population within 50km of an air monitor
Pollutant concentration cut-off values <32.4 ppb 32.4-41.4 ppb 41.4-49.8 ppb >=49.8 ppb
LVOTO
a
1 1.14 (0.75,1.72) 0.96 (0.65,1.43) 0.8 (0.52,1.24)
Aortic Stenosis
b
1 1.11 (0.49,2.52) 0.88 (0.39,1.98) 0.49 (0.18,1.33)
Coarctation of the Aorta
b
1 0.84 (0.45,1.58) 0.82 (0.46,1.48) 0.8 (0.43,1.49)
Hypoplastic Left Heart Syndrome
b
1 1.38 (0.72,2.65) 1.19 (0.63,2.25) 0.97 (0.49,1.94)
CONOTRUNCALS
a
1 1.02 (0.71,1.45) 0.93 (0.66,1.31) 0.75 (0.52,1.1)
d-TGA
b
1 0.97 (0.54,1.74) 1.04 (0.61,1.78) 0.65 (0.35,1.23)
Tetralogy of Fallot
b
1 1.1 (0.69,1.76) 0.94 (0.6,1.48) 0.9 (0.56,1.45)
Other Conotruncals
b
1 0.81 (0.33,1.95) 0.65 (0.26,1.62) 0.49 (0.18,1.35)
APVR
a
1 0.38 (0.15,0.94) 0.9 (0.46,1.76) 0.42 (0.18,0.99)
AVSD
a
1 1.80 (0.58, 6.32) 1.53 (0.52, 5.25) 1.00 (0.28, 3.73)
RVOTO
a
1 0.91 (0.58,1.42) 0.85 (0.56,1.3) 0.95 (0.62,1.46)
Pulmonary Valve Stenosis
b
1 0.97 (0.58,1.62) 0.92 (0.57,1.5) 1.01 (0.62,1.65)
SEPTALS
a
1 0.88 (0.66,1.17) 0.93 (0.7,1.23) 0.81 (0.6,1.1)
VSD-perimembranous
b
1 0.75 (0.49,1.13) 0.77 (0.52,1.14) 0.84 (0.56,1.25)
ASD-all
b
1 1.02 (0.72,1.46) 1.12 (0.77,1.62) 0.82 (0.53,1.25)
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Table A3.2 (cont.)
PM2.5 downscaler CMAQ, full population
Pollutant concentration cut-off values <8.47 μg/m3 8.47-12.2 μg/m3 12.2-17.5 μg/m3 >=17.5 μg/m3
LVOTO
a
1 0.86 (0.53,1.38) 0.92 (0.56,1.51) 0.8 (0.42,1.54)
Aortic Stenosis
b
1 0.93 (0.38,2.24) 0.71 (0.28,1.81) 0.52 (0.13,2.07)
Coarctation of the Aorta
b
1 0.74 (0.36,1.53) 0.83 (0.39,1.73) 0.89 (0.36,2.21)
Hypoplastic Left Heart Syndrome
b
1 0.92 (0.42,2.05) 1.19 (0.52,2.7) 0.96 (0.34,2.73)
CONOTRUNCALS
a
1 0.99 (0.63,1.55) 0.94 (0.59,1.5) 1.13 (0.64,1.98)
d-TGA
b
1 1.16 (0.55,2.47) 0.82 (0.37,1.8) 1.11 (0.43,2.86)
Tetralogy of Fallot
b
1 0.95 (0.51,1.75) 1.06 (0.56,1.98) 1.29 (0.62,2.68)
Other Conotruncals
b
1 0.85 (0.31,2.35) 0.86 (0.29,2.52) 0.67 (0.17,2.69)
APVR
a
1 3.75 (0.84,16.7) 2.5 (0.53,11.72) 2.63 (0.47,14.76)
AVSD
c
1 0.48 (0.15, 1.97) 0.53 (0.16, 2.23) 0.57 (0.11, 2.98)
RVOTO
a
1 0.87 (0.66,1.15) 0.79 (0.58,1.08) 0.75 (0.49,1.15)
Pulmonary Valve Stenosis
b
1 1.27 (0.65,2.47) 1.71 (0.87,3.39) 0.87 (0.36,2.13)
SEPTALS
a
1 0.94 (0.56,1.58) 1.14 (0.67,1.95) 0.56 (0.26,1.2)
VSD-perimembranous
b
1 1.12 (0.69,1.81) 1.05 (0.63,1.74) 1.04 (0.55,1.94)
ASD-all
b
1 0.84 (0.62,1.14) 0.76 (0.52,1.1) 0.74 (0.43,1.28)
Ozone downscaler CMAQ, full population
Pollutant concentration cut-off values <32.4 ppb 32.4-41.4 ppb 41.4-49.8 ppb >=49.8 ppb
LVOTO
a
1 1.1 (0.8,1.52) 0.95 (0.7,1.3) 0.81 (0.57,1.17)
Aortic Stenosis
b
1 1.09 (0.6,1.99) 0.87 (0.48,1.59) 0.51 (0.23,1.14)
Coarctation of the Aorta
b
1 0.93 (0.57,1.51) 0.82 (0.51,1.32) 0.83 (0.49,1.39)
Hypoplastic Left Heart Syndrome
b
1 1.26 (0.73,2.15) 1.22 (0.73,2.05) 1.04 (0.58,1.86)
CONOTRUNCALS
a
1 1 (0.75,1.33) 0.95 (0.72,1.25) 0.78 (0.57,1.07)
d-TGA
b
1 0.97 (0.6,1.57) 1.07 (0.69,1.66) 0.71 (0.41,1.24)
Tetralogy of Fallot
b
1 1.07 (0.74,1.55) 0.93 (0.65,1.34) 0.86 (0.57,1.29)
Other Conotruncals
b
1 0.8 (0.39,1.65) 0.8 (0.4,1.61) 0.65 (0.29,1.44)
APVR
a
1 0.58 (0.27,1.26) 1.32 (0.73,2.38) 0.62 (0.28,1.38)
AVSD
a
1 1.33 (0.56, 3.14) 1.24 (0.55, 2.83) 0.85 (0.31, 2.20)
RVOTO
a
1 1.04 (0.74,1.47) 1.19 (0.87,1.65) 1.06 (0.74,1.52)
Pulmonary Valve Stenosis
b
1 1.08 (0.72,1.63) 1.37 (0.95,1.97) 1.18 (0.78,1.77)
SEPTALS
a
1 0.94 (0.75,1.17) 0.89 (0.72,1.11) 0.83 (0.65,1.06)
VSD-perimembranous
b
1 0.91 (0.66,1.25) 0.86 (0.64,1.17) 0.94 (0.68,1.3)
ASD-all
b
1 0.97 (0.73,1.27) 0.91 (0.69,1.21) 0.75 (0.54,1.05)
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Table A3.3: Odds Ratios and 95% confidence intervals resulting from hierarchical analysis between cardiac birth defects 
and weekly exposure to PM2.5 
 
Cardiac Defect Source
<10th 
percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile >90th percentile
Aortic Stenosis CMAQ, full population 1 1.46 (0.71,2.97) 1.14 (0.54,2.4) 1.41 (0.57,3.52)
CMAQ, within 50km of monitor 1 1.47 (0.69,3.14) 1.04 (0.46,2.31) 1.42 (0.54,3.7)
AQS 1 1.03 (0.45,2.35) 1.1 (0.48,2.49) 1.19 (0.44,3.22)
Coarctation of the Aorta CMAQ, full population 1 1.3 (0.7,2.42) 1.48 (0.79,2.79) 1.01 (0.45,2.28)
CMAQ, within 50km of monitor 1 1.5 (0.77,2.94) 1.8 (0.92,3.54) 1.08 (0.45,2.56)
AQS 1 1.23 (0.64,2.37) 1.32 (0.68,2.55) 0.68 (0.27,1.72)
Hypoplastic Left Heart 
Syndrome CMAQ, full population 1 1.33 (0.71,2.49) 1.08 (0.56,2.09) 1.18 (0.53,2.62)
CMAQ, within 50km of monitor 1 1.24 (0.65,2.35) 0.97 (0.49,1.89) 0.95 (0.4,2.23)
AQS 1 1.13 (0.57,2.24) 1.02 (0.51,2.06) 1.23 (0.52,2.88)
d-TGA CMAQ, full population 1 1.03 (0.59,1.81) 1.1 (0.62,1.97) 0.95 (0.44,2.03)
CMAQ, within 50km of monitor 1 1.1 (0.63,1.95) 1.02 (0.56,1.84) 1.02 (0.47,2.2)
AQS 1 1.15 (0.64,2.05) 0.79 (0.43,1.46) 0.57 (0.24,1.36)
Tetralogy of Fallot CMAQ, full population 1 1.33 (0.8,2.21) 1.15 (0.68,1.96) 1.31 (0.7,2.47)
CMAQ, within 50km of monitor 1 1.33 (0.78,2.26) 1.13 (0.65,1.97) 1.49 (0.78,2.86)
AQS 1 1.09 (0.64,1.87) 0.99 (0.57,1.71) 1.19 (0.61,2.29)
Other Conotruncals CMAQ, full population 1 1.09 (0.53,2.25) 0.93 (0.44,2) 0.87 (0.32,2.37)
CMAQ, within 50km of monitor 1 1.08 (0.49,2.39) 1.19 (0.53,2.67) 1.14 (0.41,3.22)
AQS 1 0.84 (0.36,1.97) 1.12 (0.49,2.56) 0.58 (0.18,1.85)
Pulmonary Valve Stenosis CMAQ, full population 1 1.3 (0.78,2.17) 1.07 (0.63,1.82) 1.33 (0.71,2.51)
CMAQ, within 50km of monitor 1 1.64 (0.92,2.95) 1.48 (0.81,2.7) 1.84 (0.92,3.68)
AQS 1 1.24 (0.7,2.21) 0.87 (0.48,1.59) 1.6 (0.81,3.17)
VSD-perimembranous CMAQ, full population 1 1.01 (0.67,1.52) 1.16 (0.76,1.77) 0.89 (0.51,1.56)
CMAQ, within 50km of monitor 1 1.18 (0.76,1.82) 1.25 (0.79,1.97) 0.97 (0.53,1.77)
AQS 1 0.92 (0.58,1.44) 1.09 (0.69,1.73) 0.64 (0.33,1.22)
ASD-all CMAQ, full population 1 0.99 (0.73,1.36) 1.11 (0.78,1.59) 0.79 (0.46,1.35)
CMAQ, within 50km of monitor 1 1.1 (0.79,1.54) 1.07 (0.73,1.57) 0.79 (0.45,1.41)
AQS 1 1.12 (0.76,1.65) 1.05 (0.69,1.58) 0.56 (0.3,1.06)
Defect Groupings
APVR CMAQ, full population 1 1.83 (0.8,4.18) 1.3 (0.56,3.05) 2.09 (0.8,5.45)
CMAQ, within 50km of monitor 1 1.73 (0.79,3.78) 1.08 (0.47,2.48) 1.81 (0.7,4.68)
AQS 1 1.1 (0.49,2.45) 0.78 (0.34,1.8) 1.43 (0.56,3.67)
Conotruncals CMAQ, full population 1 1.16 (0.79,1.69) 1.07 (0.72,1.6) 1.07 (0.65,1.77)
CMAQ, within 50km of monitor 1 1.12 (0.75,1.66) 1.01 (0.66,1.54) 1.18 (0.7,1.99)
AQS 1 1.06 (0.71,1.59) 0.93 (0.61,1.41) 0.86 (0.5,1.48)
Week 2
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Table A3.3 (cont.)
Week 3
Cardiac Defect Source
<10th percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile
>90th 
percentile
Aortic Stenosis CMAQ, full population 1 0.38 (0.21,0.69) 0.33 (0.18,0.64) 0.39 (0.16,0.97)
CMAQ, within 50km of monitor 1 0.26 (0.13,0.49) 0.3 (0.15,0.58) 0.3 (0.11,0.83)
AQS 1 0.47 (0.24,0.92) 0.36 (0.18,0.75) 0.42 (0.15,1.16)
Coarctation of the Aorta CMAQ, full population 1 0.68 (0.39,1.2) 0.72 (0.4,1.3) 0.8 (0.38,1.67)
CMAQ, within 50km of monitor 1 0.69 (0.38,1.24) 0.69 (0.37,1.27) 0.85 (0.4,1.82)
AQS 1 1.03 (0.56,1.91) 0.89 (0.47,1.68) 0.6 (0.25,1.43)
Hypoplastic Left Heart 
Syndrome CMAQ, full population 1 0.74 (0.4,1.37) 0.98 (0.52,1.85) 0.92 (0.41,2.04)
CMAQ, within 50km of monitor 1 0.62 (0.32,1.18) 0.95 (0.49,1.83) 0.81 (0.35,1.88)
AQS 1 1 (0.51,1.98) 0.83 (0.41,1.68) 1.07 (0.47,2.46)
d-TGA CMAQ, full population 1 1.11 (0.6,2.05) 1.09 (0.58,2.06) 1.03 (0.47,2.24)
CMAQ, within 50km of monitor 1 0.99 (0.54,1.81) 0.94 (0.5,1.77) 0.94 (0.43,2.06)
AQS 1 0.77 (0.44,1.36) 0.72 (0.4,1.3) 0.68 (0.31,1.48)
Tetralogy of Fallot CMAQ, full population 1 0.9 (0.55,1.47) 0.85 (0.5,1.42) 0.97 (0.52,1.82)
CMAQ, within 50km of monitor 1 0.91 (0.55,1.53) 0.77 (0.45,1.32) 0.81 (0.42,1.56)
AQS 1 0.78 (0.47,1.29) 0.76 (0.45,1.27) 0.69 (0.35,1.33)
Other Conotruncals CMAQ, full population 1 0.51 (0.25,1.02) 0.61 (0.3,1.25) 0.66 (0.26,1.71)
CMAQ, within 50km of monitor 1 0.86 (0.4,1.85) 0.64 (0.29,1.44) 0.54 (0.19,1.59)
AQS 1 0.52 (0.25,1.12) 0.58 (0.27,1.26) 0.4 (0.13,1.25)
Pulmonary Valve 
Stenosis CMAQ, full population 1 0.72 (0.44,1.18) 0.93 (0.56,1.55) 0.72 (0.37,1.38)
CMAQ, within 50km of monitor 1 0.71 (0.42,1.2) 0.91 (0.53,1.55) 0.73 (0.37,1.44)
AQS 1 0.75 (0.44,1.26) 0.79 (0.46,1.35) 0.62 (0.31,1.26)
VSD-perimembranous CMAQ, full population 1 1.23 (0.79,1.91) 1.17 (0.73,1.87) 0.94 (0.52,1.69)
CMAQ, within 50km of monitor 1 1.07 (0.69,1.68) 0.98 (0.61,1.58) 0.84 (0.46,1.54)
AQS 1 1.3 (0.79,2.12) 1.02 (0.61,1.71) 0.97 (0.52,1.83)
ASD-all CMAQ, full population 1 0.92 (0.66,1.27) 0.94 (0.65,1.38) 1.37 (0.83,2.27)
CMAQ, within 50km of monitor 1 0.74 (0.53,1.03) 0.76 (0.52,1.12) 1.12 (0.66,1.88)
AQS 1 0.82 (0.56,1.2) 0.76 (0.5,1.15) 1.28 (0.75,2.18)
Defect Groupings
APVR CMAQ, full population 1 0.48 (0.25,0.92) 0.61 (0.31,1.2) 0.75 (0.3,1.87)
CMAQ, within 50km of monitor 1 0.47 (0.24,0.93) 0.68 (0.34,1.37) 0.83 (0.33,2.09)
AQS 1 0.62 (0.3,1.29) 0.67 (0.31,1.42) 0.91 (0.36,2.29)
Conotruncals CMAQ, full population 1 0.92 (0.63,1.34) 0.92 (0.61,1.37) 1.01 (0.62,1.66)
CMAQ, within 50km of monitor 1 1 (0.67,1.5) 0.88 (0.58,1.34) 0.91 (0.54,1.53)
AQS 1 0.75 (0.51,1.1) 0.73 (0.49,1.09) 0.66 (0.4,1.11)
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Table A3.3 (cont.)
Week 4
Cardiac Defect Source
<10th 
percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile
>90th 
percentile
Aortic Stenosis CMAQ, full population 1 1.04 (0.52,2.11) 1.09 (0.53,2.26) 1.9 (0.8,4.53)
CMAQ, within 50km of monitor 1 0.93 (0.43,1.98) 1.24 (0.58,2.69) 2.18 (0.88,5.37)
AQS 1 0.89 (0.39,2.03) 1.37 (0.61,3.08) 2.23 (0.88,5.64)
Coarctation of the Aorta CMAQ, full population 1 1.39 (0.73,2.63) 1.24 (0.64,2.4) 1.06 (0.47,2.37)
CMAQ, within 50km of monitor 1 1.54 (0.79,3.01) 1.44 (0.72,2.86) 1.06 (0.45,2.5)
AQS 1 1.44 (0.74,2.83) 1.36 (0.69,2.69) 1.54 (0.68,3.49)
Hypoplastic Left Heart 
Syndrome CMAQ, full population 1 0.99 (0.54,1.83) 1.02 (0.54,1.92) 0.82 (0.36,1.88)
CMAQ, within 50km of monitor 1 1.07 (0.56,2.06) 1.04 (0.53,2.04) 1 (0.43,2.33)
AQS 1 1.48 (0.75,2.92) 0.99 (0.49,2.02) 1.45 (0.63,3.36)
d-TGA CMAQ, full population 1 1.09 (0.61,1.97) 0.97 (0.52,1.79) 1.24 (0.59,2.61)
CMAQ, within 50km of monitor 1 1.08 (0.59,1.96) 1.04 (0.56,1.95) 1.47 (0.69,3.13)
AQS 1 0.94 (0.52,1.7) 1.13 (0.62,2.08) 1.5 (0.71,3.17)
Tetralogy of Fallot CMAQ, full population 1 0.89 (0.55,1.43) 0.91 (0.56,1.5) 0.66 (0.34,1.27)
CMAQ, within 50km of monitor 1 1.16 (0.68,1.96) 1.22 (0.71,2.11) 0.84 (0.42,1.7)
AQS 1 1.15 (0.67,1.97) 1.17 (0.68,2.03) 1.18 (0.61,2.31)
Other Conotruncals CMAQ, full population 1 1.05 (0.47,2.35) 1.65 (0.73,3.73) 1.14 (0.4,3.22)
CMAQ, within 50km of monitor 1 0.86 (0.37,2) 1.69 (0.74,3.87) 1.42 (0.5,4.04)
AQS 1 0.95 (0.41,2.2) 1.11 (0.48,2.57) 0.88 (0.3,2.62)
Pulmonary Valve 
Stenosis CMAQ, full population 1 1.28 (0.75,2.2) 1.36 (0.78,2.37) 0.89 (0.44,1.81)
CMAQ, within 50km of monitor 1 1.22 (0.7,2.1) 1.2 (0.68,2.11) 0.9 (0.44,1.84)
AQS 1 0.98 (0.58,1.68) 1.07 (0.62,1.85) 0.94 (0.47,1.9)
VSD-perimembranous CMAQ, full population 1 0.77 (0.52,1.16) 0.93 (0.6,1.42) 1.23 (0.72,2.09)
CMAQ, within 50km of monitor 1 0.83 (0.54,1.28) 1.02 (0.65,1.61) 1.49 (0.86,2.6)
AQS 1 1.16 (0.72,1.88) 1.3 (0.79,2.12) 1.59 (0.88,2.89)
ASD-all CMAQ, full population 1 1.2 (0.86,1.67) 1.18 (0.8,1.73) 1.04 (0.6,1.79)
CMAQ, within 50km of monitor 1 1.53 (1.07,2.17) 1.38 (0.91,2.08) 1.4 (0.79,2.46)
AQS 1 1.4 (0.94,2.11) 1.21 (0.79,1.87) 1.17 (0.65,2.1)
Defect Groupings
APVR CMAQ, full population 1 1.54 (0.73,3.25) 1.02 (0.46,2.26) 1.09 (0.41,2.94)
CMAQ, within 50km of monitor 1 1.12 (0.56,2.22) 0.8 (0.38,1.68) 0.86 (0.31,2.33)
AQS 1 1.23 (0.55,2.76) 1.41 (0.62,3.2) 1 (0.34,2.95)
Conotruncals CMAQ, full population 1 0.96 (0.66,1.4) 0.99 (0.67,1.46) 0.87 (0.52,1.43)
CMAQ, within 50km of monitor 1 1.05 (0.71,1.57) 1.17 (0.77,1.77) 1.03 (0.61,1.74)
AQS 1 0.99 (0.66,1.48) 1.08 (0.72,1.63) 1.13 (0.68,1.88)
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Table A3.3 (cont.)
Week 5
Cardiac Defect Source
<10th 
percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile >90th percentile
Aortic Stenosis CMAQ, full population 1 0.95 (0.49,1.85) 1.13 (0.57,2.27) 0.91 (0.36,2.34)
CMAQ, within 50km of monitor 1 0.99 (0.47,2.12) 1.4 (0.65,3.03) 0.93 (0.34,2.59)
AQS 1 0.81 (0.36,1.82) 1.31 (0.6,2.85) 0.76 (0.26,2.22)
Coarctation of the Aorta CMAQ, full population 1 1.18 (0.64,2.19) 1.13 (0.6,2.16) 1.58 (0.74,3.35)
CMAQ, within 50km of monitor 1 1.26 (0.66,2.4) 1.15 (0.59,2.24) 1.3 (0.58,2.89)
AQS 1 0.89 (0.49,1.63) 0.72 (0.38,1.34) 1.23 (0.59,2.57)
Hypoplastic Left Heart 
Syndrome CMAQ, full population 1 1.15 (0.61,2.15) 1.18 (0.61,2.26) 1.2 (0.53,2.7)
CMAQ, within 50km of monitor 1 1.02 (0.53,1.94) 1.03 (0.53,2.01) 0.88 (0.37,2.08)
AQS 1 1.09 (0.56,2.1) 0.85 (0.43,1.69) 0.84 (0.35,2.01)
d-TGA CMAQ, full population 1 1.03 (0.59,1.78) 0.67 (0.37,1.21) 1.18 (0.58,2.41)
CMAQ, within 50km of monitor 1 1 (0.58,1.72) 0.71 (0.4,1.28) 0.67 (0.3,1.48)
AQS 1 0.72 (0.41,1.27) 0.78 (0.44,1.38) 0.88 (0.42,1.86)
Tetralogy of Fallot CMAQ, full population 1 1.04 (0.64,1.71) 1.12 (0.67,1.88) 1.19 (0.63,2.25)
CMAQ, within 50km of monitor 1 1.09 (0.64,1.86) 1.27 (0.74,2.2) 1.2 (0.61,2.35)
AQS 1 1.11 (0.64,1.93) 1.1 (0.63,1.93) 0.87 (0.43,1.75)
Other Conotruncals CMAQ, full population 1 1.76 (0.76,4.04) 1.37 (0.58,3.24) 0.9 (0.3,2.69)
CMAQ, within 50km of monitor 1 1.68 (0.72,3.95) 1.24 (0.51,2.98) 0.74 (0.23,2.42)
AQS 1 0.86 (0.39,1.88) 0.57 (0.25,1.31) 0.7 (0.25,1.95)
Pulmonary Valve 
Stenosis CMAQ, full population 1 1.31 (0.77,2.23) 1.17 (0.67,2.03) 1.44 (0.75,2.76)
CMAQ, within 50km of monitor 1 1.34 (0.77,2.32) 1.16 (0.65,2.05) 1.2 (0.61,2.38)
AQS 1 0.81 (0.48,1.36) 0.88 (0.52,1.51) 0.69 (0.34,1.4)
VSD-perimembranous CMAQ, full population 1 0.89 (0.6,1.33) 0.82 (0.54,1.26) 0.82 (0.47,1.41)
CMAQ, within 50km of monitor 1 1.12 (0.73,1.73) 0.85 (0.54,1.35) 0.81 (0.45,1.48)
AQS 1 1 (0.64,1.55) 0.67 (0.42,1.07) 0.8 (0.44,1.45)
ASD-all CMAQ, full population 1 1.1 (0.8,1.53) 1 (0.68,1.47) 1.16 (0.7,1.94)
CMAQ, within 50km of monitor 1 1.01 (0.72,1.41) 0.9 (0.6,1.34) 0.93 (0.53,1.61)
AQS 1 0.92 (0.62,1.37) 0.94 (0.62,1.44) 0.98 (0.55,1.74)
Defect Groupings
APVR CMAQ, full population 1 1.72 (0.71,4.17) 1.82 (0.75,4.42) 1.54 (0.54,4.38)
CMAQ, within 50km of monitor 1 1.72 (0.71,4.16) 1.58 (0.64,3.86) 1.19 (0.41,3.48)
AQS 1 1.11 (0.42,2.96) 1.13 (0.43,2.99) 0.91 (0.3,2.76)
Conotruncals CMAQ, full population 1 1.08 (0.75,1.57) 0.94 (0.64,1.4) 1.11 (0.68,1.81)
CMAQ, within 50km of monitor 1 1.06 (0.72,1.56) 0.98 (0.65,1.47) 0.88 (0.52,1.48)
AQS 1 0.95 (0.65,1.41) 0.93 (0.62,1.38) 0.89 (0.53,1.47)
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Table A3.3 (cont.)
Week 6
Cardiac Defect Source
<10th 
percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile >90th percentile
Aortic Stenosis CMAQ, full population 1 0.88 (0.46,1.66) 0.88 (0.44,1.74) 0.43 (0.14,1.3)
CMAQ, within 50km of monitor 1 0.92 (0.46,1.84) 0.85 (0.4,1.8) 0.41 (0.12,1.45)
AQS 1 1.83 (0.78,4.29) 1.29 (0.54,3.1) 0.82 (0.26,2.67)
Coarctation of the Aorta CMAQ, full population 1 0.97 (0.53,1.74) 0.86 (0.46,1.59) 1.07 (0.51,2.24)
CMAQ, within 50km of monitor 1 1.15 (0.6,2.2) 1.13 (0.58,2.19) 1.24 (0.56,2.74)
AQS 1 1.44 (0.7,2.97) 1.51 (0.73,3.12) 2.17 (0.95,4.93)
Hypoplastic Left Heart 
Syndrome CMAQ, full population 1 1.25 (0.66,2.38) 1.02 (0.52,2.01) 1.02 (0.45,2.33)
CMAQ, within 50km of monitor 1 1.31 (0.65,2.62) 1.01 (0.49,2.08) 1.08 (0.46,2.57)
AQS 1 1.88 (0.83,4.24) 1.52 (0.67,3.44) 1.75 (0.69,4.45)
d-TGA CMAQ, full population 1 0.95 (0.53,1.69) 0.99 (0.54,1.79) 0.93 (0.44,1.98)
CMAQ, within 50km of monitor 1 0.86 (0.48,1.55) 1.04 (0.57,1.9) 1.05 (0.49,2.25)
AQS 1 0.97 (0.53,1.78) 1.15 (0.62,2.15) 1.32 (0.62,2.84)
Tetralogy of Fallot CMAQ, full population 1 0.75 (0.47,1.2) 0.93 (0.57,1.52) 0.51 (0.26,0.99)
CMAQ, within 50km of monitor 1 0.72 (0.44,1.2) 1.01 (0.61,1.68) 0.55 (0.28,1.1)
AQS 1 1.3 (0.74,2.29) 1.25 (0.71,2.22) 1.11 (0.55,2.23)
Other Conotruncals CMAQ, full population 1 1.22 (0.56,2.69) 0.99 (0.43,2.25) 0.98 (0.36,2.66)
CMAQ, within 50km of monitor 1 0.97 (0.43,2.21) 1.03 (0.45,2.38) 0.89 (0.31,2.52)
AQS 1 1.23 (0.49,3.08) 0.92 (0.36,2.31) 1.36 (0.49,3.81)
Pulmonary Valve 
Stenosis CMAQ, full population 1 1 (0.6,1.66) 1 (0.59,1.7) 0.94 (0.49,1.8)
CMAQ, within 50km of monitor 1 0.97 (0.57,1.64) 1.05 (0.61,1.81) 0.79 (0.4,1.58)
AQS 1 1 (0.58,1.74) 1.21 (0.69,2.12) 0.84 (0.4,1.75)
VSD-perimembranous CMAQ, full population 1 1.1 (0.73,1.67) 0.94 (0.6,1.46) 0.78 (0.44,1.39)
CMAQ, within 50km of monitor 1 1.08 (0.7,1.67) 0.95 (0.59,1.51) 0.81 (0.44,1.48)
AQS 1 1.27 (0.79,2.06) 1.29 (0.79,2.12) 1.02 (0.54,1.94)
ASD-all CMAQ, full population 1 1.04 (0.75,1.44) 1.01 (0.69,1.48) 0.71 (0.41,1.23)
CMAQ, within 50km of monitor 1 1.03 (0.73,1.45) 0.88 (0.59,1.32) 0.64 (0.35,1.14)
AQS 1 1.08 (0.73,1.59) 0.94 (0.62,1.43) 0.79 (0.44,1.43)
Defect Groupings
APVR CMAQ, full population 1 1.24 (0.59,2.59) 0.75 (0.34,1.66) 1.27 (0.5,3.22)
CMAQ, within 50km of monitor 1 0.98 (0.49,1.96) 0.63 (0.29,1.35) 1.01 (0.4,2.55)
AQS 1 0.75 (0.38,1.47) 0.47 (0.22,1.01) 0.62 (0.22,1.74)
Conotruncals CMAQ, full population 1 0.91 (0.63,1.31) 1 (0.68,1.47) 0.72 (0.43,1.18)
CMAQ, within 50km of monitor 1 0.82 (0.56,1.2) 1.06 (0.71,1.57) 0.75 (0.45,1.26)
AQS 1 1.23 (0.81,1.87) 1.23 (0.8,1.89) 1.3 (0.77,2.19)
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Table A3.3 (cont.)
Week 7
Cardiac Defect Source
<10th 
percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile >90th percentile
Aortic Stenosis CMAQ, full population 1 0.87 (0.47,1.64) 0.63 (0.32,1.27) 1.05 (0.44,2.51)
CMAQ, within 50km of monitor 1 0.62 (0.32,1.19) 0.57 (0.28,1.15) 0.69 (0.26,1.84)
AQS 1 1.11 (0.53,2.34) 0.8 (0.36,1.76) 1.07 (0.39,2.93)
Coarctation of the Aorta CMAQ, full population 1 1.26 (0.67,2.38) 1.26 (0.65,2.42) 1.54 (0.71,3.33)
CMAQ, within 50km of monitor 1 0.76 (0.42,1.37) 0.89 (0.48,1.63) 1.16 (0.55,2.46)
AQS 1 1.75 (0.88,3.5) 1.33 (0.66,2.71) 1.48 (0.64,3.45)
Hypoplastic Left Heart 
Syndrome CMAQ, full population 1 0.85 (0.47,1.55) 0.96 (0.52,1.79) 0.99 (0.45,2.19)
CMAQ, within 50km of monitor 1 0.65 (0.35,1.21) 0.9 (0.48,1.69) 1.02 (0.45,2.27)
AQS 1 1.14 (0.56,2.33) 1.42 (0.69,2.89) 1.7 (0.73,3.99)
d-TGA CMAQ, full population 1 1.52 (0.77,2.99) 1.62 (0.82,3.23) 1.75 (0.78,3.93)
CMAQ, within 50km of monitor 1 1.47 (0.74,2.9) 1.41 (0.7,2.83) 1.29 (0.56,2.99)
AQS 1 1.09 (0.6,1.99) 1.19 (0.64,2.2) 0.97 (0.43,2.21)
Tetralogy of Fallot CMAQ, full population 1 0.96 (0.6,1.55) 0.85 (0.51,1.41) 1.42 (0.78,2.59)
CMAQ, within 50km of monitor 1 1.04 (0.62,1.74) 0.87 (0.51,1.51) 1.39 (0.74,2.62)
AQS 1 1.21 (0.68,2.16) 1.5 (0.84,2.68) 1.74 (0.89,3.41)
Other Conotruncals CMAQ, full population 1 1.53 (0.67,3.5) 0.98 (0.41,2.33) 1.67 (0.62,4.46)
CMAQ, within 50km of monitor 1 1.45 (0.59,3.57) 0.76 (0.3,1.95) 1.62 (0.58,4.49)
AQS 1 1.19 (0.44,3.23) 0.95 (0.35,2.55) 1.53 (0.52,4.47)
Pulmonary Valve 
Stenosis CMAQ, full population 1 1.06 (0.65,1.74) 0.93 (0.55,1.57) 0.92 (0.48,1.76)
CMAQ, within 50km of monitor 1 0.81 (0.5,1.33) 0.72 (0.43,1.21) 0.78 (0.4,1.49)
AQS 1 1 (0.59,1.71) 0.86 (0.49,1.51) 1.31 (0.68,2.54)
VSD-perimembranous CMAQ, full population 1 1.16 (0.77,1.76) 1.04 (0.67,1.62) 0.98 (0.56,1.73)
CMAQ, within 50km of monitor 1 0.95 (0.62,1.46) 0.91 (0.58,1.43) 0.85 (0.47,1.54)
AQS 1 1.38 (0.86,2.22) 1.07 (0.65,1.76) 1.1 (0.59,2.06)
ASD-all CMAQ, full population 1 1.01 (0.74,1.39) 0.94 (0.65,1.36) 0.95 (0.56,1.62)
CMAQ, within 50km of monitor 1 0.84 (0.61,1.16) 0.74 (0.5,1.08) 0.87 (0.5,1.52)
AQS 1 1.3 (0.86,1.97) 1.13 (0.73,1.75) 1.17 (0.64,2.12)
Defect Groupings
APVR CMAQ, full population 1 2.37 (0.98,5.75) 1.53 (0.62,3.76) 1.1 (0.36,3.39)
CMAQ, within 50km of monitor 1 1.61 (0.74,3.53) 1.09 (0.48,2.48) 0.85 (0.29,2.51)
AQS 1 1.17 (0.57,2.39) 0.7 (0.32,1.55) 0.7 (0.23,2.19)
Conotruncals CMAQ, full population 1 1.25 (0.85,1.85) 1.15 (0.76,1.73) 1.72 (1.05,2.79)
CMAQ, within 50km of monitor 1 1.43 (0.94,2.17) 1.2 (0.77,1.86) 1.72 (1.03,2.89)
AQS 1 1.27 (0.82,1.94) 1.44 (0.93,2.22) 1.56 (0.92,2.62)
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Table A3.3 (cont.)
Week 8
Cardiac Defect Source
<10th 
percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile >90th percentile
Aortic Stenosis CMAQ, full population 1 1.13 (0.56,2.27) 1.65 (0.81,3.36) 0.81 (0.28,2.3)
CMAQ, within 50km of monitor 1 1.23 (0.58,2.59) 1.57 (0.73,3.38) 0.78 (0.25,2.44)
AQS 1 1.83 (0.74,4.54) 1.83 (0.74,4.56) 1.26 (0.41,3.86)
Coarctation of the Aorta CMAQ, full population 1 1.4 (0.74,2.64) 1.29 (0.67,2.47) 1.51 (0.7,3.27)
CMAQ, within 50km of monitor 1 1.24 (0.66,2.32) 1.24 (0.65,2.36) 1.49 (0.69,3.21)
AQS 1 1.72 (0.86,3.44) 1.51 (0.74,3.06) 2.2 (0.98,4.91)
Hypoplastic Left Heart 
Syndrome CMAQ, full population 1 1.01 (0.55,1.83) 1.03 (0.55,1.93) 1.29 (0.6,2.77)
CMAQ, within 50km of monitor 1 1.63 (0.79,3.37) 1.32 (0.63,2.78) 1.76 (0.75,4.12)
AQS 1 1.85 (0.85,4.01) 2.05 (0.95,4.44) 1.63 (0.64,4.15)
d-TGA CMAQ, full population 1 1.28 (0.7,2.32) 1.22 (0.66,2.27) 1.03 (0.47,2.24)
CMAQ, within 50km of monitor 1 1.07 (0.6,1.91) 1.11 (0.61,2.02) 1.05 (0.49,2.26)
AQS 1 1.48 (0.79,2.76) 1.21 (0.63,2.32) 1.36 (0.62,2.99)
Tetralogy of Fallot CMAQ, full population 1 1.17 (0.71,1.94) 1.21 (0.72,2.03) 1.65 (0.89,3.04)
CMAQ, within 50km of monitor 1 1.07 (0.64,1.8) 1.13 (0.66,1.92) 1.76 (0.94,3.28)
AQS 1 1.48 (0.81,2.72) 2 (1.09,3.67) 1.86 (0.92,3.76)
Other Conotruncals CMAQ, full population 1 1.05 (0.51,2.19) 0.93 (0.43,2.01) 1.28 (0.5,3.31)
CMAQ, within 50km of monitor 1 1.55 (0.63,3.82) 1.35 (0.54,3.36) 1.94 (0.69,5.45)
AQS 1 0.7 (0.31,1.54) 0.99 (0.46,2.17) 0.98 (0.35,2.69)
Pulmonary Valve 
Stenosis CMAQ, full population 1 1.16 (0.67,2) 1.85 (1.06,3.21) 1.9 (0.99,3.63)
CMAQ, within 50km of monitor 1 1.34 (0.74,2.43) 2 (1.1,3.64) 2.31 (1.16,4.61)
AQS 1 1.58 (0.85,2.9) 1.68 (0.9,3.12) 1.72 (0.83,3.55)
VSD-perimembranous CMAQ, full population 1 0.88 (0.59,1.33) 1.21 (0.79,1.85) 1.1 (0.64,1.89)
CMAQ, within 50km of monitor 1 1.19 (0.75,1.87) 1.46 (0.91,2.35) 1.17 (0.64,2.15)
AQS 1 1.21 (0.75,1.95) 1.43 (0.88,2.31) 1.29 (0.7,2.37)
ASD-all CMAQ, full population 1 1.07 (0.78,1.48) 1.01 (0.7,1.46) 1.15 (0.69,1.91)
CMAQ, within 50km of monitor 1 0.92 (0.66,1.28) 0.94 (0.64,1.37) 0.98 (0.57,1.68)
AQS 1 0.91 (0.62,1.33) 1.02 (0.68,1.53) 0.99 (0.57,1.73)
Defect Groupings
APVR CMAQ, full population 1 1.75 (0.8,3.82) 1.48 (0.66,3.31) 1.27 (0.45,3.55)
CMAQ, within 50km of monitor 1 1.19 (0.59,2.39) 1.04 (0.5,2.19) 1.08 (0.4,2.91)
AQS 1 1.32 (0.61,2.84) 0.99 (0.44,2.24) 1.39 (0.52,3.7)
Conotruncals CMAQ, full population 1 1.12 (0.77,1.63) 1.08 (0.73,1.61) 1.27 (0.79,2.05)
CMAQ, within 50km of monitor 1 1.05 (0.7,1.56) 1.06 (0.7,1.6) 1.39 (0.85,2.27)
AQS 1 1.19 (0.78,1.82) 1.37 (0.89,2.12) 1.33 (0.79,2.23)
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Defect Grouping Source
<10th 
percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile >90th percentile
LVOTO CMAQ, full population 1 1.45 (0.94,2.24) 1.37 (0.86,2.17) 1.24 (0.69,2.21)
CMAQ, within 50km of monitor 1 1.43 (0.9,2.27) 1.36 (0.84,2.21) 1.11 (0.59,2.07)
AQS 1 1.18 (0.73,1.89) 1.19 (0.73,1.95) 1 (0.53,1.88)
RVOTO CMAQ, full population 1 1.3 (0.83,2.03) 1.16 (0.72,1.86) 1.47 (0.83,2.59)
CMAQ, within 50km of monitor 1 1.39 (0.85,2.26) 1.4 (0.84,2.33) 1.74 (0.95,3.2)
AQS 1 1.43 (0.86,2.36) 0.86 (0.51,1.48) 1.49 (0.8,2.78)
Septals CMAQ, full population 1 0.97 (0.74,1.26) 1.08 (0.81,1.45) 0.79 (0.52,1.19)
CMAQ, within 50km of monitor 1 1.08 (0.81,1.43) 1.08 (0.79,1.48) 0.8 (0.51,1.26)
AQS 1 1 (0.73,1.36) 1.03 (0.74,1.43) 0.57 (0.35,0.93)
Week 3
LVOTO CMAQ, full population 1 0.56 (0.38,0.82) 0.62 (0.41,0.93) 0.67 (0.4,1.13)
CMAQ, within 50km of monitor 1 0.47 (0.31,0.71) 0.58 (0.38,0.89) 0.6 (0.35,1.04)
AQS 1 0.82 (0.54,1.26) 0.69 (0.44,1.08) 0.66 (0.37,1.18)
RVOTO CMAQ, full population 1 0.76 (0.49,1.16) 0.87 (0.56,1.35) 0.7 (0.39,1.24)
CMAQ, within 50km of monitor 1 0.69 (0.45,1.08) 0.79 (0.5,1.25) 0.66 (0.36,1.19)
AQS 1 0.87 (0.55,1.39) 0.88 (0.55,1.42) 0.71 (0.38,1.33)
Septals CMAQ, full population 1 1.08 (0.82,1.43) 1.06 (0.77,1.45) 1.2 (0.81,1.79)
CMAQ, within 50km of monitor 1 0.9 (0.67,1.19) 0.87 (0.63,1.19) 1 (0.66,1.52)
AQS 1 1.05 (0.76,1.44) 0.9 (0.64,1.26) 1.21 (0.79,1.86)
Week 4
LVOTO CMAQ, full population 1 1.22 (0.8,1.86) 1.19 (0.76,1.86) 1.17 (0.67,2.04)
CMAQ, within 50km of monitor 1 1.26 (0.8,1.99) 1.27 (0.79,2.03) 1.25 (0.7,2.23)
AQS 1 1.3 (0.81,2.08) 1.19 (0.73,1.93) 1.61 (0.91,2.86)
RVOTO CMAQ, full population 1 1.3 (0.83,2.04) 1.29 (0.8,2.06) 0.76 (0.41,1.4)
CMAQ, within 50km of monitor 1 1.39 (0.86,2.23) 1.26 (0.77,2.07) 0.83 (0.44,1.56)
AQS 1 0.98 (0.63,1.53) 0.94 (0.59,1.5) 0.8 (0.44,1.47)
Septals CMAQ, full population 1 1.01 (0.77,1.33) 1.1 (0.81,1.49) 1.23 (0.83,1.83)
CMAQ, within 50km of monitor 1 1.17 (0.88,1.57) 1.24 (0.9,1.72) 1.56 (1.03,2.36)
AQS 1 1.25 (0.9,1.73) 1.22 (0.87,1.71) 1.31 (0.84,2.02)
Table A3.3 (cont.)
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Table A3.3 (cont.)
Week 5
Cardiac Defect Source
<10th 
percentile 
(Referent)
10th percentile 
to median
median to 90th 
percentile >90th percentile
LVOTO CMAQ, full population 1 1.1 (0.73,1.67) 1.16 (0.75,1.79) 1.27 (0.74,2.17)
CMAQ, within 50km of monitor 1 1.15 (0.74,1.78) 1.2 (0.76,1.9) 1.12 (0.62,2)
AQS 1 0.99 (0.64,1.53) 0.93 (0.59,1.46) 1.05 (0.6,1.85)
RVOTO CMAQ, full population 1 1.08 (0.7,1.66) 0.99 (0.63,1.56) 1.28 (0.74,2.21)
CMAQ, within 50km of monitor 1 1.24 (0.79,1.96) 1.09 (0.68,1.76) 1.29 (0.73,2.3)
AQS 1 0.99 (0.62,1.57) 1.14 (0.71,1.82) 0.98 (0.54,1.8)
Septals CMAQ, full population 1 1.01 (0.77,1.32) 0.91 (0.67,1.23) 0.94 (0.64,1.4)
CMAQ, within 50km of monitor 1 1.02 (0.77,1.34) 0.83 (0.6,1.13) 0.81 (0.53,1.24)
AQS 1 1 (0.73,1.36) 0.84 (0.6,1.17) 0.96 (0.62,1.47)
Week 6
LVOTO CMAQ, full population 1 1.09 (0.73,1.64) 0.96 (0.63,1.48) 0.94 (0.55,1.62)
CMAQ, within 50km of monitor 1 1.26 (0.81,1.96) 1.12 (0.7,1.78) 1.07 (0.6,1.91)
AQS 1 1.89 (1.11,3.22) 1.66 (0.96,2.87) 1.94 (1.04,3.65)
RVOTO CMAQ, full population 1 1.13 (0.73,1.74) 1.09 (0.69,1.71) 1.01 (0.57,1.78)
CMAQ, within 50km of monitor 1 1.12 (0.71,1.75) 1.11 (0.7,1.78) 0.89 (0.49,1.62)
AQS 1 0.86 (0.55,1.35) 1.04 (0.65,1.64) 0.75 (0.4,1.4)
Septals CMAQ, full population 1 1.08 (0.82,1.41) 0.98 (0.72,1.32) 0.77 (0.51,1.16)
CMAQ, within 50km of monitor 1 1.06 (0.8,1.4) 0.91 (0.67,1.25) 0.74 (0.48,1.14)
AQS 1 1.15 (0.84,1.57) 1.07 (0.77,1.5) 0.89 (0.56,1.39)
Week 7
LVOTO CMAQ, full population 1 0.94 (0.63,1.41) 0.91 (0.6,1.39) 1.11 (0.66,1.89)
CMAQ, within 50km of monitor 1 0.64 (0.43,0.95) 0.76 (0.5,1.15) 0.92 (0.54,1.58)
AQS 1 1.32 (0.82,2.1) 1.18 (0.73,1.92) 1.37 (0.76,2.47)
RVOTO CMAQ, full population 1 0.95 (0.63,1.43) 0.8 (0.52,1.24) 0.85 (0.49,1.46)
CMAQ, within 50km of monitor 1 0.81 (0.54,1.22) 0.67 (0.44,1.04) 0.79 (0.45,1.38)
AQS 1 0.97 (0.62,1.52) 0.83 (0.52,1.32) 1.26 (0.72,2.22)
Septals CMAQ, full population 1 1.02 (0.78,1.33) 0.95 (0.7,1.27) 0.92 (0.62,1.38)
CMAQ, within 50km of monitor 1 0.87 (0.66,1.14) 0.82 (0.6,1.11) 0.85 (0.56,1.3)
AQS 1 1.28 (0.93,1.78) 1.08 (0.76,1.52) 1.08 (0.69,1.7)
Week 8
LVOTO CMAQ, full population 1 1.16 (0.77,1.76) 1.21 (0.79,1.87) 1.2 (0.7,2.07)
CMAQ, within 50km of monitor 1 1.36 (0.86,2.15) 1.31 (0.82,2.1) 1.35 (0.76,2.4)
AQS 1 1.71 (1.03,2.85) 1.64 (0.98,2.76) 1.65 (0.89,3.06)
RVOTO CMAQ, full population 1 1.12 (0.71,1.76) 1.6 (1.01,2.54) 1.67 (0.96,2.91)
CMAQ, within 50km of monitor 1 1.27 (0.78,2.07) 1.62 (0.98,2.65) 1.91 (1.07,3.41)
AQS 1 1.14 (0.71,1.83) 1.2 (0.74,1.96) 1.36 (0.76,2.45)
Septals CMAQ, full population 1 0.98 (0.75,1.28) 1.06 (0.79,1.42) 1.05 (0.71,1.55)
CMAQ, within 50km of monitor 1 0.94 (0.71,1.25) 1.03 (0.76,1.39) 0.9 (0.6,1.37)
AQS 1 0.93 (0.68,1.27) 1.06 (0.76,1.46) 0.95 (0.62,1.46)
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Table A3.4: Odds Ratios and 95% Confidence Intervals resulting from hierarchical analysis between cardiac birth defects 
and weekly exposure to ozone 
 
Cardiac Defect Source
<25th 
percentile 
(referent)
25th percetile to 
median
median to 75th 
percentile > 75th percentile
Aortic Stenosis CMAQ, full population 1 1.08 (0.58,2.01) 0.86 (0.42,1.78) 1.06 (0.49,2.29)
CMAQ, within 50km of monitor 1 0.96 (0.44,2.1) 0.8 (0.35,1.86) 1.24 (0.53,2.91)
AQS 1 0.79 (0.35,1.81) 0.56 (0.22,1.41) 1.12 (0.46,2.74)
Coarctation of the Aorta CMAQ, full population 1 0.62 (0.37,1.05) 0.61 (0.33,1.14) 0.65 (0.34,1.25)
CMAQ, within 50km of monitor 1 0.88 (0.47,1.64) 0.69 (0.34,1.4) 0.78 (0.38,1.61)
AQS 1 0.46 (0.22,0.97) 0.67 (0.32,1.39) 0.75 (0.35,1.62)
Hypoplastic Left Heart 
Syndrome CMAQ, full population 1 0.8 (0.46,1.41) 0.65 (0.34,1.26) 1.02 (0.52,2)
CMAQ, within 50km of monitor 1 0.87 (0.47,1.62) 0.66 (0.33,1.32) 0.82 (0.4,1.68)
AQS 1 0.54 (0.27,1.06) 0.58 (0.29,1.2) 0.64 (0.3,1.36)
d-TGA CMAQ, full population 1 1.08 (0.65,1.78) 0.8 (0.43,1.49) 1.28 (0.67,2.42)
CMAQ, within 50km of monitor 1 1.21 (0.68,2.15) 0.68 (0.34,1.36) 1.1 (0.55,2.2)
AQS 1 0.9 (0.47,1.72) 0.65 (0.31,1.37) 0.79 (0.37,1.7)
Tetralogy of Fallot CMAQ, full population 1 1.03 (0.68,1.57) 1.26 (0.77,2.05) 1.07 (0.63,1.83)
CMAQ, within 50km of monitor 1 1.03 (0.63,1.69) 0.88 (0.51,1.54) 0.91 (0.5,1.63)
AQS 1 0.96 (0.56,1.66) 0.73 (0.39,1.34) 0.75 (0.39,1.44)
Other Conotruncals CMAQ, full population 1 1.13 (0.58,2.23) 0.53 (0.23,1.22) 0.84 (0.37,1.92)
CMAQ, within 50km of monitor 1 1.09 (0.5,2.37) 0.45 (0.16,1.27) 0.93 (0.37,2.31)
AQS 1 1.02 (0.45,2.32) 0.34 (0.11,1.06) 0.87 (0.33,2.3)
Pulmonary Valve Stenosis CMAQ, full population 1 0.88 (0.57,1.35) 0.73 (0.44,1.21) 0.56 (0.33,0.97)
CMAQ, within 50km of monitor 1 0.82 (0.48,1.4) 0.59 (0.32,1.07) 0.66 (0.35,1.22)
AQS 1 0.8 (0.44,1.42) 0.43 (0.22,0.84) 0.43 (0.22,0.85)
VSD-perimembranous CMAQ, full population 1 0.78 (0.55,1.1) 0.68 (0.44,1.03) 0.67 (0.42,1.05)
CMAQ, within 50km of monitor 1 0.76 (0.45,1.28) 0.67 (0.38,1.19) 0.81 (0.45,1.47)
AQS 1 0.87 (0.56,1.34) 0.67 (0.41,1.11) 0.85 (0.5,1.42)
ASD-all CMAQ, full population 1 0.97 (0.72,1.32) 0.77 (0.53,1.11) 0.73 (0.49,1.11)
CMAQ, within 50km of monitor 1 1.08 (0.75,1.54) 0.76 (0.5,1.17) 0.68 (0.42,1.1)
AQS 1 1.2 (0.81,1.78) 0.74 (0.47,1.18) 0.58 (0.34,0.98)
Defect Groupings
APVR CMAQ, full population 1 0.77 (0.38,1.54) 0.79 (0.36,1.7) 1.28 (0.59,2.78)
CMAQ, within 50km of monitor 1 0.77 (0.35,1.69) 1.14 (0.52,2.48) 1.23 (0.54,2.84)
AQS 1 0.8 (0.36,1.79) 0.53 (0.21,1.33) 0.93 (0.38,2.25)
Conotruncals CMAQ, full population 1 1.12 (0.81,1.55) 1.04 (0.7,1.55) 1.18 (0.77,1.81)
CMAQ, within 50km of monitor 1 1.12 (0.77,1.65) 0.77 (0.49,1.22) 1 (0.62,1.61)
AQS 1 1.04 (0.68,1.58) 0.7 (0.42,1.15) 0.86 (0.51,1.45)
Week 2
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Table A3.4 (cont.)
Week 3
Cardiac Defect Source
<25th percentile 
(referent)
25th percetile 
to median
median to 75th 
percentile
> 75th 
percentile
Aortic Stenosis CMAQ, full population 1 1.35 (0.71,2.54) 0.88 (0.41,1.89) 1.01 (0.45,2.28)
CMAQ, within 50km of monitor 1 0.98 (0.45,2.15) 1.49 (0.65,3.38) 0.84 (0.32,2.17)
AQS 1 1.24 (0.53,2.89) 1.82 (0.76,4.39) 1.62 (0.62,4.25)
Coarctation of the Aorta CMAQ, full population 1 0.8 (0.47,1.38) 0.83 (0.43,1.59) 0.85 (0.42,1.72)
CMAQ, within 50km of monitor 1 0.89 (0.45,1.74) 1.58 (0.79,3.18) 1.27 (0.58,2.76)
AQS 1 1.63 (0.81,3.28) 1.49 (0.69,3.25) 1.16 (0.5,2.68)
Hypoplastic Left Heart 
Syndrome CMAQ, full population 1 0.8 (0.44,1.46) 1.03 (0.53,2.01) 0.79 (0.38,1.66)
CMAQ, within 50km of monitor 1 1.59 (0.85,2.98) 1.14 (0.56,2.34) 0.87 (0.39,1.91)
AQS 1 1.59 (0.81,3.13) 1.23 (0.58,2.63) 1.07 (0.48,2.4)
d-TGA CMAQ, full population 1 1.05 (0.62,1.77) 0.82 (0.43,1.57) 0.9 (0.45,1.8)
CMAQ, within 50km of monitor 1 1.6 (0.87,2.93) 1.33 (0.66,2.66) 1.29 (0.61,2.75)
AQS 1 1.58 (0.82,3.03) 1.2 (0.57,2.52) 1.09 (0.49,2.43)
Tetralogy of Fallot CMAQ, full population 1 0.69 (0.44,1.08) 1.03 (0.62,1.73) 1.01 (0.57,1.79)
CMAQ, within 50km of monitor 1 0.92 (0.55,1.55) 1.31 (0.74,2.31) 1.25 (0.67,2.33)
AQS 1 1.48 (0.83,2.61) 1.5 (0.79,2.82) 1.49 (0.75,2.96)
Other Conotruncals CMAQ, full population 1 0.67 (0.32,1.42) 1.19 (0.55,2.56) 0.69 (0.28,1.68)
CMAQ, within 50km of monitor 1 0.92 (0.39,2.15) 1.79 (0.77,4.17) 0.81 (0.29,2.26)
AQS 1 0.95 (0.38,2.36) 1.96 (0.81,4.71) 0.95 (0.33,2.72)
Pulmonary Valve 
Stenosis CMAQ, full population 1 0.83 (0.52,1.34) 1.2 (0.7,2.05) 1.21 (0.68,2.17)
CMAQ, within 50km of monitor 1 1.13 (0.64,2) 1.59 (0.86,2.97) 1.53 (0.79,2.98)
AQS 1 1.87 (0.99,3.55) 2.04 (1.01,4.11) 2.22 (1.06,4.67)
VSD-perimembranous CMAQ, full population 1 0.95 (0.66,1.39) 1.15 (0.73,1.81) 1.11 (0.67,1.83)
CMAQ, within 50km of monitor 1 1.6 (0.94,2.75) 1.78 (0.98,3.23) 1.44 (0.76,2.74)
AQS 1 1.46 (0.93,2.29) 1.52 (0.91,2.55) 1.21 (0.68,2.15)
ASD-all CMAQ, full population 1 0.95 (0.68,1.31) 0.93 (0.63,1.38) 0.97 (0.62,1.52)
CMAQ, within 50km of monitor 1 1.19 (0.82,1.73) 1.21 (0.77,1.89) 1.11 (0.67,1.85)
AQS 1 1.14 (0.76,1.72) 1.19 (0.74,1.93) 1.34 (0.78,2.29)
Defect Groupings
APVR CMAQ, full population 1 1.47 (0.74,2.93) 0.99 (0.45,2.21) 0.88 (0.38,2.04)
CMAQ, within 50km of monitor 1 1.35 (0.64,2.86) 1.22 (0.54,2.76) 0.84 (0.34,2.07)
AQS 1 1.23 (0.55,2.74) 1.4 (0.6,3.29) 0.94 (0.36,2.46)
Conotruncals CMAQ, full population 1 0.78 (0.55,1.1) 0.96 (0.63,1.46) 0.92 (0.58,1.45)
CMAQ, within 50km of monitor 1 1.08 (0.72,1.62) 1.32 (0.84,2.08) 1.16 (0.71,1.91)
AQS 1 1.3 (0.83,2.04) 1.3 (0.78,2.14) 1.11 (0.65,1.91)
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Table A3.4 (cont.)
Week 4
Cardiac Defect Source
<25th 
percentile 
(referent)
25th percetile 
to median
median to 75th 
percentile
> 75th 
percentile
Aortic Stenosis CMAQ, full population 1 1.1 (0.57,2.13) 1.41 (0.66,2.98) 1.55 (0.67,3.6)
CMAQ, within 50km of monitor 1 0.93 (0.43,2.03) 0.82 (0.34,1.94) 0.94 (0.37,2.38)
AQS 1 0.87 (0.38,1.98) 0.81 (0.32,2.02) 1.08 (0.42,2.8)
Coarctation of the Aorta CMAQ, full population 1 1.4 (0.82,2.39) 1.07 (0.54,2.1) 0.9 (0.43,1.89)
CMAQ, within 50km of monitor 1 0.69 (0.37,1.3) 0.61 (0.3,1.24) 0.43 (0.2,0.94)
AQS 1 0.75 (0.37,1.52) 0.96 (0.45,2.02) 0.5 (0.22,1.15)
Hypoplastic Left Heart 
Syndrome CMAQ, full population 1 1.16 (0.64,2.09) 0.92 (0.46,1.83) 1 (0.48,2.1)
CMAQ, within 50km of monitor 1 0.83 (0.44,1.57) 0.53 (0.25,1.11) 0.96 (0.45,2.05)
AQS 1 0.76 (0.38,1.51) 0.83 (0.39,1.74) 0.93 (0.42,2.06)
d-TGA CMAQ, full population 1 1.15 (0.67,1.96) 1.25 (0.65,2.41) 1.34 (0.65,2.75)
CMAQ, within 50km of monitor 1 0.85 (0.47,1.56) 0.78 (0.39,1.56) 0.84 (0.4,1.79)
AQS 1 0.47 (0.23,0.95) 1.03 (0.51,2.06) 0.91 (0.41,2)
Tetralogy of Fallot CMAQ, full population 1 1.51 (0.98,2.35) 1.17 (0.67,2.04) 0.96 (0.53,1.77)
CMAQ, within 50km of monitor 1 1.11 (0.66,1.84) 0.76 (0.42,1.39) 0.65 (0.34,1.24)
AQS 1 1.24 (0.71,2.18) 0.79 (0.41,1.53) 0.8 (0.4,1.6)
Other Conotruncals CMAQ, full population 1 0.94 (0.44,2.01) 1.78 (0.79,4.02) 1.81 (0.73,4.48)
CMAQ, within 50km of monitor 1 0.77 (0.33,1.79) 0.86 (0.35,2.15) 1.15 (0.44,3.02)
AQS 1 0.97 (0.42,2.27) 0.56 (0.19,1.62) 1.18 (0.43,3.24)
Pulmonary Valve 
Stenosis CMAQ, full population 1 1.41 (0.88,2.27) 1.33 (0.75,2.36) 1.54 (0.83,2.83)
CMAQ, within 50km of monitor 1 0.78 (0.44,1.36) 0.69 (0.36,1.29) 0.65 (0.33,1.28)
AQS 1 0.75 (0.4,1.42) 0.75 (0.37,1.5) 1.11 (0.54,2.28)
VSD-perimembranous CMAQ, full population 1 1.16 (0.8,1.69) 1.1 (0.68,1.77) 1.26 (0.75,2.12)
CMAQ, within 50km of monitor 1 0.92 (0.54,1.58) 1.08 (0.59,1.98) 1.16 (0.61,2.2)
AQS 1 0.92 (0.58,1.45) 0.89 (0.52,1.53) 0.96 (0.54,1.72)
ASD-all CMAQ, full population 1 1.03 (0.74,1.44) 1.09 (0.72,1.64) 1.23 (0.78,1.95)
CMAQ, within 50km of monitor 1 0.75 (0.51,1.08) 0.76 (0.49,1.18) 0.81 (0.49,1.34)
AQS 1 0.92 (0.61,1.39) 1.06 (0.66,1.7) 0.89 (0.51,1.55)
Defect Groupings
APVR CMAQ, full population 1 0.91 (0.44,1.88) 1.36 (0.62,2.97) 1.06 (0.44,2.51)
CMAQ, within 50km of monitor 1 0.57 (0.25,1.29) 1.13 (0.5,2.54) 0.75 (0.31,1.85)
AQS 1 0.87 (0.39,1.96) 0.83 (0.34,2.04) 1.06 (0.42,2.71)
Conotruncals CMAQ, full population 1 1.29 (0.92,1.81) 1.25 (0.82,1.93) 1.16 (0.72,1.86)
CMAQ, within 50km of monitor 1 1.09 (0.73,1.62) 0.9 (0.56,1.43) 0.88 (0.53,1.46)
AQS 1 0.91 (0.6,1.4) 0.85 (0.52,1.38) 0.87 (0.52,1.48)
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Table A3.4 (cont.)
Week 5
Cardiac Defect Source
<25th 
percentile 
(referent)
25th percetile 
to median
median to 75th 
percentile > 75th percentile
Aortic Stenosis CMAQ, full population 1 0.87 (0.46,1.66) 1.04 (0.5,2.17) 1.02 (0.44,2.35)
CMAQ, within 50km of monitor 1 0.87 (0.4,1.88) 0.98 (0.42,2.29) 0.93 (0.37,2.37)
AQS 1 1 (0.46,2.15) 0.72 (0.29,1.8) 0.73 (0.27,1.97)
Coarctation of the Aorta CMAQ, full population 1 0.78 (0.45,1.36) 0.68 (0.34,1.34) 1.37 (0.67,2.8)
CMAQ, within 50km of monitor 1 0.84 (0.43,1.63) 0.97 (0.46,2.05) 1.8 (0.85,3.84)
AQS 1 0.44 (0.2,0.96) 0.68 (0.31,1.49) 1.47 (0.67,3.2)
Hypoplastic Left Heart 
Syndrome CMAQ, full population 1 0.82 (0.44,1.52) 1.86 (0.95,3.63) 1.1 (0.51,2.35)
CMAQ, within 50km of monitor 1 0.71 (0.35,1.45) 2.25 (1.12,4.53) 1.11 (0.49,2.48)
AQS 1 1.02 (0.52,2.01) 1.33 (0.64,2.77) 0.95 (0.42,2.13)
d-TGA CMAQ, full population 1 1.02 (0.6,1.74) 1.26 (0.67,2.37) 0.84 (0.41,1.72)
CMAQ, within 50km of monitor 1 1.12 (0.62,2.05) 1.14 (0.58,2.25) 0.71 (0.33,1.57)
AQS 1 1.4 (0.74,2.65) 1.39 (0.66,2.89) 0.95 (0.42,2.17)
Tetralogy of Fallot CMAQ, full population 1 0.83 (0.53,1.29) 0.78 (0.46,1.34) 0.92 (0.52,1.66)
CMAQ, within 50km of monitor 1 1 (0.59,1.69) 1.15 (0.63,2.1) 1.4 (0.74,2.63)
AQS 1 0.82 (0.47,1.45) 1.28 (0.69,2.38) 1.39 (0.71,2.73)
Other Conotruncals CMAQ, full population 1 0.82 (0.39,1.71) 1.17 (0.52,2.59) 1 (0.41,2.42)
CMAQ, within 50km of monitor 1 1.24 (0.55,2.8) 1.17 (0.47,2.95) 1.15 (0.43,3.08)
AQS 1 0.9 (0.38,2.12) 1.02 (0.4,2.63) 1.09 (0.39,3.04)
Pulmonary Valve 
Stenosis CMAQ, full population 1 1.01 (0.63,1.61) 0.99 (0.57,1.73) 0.94 (0.52,1.71)
CMAQ, within 50km of monitor 1 1.17 (0.66,2.06) 1.17 (0.61,2.24) 1.26 (0.64,2.49)
AQS 1 1.03 (0.55,1.92) 1.24 (0.63,2.47) 1.17 (0.57,2.42)
VSD-perimembranous CMAQ, full population 1 1.41 (0.96,2.06) 1.26 (0.79,2.03) 1.23 (0.73,2.07)
CMAQ, within 50km of monitor 1 1.06 (0.63,1.76) 0.97 (0.54,1.73) 1 (0.54,1.85)
AQS 1 1.35 (0.85,2.15) 1.38 (0.8,2.36) 1.24 (0.69,2.21)
ASD-all CMAQ, full population 1 1.01 (0.72,1.42) 1.21 (0.81,1.81) 1.18 (0.75,1.86)
CMAQ, within 50km of monitor 1 1.38 (0.93,2.06) 1.8 (1.13,2.86) 1.68 (1,2.83)
AQS 1 1.06 (0.7,1.61) 1.14 (0.7,1.84) 1.48 (0.87,2.52)
Defect Groupings
APVR CMAQ, full population 1 0.65 (0.31,1.39) 1.14 (0.51,2.52) 1.48 (0.64,3.45)
CMAQ, within 50km of monitor 1 1.24 (0.57,2.71) 1.79 (0.77,4.14) 1.59 (0.64,3.94)
AQS 1 1.22 (0.56,2.69) 1.41 (0.6,3.33) 0.8 (0.3,2.14)
Conotruncals CMAQ, full population 1 0.88 (0.63,1.24) 0.95 (0.63,1.44) 0.87 (0.55,1.37)
CMAQ, within 50km of monitor 1 0.97 (0.65,1.44) 0.99 (0.63,1.57) 0.94 (0.57,1.55)
AQS 1 1.02 (0.67,1.56) 1.32 (0.81,2.13) 1.23 (0.73,2.09)
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Table A3.4 (cont.)
Week 6
Cardiac Defect Source
<25th 
percentile 
(referent)
25th percetile to 
median
median to 75th 
percentile > 75th percentile
Aortic Stenosis CMAQ, full population 1 1.81 (0.95,3.43) 1.6 (0.76,3.37) 0.73 (0.3,1.79)
CMAQ, within 50km of monitor 1 1.54 (0.71,3.32) 1.54 (0.66,3.6) 0.54 (0.18,1.59)
AQS 1 1.87 (0.86,4.09) 1.19 (0.48,2.94) 0.46 (0.14,1.46)
Coarctation of the Aorta CMAQ, full population 1 1.49 (0.87,2.56) 1.25 (0.64,2.43) 1.01 (0.48,2.1)
CMAQ, within 50km of monitor 1 1.86 (0.98,3.54) 1.03 (0.48,2.23) 1.04 (0.46,2.32)
AQS 1 1.28 (0.64,2.55) 1.13 (0.52,2.48) 0.79 (0.34,1.83)
Hypoplastic Left Heart 
Syndrome CMAQ, full population 1 0.71 (0.39,1.29) 0.88 (0.46,1.69) 0.76 (0.37,1.57)
CMAQ, within 50km of monitor 1 1.1 (0.57,2.12) 1.09 (0.53,2.24) 1.08 (0.49,2.37)
AQS 1 1.23 (0.61,2.46) 1.68 (0.79,3.56) 1.23 (0.53,2.81)
d-TGA CMAQ, full population 1 0.78 (0.46,1.31) 0.62 (0.33,1.18) 0.7 (0.35,1.4)
CMAQ, within 50km of monitor 1 0.96 (0.52,1.76) 0.93 (0.47,1.85) 0.8 (0.37,1.72)
AQS 1 1.02 (0.54,1.93) 1.05 (0.51,2.17) 0.74 (0.33,1.66)
Tetralogy of Fallot CMAQ, full population 1 1 (0.65,1.54) 0.87 (0.51,1.49) 0.71 (0.39,1.28)
CMAQ, within 50km of monitor 1 1.21 (0.72,2.03) 1.11 (0.6,2.03) 0.89 (0.46,1.73)
AQS 1 1.24 (0.72,2.12) 0.91 (0.48,1.71) 0.65 (0.33,1.31)
Other Conotruncals CMAQ, full population 1 1.03 (0.51,2.08) 0.96 (0.43,2.12) 0.65 (0.26,1.6)
CMAQ, within 50km of monitor 1 1.15 (0.52,2.56) 1.16 (0.48,2.83) 0.56 (0.19,1.66)
AQS 1 1.23 (0.54,2.8) 0.95 (0.37,2.42) 0.52 (0.17,1.57)
Pulmonary Valve 
Stenosis CMAQ, full population 1 0.98 (0.62,1.56) 0.92 (0.53,1.59) 1.07 (0.6,1.93)
CMAQ, within 50km of monitor 1 0.94 (0.53,1.67) 1.04 (0.54,1.97) 1.12 (0.57,2.2)
AQS 1 0.82 (0.44,1.54) 0.91 (0.46,1.81) 1.17 (0.57,2.42)
VSD-perimembranous CMAQ, full population 1 1.05 (0.72,1.52) 0.85 (0.53,1.35) 1.03 (0.62,1.71)
CMAQ, within 50km of monitor 1 1.13 (0.68,1.9) 1.05 (0.58,1.9) 1.24 (0.65,2.35)
AQS 1 1.09 (0.69,1.73) 0.9 (0.52,1.57) 1.25 (0.7,2.24)
ASD-all CMAQ, full population 1 1.08 (0.78,1.51) 1.24 (0.83,1.85) 0.95 (0.6,1.5)
CMAQ, within 50km of monitor 1 1.08 (0.73,1.6) 1.18 (0.75,1.88) 0.85 (0.5,1.45)
AQS 1 1.24 (0.82,1.88) 1.32 (0.82,2.11) 0.75 (0.43,1.34)
Defect Groupings
APVR CMAQ, full population 1 0.67 (0.33,1.38) 0.8 (0.37,1.73) 0.73 (0.32,1.69)
CMAQ, within 50km of monitor 1 0.68 (0.31,1.49) 0.64 (0.27,1.5) 0.73 (0.3,1.77)
AQS 1 0.74 (0.33,1.67) 0.92 (0.39,2.17) 0.89 (0.35,2.32)
Conotruncals CMAQ, full population 1 0.92 (0.66,1.28) 0.78 (0.52,1.18) 0.68 (0.43,1.08)
CMAQ, within 50km of monitor 1 1.09 (0.73,1.62) 1.04 (0.65,1.64) 0.8 (0.48,1.33)
AQS 1 1.09 (0.72,1.65) 0.88 (0.54,1.43) 0.61 (0.35,1.04)
186 
 
 
Table A3.4 (cont.)
Week 7
Cardiac Defect Source
<25th 
percentile 
(referent)
25th percetile to 
median
median to 75th 
percentile > 75th percentile
Aortic Stenosis CMAQ, full population 1 0.73 (0.39,1.38) 0.7 (0.34,1.45) 0.59 (0.26,1.34)
CMAQ, within 50km of monitor 1 0.71 (0.33,1.53) 0.65 (0.28,1.5) 0.65 (0.26,1.62)
AQS 1 0.8 (0.36,1.77) 0.72 (0.3,1.74) 0.76 (0.29,2.02)
Coarctation of the Aorta CMAQ, full population 1 0.79 (0.45,1.37) 0.95 (0.5,1.82) 1.16 (0.58,2.32)
CMAQ, within 50km of monitor 1 0.8 (0.42,1.54) 0.89 (0.44,1.83) 0.93 (0.43,1.99)
AQS 1 0.94 (0.47,1.88) 0.82 (0.38,1.79) 0.91 (0.4,2.05)
Hypoplastic Left Heart 
Syndrome CMAQ, full population 1 0.92 (0.51,1.64) 0.82 (0.42,1.61) 0.76 (0.37,1.57)
CMAQ, within 50km of monitor 1 0.93 (0.49,1.76) 0.7 (0.35,1.43) 0.63 (0.29,1.35)
AQS 1 1.11 (0.57,2.16) 0.74 (0.35,1.58) 0.8 (0.36,1.77)
d-TGA CMAQ, full population 1 0.67 (0.39,1.15) 0.92 (0.49,1.71) 0.82 (0.41,1.63)
CMAQ, within 50km of monitor 1 0.72 (0.38,1.35) 1.1 (0.57,2.16) 0.83 (0.39,1.76)
AQS 1 0.58 (0.3,1.13) 0.83 (0.42,1.66) 0.63 (0.29,1.37)
Tetralogy of Fallot CMAQ, full population 1 1.1 (0.71,1.71) 1.12 (0.66,1.9) 0.92 (0.51,1.65)
CMAQ, within 50km of monitor 1 0.73 (0.44,1.24) 0.85 (0.48,1.51) 0.65 (0.35,1.22)
AQS 1 0.77 (0.44,1.33) 0.76 (0.41,1.39) 0.68 (0.35,1.32)
Other Conotruncals CMAQ, full population 1 0.91 (0.45,1.82) 0.75 (0.33,1.68) 0.76 (0.32,1.79)
CMAQ, within 50km of monitor 1 0.68 (0.31,1.51) 0.47 (0.19,1.21) 0.59 (0.23,1.55)
AQS 1 1.08 (0.48,2.44) 0.53 (0.2,1.45) 0.6 (0.22,1.68)
Pulmonary Valve 
Stenosis CMAQ, full population 1 0.98 (0.61,1.56) 0.95 (0.55,1.63) 0.85 (0.47,1.51)
CMAQ, within 50km of monitor 1 0.77 (0.43,1.37) 0.91 (0.49,1.7) 0.82 (0.42,1.59)
AQS 1 0.69 (0.38,1.27) 0.53 (0.27,1.04) 0.62 (0.31,1.25)
VSD-perimembranous CMAQ, full population 1 0.93 (0.64,1.36) 0.88 (0.56,1.39) 0.67 (0.41,1.1)
CMAQ, within 50km of monitor 1 0.65 (0.4,1.06) 0.49 (0.28,0.87) 0.45 (0.24,0.82)
AQS 1 0.57 (0.36,0.89) 0.56 (0.34,0.92) 0.46 (0.27,0.8)
ASD-all CMAQ, full population 1 0.72 (0.52,1) 0.74 (0.5,1.09) 0.66 (0.43,1.03)
CMAQ, within 50km of monitor 1 0.7 (0.48,1.05) 0.73 (0.47,1.14) 0.83 (0.51,1.38)
AQS 1 0.59 (0.39,0.89) 0.54 (0.33,0.87) 0.81 (0.48,1.37)
Defect Groupings
APVR CMAQ, full population 1 0.82 (0.4,1.65) 1.03 (0.48,2.21) 0.69 (0.3,1.62)
CMAQ, within 50km of monitor 1 0.65 (0.3,1.42) 0.73 (0.32,1.65) 0.6 (0.25,1.46)
AQS 1 0.82 (0.38,1.78) 0.66 (0.28,1.56) 0.49 (0.19,1.29)
Conotruncals CMAQ, full population 1 0.97 (0.69,1.35) 1.07 (0.72,1.61) 0.93 (0.59,1.46)
CMAQ, within 50km of monitor 1 0.79 (0.53,1.18) 0.98 (0.63,1.52) 0.79 (0.48,1.28)
AQS 1 0.84 (0.55,1.28) 0.9 (0.56,1.42) 0.78 (0.47,1.3)
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Table A3.4 (cont.)
Week 8
Cardiac Defect Source
<25th 
percentile 
(referent)
25th percetile to 
median
median to 75th 
percentile
> 75th 
percentile
Aortic Stenosis CMAQ, full population 1 0.79 (0.42,1.49) 1.03 (0.52,2.03) 0.76 (0.34,1.69)
CMAQ, within 50km of monitor 1 1.79 (0.85,3.79) 1.57 (0.69,3.6) 0.86 (0.32,2.28)
AQS 1 1.54 (0.72,3.29) 1.5 (0.65,3.5) 0.75 (0.26,2.17)
Coarctation of the Aorta CMAQ, full population 1 1.29 (0.76,2.19) 1.38 (0.74,2.56) 1.08 (0.54,2.16)
CMAQ, within 50km of monitor 1 1.21 (0.65,2.23) 1.01 (0.5,2.03) 1.15 (0.55,2.4)
AQS 1 0.91 (0.47,1.77) 1.3 (0.64,2.66) 0.99 (0.46,2.17)
Hypoplastic Left Heart 
Syndrome CMAQ, full population 1 1.38 (0.77,2.47) 1.95 (1.02,3.75) 1.26 (0.61,2.61)
CMAQ, within 50km of monitor 1 1.93 (1,3.73) 1.85 (0.89,3.82) 1.64 (0.75,3.58)
AQS 1 1.47 (0.77,2.79) 1.3 (0.64,2.66) 1.23 (0.57,2.69)
d-TGA CMAQ, full population 1 1.26 (0.76,2.11) 1.35 (0.73,2.47) 1.03 (0.52,2.03)
CMAQ, within 50km of monitor 1 1.5 (0.84,2.7) 1.07 (0.54,2.1) 1.23 (0.59,2.54)
AQS 1 1.88 (1.03,3.44) 1.17 (0.57,2.42) 1.55 (0.73,3.29)
Tetralogy of Fallot CMAQ, full population 1 0.67 (0.43,1.03) 0.88 (0.53,1.44) 1.09 (0.63,1.87)
CMAQ, within 50km of monitor 1 0.9 (0.54,1.49) 0.9 (0.51,1.59) 1.27 (0.7,2.29)
AQS 1 1.04 (0.61,1.76) 1.02 (0.56,1.86) 1.62 (0.87,3)
Other Conotruncals CMAQ, full population 1 1.09 (0.56,2.13) 0.8 (0.36,1.77) 0.87 (0.37,2.02)
CMAQ, within 50km of monitor 1 1.05 (0.47,2.34) 1.14 (0.48,2.71) 0.87 (0.32,2.34)
AQS 1 0.69 (0.28,1.68) 1.34 (0.56,3.18) 1.05 (0.39,2.87)
Pulmonary Valve 
Stenosis CMAQ, full population 1 1.28 (0.8,2.02) 1.55 (0.92,2.63) 1.58 (0.9,2.79)
CMAQ, within 50km of monitor 1 1.37 (0.79,2.37) 1.37 (0.74,2.54) 1.46 (0.76,2.79)
AQS 1 1.46 (0.81,2.62) 1.58 (0.82,3.04) 1.5 (0.75,2.99)
VSD-perimembranous CMAQ, full population 1 0.98 (0.68,1.42) 1.06 (0.69,1.63) 1.23 (0.77,1.97)
CMAQ, within 50km of monitor 1 1.25 (0.78,2) 0.9 (0.51,1.59) 1.41 (0.79,2.51)
AQS 1 1.23 (0.79,1.9) 1.03 (0.62,1.72) 1.25 (0.73,2.16)
ASD-all CMAQ, full population 1 1.05 (0.76,1.44) 1.06 (0.73,1.54) 0.94 (0.62,1.43)
CMAQ, within 50km of monitor 1 0.96 (0.66,1.4) 1.04 (0.68,1.6) 0.92 (0.56,1.52)
AQS 1 1.46 (0.98,2.17) 1.54 (0.98,2.42) 1.2 (0.71,2.05)
Defect Groupings
APVR CMAQ, full population 1 0.91 (0.46,1.78) 0.91 (0.43,1.91) 0.76 (0.34,1.71)
CMAQ, within 50km of monitor 1 0.67 (0.31,1.47) 0.75 (0.33,1.68) 0.75 (0.32,1.76)
AQS 1 1.15 (0.54,2.43) 1.03 (0.44,2.43) 1.15 (0.46,2.88)
Conotruncals CMAQ, full population 1 0.86 (0.62,1.19) 0.94 (0.64,1.39) 0.99 (0.65,1.52)
CMAQ, within 50km of monitor 1 1.03 (0.7,1.5) 0.92 (0.59,1.42) 1.12 (0.7,1.79)
AQS 1 1.12 (0.76,1.67) 1.01 (0.64,1.61) 1.4 (0.86,2.27)
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Defect Grouping Source
<25th 
percentile 
(referent)
25th percetile to 
median
median to 75th 
percentile > 75th percentile
LVOTO CMAQ, full population 1 0.8 (0.56,1.15) 0.7 (0.45,1.1) 0.9 (0.56,1.44)
CMAQ, within 50km of monitor 1 0.96 (0.62,1.49) 0.75 (0.45,1.25) 0.96 (0.57,1.63)
AQS 1 0.57 (0.35,0.92) 0.66 (0.39,1.14) 0.83 (0.47,1.46)
RVOTO CMAQ, full population 1 1.03 (0.7,1.5) 0.81 (0.51,1.27) 0.68 (0.42,1.12)
CMAQ, within 50km of monitor 1 0.87 (0.54,1.4) 0.67 (0.39,1.15) 0.85 (0.49,1.48)
AQS 1 0.74 (0.44,1.24) 0.48 (0.27,0.87) 0.58 (0.32,1.05)
Septals CMAQ, full population 1 0.88 (0.69,1.12) 0.73 (0.54,0.99) 0.7 (0.5,0.98)
CMAQ, within 50km of monitor 1 0.98 (0.73,1.32) 0.74 (0.52,1.05) 0.77 (0.52,1.12)
AQS 1 1.06 (0.76,1.48) 0.76 (0.51,1.12) 0.72 (0.47,1.09)
Week 3
LVOTO CMAQ, full population 1 0.87 (0.59,1.27) 0.87 (0.54,1.38) 0.83 (0.5,1.37)
CMAQ, within 50km of monitor 1 1.03 (0.65,1.63) 1.19 (0.71,1.99) 0.87 (0.49,1.52)
AQS 1 1.39 (0.84,2.29) 1.27 (0.72,2.25) 1.05 (0.58,1.91)
RVOTO CMAQ, full population 1 0.71 (0.47,1.07) 1.11 (0.69,1.79) 1.21 (0.73,2.02)
CMAQ, within 50km of monitor 1 0.96 (0.58,1.59) 1.38 (0.8,2.4) 1.51 (0.85,2.7)
AQS 1 1.62 (0.92,2.83) 1.87 (1.01,3.46) 1.97 (1.04,3.73)
Septals CMAQ, full population 1 0.94 (0.72,1.23) 1.02 (0.74,1.41) 1.03 (0.72,1.47)
CMAQ, within 50km of monitor 1 1.22 (0.9,1.67) 1.23 (0.86,1.77) 1.08 (0.72,1.61)
AQS 1 1.16 (0.82,1.65) 1.2 (0.8,1.79) 1.19 (0.77,1.83)
Week 4
LVOTO CMAQ, full population 1 1.23 (0.84,1.79) 1.02 (0.63,1.64) 1.01 (0.6,1.69)
CMAQ, within 50km of monitor 1 0.87 (0.56,1.35) 0.67 (0.4,1.11) 0.78 (0.45,1.34)
AQS 1 0.83 (0.51,1.33) 0.91 (0.54,1.56) 0.78 (0.44,1.39)
RVOTO CMAQ, full population 1 1.32 (0.88,1.97) 1.21 (0.74,1.98) 1.22 (0.72,2.08)
CMAQ, within 50km of monitor 1 0.72 (0.45,1.17) 0.72 (0.42,1.23) 0.59 (0.33,1.05)
AQS 1 0.63 (0.37,1.08) 0.81 (0.46,1.43) 0.86 (0.47,1.58)
Septals CMAQ, full population 1 1.07 (0.82,1.38) 1.05 (0.76,1.46) 1.18 (0.82,1.7)
CMAQ, within 50km of monitor 1 0.85 (0.63,1.15) 0.87 (0.61,1.25) 0.93 (0.62,1.38)
AQS 1 0.98 (0.7,1.38) 1.16 (0.79,1.72) 1.07 (0.69,1.65)
Table A3.4 (cont.)
Week 2
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Table A3.4 (cont.)
Week 5
Cardiac Defect Source
<25th 
percentile 
(referent)
25th percetile 
to median
median to 75th 
percentile > 75th percentile
LVOTO CMAQ, full population 1 0.81 (0.55,1.19) 1.08 (0.68,1.71) 1.15 (0.69,1.91)
CMAQ, within 50km of monitor 1 0.69 (0.44,1.1) 1.17 (0.71,1.93) 1.11 (0.64,1.91)
AQS 1 0.67 (0.42,1.08) 0.76 (0.45,1.29) 0.95 (0.54,1.66)
RVOTO CMAQ, full population 1 0.82 (0.55,1.23) 0.93 (0.58,1.49) 0.88 (0.53,1.47)
CMAQ, within 50km of monitor 1 0.93 (0.57,1.5) 0.97 (0.56,1.66) 1.04 (0.59,1.83)
AQS 1 1.03 (0.61,1.73) 1.16 (0.65,2.06) 1.16 (0.63,2.12)
Septals CMAQ, full population 1 1.19 (0.91,1.55) 1.24 (0.9,1.72) 1.2 (0.84,1.73)
CMAQ, within 50km of monitor 1 1.33 (0.97,1.83) 1.52 (1.05,2.2) 1.37 (0.91,2.06)
AQS 1 1.02 (0.73,1.43) 1.03 (0.7,1.52) 1.19 (0.78,1.81)
Week 6
LVOTO CMAQ, full population 1 1.33 (0.91,1.94) 1.3 (0.82,2.06) 0.95 (0.57,1.59)
CMAQ, within 50km of monitor 1 1.55 (0.99,2.43) 1.26 (0.75,2.13) 1.01 (0.57,1.79)
AQS 1 1.42 (0.88,2.27) 1.42 (0.83,2.44) 0.89 (0.49,1.63)
RVOTO CMAQ, full population 1 0.92 (0.62,1.36) 0.75 (0.47,1.21) 0.95 (0.58,1.57)
CMAQ, within 50km of monitor 1 0.93 (0.58,1.51) 0.89 (0.52,1.54) 1.03 (0.58,1.81)
AQS 1 0.82 (0.49,1.39) 0.88 (0.49,1.56) 1.14 (0.62,2.09)
Septals CMAQ, full population 1 1.1 (0.85,1.43) 1.11 (0.81,1.52) 1.04 (0.73,1.49)
CMAQ, within 50km of monitor 1 1.09 (0.8,1.49) 1.1 (0.76,1.6) 1.07 (0.71,1.61)
AQS 1 1.19 (0.85,1.67) 1.23 (0.84,1.81) 0.99 (0.64,1.54)
Week 7
LVOTO CMAQ, full population 1 0.85 (0.58,1.24) 0.9 (0.58,1.41) 0.91 (0.55,1.48)
CMAQ, within 50km of monitor 1 0.93 (0.59,1.45) 0.89 (0.54,1.47) 0.86 (0.5,1.47)
AQS 1 1.24 (0.77,1.98) 1.04 (0.61,1.78) 1.15 (0.65,2.03)
RVOTO CMAQ, full population 1 1.12 (0.75,1.67) 1.12 (0.7,1.78) 0.93 (0.56,1.53)
CMAQ, within 50km of monitor 1 0.95 (0.59,1.53) 1.06 (0.63,1.79) 0.95 (0.54,1.66)
AQS 1 0.82 (0.5,1.37) 0.65 (0.37,1.15) 0.69 (0.38,1.24)
Septals CMAQ, full population 1 0.82 (0.63,1.07) 0.82 (0.6,1.12) 0.69 (0.48,0.97)
CMAQ, within 50km of monitor 1 0.67 (0.49,0.92) 0.69 (0.49,0.98) 0.68 (0.46,1)
AQS 1 0.64 (0.46,0.89) 0.56 (0.39,0.82) 0.66 (0.44,1)
Week 8
LVOTO CMAQ, full population 1 1.14 (0.79,1.65) 1.4 (0.91,2.15) 0.98 (0.61,1.59)
CMAQ, within 50km of monitor 1 1.6 (1.03,2.47) 1.41 (0.86,2.32) 1.23 (0.72,2.11)
AQS 1 1.1 (0.71,1.7) 1.16 (0.71,1.9) 0.84 (0.48,1.46)
RVOTO CMAQ, full population 1 1.3 (0.88,1.93) 1.57 (1,2.47) 1.5 (0.92,2.46)
CMAQ, within 50km of monitor 1 1.53 (0.97,2.43) 1.42 (0.84,2.39) 1.36 (0.78,2.38)
AQS 1 1.44 (0.88,2.34) 1.41 (0.81,2.44) 1.26 (0.7,2.27)
Septals CMAQ, full population 1 0.99 (0.77,1.28) 1.01 (0.75,1.36) 1.02 (0.73,1.42)
CMAQ, within 50km of monitor 1 1 (0.74,1.36) 0.97 (0.69,1.37) 0.98 (0.67,1.44)
AQS 1 1.3 (0.94,1.79) 1.17 (0.81,1.69) 1.2 (0.8,1.8)
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